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Recent Research Suggests...
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1.

clindamycin

2

clindamycin concentrating in PMN lysosomes

.

4.

3.

clindamycin-laden PMN moving
toward the site of infection

the invading bacteria

O

Phosphate S.S.

enhances
HOST DEFENSE
Recent in-vitro research has shown that clindamycin concentrates within
the PMN in amounts greater than are found outside of the PMN.1 The
rates of chemotaxis, phagocytosis and killing of bacteria by PMNs are also
enhanced by the presence of this antibiotic.2^3 These characteristics may
help explain clindamycin’s outstanding record of clinical efficacy in both
anaerobic and gram-positive aerobic infections.
Since host defense factors may be crucial in determining the outcome of
an infection, selection of antibiotics based on host defense parameters
may become a trend in infectious disease therapy.
1) Klempner MS, et al (Nov 1981) J Infect Dis 144( 5)
2) Johnson JD, et al (March 1980) J Lab Clin Med 95(3)
3) Gemmell C, et al (1980) Current Chemotherapy and Infectious Disease
(eds. J Nelson, C Grassi) Am Soc Microbiol Vol 2

5.

phagocytosis of the bacterium
by antibiotic-enhanced PMN

6.

degranulation and killing
of engulfed bacterium
j
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clindamycin levels
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QUILL ON SCALPEL

1
»»

This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Metabolic Indicators of Outcome in Trauma
*

In the January 1984 issue o f the Journal
1 ►(pages 64 to 69), Kassum and colleagues
^ showed that simple measurements o f
| metabolic function correlate quite well
with outcome for patients with multiple
injuries. Their work suggests an alter^ native to trauma indices as a way o f
predicting outcome and measuring the ef
fectiveness o f trauma units. Further, the
positive correlation between metabolic
f J derangement and outcome is a strong
'
reminder that the multiple trauma patient
is more than a collection o f various
► injuries.
The evolution o f trauma units has met
, with criticism and resistance in many cen
tres. The hypothesis that centralization o f
i trauma patients with dedicated personnel
i and facilities will result in decreased morr fality and morbidity is not yet proved.
However, during the past 10 years,
* reliable indices o f severity and outcome
have been developed and are being used
r to assess the effectiveness o f trauma care
systems. Such indices will help in the
triage and management o f accident
V victims.
Most systems for evaluating the severir ty o f trauma have been based on
anatomic and physiologic abnormalities
> determined from the physical examina\ tion. They are complex and many times
* revised. In 1971, Kirkpatrick and
r Youmans1 developed the trauma index,
a numerical value based upon the area in» jured, the type o f injury and the status
o f the cardiovascular, central nervous and
► respiratory systems. Bever and
Veenker’ s2 illness-injury severity index
(IISI) assessed eight variables adding to
. the trauma index the skin colour and
bleeding. Teasdale and Jennett3
developed and tested a severity scale for
predicting outcome in patients with severe
> head injury. It has come to be known as
the Glasgow coma scale. Champion and
^ colleagues4 have developed the triage in
dex based on five variables, which include
k Respiratory expansion, capillary refill, eye
opening, and verbal and motor responses.

An anatomic index o f injury severity, the
injury severity score (ISS) was used by
Baker and associates5 in 1974 to evaluate
emergency care. More recently, Cham
pion and associates6 presented the
trauma score (TS) as a modification o f
the triage index and suggested the com
bined use o f TS, ISS and age. Assessing
trauma by indices and scores is a rather
pragmatic approach which, while useful,
tends to view the patient as the sum o f
his many injuries and ignores the general
effects o f injury and responses.
Kassum and colleagues analyse the out
come o f patients who sustained multiple
injuries and describe predictive indices
based on the plasma glucose and the
serum potassium levels, the leukocyte
count and the Glasgow coma scale. They
found good correlation coefficients with
outcome between serum potassium and
plasma glucose levels and the coma scale
score. Moreover, the plasma glucose level
and the coma scale score were most im
portant in predicting outcome. Despite
good correlation with outcome, the serum
potassium levels and the leukocyte counts
did not contribute to predictability.
Many readers will be surprised that
such simple everyday measurements can
be correlated with the outcome o f patients
with a complex assortment o f injuries.
However, there is good rationale for stu
dying the use o f serum potassium and
plasma glucose levels as metabolic
measures o f severe injury. Plasma levels
o f epinephrine are elevated following
stressful events such as trauma7 and
myocardial infarction.8 Epinephrine is
know n to cause h ypokalem ia in
animals.9 In healthy young men, infu
sions o f epinephrine to achieve plasma
levels comparable to those seen in patients
with myocardial infarction cause a
decrease in serum potassium concentra
tion by 0.8 m m ol/L . This effect o f
epinephrine is blocked by a specific B2
antagonist.10 Since the uptake o f
potassium by skeletal muscle is under
B2-receptor c o n tr o l,11 it can be

postulated that the epinephrine-induced
hypokalemia is due to increased uptake
o f potassium by skeletal muscle. This re
cent experimental work provides a
reason able
exp lan ation
of
the
hypokalemia observed by the authors in
their severely injured patients.
Epinephrine infusions also cause a fall
in plasma insulin and a rise in plasma
glucose levels.10 However, as the authors
point out, the hyperglycemia o f severe in
jury is likely due to the elevation and
synergistic effects o f the three counterregulatory horm ones, epinephrine,
glucagon and cortisol. Unfortunately,
they did not measure the plasma levels o f
insulin and the counterregulatory hor
mones. They point out that such
measurements are esoteric and timeconsuming and that they have not been
useful in predicting outcome. This may
be so, but the lack o f these measurements
makes it virtually impossible to draw con
clusions about how such changes cause
death or how such changes might be
altered therapeutically to im prove
survival.
The paper raises important questions
quite apart from those related to out
come. Are some o f these changes harm
ful? Hypokalemia following myocardial
infarction, thought to be epinephrineinduced, is associated with a worse prog
nosis presumably because o f cardiac
arrhythmias.12 Surgeons who are more
attuned to looking for high serum
potassium levels in injured patients
should be alerted by this paper to the fre
quency o f hypokalemia and its harmful
effects. Assuming that hyperglycemia is
due to elevation o f the counterregulatory
hormones, one might ask whether this
“ normal” response to trauma, which is
distinctly catabolic, can become harmful
if prolonged.
By focusing on the metabolic response
to trauma, this study suggests a fresh ap
proach to both the prediction o f outcome
and the metabolic management o f the
trauma patient. Metabolic changes are the

VOLUME 27, NO. 2, M A R C H 1984 / THE CAN A D IAN JOURNAL OF SURGERY

105

end result of injury and they can be
measured precisely. Further work may
well vindicate this approach to assessing
severity in multiple trauma.
J ohn H. D uff , md , frcs[C]
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4.

Department of Surgery,
University Hospital,
University of Western Ontario,
London, Ont.
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Symposium on the Surgical Treatment of Morbid Obesity \
The first Canadian Symposium on the
Surgical Treatment of Morbid Obesity
was held at the Ottawa General Hospital,
University of Ottawa, May 19-21, 1983.
It was conceived by a group of physicians
and paramedical personnel during the fall
of 1982. The medical planning commit
tee consisted of Drs. L.D. MacLean, A.
Anand, J.A . Palmer and J.B. Freeman.
Dr. William Davis, now Chairman of the
Faculty of Family Medicine at McGill
University, was then a senior medical ad
viser with the Department of National
Health and Welfare. He participated ac
tively in organizing the symposium and
provided valuable advice and assistance
at the time of the symposium.
The Ottawa General Hospital Nutri
tional Support Committee, chaired by Dr.
R. J. Fairfull-Smith, provided a working
format for the symposium, that ac

counted for its superb organization and
smooth functioning.
We appreciated the support of the ad
ministrative staff of the Ottawa General
Hospital, in particular Dr. F. Lortie and
Mr. L. St. Laurent and his staff from
medical communications.
The symposium was intended to
educate Canadian physicians on the many
interesting and occasionally controversial
areas of obesity surgery. The papers
will be published in two consecutive issues
of the Journal in the order of their presen
tation. In the current issue (pages 119 to
136) is all of the material dealing with the
physiology and medical treatment of mor
bid obesity. The May 1984 issue will con
tain all of the surgical presentations. By
the choice of the planning committee and
the Editors, there is a mixture of short
papers and abstracts.
The Second Canadian Symposium will

be held at the Ottawa General Hospital, ^
University of Ottawa on May 17-19,
1984. Please note that, as in 1983, the first a
day (Thursday, May 17) will be dedicated
to nutritional support and Friday and 1
Saturday morning, May 18 and 19, to
obesity. We hope that you (and your
families) will take advantage of the Tulip
Festival — a particularly beautiful time
of the year in Ottawa. Please write to the „
address below for further information.
J oel B. F reeman, md , frcsicj
\

Head, Division of General Surgery,
Ottawa General Hospital,
501 Smyth Rd.,
Ottawa, Ont. K1H 8L6

•*
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For the Obesity Symposium Organization
Committee: Dr. L.D. MacLean, McGill *
University, Montreal; Dr. A. Anand, Johns
Hopkins School of Hygiene, Baltimore; Dr. Ml* T
Deitel, University of Toronto.
<

Postinfarction Resection of Left Ventricular Aneurysm
Novick and associates are to be com
mended for their honest and forthright
paper in this issue (pages 161 to 167) on
the prognostic factors and long-term
follow-up of surgery for postinfarction
left ventricular aneurysm. In recent years,
the selection of patients has changed
greatly, to include those with smaller
aneurysms and with mild congestive heart
failure in whom angina, mitral valve in
sufficiency or uncontrolled arrhythmias
may be of equal or even greater impor
tance than the aneurysm itself. Every ef
106

fort must be made to avoid residual mitral
insufficiency after resection of a left ven
tricular aneurysm. In the few patients
who present with severe mitral regurgita
tion, concomitant mitral valve replace
ment must be done. Novick and asso
ciates report that only 1 of 67 patients re
quired valve replacement. Valve replace
ment through the aneurysm incision itself
affords excellent exposure and the use of
a low profile valve facilitates the
procedure.
Congestive heart failure and angina are

the principal symptoms of long-standing
postinfarction left ventricular aneurysms.
Angina occurs more frequently in patients
with aneurysm and multivessel disease 4
while congestive heart failure tends to oc
cur more often in patients with aneurysm 4
and single-vessel disease. Novick and coli
leagues report a higher percentage of pa- -*■
tients suffering from angina without con
gestive heart failure who underwent^
operation (52.2%) than that reported by4 ^
most other authors. This is reflected in
their mortality figures. They conclude
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that the absence of congestive heart
failure correlates directly with long-term
mortality. Their early mortality of 8.9%
T reflects the experience of others. In the
^ literature, the operative mortality had
ranged from 0% in a small group of pa^ tients reported by Otterstad and
* colleagues1 in 1981 to 19% reported by
t Rrawley and colleagues2 in 1983. Con
current revascularization of obstructed
>-. coronary arteries is positively related to
long-term survival and argues for a more
^ aggressive policy towards bypass grafting
in these patients, to prevent or postpone
myocardial damage. Their data and those
i j f others can be interpreted as indicating
that the determinants of early and late
< mortality are similar in patients with left
ventricular aneurysm and with coronary
* disease. When the remaining left ven
tricular function is reasonable and con* gestive heart failure is mild or absent, the
results of complete revascularization per* formed electively are good. The results of
^ conventional techniques of ventricular
resection and revascularization to treat
^ refractory ventricular arrhythmias remain
unpredictable. Several centres are now in4 volved in careful electrophysiologic
studies of these patients but the operative
* techniques require further definition.
It is imperative to make a careful
preoperative hemodynamic assessment of
left ventricular function and to continue
this assessment by both noninvasive and
^ invasive methods postoperatively to assess
the hemodynamic recovery. Our own im^pression is that one must try to be as
radical as possible in resecting the scar
''tissue to achieve as much of a decrease
as possible in the end-diastolic volume of
the left ventricle, since improvements in
symptoms tend to parallel the reduction
in left ventricular end-diastolic pressure.
However, continued careful hemodyna
mic evaluation is also necessary to corre
late improvement of end-diastolic pres
sure with the surgical technique used. In
this way the optimum surgical technique
for handling these patients can be
developed.
„W.J.

KEON, MD, FRCS[C], FACS

Member,
Editorial Board.

Director,
University of Ottawa Heart Institute,
Ottawa Civic Hospital,
L A 1053 Carling Ave.,
f Ottawa, Ont.
>K1Y 4E9
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Investigation of
Obstructive Jaundice
To the Editors.—We enjoyed Dr.
Mullens’ MacKenzie Day abstract on in
vestigation of obstructive jaundice (Can
J Surg 1983; 26: 452) and would like to
respond to it and perhaps provoke com
ments from your readers.
The evolved investigation policy that
Mullens describes leads to percutaneous
cholangiography and drainage, preferably
internal, if the biliary tree is dilated.
When no duct dilatation is seen and car
cinoma is found, a stent is placed at the
time of endoscopic retrograde cholangio
pancreatography (ERCP). This “ provides
better drainage than a proximal per
cutaneous catheter” . If ERCP drainage
is as good as percutaneous internal
drainage and better than percutaneous
transhepatic proximal drainage, why do
the transhepatic procedure at all? In our
experience, it is often not possible to place
a percutaneous drain internally at the first
attempt and proximal drainage has to be
accepted for a time. Furthermore, we
have found the complications from per
cutaneous biliary drainage unacceptably
high. Of our first 30 patients, 3 died
directly or indirectly as a result of the
transhepatic drainage procedure. Two
prospective studies1,2 have shown no
decrease in morbidity or mortality from
preoperative transhepatic biliary
drainage, and Mueller and associates3
report from the Massachusetts General
Hospital a cumulative complication rate
for biliary drainage approaching 50%.
With increased experience of papillo
tomy, the advent of better duodenoscopes
with larger channels, and the availability
of a variety of endoscopic stents and
drains, we are shifting from transhepatic
cholangiography to ERCP as the invasive
procedure of choice in obstructive jaun
dice, regardless of duct size.4 When
ERCP drainage is not possible, guidance
of transhepatic catheter placement by
real-time ultrasonography may reduce the
complication rate; early results from
Chiba University (Ohto M: Personal com
munication, 1983) with this technique are
impressive. Our experience of this tech
nique is minimal, but in our first patient
with an obstructed choledochojejunostomy, real-time ultrasonography of

a dilated right intrahepatic duct permit
ted proximal drainage to be established
with a single needle puncture into that
duct.
We would be interested in the com
ments of others on complication rates of
transhepatic biliary drainage, on whether
ERCP should now be the procedure of
choice as a less-invasive method of
establishing biliary drainage in hospitals
where both procedures are readily
available, and on the experience of others
of ultrasonography to guide transhepatic
biliary drainage.
G iles W. Stevenson , m a , m r c p , frcpic ]
Professor,
Diagnostic Radiology,
P eter Y.T. T a m , md
Associate Professor,
Department of Surgery,
McMaster University,
1200 Main St. W,
Hamilton, Ont.
L8N 3Z5
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As an adjunct to surgery
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500
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the risk of antibiotic failure
in anaerobic infections
consistently bactericidal
against virtually all clinically
important anaerobes. In fact, Flagyl
500 Inj. is “ the only com pound...
with consistent bactericidal activity
against anaerobic bacteria, including
B fragi lis!”
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concentrates
at bactericidal levels in wound tissue.
In an animal study comparing Flagyl
500 Inj. with clindamycin and
cefoxitin, only Flagyl 500 Inj.
achieved therapeutic concentrations in
both fresh and healing colonic tissue.5

eradicates
pathogens from within the abscess
cavity, achieving significantly greater
reductions in Bacteroides count than
clindamycin or cefoxitin.4
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penetrates
rapidly into colonic tissue, achieving a
significant reduction in Bacteroides
content of the colon within one hour.2
Flagyl 500 Inj. is distributed in all
body tissues and fluids, including
abscesses.'4
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3 .8 ± 0 .6
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C e fo x itin
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f Mice given no antibiotic had mean (* SEM) counts o f
I 09.9,. OJcfu pH.r abscess at five davs.
'Results for drugs with the same numerical designation were
not significantly different (P > 0.05) by Student’s t- test of
independent means.

Excellent safety profile
Flagyl 500 Inj. is well tolerated, with a
low incidence of side effects.6
Pseudomembranous colitis is unlikely
to occur, as Flagyl 500 Inj. is highly
effective against C. difficile,78 which is
usually associated with this disease.5
Clindamycin and cefoxitin, on the
other hand, show little activity against
C. difficile 7-8
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A selective anaerobicide
ACTIONS
Flagyl (metronidazole) is bactericidal against
anaerobic bacteria, it exerts trichomonacidal activity
and is also active against Giardia lamblla and
Entamoeba histolytica. Its exact mechanism of action
has not been entirely determined as yet. It has been
proposed that an intermediate in the reduction of
metronidazole, produced only in anaerobic bacteria
and protozoa is bound to deoxyribonucleic acid and
proteins, and inhibits subsequent nucleic acid
synthesis.

INDICATIONS AND CLINICAL USES
Bacterial Infections: The treatment of serious
anaerobic abdominal infections due to susceptible
anaerobic bacteria, such as Bacteroides fragilis (and
other species o f Bacteroides), Clostridium,
Fusobacterium, Peptococcus, and Peptostreptococcus
species.
Culture and susceptibility studies should be
performed to determine the causative organisms and
their susceptibility to metronidazole. Based on clinical
judgment and anticipated bacteriological findings,
therapy may be started while awaiting the results of
these tests. In mixed aerobic and anaerobic infections,
consideration should be given to the concomitant
administration o f an antibiotic appropriate for the
treatment of the aerobic component of the infection.
(See Warnings).
Flagyl (metronidazole) has also been used in the
treatment of a small number of cases of brain or lung
infections (some with abscesses) caused by anaerobic
bacteria.

CONTRAINDICATIONS
Flagyl (metronidazole) is contraindicated in
patients with a prior history of hypersensitivity to
metronidazole or other nitroimidazole derivatives.
Flagyl should not be administered to patients with
active neurological disorders or a history of blood
dyscrasia, hypothyroidism and hypoadrenalism.

WARNINGS
Flagyl (metronidazole) has no direct activity
against aerobic or facultative anaerobic bacteria. In
patients with mixed aerobic/anaerobic infections,
appropriate concomitant antibiotics active against the
aerobic component should be considered.
Known or previously unrecognized moniliasis may
present more prominent symptoms after treatment
with Flagyl.
Studies in rats and mice have provided some
evidence that metronidazole may cause tumors in
these species when administered orally for a long
period at high doses. The relevance of these findings
in humans is not known.
Severe neurological disturbances (i.e. convulsive
seizures and peripheral neuropathy) have been
reported in patients treated with Flagyl (administered
orally or intravenously). These have oeen observed
very infrequently.

PRECAUTIONS
Patients taking Flagyl (metronidazole) should be
warned against consuming alcohol, because of a
possible disulfiram-like reaction. For the same
reason, patients receiving Flagyl should not be
administered disulfiram concomitantly.
Transient eosinophilia and leukopenia have been
observed during treatment with Flagyl. Regular total
and differential leukocyte counts are advised if
administration for more than 10 days or a second
course of therapy is considered to be necessary.
Metronidazole crosses the placental barrier.
Although Flagyl has been given to pregnant women
without apparent complication, it is advisable that
oral administration be avoided in pregnant patients
and Flagyl be withheld during the first trimester of
pregnancy. In serious anaerobic infections, if the
administration of Flagyl to pregnant patients is
considered to be necessary, its use requires that the
potential benefits be weighed against the possible
risks to the fetus.

Metronidazole is secreted in breast milk in
concentrations similar to those found in plasma.
Intravenous or oral administration of Flagyl should be
avoided in the nursing mother.
Metronidazole has been reported to potentiate the
anticoagulant elect of warfarin resulting in a
prolongation of prothrombin time. This possible drug
interaction should be considered when Flagyl is
prescribed for patients on this type of anticoagulant
therapy. Clinical experience in children is very limited.
The monitoring of this group of patients is particularly
important. The safety and effectiveness of intravenous
Flagyl in children has not been established.
A rare case of reversible but profound neurological
deterioration has been reported following a single oral
dose of Flagyl; it is therefore advisable that a patient
taking Flagyl for the first time not be left unattended
for a period of two hours. The appearance of abnormal
neurologic signs demands prompt discontinuation of
Flagyl therapy and, when severe, immediate medical
attention. Gastric lavage may be considered if no
more than two or three hours have elapsed since
administration of the drug.
Treatment with Flagyl should be discontinued if
ataxia or any other symptom of CNS involvement
occurs.
Patients with severe hepatic disease metabolize
metronidazole slowly with resultant accumulation of
metronidazole and its metabolites in the plasma.
Accordingly, for such patients, doses of Flagyl below
those usually recommended should be administered
and with caution. The determination of serum
glutamic oxaloacetic transaminase (SGOT) by the
Technicon SMA 12/60 system in blood samples from
patients receiving Flagyl may give abnormally low
values. This abnormality is artifactual and caused by
the absorption of metronidazole at the wavelength
where the enzymatic reaction is monitored
spectrophotometrically.

ADVERSE REACTIONS
Gastrointestinal: diarrhea, nausea, vomiting,
anorexia, epigastric distress, dyspepsia, constipation.
Month: furred tongue, dry mouth, unpleasant
metallic taste.
Hematopoietic: transient eosinophilia or
leucopenia.
Derm atologic: rash and pruritus.
Cardiovascular: palpitation and chest pain.
Central Nervous System: convulsive seizures,
peripheral neuropathy, transient ataxia, dizziness,
drowsiness, confusion, insomnia and headache.
Peripheral neuropathies have been reported in a few
patients on moderately high to high-dose prolonged
oral treatment with metronidazole. It would appear
that the occurence is not directly related to the daily
dosage and that an important predisposing factor is
the continuation of oral and/or I.V. medication for
several weeks or months. Profound neurological
deterioration, within 2 hours after Flagyl
administration has been reported. The occurrence is
not directly related to the dosage level.
Metabolic: An antithyroid effect has been reported
by some investigators but three different clinical
studies failed to confirm this.
Local Reactions: Thrombophlebitis has occurred
with I.V. administration.
Other: Proliferation of Candida albicans in the
vagina, vaginal dryness and burning; dysuria;
occasional flushing and headaches, especially with
concomitant ingestion of alcohol; altered taste of
alcoholic beverages. Darkening of the urine has been
reported. This is probably due to a metabolite of
metronidazole and seems to have no clinical
significance.

SYMPTOMS AND TREATMENT OF
OVERDOSAGE
Symptoms
Massive ingestion may produce vomiting and slight ^
disorientation.
Treatment
There is no specific antidote. Early gastric lavage^
may remove a large amount of the drug; otherwise,
symptomatic treatment.

DOSAGE AND ADMINISTRATION
TREATMENT OF ANAEROBIC
INFECTIONS
Treatment should be initiated by the I.V. route. Oral
medication may be substituted when it is feasible
and/or practical Duration of therapy depends upon ^
clinical and bacteriological assessment. Treatment for
seven days should be satisfactory for most patients.
However in cases where infection sites cannot be *
drained or which are liable to endogenous
recontamination by anaerobic pathogens, a longer
treatment may be required.

1

I.V. ADMINISTRATION:
100 mL (500 mg) by intravenous infusion every 8
hours. The injection should be infused intravenously
‘
at the rate of 5 mL per minute.
Flagyl injection is compatible in a volume ratio of
1:5 with normal saline, dextrose-saline, dextrose 5 perw
cent w/v or potassium chloride injections (20 mmol
and 40 mmol). It should not be mixed with sodium
lactate injection 5% w/v, or dextrose injection 10%
w/v.

AVAILABILITY
Injection 0.5% w/v in Viaflex* plastic bags of
100 mL (500 mg) for intravenous infusion.
FULL PRODUCT MONOGRAPH AVAILABLE ON
REQUEST.
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Retroperitoneal Fibrosis
Retroperitoneal fibrosis is a rare disease
but is important surgically because it can
produce ureteral obstruction and renal
failure. A wide variety of inflammatory,
’ infective and neoplastic conditions can
result in secondary retroperitoneal
fibrosis and it is essential to look careful
ly for an underlying neoplastic condition
in all cases of retroperitoneal fibrosis.
Idiopathic retroperitoneal fibrosis oc
curs predominantly in men and results in
some form of renal failure in 75% of pa
tients. The classic triad of medial devia
tion of ureters, ureteral narrowing at
L 4 -5 and proximal hydronephrosis is
usually seen in high-dose intravenous
pyelograms and the ease of retrograde
ureteral catheterization is often
diagnostic.
Management depends on the degree of
r renal impairment, with laparotomy, multi
ple biopsies and ureterolysis being the
treatment of choice. Steroids are
beneficial, if used early, and the prog
nosis is excellent if there is no under
lying malignant condition.

fisance renale dans 75% des cas. La
triade classique comprenant deviation
mediane des uret&res, st6nose des uret&res au niveau de L 4 -5 et hydrongphrose
proximate est habituellement constatee a
la py6lographie intraveineuse a forte
dose et la facility du cathet6risme urete
ral retrograde a souvent valeur
diagnostique.
La conduite a prendre depend du degr6
d'insuffisance renale. La laparotomie,
biopsies multiples et liberation chirurgi
cale des uretdres repr6sente le traitement
de premier choix. Les st6roides employes
tot sont utiles et, en I'absence d'affection maligne sous-jacente, le pronostic
est excellent.

Secondary Retroperitoneal Fibrosis

Injury or Inflammation
Retroperitoneal injury can cause a
hematoma that becomes organized and
ultimately results in retroperitoneal
fibrosis. Leaking aneurysms may behave
in a similar fashion;1 the presence of
hemosiderin in the fibrous tissue substan
tiates this view.2 Retroperitoneal hemor
rhage, occurring in Henoch-Schonlein
purpura, may also precede the onset of
retroperitoneal fibrosis in some cases.1
Retroperitoneal infection may be
chronic and produce minimal symptoms.
It occurs as a complication of many con
ditions, such as ulcerative colitis,
perinephric abscess, retrocecal appen
regional enteritis and pancreati
Retroperitoneal fibrosis is caused by a dicitis,
wide variety of conditions and is best con tis.3 The inflammation thus produced
sidered as either secondary or idiopathic may gradually subside and result in
retroperitoneal fibrosis. Numerous con fibrosis with scarring and the clinical pic
ditions result in the secondary form ture of retroperitoneal fibrosis becomes
(Table I) and all identifiable causes should apparent.1
Previous abdominal, pelvic or retro
be excluded before labelling a condition
peritoneal
surgery can also induce the
as idiopathic retroperitoneal fibrosis.
development of retroperitoneal fibrosis,
either by inciting a sclerotic healing pro
•Affection rare, la fibrose retrop^ritoneale
cess or by producing an organizing
est une importante indication chirurgicale
Table I—Causes of Secondary
hematoma.4
car elle peut etre la cause d e s tru c tio n
Retroperitoneal Fibrosis_________
Urinary extravasation following ure
ureterale et d’insuffisance r§nale. Une
Injury or inflammation
teral obstruction due to calculi has
fibrose r6trop6riton6ale secondaire peut
Trauma with hemorrhage
resulted in periureteral and perirenal
r£sulter d'un grand nombre d'affections
Aneurysm
fibrosis. Peripelvic granulomas may be
inflammatoires, infectieuses et n6oplasiAppendicitis, diverticulitis, ulcerative colitis
followed by peripelvic fibrosis when the
Previous surgery
.ques. II est done essentiel de rechercher
urine is sterile.5
Extravasation of urine
soigneusement un processus n6oplasique
Occasionally, radiotherapy can result
Radiation
sous-jacent dans chaque cas de fibrose
Infection
in sclerosis and thus produce retro
r6trop6ritoneale.
Drugs
peritoneal fibrosis.6
La fibrose r6trop6ritoneale idiopathique
Methysergide
Specific infections such as tuberculosis
s'observe davantage chez I'homme et
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and
syphilis have also been considered
elle entrafne une forme ou I'autre d'insufMethyldopa
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Hydralazine
they have not been well documented.7
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Drugs
Methysergide, a powerful serotonin an
tagonist widely used in the treatment of
migraine,9 has been implicated in many
cases of retroperitoneal fibrosis since this
complication was first reported in
1965.10 Recently, reports of retroperito
neal fibrosis associated with the intake of
methyldopa, excessive intake of analge
sics, hydralazine and /3-adrenergic block
ing agents have appeared in the
literature.11
Tumours

of retroperitoneal fibrosis, 68% were
found to be idiopathic.21
Pathologic Features
A glistening, white, fibrous plaque,
overlying the great vessels and extending
from the renal vessels to the pelvic brim
and laterally behind the peritoneum, is
present in most patients; the fibrosis does
not invade the aorta, vena cava or
ureter.22 The plaque consists mainly of
fibrous tissue with varying amounts of
cellular infiltration with plasma cells and
lymphocytes; some areas show mainly
collagen. Few lipid-laden macrophages
are found and the smooth-muscle and
nerve cells seen are presumably trapped
by the proliferating fibrous tissue.20

Primary retroperitoneal tumours such
as lymphomas, those associated with
Hodgkin’s disease and reticulum cell sar
coma can either produce extensive
sclerotic reactions or encase the ureter
with bulky tumour or lymph nodes, or Clinical Manifestations
both, and cause retroperitoneal
Idiopathic retroperitoneal fibrosis oc
fibrosis.12-13 This condition due to curs predominantly in men in the fifth
periureteral metastatic disease can occur and sixth decades of life; the male to
with carcinoma of the lung, stomach, col female ratio is approximately 3 to l.6
on, pancreas, prostate and breast.14 About 12 cases of this condition have
Although retroperitoneal fibrosis secon been reported in children under 15 years
dary to metastatic breast cancer is rare,15 of age.23 The early symptoms are
it does occur and occasionally results in nonspecific and the correct diagnosis is
acute renal failure.16 The ureteral usually made only when obstructive
obstruction follows the sclerotic reaction uropathy or renal failure occurs. Pain was
to the malignant cells in the periureteral the presenting symptom in over 80% of
lymphatics and fibroadipose tissue. Direct patients in some series. The pain was dull,
invasion of the ureteral lumen by the noncolicky, insidious in onset and located
tumour is uncommon. Occasionally, the mainly in the back and flank. Other
diagnosis is made easy by the presence of symptoms were weight loss and anorexia
an obvious primary tumour elsewhere. and vague gastrointestinal symptoms;
However, retroperitoneal fibrosis due to anuria occurred in 10%.6 Other
a malignant tumour is often in investigators20 have found that the back
distinguishable from the idiopathic varie pain is nonspecific and often attributed
ty and only diligent histologic examina to an orthopedic problem. Over 75% of
tion of all biopsy material reveals a their patients presented with some
metastatic tumour.17
manifestation of renal failure and 30%
of them had oliguria or anuria.
Miscellaneous Causes
Hematuria is rare but hypertension occurs
in
40% to 50% of patients with
Circulating serotonin or serotonin
metabolites of carcinoid are considered retroperitoneal fibrosis and some
responsible for fibrosis of the right side manifestation of hypertension may be the
of the heart in carcinoid syndrome. It is first evidence of the disease.20 Scoliosis
possible that asymptomatic carcinoids of secondary to retroperitoneal fibrosis has
the bowel release high concentrations of occurred in two children.24
serotonin locally and give rise to
mesenteric fibrosis and retroperitoneal Diagnosis
fibrosis.18 Other rare conditions, such as
The provisional diagnosis is usually
mesenteric panniculitis and systemic made by high-dose intravenous pyelo
Weber-Christian disease have also been graphy which shows the classic triad of
associated with retroperitoneal fibrosis.19 medial deviation of the ureters, bilateral
ureteral narrowing at L4 or L5 and pro
ximal hydronephrosis and hydroureter.25
Idiopathic Retroperitoneal Fibrosis
In severely azotemic patients, intravenous
Only when all of the causes cited have pyelography may not be useful;
been excluded can the condition be term retrograde pyelography will help in mak
ed idiopathic retroperitoneal fibrosis.
ing the diagnosis (Fig. 1). Even in the
Although Ormond is credited with most severe cases of obstruction, a no. 5
establishing this condition as a clinical en or 6 French ureteral catheter can be pass
tity in 1948, it was Albarran who first ed easily beyond the obstruction and a
recognized it in 1905.20 We do not know hydronephrotic urine drip is often obtain
the exact number of reported cases;
ed. This is one of the characteristic
however, in a review of 481 reported cases features of retroperitoneal fibrosis and
112

FIG. lb
FIG. 1—(a) Retrograde pyelogram shows
1
medial deviation of ureter with narrowing op- .
p osite sacroiliac jo in t, (b) Proxim al
hydronephrosis with hydroureter. Severe
obstruction causes intrarenal reflux of contrast 4 '
medium.
,
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suggests that much of the obstruction is
secondary to loss of ureteral peristalsis.6
^ However, it is important to realize that
the distinction between fibrosis caused by
> benign and malignant processes cannot be
made adequately by pyelography.
►Ultrasonography usually shows a smooth^ bordered, echo-free mass anterior to the
» tacral promontory, but the reported cases
are too few to evaluate its usefulness.26
^ Although the large fibrotic mass is easily
^ recognizable on computerized tomo
graphy, neither the appearance nor the
t site of the mass permits a definite dif
ferentiation between benign fibrosis and
► a malignant process. Lymphomas, sar
comas and lymph-node metastases look
T like retroperitoneal fibrosis on com
puterized tomography and even the at** tenuation values do not help to dis
tinguish between these conditions.26’27
The erythrocyte sedimentation rate is
>/ strikingly elevated in most patients and
probably reflects the inflammatory activi, ty of this disease. The sedimentation rate
I may be of prognostic significance and is
f- often used as an indicator for starting or
. terminating steroid therapy.28 A few
’ reports have suggested a genetic
4 predisposition for the development of
[ idiopathic retroperitoneal fibrosis in pa
tients who are HLA-B27 antigen
positive;29 however, this requires confiry mation and further investigation.30

r

Management

the kidney drained either by a
nephrostomy34 or application of an in
ternal Silastic splint.31 However, strictures commonly result.
According to some,35 30% of patients
are at risk of thromboembolism either
before or after ureterolysis; in selected
cases preoperative administration of
heparin and long-term anticoagulant
therapy may be useful.20
If the kidney has not been badly
damaged and if ureterolysis is adequate,
the prognosis is good with long-term suc
cess rates of over 90%.7’20
Steroid therapy seems to be useful in
the early cellular inflammatory stage
before fibrosis has actually occurred and
in certain circumstances when a definite
diagnosis of idiopathic retroperitoneal
fibrosis has been made, the use of
steroids, in an adjuvant fashion after
surgery, should be considered.36 Since an
elevated erythrocyte sedimentation rate
possibly reflects the inflammatory part of
the disorder, its persistent elevation might
be an indication for steroid therapy.37
Since the recurrence of ureteral stenosis
is unpredictable and may occur any time
from 3 months to 9 years postoperatively,38 it might be advisable to measure
the erythrocyte sedimentation rate at
regular intervals and consider initiating
steroid therapy when that value begins to
rise.
The diagnosis of idiopathic retro
peritoneal fibrosis should be arrived at
only after eliminating all the causes of
secondary retroperitoneal fibrosis,
especially malignant conditions. Ap
propriate therapy should produce ex
cellent results.

It is essential to rule out a malignant
condition in all cases of retroperitoneal
r 'fibrosis and diligent examination of
, multiple biopsy specimens is advisable.
► The initial management of all patients
depends on the level of renal impairment.
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The first effective anti-herpes
therapy is now available in an I.V
infusion for treatment of initial and
recurrent m ucosal and cutaneous
herpes sim plex infections in im
munocompromised adults and chil
dren. It is also indicated for severe
initial episodes of herpes sim plexf
in fection s in im m unocom petent^
patients.
Highly efficacious in co n 
trolled clinical studies, ZOVIRAX I.V selectively blocks the viral replica—
tion process and significantly short
ens the period o f viral shedding.
ZOVIRAX-treated patients
becom e contagion-free faster.
W hat’s m ore, if therapy is
initiated at the earliest possible m o
ment, patients will heal faster and
experience significantly less pain. A
To date, efficacy has not
been complicated or com prom ised*
by side effects.
Note: ZOVIRAX I.V Infusion
is for intravenous infusion only
Therapy is recom m en d ed
for at least 5 days for immunocom i
petent p atien ts and for at least 7
days for im m u n o co m p ro m ise d
patients.
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Now, the first effective anti-herpes therapy is

y available in an I.V. infusion form: Indicated for immuno

compromised adults and children with initial or recar, rent mucosal or cutaneous herpes simplex infections
...and for normal patients with severe initial episodes
v o f herpes simplex infections.
4 ZOVIRAX

▼(ACYCLOVIR SODIUM)
I.V. INFUSION

f-

ZOVIRAX (acyclovir), an acyclic nucleoside analog, is a substrate specific for herpesvirusspecified thymidine kinase. It inhibits replication of these viruses. Normal cellular thymidine
kinase does not effectively utilize acyclovir as a substrate. Herpesvirus-specified thymidine
kinase transforms acyclovir to its monophosphate which is then transformed by cellular
enzymes to acyclovir diphosphate and acyclovir triphosphate. Acyclovir triphosphate is both
an inhibitor of, and a substrate for, herpesvirus-specified DNA polymerase. Although the cellular
oc-DNA polymerase in infected cells may also be inhibited by acyclovir triphosphate, this occurs
only at concentrations of acyclovir triphosphate which are higher than those which inhibit the
herpesvirus-specified DNA polymerase. Acyclovir is preferentially taken up and selectively
converted to its active form by herpesvirus-infected cells. Thus, acyclovir has a very much lower
toxic potential for normal uninfected cells because: 1) less is taken up; 2) less is converted to
the active form; 3) cellular oc-DNA polymerase has a lower affinity for the active form of the drug.

INDICATIONS AND CLINICAL USE
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ADVERSE REACTIONS
The m ost frequent adverse reactions reported during controlled clinical trials of acyclovir
were inflammation or phlebitis (14%) at the injection site following infiltration of the I.V. fluid,
and rash or hives (4.7%). Of the patients receiving placebo, 4.8% experienced the sam e reactions
(inflammation/phlebitis, rash or itching).
Less frequent adverse reactions were diaphoresis, hematuria, hypotension, headache and
nausea, each of which occurred in 1.6% of the patients. Hematuria and nausea were experienced
by placebo recipients at the same frequency. These reactions were observed in severely
immunocompromised patients who often have multisystem diseases unrelated to herpes
infections and, therefore, it is difficult to state conclusively that these reactions were caused
by ZOVIRAX therapy.
Additional adverse reactions were reported in uncontrolled trials. The m ost frequent
adverse reaction was elevated serum creatinine. This occurred in 9.8% of patients, usually
but not always following rapid (less than 10 minutes) intravenous infusion. It is not known
whether this phenomenon is drug related but in view of the feet that the drug is known to
crystallize in urine there exists a possibility that this occurred due to inadequate hydration of
the patients. Less frequent adverse experiences were thrombocytosis (0.4%) and jitters (0.4%).

SYMPTOMS AND TREATMENT OF OVERDOSAGE

^ Ac t io n s
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dosing regimen. In other instances, renal function improved following increased hydration,
dosage adjustment, or discontinuation of ZOVIRAX therapy.
When dosage adjustments are required they should be based on estimated creatinine
clearance (See DOSAGE AND ADMINISTRATION).
It is not known whether acyclovir is excreted in hum an milk. Because many drugs are
excreted in human milk, caution should be exercised when ZOVIRAX is administered to a
nursing mother.
All animal studies carried out to date on reproduction and teratology have been negative.
However, since animal reproduction studies are not always predictive of hum an response,
ZOVIRAX should be used during pregnancy only if the physician feels the benefit will outweigh
the possible harm to the fetus.
There exists no data, at this time, which dem onstrates that the use of ZOVIRAX will
prevent transmission of herpes simplex infection to other persons.
Consideration should be given to an alternative treatm ent regimen if after 5 days of treat
ment there is no expected clinical improvement in the signs and sym ptom s of the infection.
Strains of herpes simplex virus which are less susceptible to ZOVIRAX have been isolated
from herpes lesions and have also emerged during intravenous treatment with ZOVIRAX.

ZOVIRAX Sterile Powder is indicated for treatment of initial and recurrent mucosal and
cutaneous herpes simplex infections in immunocompromised adults and children. It is also
indicated for severe initial episodes of herpes simplex infections in patients who may not be
immunocompromised. It is not recom mended for use in herpes encephalitis or other herpes
group infections all of which are still the subject of ongoing investigations.
The indications are based on the results of a number of double-blind, placebo-controlled
studies which examined changes in virus excretion, total healing of lesions, and relief of pain.
Because of the wide biological variations inherent in herpes simplex infections, the following
summary is presented merely to illustrate the spectrum of responses observed to date. As in
the treatment of any infectious disease, the best response may be expected when the therapy
Vis begun at the earliest possible moment.
In patients experiencing initial episodes of herpes genitalis, virus excretion had ceased
in 100% of initial lesions within 3 days after the start of a 5-day course of intravenous ZOVIRAX
therapy. Only 20% of placebo recipients were virus-free at this time, as well as when therapy
was discontinued. ZOVIRAX therapy arrested virus excretion in over 90% of immunocompromised
patients with mucocutaneous disease at the end of 7 days of therapy, while only 26% of placebotreated patients were virus negative at the sam e time.
Because complete re-epithelialization of herpes-disrupted integument necessitates recruit
ment of several complex repair mechanisms, the physician should be aware that the dis
appearance of visible lesions is somewhat variable and will occur later than the cessation of
virus excretion. In spite of these limitations, 100% of ZOVIRAX-treated patients with initial
episodes of herpes genitalis healed within 15 days after initiation of treatment. Only 50% of
►placebo recipients were healed at this same interval. The lesions of 61% ofimmunocompromised
patients who received ZOVIRAX were healed within 15 days after the initiation of a 7-day course
of therapy-, only 38% of placebo patients had healed their lesions at that point.
y Pain associated with herpes infections is highly variable in frequency and intensity. These
clinical studies, however, demonstrated that ZOVIRAX therapy plays a significant role in reduc
tion of pain in cutaneous herpes infections in immunocompromised patients. For example,
61% of ZOVIRAX-treated immunocompromised patients were pain-free by day 10, whereas
44% of placebo-treated patients were pain-free in the same period of time.
Whereas cutaneous lesions associated with herpes simplex infections are often pathogno
monic, Tzanck smears prepared from lesion exudate or scrapings may assist in diagnosis.
Positive cultures for herpes simplex virus offer the only absolute means for confirmation of
the diagnosis.
+ CONTRAINDICATIONS
ZOVIRAX Sterile Powder is contraindicated for patients who develop hypersensitivity to
the drug.
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Wa r n i n g s
ZOVIRAX Sterile Powder should not be administered by any route [i.e. topically (skin or
eye), intramuscularly, orally or subcutaneously] other than by intravenous infusion.

PRECAUTIONS
Precipitation ofZOVIRAX crystals in renal tubules can occur if maximum solubility (1.3 mg/mL
in water) is exceeded. This phenom enon is reflected by a rise in serum creatinine and blood
urea nitrogen and a decrease in creatinine clearance. With sufficient renal tubular compromise,
urine output decreases.
^
Acute increases in serum creatinine and decreased creatinine clearance have been observed
in humans receiving ZOVIRAX and: (1) who were poorly hydrated; (2) who were receiving
concomitant nephrotoxic drugs (e.g., amphotericin B. and aminoglycoside antibiotics); (3) who
y j>ad pre-existing renal compromise or damage; and (4) in whom the dose was administered
by rapid intravenous injection (less than 10 minutes). Observed alterations in renal function
have been transient, in some instances resolving spontaneously without change in ZOVIRAX

*Trade Mark

W-2055

No acute massive overdosage of the intravenous form has been reported.
Doses administered to hum ans have been as high as 1200 m g /m 2 (28 mg/kg) three
times daily for up to two weeks. Peak plasma concentrations have reached 80 /ig/mL. Possible
evidence of central nervous system (CNS) toxicity (coarse tremors, confusion and agitation)
and/or bone marrow toxicity were seen in four patients at 2100 and 2700 m g /m 2/d a y The
CNS side effects resolved upon lowering the dosage or discontinuing ZOVIRAX therapy. Pre
cipitation of acyclovir in renal tubules may occur when the solubility (1.3 mg/mL) in the intra
tubular fluid is exceeded. Precipitation m ay be avoided or overcome by adequate hydration of
the patient. Acyclovir is dialyzable. In the event of acute renal failure and anuria, hemodialysis
should be initiated until renal function is restored.

DOSAGE AND ADMINISTRATION
CAUTION-RAPID OR BOLUS INTRAVENOUS AND INTRAMUSCULAR OR SUBCUTANEOUS
INJECTION ARE TO BE AVOIDED.
Therapy is recommended for at least 5 days for im munocom petent patients and for at
least 7 days for immunocompromised patients.
Adults: 5 mg/kg infused at a constant rate over a 1-hour period, every 8 hours (15 mg/kg/day)
in patients with normal renal function.
Children Under 12 Years: In children under 12 years of age, m ore accurate dosing can be
attained by administering 250 m g /m 2 infused at a constant rate over a 1-hour period, every
8 hours (750 mg/mVday).
Patients with Acute or Chronic Renal Impairment: Use the recom m ended doses and
methods of administration; and adjust the dosing interval as indicated in the following table.
Creatinine Clearance
Dose
Dosing Interval
(mL/min/1.73m2)
(mg/kg)
(hours)
>50
5
8
25-50
5
12
10-25+
5
24
0-10+
2.5
24-48
t Hemodialysis: For patients who require hemodialysis, the mean plasm a half-life of
acyclovir during dialysis is approximately 5 hours, which results in a 60% decrease in plasm a
concentrations following a 6-hour dialysis period. Recommended doses should be administered
every 24-48 hours, and after hemodialysis.

PHARMACEUTICAL INFORMATION
Reconstitution
Reconstitute as follows:

Solutions for Reconstitution
Sterile Water for Injection
Reconstitution Table
Volume to be
Approximate Available
Approximate Average
Vial Size
Added to Vial
______ Volume______
Concentration
500 mg
10 mL
10 mL
50 mg/mL
SHAKE WELL UNTILDISSOLVED. ASSURE COMPLETE DISSOLUTION BEFORE MEASURING
AND TRANSFERRING EACH INDIVIDUAL DOSE.
Intravenous Infusion: The calculated dose of the reconstituted solution should be removed
and added to an appropriate intravenous solution listed below at a volume selected for ad 
ministration during each 1-hour infusion. Infusion concentrations exceeding 10 mg/mL are
not recommended. Since the vials do not contain any preservatives any unused portion of
the reconstituted solution should be discarded
Solutions for I.V. Infusion
5% Dextrose Injection
Ringer’s Injection
5% Dextrose and 0.9% Sodium Chloride Injection
Normal Saline Injection
5% Dextrose and 0.2% Sodium Chloride Injection
Lactated Ringer's Injection
Stability o f Solution
Storage: Reconstituted solutions at a concentration of 50 mg/mL should be used within
12 hours if kept at room temperature. Refrigeration m ay result in the formation of a precipitate
which will redissolve at room temperature.
Once diluted, the admixtures are to be administered within 24 hours of the preparation.
The admixtures are not to be refrigerated.
Incompatibility: ZOVIRAX should not be added to biologic or colloidal fluids (e.g. blood
products, protein hydrolysates or amino acids, fet emulsions, etc.).

DOSAGE FORMS
Availability: ZOVIRAX is available as sterile powder in 10 mL vials, each containing acyclovir
sodium equivalent to 500 mg of acyclovir.
Storage: ZOVIRAX should be stored at 15°-30°C.
Product Monograph available on request.

WELLCOME MEDICAL DIVISION
BURROUGHS WELLCOME INC.
KIRKLAND, QUE.

N ow ,
control
hyperacidity
without drug
interactions.
Effectively treats hypersecretory conditions
with fewer patients at risk.®
“This study suggests that (Zantac)...increases
the mean gastric p H and decreases
the num ber of “at risk days’ in seriously ill
patients.”®
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Prevents acid aspiration syndrome without
the hepatic drug interactions found with
other H 2 antagonists.
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Effectively inhibits gastric acid secretion one of
ma)°r factors involved in the
pathogenesis of stress ulcers.
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Prescribing Information
ZANTAC® INJECTION (ranitidine hydrochloride)
PHARMACOLOGICAL CLASSIFICATION
Histamine H2-receptor antagonist

ACTION
Ranitidine is a selective antagonist of histamine at gastric H2-receptor sites. Thus
ranitidine inhibits both basal gastric secretions and gastric acid secretion induced
by histamine, pentagastrin and other secretagogues. On a weight basis, ranitidine is
between 4 and 9 times more potent than cimetidine. Inhibition of gastric acid secre
tion has been observed following intravenous, intraduodenal and oral admin
istration of ranitidine and it is dose related, a maximum response being achieved at
an oral dose of 150 mg.
Pepsin secretion is also inhibited but secretion of gastric mucus is not affected.
Ranitidine does not alter the secretion of bicarbonate or enzymes from the pancreas
in response to secretin and pancreozymin.
Ranitidine is rapidly absorbed after oral administration, peak plasma concentra
tions being achieved within 2 to 3 hours. These plasma concentrations are not
significantly influenced by the presence of food in the stomach at the time of the
oral administration nor by regular doses of antacids.
Bioavailability of ranitidine administered orally is approximately 50%. Serum
protein binding of ranitidine in man is in the range of 10% to 19%. The elimina
tion half-life is approximately 3 hours. The principal route of excretion is the urine
(40% recovery of free and metabolised drug in 24 hours).
Intramuscular ranitidine is fully bioavailable in comparison to intravenous
ranitidine. The median elimination half-life of ranitidine injection 50 mg, adminis
tered intravenously or intramuscularly was found to be 140 minutes (range 120 to
160 minutes.) The half-life of ranitidine in patients with renal dysfunction is
prolonged. However, in a study of 27 patients with varying degrees of renal impair
ment therapeutic plasma levels of ranitidine were shown to be achieved without
risk of drug accumulation, using half the normal dose of ranitidine in patients with
plasma creatinine concentration greater than 300 pmols/litre.
There is a significant linear correlation between the dose administered and the
inhibitory effect upon gastric acid secretion for doses up to 150 mg orally.
A plasma ranitidine concentration of 50 ng/mL has an inhibitory effect upon stimu
lated gastric acid secretion of approximately 50%. Estimates of the ICso range from
36 to 94 ng/mL. Following the administration of 150 mg ranitidine orally, plasma
concentrations in excess of this lasted for more than 8 hours and after 12 hours the
plasma concentrations were sufficiently high to have a significant inhibitory effect
upon gastric acid secretion. In patients with duodenal ulcer, 150 mg ranitidine
given by mouth every 12 hours significantly reduced mean 24 hour hydrogen ion
activity by 69% and nocturnal gastric acid output by 90%.
Following intramuscular injection of 50 mg ranitidine, plasma concentrations
in excess of 100 ng/mL were achieved within five minutes of administration and
remained above this level for 4 to 6 hours.
Intravenous infusion of ranitidine in seriously ill patients at a rate of
0.125 mg/kg/hour produced a rise of intragastric pH between 5.6 and 7.0 after two
hours and maintained this level over the test period. The volume of gastric secre
tion was reduced by more than 55%. Doubling the infusion rate to
0.25 mg/kg/hour produced no further increases in gastric acid inhibition.
A single 50 mg intravenous bolus dose of ranitidine produced significant acid
inhibition 8 to 9 hours after administration. When 13 seriously ill patients with two
or more risk factors (shock, sepsis, respiratory failure, jaundice, renal insufficiency
and peritonitis) were treated with a 50 mg intravenous bolus dose of ranitidine
followed by a continuous infusion of 0.2 mg/kg/hour the number o f ‘at risk’ days
when gastric pH was less than 3.5 on three consecutive four-hourly aliquots, was
approximately half that for placebo treated patients.
Furthermore, in respect of both 24 hour acidity and nocturnal acid output,
ranitidine, 150 mg twice daily was superior to cimetidine 200 mg three times daily
and 400 mg at night (P <0.001 and <0.05, respectively).
Ranitidine injection is well tolerated following intravenous administration at
dose levels of up to 100 mg four times daily for ten days. These levels are in excess
of those recommended for normal clinical use.
Treatment of volunteers with ranitidine 150 mg twice daily for 7 days did not
cause bacterial overgrowth in the stomach.
Volunteers treated with ranitidine have reported no significant gastrointestinal
or central nervous system side effects; moreover, pulse rate, blood pressure, electro
cardiogram and electroencephalogram were not significantly affected in man
following ranitidine administration.
In healthy human volunteers and patients, ranitidine did not influence plasma
levels of the following hormones: cortisol, testosterone, estrogens, growth
hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating
hormone, aldosterone or gastrin - although like cimetidine, ranitidine reduced
vasopressin output. Treatment for up to 6 weeks with ranitidine 150 mg twice
daily by mouth did not affect the human hypothalamic-pituitary-testicular-ovarian
or -adrenal axes.
At 50 mg intravenously, ranitidine had no effect on prolactin levels. Only at
the 300 mg i.v. dose level was an increase in prolactin secretion, equivalent to that
produced by 200 mg of cimetidine i.v., observed.
At the high dose levels used in the tolerance studies, minor, transient increases
in serum alanine transaminase (ALT/SGPT) and aspartate transaminase
(AST/SGOT) levels were observed in some patients. No other liver function tests
were abnormal for these subjects and the cause and clinical significance of these
findings are unknown.
Laboratory studies have shown that ranitidine has negligible affinity for the
cytochrome P4So-hnked hepatic mixed function oxidase system. In man, ranitidine
treatment has been shown not to impair the metabolism of antipyrine,
aminopyrine, warfarin or diazepam.

PRECAUTIONS
Use in pregnancy and nursing mothers - The safety of Zantac in the treatment
of conditions where a controlled reduction of gastric secretion is required during
pregnancy has not been established. Reproduction studies performed in rats and
rabbits have revealed no evidence of impaired fertility or harm to the fetus due to
Zantac. I f the administration o f Zantac during pregnancy is considered to be neces
sary, its use requires that the potential benefits be weighed against possible hazards
to the patient and to the fetus. However, therapeutic doses of Zantac administered
to obstetric patients in labour or undergoing caesarean section have been without
adverse effect on labour, delivery, or subsequent neonatal progress.
Ranitidine is secreted in breast milk in lactating mothers but the clinical
significance of this has not been fully evaluated.
Use in impaired renal function - Ranitidine is excreted via the kidney and in
the presence of severe renal impairment, plasma levels o f ranitidine are increased
and prolonged. Accordingly, in the presence of severe renal impairment, clinicians
may wish to reduce the oral dose to half of the usual dose taken twice daily, simi
larly it is recommended that ranitidine injection be administered in doses of 25 mg
to patients with renal dysfunction.
Children - Experience with Zantac in children is limited and such use has not been
fully evaluated in clinical studies. It has however been used successfully in children
aged 8-18 years in doses up to 150 mg orally twice daily without adverse effect.

ADVERSE REACTIONS
No serious adverse effects have been reported to date in patients treated with
Zantac. There has been no clinically significant interference with endocrine,
gonadal or liver function, nor has the drug adversely affected the central nervous
system even in elderly patients.
The incidence of adverse events among Zantac-treated patients (8.1%) was very
little greater than that among placebo-treated patients (7.7%). Only five adverse
events, namely, tiredness (0.38%), headache (0.90%), dizziness (0.32%), diarrhea
(0.52%) and skin rashes (0.52%) had a greater incidence in the ranitidine treated
group than in the control group.
A small proportion (1.99%) of patients treated with ranitidine injection experi
enced itching or burning at the injection site. This reaction was mild and usually
subsided within 10-15 minutes.
Headache was experienced by 2.54% of patients receiving ranitidine injection.
The majority of these cases were not thought to be treatment-related. In some in
stances the headache was thought to be due to over-rapid injection of ranitidine,
and did not recur on rechallenge with slow intravenous injection. Similarly, some
patients experienced nausea after rapid injection of the drug, but on subsequent
occasions with slow-intravenous injection, experienced no ill-effects.

OVERDOSAGE
Zantac is very specific in action and accordingly no particular problems are
expected following overdosage with the drug. Symptomatic and supportive therapy
should be given as appropriate. If need be, the drug may be removed from the
plasma by haemodialysis.

DOSAGE AND ADMINISTRATION
Adults: Zantac injection may be given either as a slow (over one minute) intra
venous injection of 50 mg, which may be repeated every six to eight hours; or as an
intravenous infusion at a rate of 25 mg per hour for two hours; the infusion may be
repeated at six to eight hour intervals.
In the prophylaxis of haemorrhage from stress ulceration in seriously ill
patients or the prophylaxis of recurrent haemorrhage in patients bleeding from
peptic ulceration, parenteral administration may be continued until oral feeding
commences. Patients considered to be still at risk may then be treated with Zantac
tablets 150 mg twice daily.
In patients considered to be at risk of developing acid aspiration syndrome
Zantac injection 50 mg may be given intramuscularly or by slow intravenous injec
tion (over one minute) 45-60 minutes before induction of general anaesthesia.
Experience with Zantac in children is limited and it has not been fully eval
uated in clinical studies - see PRECAUTIONS.

AVAILABILITY
Zantac Injection is available as 2mL ampoules each containing 50 mg ranitidine
(as hydrochloride) in 2mL solution for intravenous or intramuscular administra
tion. Packages of 10 ampoules.
Zantac Tablets are available as white film-coated engraved ZANTAC 150 on
one face and GLAXO on the other containing 150 mg ranitidine (as the
hydrochloride), in packs of 28 & 56 tablets.

REFERENCES
1. Morison, David H. et al: A Double-Blind Comparison of Cimetidine and
Ranitidine as Prophylaxis Against Gastric Aspiration Syndrome, Anesthesia and
Analgesia, Vol. 61, No: 12, December 1982.
2. van Blankenstein, M. and van den Berg, B., The Prevention of Stress-Induced
U pper Gastrointestinal Bleeding by Ranitidine in Critically 111 Patients,
In: Tytgat G.N. (ed) Ranitidine, The Selective New H 2-Receptor Antagonist,
Theracom 1982, Pages 41-45.

INDICATIONS AND CLINICAL USE
Zantac injection is indicated for the treatment of duodenal ulcer, benign gastric
ulcer, post-operative ulcer, reflux esophagitis, Zollinger-Ellison syndrome and
other conditions where reduction of gastric secretion and acid output is desirable.
These include the prophylaxis of gastrointestinal haemorrhage from stress ulcera
tion in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients
with bleeding peptic ulcers and before general anaesthesia in patients considered to
be at risk of acid aspiration (Mendelson’s) syndrome, particularly obstetric patients
during labour.
For appropriate cases Zantac Tablets are also available.

THE B E T T E R ,^ ANTAGONIST.

CONTRAINDICATIONS
There are no known contraindications to the use of Zantac (Ranitidine).

WARNINGS
Gastric ulcer - Treatment with a histamine Hj-antagonist may mask symptoms
associated with carcinoma of the stomach and therefore may delay diagnosis of the
condition. Accordingly, where gastric ulcer is suspected the possibility of malig
nancy should be excluded before therapy with Zantac is instituted.
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An important
surgical tool:
Ensure*
complete nutrition
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Protein-calorie malnutrition threatens almost 50% of
hospitalized patients1. Its consequences - slow healing,
anemia, increased susceptibility to infection, wound
dehiscence - can compromise the outcome of treatment or
surgery and even jeopardize the patient’s life.
Ensure, complete nutrition for hospitalized patients
Before surgery, to help build up the patient’s strength and
immunocompetence2.
by mouth or by tube

ENSURE

After surgery, to help restore a positive nitrogen balance
and help speed recovery3.
References:
1. Bistrian BR et al. JAMA 1976; 235:15.. 2. Chandra R K e ta l. Nutrition Research 1982;2:223-232.
3. Hoover C Je tal. JPEN 1977; 14A(1).

complete liquid nutrition

Helps surgical patients
back to good health
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Total commitment to nutrition
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OBESITY SYMPOSIUM
First Canadian Symposium on the Surgical
Treatment of Morbid Obesity: Part I

v
►

J o e l B. F r e e m a n ,

► ►

m d , f r c s ic i *

1. Overview
■v

* The comments that follow reflect my
^ f notes and personal interpretations of
many fine papers presented during the
i First Canadian Symposium on the
Surgical Treatment of Morbid Obesity. In
J
particular, they summarize the consensus
forum held at the end of the symposium.
4 Conservative treatment for patients
4 who weigh more than twice their ideal
fails to achieve significant weight loss in
95% of cases. More positive claims have
been made by the multitude of diet clinics
p, that have mushroomed in recent years but
few, if any, of these clinics provide 2-year
r
follow-up data proving sustained weight
loss. The reasons for the persistence of
»- morbid obesity remain unclear but are un
doubtedly multifactorial. Some patients
r ' clearly overeat whereas others may have
reduced energy expenditure permitting
l
’
easy weight gain on low caloric intake.
L Metabolic studies of cultured adipocytes
f
suggest that cells from obese patients
I t behave differently than do cells from lean
patients. Similarly, patients who are ap> *■parently lean despite massive energy in
takes may have an increased ability to
r
“ burn off” energy — the reverse of the
situation found in obesity,
r
The causes, and thus the ideal treat4 ment, of obesity remain obscure and this
fact accounts for the introduction of
f *■surgical procedures more than two de
cades ago. The surgical history of mor• bid obesity encompasses at least four ma-

r

The symposium was supported by grants
fro m the Department o f National Health
and Welfare, Government o f Canada, and
by Autosuture Corporation o f Canada Ltd.

v y
\

l

*Chief, Division o f General Surgery,
Ottawa General Hospital. Professor o f
Surgery, University o f Ottawa, Ottawa,
Ont.

Reprints o f all papers and abstracts from
the symposium published in the Journal
may be obtained by writing to: Dr. J.B.
> ► Freeman, Chief, Division o f General
Surgery, Ottawa General Hospital, 501
Smyth R d., Ottawa, Ont. K 1H 8L6
y

Papers and abstracts for the First Canadian
Symposium on the Surgical Treatment of
Morbid Obesity were edited by Joel B.
Freeman, MD, FRCS[C].

jor procedures: jejunocolic bypass, which
failed miserably due to severe side-effects;
jejunoileal bypass, which lasted a decade
but eventually was abandoned by all but
a few, again because of metabolic sideeffects; gastric bypass, which has evolv
ed through a number of technical varia
tions and, in its Roux-en-Y form, is the
most effective gastric partitioning pro
cedure today; and many variations of gas
troplasty, an operation that is in a cons
tant state of evolution and shares equal

popularity with Roux-en-Y gastric by
pass. The Roux-en-Y gastric bypass,
although providing the best weight loss
and having the best prospective data re
ported in the literature, is technically a
more difficult procedure; it is not current
ly being performed by its inventor, P ro
fessor Mason. Gastroplasty is a less difficult
operation yet, surprisingly, surgical com
plications persist probably due to the
devascularization that is necessary in
some forms of the procedure. Further
more, gastroplasty, despite its technical
ease, is associated with a very high failure
rate. The transverse or horizontal
gastroplasty had been abandoned by
almost all members of our symposium.
Metabolic complications of all forms
of gastric partitioning are uncommon, in
contrast to the jejunoileal bypass.
However, thiamine deficiency which pro
duces in rare instances an irreversible
neurologic deficit was emphasized by
several surgeons. Our consensus forum
reported a very low mortality (less than
1%) but internationally this varies from
0% to 4%. The reoperation rate was 10%
to 20% with leaks occurring in 2% to
10% o f patients. Because the failure rate
of horizontal gastric partitioning is unac
ceptably high, practically all of those at
the symposium who did not perform
gastric bypass had switched to the vertical
banded type o f gastroplasty. The techni
que used for the latter operation is similar
to that described by Mason, although
several surgeons had switched from
Marlex to Prolene mesh and had reduc
ed the external diameter of the stoma
from 50 to 45 or even 40 mm. Despite the
apparent simplicity of this procedure,
leaks do occur. Several surgeons em
phasized the im portance o f using
methylene blue or air insufflation with the
staple line under water to diagnose leaks
intraoperatively.
Except for two or three surgeons who
still believe in jejunoileal bypass, all those
present had switched to either a gastric
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bypass with a Roux-en-Y anastomosis or
the vertical banded type of gastroplasty.
It was accepted that superheavyweight pa
tients might still be candidates for je
junoileal bypass because, even with
gastric bypass, maximum weight loss
seldom exceeds 40% of initial body
weight and is usually closer to 35% 2
years postoperatively.
Concern was expressed regarding
methods of reporting bariatric surgical
data in the literature and a number of sug
gestions were made. The most important
was that all surgeons should use similar
methods for reporting data and that these
methods be followed by journal editors.
Weight loss should be expressed as
percentage o f weight lost and not mean
kilograms lost. Failure should be defin
ed. We suggested that any patient who
had lost less than 25% of preoperative
weight 2 years after operation or required
a revision or was lost to follow-up was a
failure. Such failures should be in
dividually listed. Otherwise, an erroneous
impression can be created. For example,
one could report that of 10 patients
treated, 5 lost no weight and 5 lost 50 kg
each for a total weight loss of 250 kg, the

average weight loss being 25 kg per pa
tient while the failure rate would also be
50%! Other important questions regard
ing data interpretation included length of
follow-up, number of patients followed
up and lost, patients grouped according
to results as “ excellent” (30% weight loss
or over), “ good” (25% to 29% weight
loss) and “ poor” (under 25% weight
loss), a clear statement of major morbidi
ty and mortality for the total experience
in a centre and some assessment of life
style in those patients whose operation is
“ successful” (e.g., the miserable patient
who vomits continually despite having at
tained a good weight loss).
A national obesity registry form was
also considered and such a form was
designed by John Davies and his staff
from Statistics Canada. Ultimately, those
who attended the symposium decided that
the final form (Fig. 1) should be as sim
ple as possible to ensure compliance from
all surgeons who might participate in a
national registry. Hence, although many
readers may justifiably find fault with this
form, it must be understood that our
prime purpose is to acquire and ac
cumulate long-term data from each Cana

dian centre in order to ascertain the ac
tual results of surgery and properly to
assess long-term complications.
Stimulated by Professor White’s ex
cellent lecture and his many pertinent A
comments during the symposium, we all
left with a concern about the true A
deleterious effects of obesity on health.
They do not seem to be as clearlyestablished as we initially believed. Fur
thermore, the effects of weight loss after
operation on longevity were even less
clearly established. We all agreed that it
was certainly beneficial to lose weight
with respect to hypertension, diabetes, ab
A
normal lipids, arthritis and psychosocial
life-style. In addition, the short-term
(2-year) weight loss after operation is cer r
tainly better than that obtained with con
r
servative treatment but there seems to be
a serious paucity of 5-year follow-up data
•«
after surgery. The innumerable technical
variations, particularly in gastroplasty, ■« A
the absence of a national registry and the
large numbers of patients lost to follow
up have contributed to this lack of data
and stimulated all of us to join efforts in
establishing a national obesity surgical
k
registry.
A 1

F r a n k l in M .M . W h it e , m d , c m , m s c , f r c p ic ]; L in d a H. P e r e ir a , ba
A

2. Obesity: Epidemiology and the Problem of Measurement
Obesity is a condition in which there is
a surplus of body fat. Subgroups may dif
fer with regard to etiology, morbidity,
mortality and therapeutic response. A
person whose excess weight has a negative
impact on health or function may be
termed obese. A simple, accurate and
reliable measure of obesity has not yet
been found.
Measurement
The first attempt to assess obesity was
made by the medico-actuarial investiga
tions of 1912. The Society of Actuaries
Build Study examined the relation be
tween weight and mortality in 1959 and
1979. Mean weights by sex and by height
From the Department o f Community
Health and Epidemiology, Faculty o f
Medicine, Dalhousie University, Halifax,
NS
Reprint requests to: Dr. F.M.M. White,
Department o f Community Health and
Epidemiology, Dalhousie University, 5849
University Ave., Halifax, NS B3H 4H7
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were calculated for seven age groups of
insured people from 15 to 69 years.1
Those 20% or more above average weight
were identified as obese. Over the past 30
years several surveys, using a variety of
methods, have attempted to determine the
prevalence of obesity (Table I1-8).
In the light of the 1959 Build-Study
finding that mortality increases with
weight, the Metropolitan Life Insurance
Company inferred that weight gain with
age should not be considered normal.9
The British Medical Research Council
recently concurred, since relative weight
is associated with systolic blood pressure
and serum cholesterol and uric acid
levels.5 Metropolitan Life devised ideal
weight ranges based on mortality for 15
categories of height and 3 categories of
body frame, in those aged 25 years and
over. Recently revised tables are based on
the 1979 Build Study. Acceptable weight
ranges have been increased by 1% to 13%
in different height and sex groups.10
The Framingham Study3 used the 1959
Metropolitan Life tables to calculate a
relative weight index. The 1971 to 1974

United States Health and Nutrition Ex
amination Survey (HANES)11 derived ^
ideal weights from a regression of weight
on height for men and nonpregnant < f
women 20 to 29 years of age. Prevalence
rates using ideal weights, as expected,
4
showed higher rates of obesity in older
age groups than those based on excess
4
weight above the age group mean (Table
!
1).

Both concepts of relative weight have
flaws. One should not assume that an in
dividual can be judged by the mean
weight of a group. Furthermore, results
of population surveys are difficult to
compare when different standards (each
population mean) are used. Standards
based on insured individuals should not
be generalized to the general population.
Likewise, ideal weights for those aged 20
to 29 years may not be ideal for health
in later life.
In view of these inadequacies, HANES
utilized the body mass index (BMI =
W /H p, where W = weight in kilograms,
H = height in metres, and p = 2 for men
and 1.5 for women),11 a continuous scale
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suitable for population studies. (A value
of 30 has been suggested to identify the
obese,12 based on analysis of mortality
from insurance data.) The Nutrition
Canada survey7 used the ponderal index
(PI = H/Zl W, where H = height in inches and W = weight in pounds. An in
dex of 11.6 or less defined obesity. All
* three versions of this index (strongly cor
related with height) are poor indicators
of overweight.13
All measurements based on height and
weight are calculations of excess weight,
not excess fat. The proportions of body
weight as fat commonly accepted as nor,.mal are 15% to 20% for men and 20%
to 25% for women.14 Obesity has been
defined as fat content above 25% for men
and above 30% for women.12
Direct m easurem ent o f skinfold
thickness may be a more valid indicator
► than weight, despite variability among instruments (calipers) and observers, and a
lack of consensus on which skinfolds to
m easure.15 The triceps skinfold is
sometimes the only one measured, but ad
ditional measurements (biceps, subscap
ular, suprailiac) provide more reliable
4 assessment of persons with abnormal fat
distribution.
4 Skinfolds at multiple sites are usually
measured to create a single index, but
could also describe different body types.
Durnin and Womersley16 estimated the
fat portion of body weight for different
values of the sum of four skinfold
measurements. The proportion of body
► fat situated subcutaneously varied with
age and sex, and a larger proportion was
f situated internally in women and those in
older age groups. Large increases in skin
fold thickness in each age-sex category
were associated with small changes in
body density. Therefore, with increasing
^ obesity, larger proportions o f total body
fat are accumulated subcutaneously.
* Most recent surveys use several indices.
The HANES included height, weight, two
skinfolds, upper arm girth and two
breadth measurements.17 Triceps and
subscapular skinfolds were added to
define as severely obese, persons aged 20
^ to 29 years who exceeded the 95th percenv tile (men more than 51 mm; nonpregnant
women more than 70 m m ).11 Thus,
4.9% of men and 7.2% of women were
severely obese.
Health and Welfare Canada conducted
a national survey in 1957.6 Those above
r the 60th percentile in weight in each agesex category and also above the 75th
percentile in triceps skinfold measure
ments (men more than 9 mm, women
more than 16 mm) were defined as obese
(Table I). Although these percentiles ap
pear arbitrary, the notion of using both
A- measurements to provide categories of
body types has interesting possibilities.
*
Various weight and skinfold measure
ments have been com pared with

cern about excess weight and mortality.
Framingham data have since been com 
pared, using the same definitions.20 M or
tality was lower for the insured popula
tion than for the Framingham group,
which had a lower mortality than
reported US rates. Compared with the
steady increase in mortality for men and
women in the Build Study, increasing
weight among men in the Framingham
Study was associated with decreasing
mortality; among women, mortality was
highest for both leanest and heaviest.
Multivariate analysis of Framingham data
(overall and cardiovascular death rates)
has shown the inverse relation for men to
be statistically significant.21 In a Swedish
study of 1462 middle-aged women follow
ed up for 10 years, a statistically signifi
cant negative relation was shown between
overall death rate and skinfold measure
ments.22
The seven countries study23 followed
male cohorts initially aged 40 to 59 years
from America, Finland, Japan and nor
thern and southern Europe for 10 years.
A significant relation between BMI (body
mass index) and mortality from all causes
was found for southern Europeans and
Americans. When adjusted for age,
systolic blood pressure, serum cholesterol
level, smoking and pulse rate, the relation
between weight and mortality was cur
vilinear. Death rates were highest among
the leanest men, but were also high
among the heaviest. Men somewhat
above average relative weight had the
lowest mortality. Similar analysis o f cor
onary deaths revealed no significant con
tribution by weight.

laboratory techniques for assessing body
fat, based on measurements of body den
sity, water or potassium. Density, the
most commonly used measurement, is
usually derived from underwater weighing
and assumes that density of lean body
mass is constant. However, as propor
tions and density of bone vary, this
method is also subject to erro r.16
Womersley and Durnin18 evaluated
relative weight, body mass and skinfold
measurements against body density. Skin
fold measurements were superior to
height-weight indices for men and
younger women, but height-weight in
dices were equally good and sometimes
better for women aged 30 to 49 years.
These investigators also compared19 limb
circumferences, height-weight indices and
skinfold measurements with density, and
found in younger men and older women
that “ the use of several variables rather
than skinfold thickness alone brings
about a significant increase in the ac
curacy of predictions of body density” ,
although the particular selection of
variables may not be appropriate for dif
ferent populations.
The 1978 Canada Health Survey and
the 1980 Canada Fitness Survey, which
collected height, weight and triceps skin
fold measurements, should permit further
examination of relationships. Desirable
weight standards for Canadians, based on
these national samples, should be
constructed.
Mortality and Morbidity
The 1959 Build Study generated con

T ab le 1--Surveys of Obesity P revalence
Prevalence, %
Study
S ociety of A ctuaries and A ssociation
o f Life Insurance M edical D irectors
of America1 (Build Study, 1 9 5 4 - 7 2 )
Lew and G arfinkelz (Am erican Cancer
Society, 1 9 5 9 - 7 2 )
Kannel and Gordon3 (Fram ingham
study, 1 9 4 8 - 9 )
US H ealth and N utrition
Examination Survey, 1 9 7 1 - 4 (Bray4)
M edical Research Council (UK,
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The Chicago Peoples Gas Company
Study24 evaluated the BMI against the
14-year mortality in 1233 men aged 40 to
59 years, including in the analysis age,
systolic blood pressure, serum cholesterol
level and cigarette smoking. Significant
quadratic (U-shaped) relations were
found between the BMI and all causes of
death, cardiovascular renal death and cor
onary disease death. Mortality was lowest
among men 25% to 35% over the
Metropolitan Life ideal weight. Men at
highest risk were either near the
Metropolitan ideal weight or more than
50% above it. Drenick and associates25
reported that mortality of a group of 200
morbidly obese men (50% to 200% above
ideal weight), who voluntarily attended
the US Veterans’ Administration weight
control clinic, was 12 and 6 times, respec
tively, that o f the US men aged 25 to 34
and 35 to 44 years. However, the selfselected nature of this series renders
generalization questionable.
Obesity m ay c o n trib u te to the
pathogenesis of cardiovascular disease,
Pickwickian syndrome, diabetes, gout,
osteoarthritis, cholelithiasis, endometrial
cancer and psychosocial dysfunction.26
Although there is little dispute about the
increased risk of maturity onset diabetes,
gallstones and arthritis among the obese,
considerable debate surrounds the role of
excessive weight in cardiovascular disease.
Inconsistencies from different studies
may be attributed to differences in
diagnostic criteria, weight indices, age
groups observed, choice of population,
length of follow-up, statistical methods
and interpretation.
The Framingham Study21 of 5127 ran
domly selected men and women, initially
aged 30 to 62 years and followed up for
18 years, is frequently cited. Car
diovascular end points considered were
congestive heart failure, atherothrombotic brain infarction, interm ittent
claudication and coronary heart disease
(including angina pectoris, myocardial in
farction, coronary insufficiency and sud
den death). If no adjustment is made for
other factors, a statistical relationship is
evident between relative weight and
angina in men, congestive heart failure,
stroke and angina in women. After ad
justment for systolic blood pressure,
serum cholesterol level, cigarette smok
ing, glucose intolerance and electrocar
diographic left ventricular hypertrophy,
weight contributes only to angina in men
and to congestive heart failure in women.
In the seven countries study,23 neither
the BMI nor skinfold measurements were
significantly related to the incidence of all
coronary heart disease events in Italy, the
Netherlands and Serbia, and only to
angina in the US and Croatia. When
other factors were analysed, serum
cholesterol level and systolic blood
122

pressure emerged as important risk fac
tors, but weight had no independent ef
fect on any coronary events.
The Manitoba Study27 offers a rare
opportunity to examine the effects of
weight on coronary heart disease in
younger age groups. In 1948, 3983 pilots
(3055 under 35 years of age) were follow
ed up for 26 years. The relation between
BMI and myocardial infarction, angina
pectoris, coronary insufficiency and sud
den death was assessed by multiple
logistic analysis. The only other factors
included were age and blood pressure.
(The absence o f serum cholesterol levels
and mention o f smoking habits weakens
this analysis.) The BMI was significantly
(p < 0.05) related to sudden death in men
up to age 39 years after 16 years of obser
vation. Weight was significantly (p <
0.05) related to myocardial infarction on
ly when associated with sudden death in
men under 35 years of age after more than
20 years of follow-up.
The relatively greater risk of obese men
under 40 years of age, apparent from the
Manitoba Study, is consistent with the
1979 Build Study,1 which compared men
15 to 39 years of age with men 40 to 69
years at increasing levels of excess weight.
In the Build Study, mortality ratios were
similar for those up to 45% overweight
in the two age groups. For those 45% to
55% overweight aged 15 to 39 years, the
ratio of actual to expected mortality was
198% compared with 131% for the 40to 69-year age group. Those 55% to 65%
overweight aged 15 to 39 years also had
a ratio of 198% compared with 140% for
the 40- to 69-year age group.
Metabolic Complications of Obesity
Despite equivocal evidence from
epidemiologic studies of obesity and car
diovascular disease, known coronary risk
factors have been described as metabolic
complications of obesity, although their
relation to relative weight appears to be
weak.
Sims and colleagues28 reported out
comes for 19 volunteer men who increas
ed caloric intake to gain 21% above their
basal w eight. Increases in blood
cholesterol, triglyceride, glucose and in
sulin levels, and a decrease in glucose
tolerance were observed. Except for
cholesterol, all changes were statistically
significant. In a review of recent research
into the mechanisms of hypertension in
overweight patients, Sims29 points out
that middle-aged hypertensive people tend
to have hyperinsulinemia and glucose in
tolerance and therefore some degree of in
sulin resistance, and that this combina
tion is more common in those with hyper
trophic adult-onset obesity and a central
distribution o f fat. He suggests that the
hyperinsulinemia may contribute to
sodium retention and hypertension. Many

studies document a decline in blood
pressure with weight decrease.3,30 It has
been suggested th at weight gain
precipitates hypertension in those with a
genetic predisposition.31
^
Correlations between relative weight
and various cardiovascular risk factors ^
have been reported from the Framingham
Study.32 For men, the correlation coeffi-4 A
cient with serum cholesterol ranged from
-0 .0 2 to 0.22 in different age groups.
■*
For women, the range was - 0.01 to 0.19.
Noppa and associates33 reported a cor- A
relation of 0.11 among middle-aged
women, and Keys23 reported a mean cor
relation of 0.199 for men aged 40 to 59., ^
years. By squaring this coefficient of
0.199, we find only 4% of the variation
{
in cholesterol in the seven countries study
accounted for by the BMI.
^
Relative weight accounted for no more
than 2.6% o f variation in the blood '1
glucose level in any age-sex group in the 4 f
Framingham Study.32 Correlation be;!
tween relative weight and uric acid levels
*.
was higher — between 0.19 and 0.44. Of
greatest interest is hypertension. Correiav
tions from the Framingham Study32 for
systolic blood pressure ranged from 0.18 >
to 0.31 for men (r2 = 3.2% to 9.6%)
.
and 0.23 to 0.42 for women (r2 = 5.3%
to 17.6%). Noppa and colleagues33
i
reported a correlation of 0.27 for all age
j
categories while Keys23 reported a co- ^
efficient of 0.21.
T

Towards a Classification
Unfortunately, a specific cause of
obesity is identified in only about 5% of
cases,14 reflecting lack of fundamental
!
knowledge. Classification is an important
^
goal if we are to judge the prognosis and
j
define the roles of prevention and
1
therapy.
Obesity can be characterized by fat-cell *
enlargement (hypertrophy) or prolifera- 4 4
tion (hyperplasia), or both. Hypertrophy
is associated with increased blood
<
pressure, impaired glucose tolerance and
hyperinsulinem ia.34 Hyperplasia is
<
associated with early age of onset.35
Positive correlation has also been 4
shown36 between the amount of body fat
and fat-cell numbers irrespective of age
of onset, suggesting that whenever
adipose cells reach a maximum size, cell
division is triggered. Genetic factors are
(
not yet understood.
]
Excess fat in men is usually concen- -«
trated centrally, whereas in women either
i
the central or lower portions (hips, thighs) ’
are affected. Kissebah and associates37
*
studied women with both types of obesi
ty and nonobese control subjects. Obese u
women with the excess fat in the upper
body had enlarged abdominal fat cells, _4
while fat in the thighs of obese women
with excess fat in the lower body contain- * 4
ed normal cells. Abdominal cell hyper-
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trophy was associated with hyper
triglyceridemia, hyperinsulinemia and
glucose intolerance. The cell size of fat
in the thighs was not associated with
metabolic complications. Data from the
>
HANES support Kissebah’s findings. The
subscapular measurement (an appropriate
*
indicator of central fat), was significant
l y related to systolic blood pressure,
diabetes and hypercholesterolemia,
►
whereas the triceps measurement was
not.15 In the Framingham study, cor
onary heart disease correlated with sub
► scapular but not triceps measurements.38
At this stage, the following may con
trib u te to a classification:15 (a) weight
►
distribution (central or peripheral); (b)
size and number of adipocytes; (c) en
docrine or metabolic disorders; (d) age at
*
onset and (e) magnitude of excess weight.
Other factors that should be elucidated
further are caloric intake, diet composi
V t i o n , eating patterns, history of weight
I
gain, family history, personality, activi
ty and response to weight reduction
programs.

►

p

!►

J

Conclusions

4

Measurement of obesity in populations
-i serves several purposes: (a) to evaluate the
role of body fat in disease and death; (b)
to determine the proportion of those
whose health is at risk and who may re
► quire intervention; and (c) to assist in
classifying various subgroups.
Y
Although various height-weight indices
1
are highly correlated, skinfold and
weight measurements are not. Only
►50% to 60% of variation in skinfold
measurements can be accounted for by a
weight index. There is evidence that fat
comprising enlarged cells located centrally
► may be more hazardous than hypercellularity in the extremities so that skinfold
»■
measurements may be necessary to detery mine variations in health for different
r
types of obesity.
Population surveys of obesity so far
►
have defined this condition as a statistical
► phenomenon. More appropriate weight
standards are required, based on a
► representative sample of the population,
y taking into account emerging knowledge
►
about the lifetime role of fat.
t
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3. Is Obesity Due to a Defective Sodium Pump?
It is commonly known that most obese
patients do not have an endocrine
derangement such as hypothyroidism or
Cushing’s syndrome to account for their
excess weight. It has also been observed
that food intake is not always higher in
obese than in lean people.1'3 It is increas
ingly recognized (perhaps not widely
enough) that excessive food intake is not
the only basis of obesity. These observa
tions have prompted researchers to look
for a metabolic cause for the condition.
It must be assumed that the problem
is one of energy balance. For excessive in
crease in adipose tissue to occur, caloric
intake must be greater than expenditure.
Since many obese people do not eat ex
cessively, by conventional standards, at
tention has rightly been focused on a
possible defect in the regulation of energy
expenditure. To study this, workers have
recently investigated the ubiquitous
sodium pump, which transports sodium
out of cells and potassium into cells. The
energy required for this activity may be
responsible for 20% to 50% of total
cellular thermogenesis. Any decrease in
activity of the sodium pump could
therefore result in an important decrease
in energy expenditure.
Interest in this area was initiated by the
demonstration that levels of sodiumpotassium-ATPase (the enzyme of the
sodium pump) were reduced in the
muscle4 and liver5 of the genetically
obese (ob/ob) mouse. In 1980, De Luise
and colleagues6 reported that erythro
cytes of obese people had fewer sodiumpotassium pump units than those of
nonobese controls, as measured by the
ouabain-binding assay; reduced cationtransport activity of the pump, as
measured by the uptake of rubidium 86
in the cells, and increased concentration

of sodium inside the erythrocytes of obese standard deviation, p < 0.05). It was also
subjects supported their finding. This higher in the previously obese group than
study suggested that a defective sodium in the controls (862 ± 276 v. 372 ± 162
pump might play a role in the mmol/h-kg-1, p < 0.05). There was no
pathogenesis of obesity. The findings in difference between the obese and
this study were later confirmed by Beutler previously obese groups. When the cells -»
and colleagues,7 using the same were cultured in fetal calf serum, no dif
measurements of sodium-pump activity. ference was noted between any of the
Klimes and associates8 also showed three groups.
reduced activity in the sodium pump of
There was no significant difference in
erythrocytes from obese Pima Indians. intracellular sodium and potassium be
However, contrary results have also been tween any of the three groups, under both
reported. Bray and associates9 culture conditions.
demonstrated higher sodium-potassiumWe cannot explain the difference in
ATPase activity in liver tissue of six obese sodium influx results between the two
subjects than in three nonobese controls. culture conditions. Our preliminary
Mir and colleagues10 found erythrocyte results using bobby calf serum point to
sodium-potassium-ATPase activity and increased sodium-pump activity in cells
ouabain-inhibitable sodium efflux from from obese subjects. This is contrary to
erythrocytes to be higher in obese than in the expectation that obesity results from
thin subjects. In two recent studies on reduced energy expenditure through
animal cells, no significant difference in reduced sodium transport activity. It is,
sodium-potassium-ATPase levels was however, interesting that a difference may
noted in muscles from lean and obese exist between cells from obese and lean
mice11 and in preadipocyte cell lines subjects and particularly that the dif
from genetically obese and nonobese ference is still present after significant
mice.12
weight loss. The change in sodium-pump
In the past year, we have studied the activity is therefore not secondary but
sodium pump in cultured human possibly primary to the obesity.
preadipocytes obtained from three groups
The role of a defective sodium pump
of subjects — lean (three subjects, mean in human obesity is still not clear. The
weight 55.3 kg), obese (three subjects, conflicting results obtained by various
mean weight 105.3 kg) and previously groups may result from differences in
obese (four patients after gastroplasty, methods or the type of tissue studied since
mean weight before operation 122.8 kg, there is no reason why different body
and after 61.7 kg). The cells were tissues should behave in the same way
prepared and cultured as previously with regard to the sodium pump. The
described,13 using either 10% fetal calf matter is obviously becoming more com
serum or bobby calf serum. Since the plex. Further research may assign little or
main determinant of sodium transport no role to the sodium pump, but work
out of cells is sodium influx, this was generated by an interest in it will no doubt
measured using radioactive sodium open new avenues of thinking about the
chloride (22Na) as previously described.14 metabolic basis of obesity.
Intracellular sodium and potassium were
also measured by flame photometry. As
more subjects are being recruited for the References
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4. Impaired Thermogenesis and Brown Fat in Obesity
>
4 The expenditure of energy to produce small lipid droplets), as opposed to the
heat (thermogenesis) in brown fat (brown unilocular white adipose tissue cells
"'adipose tissue) has been recognized only (single large lipid droplet), but may be
in the last 5 years as an important com unilocular when they are metabolically in
ponent of overall energy expenditure and active. They usually-contain many large
y thus important in regulating energy mitochondria, which are unique in that
balance. Variations of thermogenesis in they possess a controllable proton leakage
t brown fat can serve to buffer changes in mechanism, allowing them to become
energy intake in laboratory rodents. reversibly uncoupled when the cell is
► Defective thermogenesis in brown fat has stimulated by norepinephrine and thus to
been shown to underlie the high metabolic produce heat at a maximum rate.
In two types of hyperphagic but lean
' ^efficiency and obesity of a number of dif
animals, thermogenesis in brown fat has
ferent types of obese animal.
^
Brown fat is diffusely distributed in the been demonstrated to account for 10%
body in contrast to white adipose tissue. to 40% of the food ingested. The hyper
’ Whereas the function of white adipose phagic and hypermetabolic coldy. tissue (the storage of excess energy acclimatized rat (one living at 4°C for 2
reserves) is controlled primarily by cir- weeks or more) burns up to 40% of its
r *culating factors (insulin, epinephrine), the elevated food intake in its hypertrophied
thermogenic function of brown fat is con- brown fat to m aintain its body
► trolled by the direct sympathetic innerva temperature in the cold. The cafeteria-fed
tion of its cells. Two major stimuli that rat (one induced to overeat by offering
^ activate the sympathetic nervous system, it a varied and palatable diet) can burn
y eating and exposure to cold, stimulate up to 10% of its elevated food intake for
thermogenesis in brown fat. Brown fat thermogenesis in brown fat, thus becom
► >cells are usually multilocular (several in g less obese than expected from the ex
cess energy intake.
In five types of obese animal, defective
brown-fat thermogenesis is associated
From the Department o f Biochemistry,
r University o f Ottawa, Ottawa, Ont.
with the development of obesity. In two
of these (ob/ob and db/db mice, which
► Correspondence to: Dr. J. Himms-Hagen,
are genetically obese) the brown fat
Department o f Biochemistry, Ottawa
appears to be refractory to norepine
r-~ Oeneral Hospital, 451 Smyth Rd., Ottawa,
' Ont. K1H 8M5
phrine and thermogenesis is switched on

neither by cold nor by diet. In the other
three types — the genetically obese fa/fa
rat, and the gold-thioglucose-obese mouse
and the rat with a ventromedial hypothal
amic lesion (obesity in the last two being
due to hypothalamic causes) — the defect
in brown-fat thermogenesis appears to be
a central one. In these animals, diet fails
to activate thermogenesis whereas coldinduced thermogenesis occurs normally.
The extent to which the concept of
brown-fat thermogenesis as an energy
buffer applies to man is uncertain. In
human subjects, both sympathetic ner
vous activity and metabolic rate increase
with exposure to cold or eating and
decrease at thermoneutrality or fasting,
just as they do in laboratory animals.
However, the destructive methods that
have been used to quantitate the contribu
tion of brown-fat thermogenesis to
overall energy expenditure in animals are
not applicable to humans and it is not
possible at present to ascertain the quan
titative importance of brown-fat ther
mogenesis in man. Some differences bet
ween obese and lean human subjects in
their capacity to respond to administered
norepinephrine or to food by an increase
in thermogenesis have been detected.
More work is needed, however, to find
out whether the different types of defect
found in laboratory animals have their
counterpart in humans.

t

>

►r
VOLUME 27, NO. 2, MARCH 1984 / THE CANADIAN JOURNAL OF SURGERY

125

Lloyd D. Mac Lean , md, ph d , frcs[cj; Barbara M. Rhode, p dt , m sc(nutr)

<
4 A

5. The History of Surgery for Morbid Obesity
Operative treatment of morbid obesity is
based on the dual premise that this degree
of obesity is life-threatening and that
there is no suitable nonoperative treat
ment. The first surgical attempt to con
trol morbid obesity was made by
Henrikson1 of Sweden who resected a
large portion of the small intestine in two
obese patients with an early favourable
response. Since 1952, more than 450
reports have appeared on 10 500 patients
who underwent intestinal bypass and on
more than 5000 patients who underwent
gastric operations designed to limit
intake.
Intestinal Bypass

In 1954, Kremen and associates2
reported that a large portion of the small
intestine might be bypassed successfully
and still provide the opportunity to
restore normal gastrointestinal continui
ty, if necessary, at a later date. These
authors found that if 50% of the prox
imal small bowel was removed from cir
cuit in animals, it made no difference
whether the ileocecal valve was retained.
If the distal 50% was bypassed, the
animals lost weight, and if the bowel was
restored into circuit, they regained the
weight. In animals with progressive
weight loss, placement of the ileocecal
valve in circuit helped stabilize the weight,
even though 50% of the distal small
bowel was bypassed.
In 1963, Payne and associates3
reported the first jejunocolic shunt.
Although the initial results suggested
minimal complications, this operation
was discontinued only 6 years later
because of intractable diarrhea, elec
trolyte depletion and liver failure. This led
to various other forms of jejunoileal
bypass, which can be divided into two
types, depending on the type o f
anastomosis between the proximal je
junum and distal ileum.
In the end-to-side operation,4 35 cm of
From the Department o f Surgery, Royal
Victoria Hospital, McGill University, Mon
treal, PQ
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jejunum was anastomosed to 10 cm of il
eum. The bypassed small bowel was
drained into the cecum, or transverse or
sigmoid colon. A modification of the endto-side operation5 included an anasto
mosis of the gallbladder to the proximal
end of the bypassed loop to reduce diar
rhea.
With the end-to-end procedure,6 30 cm
of jejunum was anastomosed to either
15, 20 or 30 cm of ileum.
A more recent modification is the
biliary pancreatic bypass that consists of
partial gastrectomy and closure of the
duodenal stump. The jejunum is then
transected 20 cm distal to the ligament of
Treitz and a gastrojejunostomy is per
formed using the distal part of a Roux
loop. The proximal jejunum is then an
astomosed to the distal ileum. This
anatomic arrangement causes malabsorp
tion of fat and carbohydrate, leaving the
enterohepatic bile circulation intact.
There is approximately 35% weight loss
at 12 months, with no late complications
such as stomal ulcer, which might be
expected.7
Complications
Intestinal bypass is associated with
several problems. Weight loss cannot be
predicted. Comparisons of reports are
difficult to make because the technique
and follow-up vary. Bowel adaptation oc
curs to varying degrees and can account
for subsequent weight gain. There is
lengthening of the bowel in circuit, as well
as an increase in width and in villus
height.
Centrilobular fibrosis of the liver or
frank cirrhosis are the most serious
postoperative problems, most severe at 6
to 12 months after the operation, coin
ciding in time with maximal weight loss.
Our own studies suggest that liver failure
is nutritionally provoked.8 Lifethreatening liver failure is frequently seen
with a contraction of body cell mass. This
can be corrected by providing a protein
supplement intravenously. Liver failure
has accounted for at least one third of the
reoperations for complications of in
testinal bypass.
Bone disease occurs in many patients.

In histologically proven bone disease, thC 4
level of plasma 25-hydroxy vitamin D3 is
low and the plasma parathyroid hor- *
mone value is elevated. Alterations in
vitamin-D metabolism are due to malab- ^
sorption, steatorrhea, liver disease and the ^
blind-loop syndrome. Characteristic
histologic changes include osteopenia and* *
excessive osteoid formation. Vitamin D
■
might prevent these complications. Other K
troublesom e com plications include
arthromyalgia, found in at least 20% of ^
patients within 3 years of jejunoileal y
bypass; urinary calculi affect up to one
}
third of patients and biliary calculi are,, t
found increasingly after bypass
operations.
Intestinal complications include in
tussusception, bypass enteropathy, in- <
testinal pneumotosis, pseudo-obstruction
and transmural ileocolitis. These com- T
plications are more common with the endto-end than with the end-to-side operation and may relate to the fact that the, .
bypassed segment is contaminated from
the colon. This is associated with partial ^
obstruction or twisting at the anastomosis
of the small intestine to the colon.
\
Intestinal bypass has been abandoned
by most surgeons interested in bariatric 1
surgery because of the complications and
unpredictable weight losses.
Gastroplasty

Gastric procedures to control morbid *
obesity were developed and first reported ^
by Mason and Ito in 1967.9 Several types
have been used since then. The originals .
idea was to bypass 90% of the stomach
with division of the upper and lower 1
pouches with a retrocolic short afferentloop gastrojejunostomy. This operation
'
is difficult in morbidly obese patients. It
led to complications and an appreciable
m ortality. An antecolic gastroje-^ A
junostomy was suggested by Alden.10
Gastric bypass with stapling of the ,
stomach and Roux-en-Y gastrojeju>
nostomy has been the operation of choice c
of Griffen and associates.11 All agree
that a 50-ml gastric pouch, a measured A
outlet of 10 to 12 mm, with a secure par
tition, are three necessary conditions for"* ^
success.
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In gastroplasty, the stomach was divid
ed from the lesser towards the greater cur
vature and a greater curvature channel
"*■ combined with a small upper gastric
pouch was intended to decrease oral int take. Mason’s operation was not initial^ ly successful because of the size of the
channel. Newer forms of gastroplasty are
t i>still being evaluated. These include gastric
partitioning with the removal of staples
*- from the TA-90 or TA-55 stapling devices
to leave a small channel, which can be
*- reinforced with a nonabsorbable suture
passing circumferentially about the chan^ nel, with Teflon pledgets or with Marlex
k jnesh to prevent enlargement of the
stoma. In some operations, a direct
^ anastomosis is made between the upper
and lower gastric pouches after partitiony ing. This anastomosis can be encircled
with silicone tubing to prevent
► enlargement.
I
More recently, Mason12 has suggested
I f the vertical banded gastroplasty. In this
i x operation, a channel is made with an EEA
circular stapler through both walls of the
j
stomach adjacent to a Maloney bougie
lying along the lesser curvature. A
i small vertical gastric pouch can then be
made above this by placing two rows of
1 •*staples parallel to the lesser curvature ad
jacent to the Maloney bougie and to the
left side of the esophagus. The orifice
.
from the pouch is reinforced with Marlex
^ mesh.
t
The vertical banded gastroplasty and
Roux-en-Y gastric bypass are the two
y operations that have gained greatest
favour for controlling obesity. It seems
r

clear that any form of gastroplasty re
quires external support to prevent
enlargement and subsequent weight gain.
It is now obvious that nonabsorbable
material when sutured to the gastric wall
to prevent enlargement of the stoma fails,
because the foreign body is commonly
sloughed into the lumen with the creation
of either stenosis or, more frequently,
stomal enlargement. External support not
sutured to the gastric wall, such as silicone
tubing or Marlex, if placed near an
anastomosis, will also slough into the
lumen in an appreciable number of pa
tients. In this instance, it usually causes
stenosis which is difficult to manage
nonoperatively. It is not yet certain
whether gastric bypass requires external
support, but most surgeons do not use it.
The results of surgery for obesity
should include the number of patients and
the duration of follow-up of all patients.
If patients are lost to follow-up, they must
be considered as failures. Weight loss
should be expressed as a percentage of
preoperative weight and documented in
such a way that each patient is definable.
That is, a good result could be weight loss
exceeding 25% of preoperative weight,
and remaining within 30% of the ideal.
A satisfactory result could be classified
as loss of at least 25% of preoperative
weight but weight remaining more than
30% above the ideal and an unsatisfac
tory result is loss of less than 25% of
preoperative weight. Expressing results in
this fashion avoids classifying an opera
tion as satisfactory on the basis of a mean
weight loss, when in fact many patients

may have an unsatisfactory loss of
weight. The long-term results are best
identified by indicating the stability of
percentage weight lost 2 to 4 years after
the operation.
These o p e ra tio n s are in the
developmental stage but have the poten
tial o f substantially decreasing the
physical risks o f obesity, changing
psychosocial behaviour and improving
the economic well-being of a large group
o f people in our society.
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6. Overview of Jejunoileal Bypass

y
►
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” Jejunoileal bypass for morbid obesity is
designed to bring about weight loss by
* reducing food absorption in the small
intestine. The procedure bypasses about
90% of the small bowel. In the
end-to-side operation, 35 cm of jejunum
is anastomosed to 10 cm of ileum. In the
y- vend-to-end operation, 30 cm of jejunum

'

'
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is joined to 15 to 30 cm of ileum and the
bypassed small intestine is drained into
the cecum or transverse or sigmoid colon.
Maximum weight loss with the least
morbidity is achieved when the total
length of functioning bowel is between 45
and 75 cm. Seroma, infection and
dehiscence are the com m onest
postoperative complications. The overall
operative mortality of 3% has resulted
from myocardial infarction, pulmonary
embolism, sepsis and liver failure.
The weight loss resulting from
jejunoileal bypass is 30% of preoperative
weight by 1 year. After 2 years it may
reach 40% to 50% of preoperative

weight. Blood pressure, and glucose and
lipid levels m ay be reduced and
self-esteem and normal activity levels
restored.
By the end o f 2 years, the absorptive
surface o f the small intestine has
increased threefold due to elongation,
hypertrophy, dilatation, increased blood
supply and increased mucosal enzyme
activity.
Complications
Diarrhea, caused by decreased transit
time and increased bile, fatty acids,
nonabsorbed fat and disaccharides in the
colon, occurs in all patients, with 8 to 12
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watery stools daily immediately after
operation, 6 to 8 loose stools by 3 to 6
months, and 3 to 4 soft semi-formed
stools by 1 year. Intestinal complications
include the blind loop syndrome (proba
bly due to bacterial overgrowth), colonic
pseudo-obstruction with acute or
intermittent abdominal distension and
intussusception of the oversewn proximal
end of the bypassed segment (which can
be diagnosed by ultrasonography).
Lithogenic factors present before
operation are increased postoperatively
due to further alterations in bile-salt and
cholesterol metabolism and perhaps
bacterial overgrowth. Cholelithiasis is
present before or after bypass in 50% of
patients.
Fatty metamorphosis, present in two
thirds of patients at the time of bypass,
develops or increases over the next 12
months, and usually diminishes as the rate
of weight loss decreases. Some degree of
liver failure occasionally develops during
the first 4 to 24 months, manifested by
increasing lassitude, an enlarging, tender
liver and abnormal values of liver
function tests. Inflammatory changes and
fibrosis may lead to cirrhosis, causing
death in up to 2% of patients. The
relation between fatty metamorphosis and
liver failure or cirrhosis does not appear
to be a direct one. Protein malnutrition,
vitamin deficiency and malabsorption of
fat probably are major causes of liver
failure, fibrosis and cirrhosis, but
anaerobic overgrowth, and the presence
of hepatotoxins, increased chenodeoxycholic acid and alcohol, or a combination
of all of these, may contribute.
Transient or recurrent arthralgia of
hands, wrists, feet or ankles occurs in
10% to 20% of patients. Circulating
antibodies to Escherichia coli and
Bacteroides fragilis in some patients
suggest bacterial overgrowth in the blind
loop.
Bone disease due to malabsorption may
develop years after the bypass operation
but may be revealed by routine
biochemical and radiologic investigation.
Urinary calculi may form and
interstitial nephropathy occasionally
occurs after operation. Unabsorbed fatty
acids combine in the colon with ingested
calcium allowing increased oxalate
absorption and consequent oxalemia
and hyperoxaluria. Diarrhea leading to
dehydration contributes.
Regular follow-up is essential after
intestinal bypass so that undesirable
sequelae can be reduced and
complications prevented or treated.
Ideally, trained personnel should
supervise the nutritional program of
patients who have undergone intestinal
bypass. The program includes a diet high
in protein, potassium, calcium and
magnesium and low in fat and oxalate;
128

mineral and vitamin supplements may be
required. Antidiarrheal medications may
be needed and antibiotics may be useful
in blind loop syndromes and arthralgias.
Liver, renal and bone biopsies reveal
abnormalities more accurately than
routine biochemical or radiologic
investigations.
Revision

Revision surgery includes shortening of
the functioning segment for insufficient
weight loss or lengthening for excessive
weight loss, diarrhea, malnutrition or
electrolyte insufficiency. Take-down is
necessary for diarrhea or malnutrition
unresponsive to conservative measures
and for advancing cirrhosis or renal
disease. Take-down may result in the
patient regaining all the weight lost and
consideration should be given to a
synchronous gastric partitioning pro
cedure.
Present Status of Jejunoileal Bypass

Weight usually stabilizes at 18 months
with a loss of 50% to 90% of excess
weight. In 60% of patients, there are few
if any undesirable sequelae. The remaining
40% have intestinal, hepatic, bone and
joint, or renal problems, most of which
can be effectively treated.
Compared with other operations for
morbid obesity, jejunoileal bypass is the
safest, fails infrequently, and has
flexibility, in that weight loss can be
tailored to patient size. The technique is
now standardized, in contrast to gastric
partitioning. It does not require
specialized and expensive instruments.
Compared with the end-to-end
procedure, the end-to-side operation gives
equal weight loss with one instead of two
anastomoses, and avoids fecal back-wash
from the colon into the excluded small
bowel. This anastomosis can easily be
shifted more distally or proximally if
revision is necessary.
Adaptation of the functioning intestine
reaches a maximum by 2 years and
thereafter, failure due to the original
technique is rare. Revision of the
anastomosis is as safe as the original
procedure and often results in satisfactory
improvement. In contrast, revision of
gastric partitions is hazardous.
Reduction in appetite is often achieved
and appropriate satiety levels are restored.
Increased understanding of the short gut
syndrome and development of readily
absorbed oral and, when necessary,
parenteral nutrients, continues to improve
and simplify the management of
undesirable sequelae of intestinal bypass.
Cola addicts, who usually should not be
offered a gastric procedure, can be
accepted, albeit grudgingly, for intestinal
bypass. Intestinal bypass is not suitable
for the alcohol addict, however.

Clinically, morbid obesity is a
nutritional problem and remains so after
operation. Surgery is only one component
of a total team program in which the
dedicated internist, dietician, psychiatrist, ^
nursing team, physiotherapist, anesthetist
and surgeon play complementary roles. 4
An interested family doctor and a loyal
family complete the support group .* 4
Success of surgery is also influenced by
strict criteria for the selection of 1
candidates, careful attention to medical
evaluation and surgical technique, and by
close follow-up of every patient.
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7. Preoperative Psychologic Assessment in Determining
Outcome from Gastric Stapling for Morbid Obesity

k “-Research into the outcome of surgical
treatment for obesity has yielded discre^ pant findings and in general has several
methodologic shortcomings. It tends to
^ rely on retrospective measures and sub1 jective patient reports and lacks multiple
' f measures of change.1'3 In particular, the
L flack of preoperative screening has been
strongly emphasized by those dealing with
* surgical treatment of obesity.3’4 Because
gastric stapling is a radical and increasingly popular approach to weight loss, it
is important not only to assess its effec^ tiveness, but to improve success rates by
( A determining which patients benefit most
medically and psychosocially and which
do not, so that problems may be manag
ed or prevented. The present study is an
y initial attempt to answer this, as well as
to correct some methodologic problems
-f of previous research. It will report on out|
come 1 year after operation.
►

consisted of two transverse staple lines
placed across the upper stomach, leaving
a pouch with a volume of 100 ml. Marlex
mesh was applied to the greater curvature
to prevent enlargement of the pouch.
Patients underwent psychologic assess
ment preoperatively and 1 year
postoperatively. Each patient was rated
as having no, mild, moderate or severe
medical complications related to the
surgical procedure in the first year. Pa
tients hospitalized for complications
received a higher rating. Patients who
were referred for or who sought
psychologic treatment were defined as
having a psychologic complication. Pear
son correlations6 measured the reaction
between predictors and outcome.
Results and Discussion

Table I shows the relation between
predictors and postoperative compli

^ Method

r *•

The predictors of outcome include
► preoperative psychiatric history, a
preoperative Minnesota Multiphasic Per► sonality Inventory (MMPI), major life
events (Life Events Survey5) and the
^ quality of the social support system. The
c. t outcome variables include psychologic
T and medical complications. Other predic► tors (demographic data and diet history)
and outcome (weight loss and quality of
► life) are now being analysed and will be
published later. A 3-year follow-up study
* is also planned.

►

V

Patients

*

Six men and 51 women underwent
gastric stapling operations. All patients
r
were at least 45 kg over the ideal weight;
they ranged in age from 22 to 56 (mean
38 years). All operations were perform> ed by the same surgeon. The procedure

f

>

y
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FIG. 1—Medical (hatched bars) and
psychologic (dotted bars) complications or no
complications (white bars) postoperatively as
function of inpatient psychiatric history.

cations. Preoperative inpatient psychiatric
history was significantly related to both
medical and psychologic complications (p
< 0.001, p < 0.02 respectively) (Table
I). Fig. 1 illustrates this relationship.
Twelve of 16 patients who had an inpa
tient psychiatric history had moderate to
severe medical complications and 9 had
psychologic complications. Only two in
this group had neither problem. Of 41 pa
tients with no inpatient psychiatric
history, 33 had no complications, 6 had
medical and 4 had psychologic complica
tions. In comparison with an inpatient
psychiatric history, an outpatient
psychiatric history did not relate
significantly to either complication. The
next predictor, the MMPI, showed
similar significant results (Table I).
The MMPI is a widely used clinical tool
that assesses m ajor personality
characteristics and psychopathology. It
has 10 clinical scales. A scaled score of
70 or more is two standard deviations
above the mean and represents significant
psychopathology. For the purposes of
analysis, the number of scales over 70 was
compared to complications. The number
of scales over 70 correlated with medical
(p < 0.001) and psychologic (p < 0.03)
complications.
The third variable relating to compli
cations was negative life events. The
number of major negative life events in
the first postoperative year (e.g., divorce,
children leaving home, financial prob
lems) correlated with medical (p < 0.001)
and psychologic (p < 0.01) complica
tions.
The fourth significant variable was
social support. The quality of social sup
port (family and friends who could be

Table 1—Significance Levels of Pearson Correlations
between Predictors and Outcome Variables
Outcome, p value
Psychologic
Medical
Predictors
complications
complications
Inpatient psychiatric history
0.02
0.001
Minnesota Multiphasic Personality
Inventory, score >70
0.001
0.03
Negative life events
0.01
0.001
Social support
0.02
0.005
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confided in about personal issues or relied
on for help) correlated with medical (p <
0.005) and psychologic (p < 0.02) com
plications during the first postoperative
year.
When all four predictors were fed into
a multiple regression equation, 44% of
the variance in medical complications and
31 % of the variance in psychologic com
plications were accounted for. Inpatient
psychiatric history was the strongest single
predictor of medical and psychologic
complications. If there are also many
disruptive life events and a poor social
support system, the likelihood of pro
blems within the first postoperative year
is greater.
Authors o f previous studies4’7,8 have
stated that psychologic complications are
the result of medical problems. The pre
sent findings suggest the converse: that
the key to the development of both

psychologic and medical complications is
the extent of psychopathology. Medical
com plications (usually prolonged
vomiting) may be related to a strong oral
dependency; that is, the inability to give
up food as a way of reducing anxiety, or
as a source of pleasure.
One indication of psychopathology is
a history of inpatient psychiatric admis
sion. In these cases, consultation with a
psychologist or psychiatrist can be sought
to obtain more detail. In cases of severe
psychopathology, it may be appropriate
to seek alternative treatments, or at least
postpone operation. One unanswered
question is whether the complications en
countered are temporary. The 3-year
follow-up study should provide more
definitive answers as to whether other
treatments may be more appropriate for
some patients. One implication of the pre
sent study is that if patients with signifi

cant psychopathology are operated upon,
psychologic support should be included
as part of the treatment.
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8. Radiologic Evaluation of Gastroplasty Leaks
A thorough understanding of the
anatomy involved in gastroplasty is essen
tial to assess patients with suspected
leakage. Diagrams of the different types
o f gastroplasty do not always accurately
depict the topographic anatomy. For ex
ample, a diagram of the vertical banded
gastroplasty shows the stoma to be medial
to the gastric window, when in fact the
stoma can lie anterior to the window,
which is seen because of its surrounding
do u b le ring o f staples. In the
anteroposterior roentgenogram, the
stoma can lie anterior, medial or lateral
to the gastric window.
Every p a tie n t who undergoes
gastroplasty has upper gastrointestinal
roentgenography 5 days after operation
or earlier if a leak is suspected. The erect

Correspondence to: Dr. R.E. Seppala, 1
Swans Way N, Gloucester, Ont. K1J 6JI

position is preferred and water-soluble
contrast medium should be used first. If
a large leak is excluded, barium is given
because of the superior definition it
provides.
Oblique views are recommended for
vertical banded gastroplasty to show the
gastric window en face, thereby allowing
easier differentiation of a patent stoma
from staple dehiscence, which is indicated
by abnorm al channels of contrast
material passing posterior to the window
from the gastric pouch to the distal
stomach.
Multiple roentgenographic projections
and delayed films are necessary when ab
normal channels are demonstrated to
determine whether they connect the
gastric pouch to the distal stomach, in
dicating staple dehiscence, or terminate
outside the gastrointestinal tract, in
dicating a leak.

Care must be taken to distinguish
\
opacification of the potential space be- •<
tween the double row of staples in cases
of staple dehiscence from a gastroplasty
leak. Such leaks invariably originate from ^
the circular EEA staple line and they may
closely resemble the normal passage of
^
barium down the lesser curvature
channel.
-f
The imaging approach to the diagnosis
of gastroplasty leaks is based on detec1
tion of the leak itself or a subphrenic
abscess. Plain roentgenograms of the
chest and abdomen are made first,
^
followed by contrast studies. If a leak is
demonstrated, surgical repair is usually ^
indicated. If no leak is shown, then
ultrasonography or com puterized < >
tomography, or both, are performed to
detect subphrenic abscess. Occasionally,
radionuclide scanning with gallium-67
citrate or leukocytes labelled with
indium-111 is helpful.

A
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9. Some Comments about Informed Consent
►

^

If, in patients who undergo surgical treat
ment for morbid obesity, the validity of
y a consent is called into question, it will
likely be alleged that the doctor gave iny adequate information about the nature,
consequences or risks of the proposed
* f treatment. In a landmark decision by the
Supreme Court of Canada in 1980, the
court set out in general terms the scope
V of the doctor’s duty in informing patients
before treatment as follows:
*

In obtaining the consent of a patient for the
1 ■* performance upon him of a surgical operation,
a surgeon, generally, should answer any
specific questions posed by the patient as to
the risks involved and should, without being
1questioned, disclose to him the nature of the
proposed operation, its gravity, any material
f
risks and any special or unusual risks attendant
upon the performance of the operation.
► However, having said that, it should be add
ed that the scope of the duty of disclosure and
- ►whether or not it has been breached are mat
ters which must be decided in relation to the
r
circumstances of each particular case.

This provides doctors with a general
basis for deciding the nature and extent
^ of pretreatment information. Because it
y can be difficult to apply legal generalizar
tions to specific clinical situations, some
comment about the judgement may be
helpful.
Throughout this and other recent legal
judgements, there is repeated reference to
* the need to disclose material risks to pav tients, but there could be some
understandable uncertainty as to what
constitutes a material risk. One court has
defined it as follows: “ A risk is thus
material when a reasonable person in
what the physician knows or should know
► to be the patient’s position would be likely
to attach significance to the risk or cluster
of risks in determining whether or not to
undergo the proposed therapy.” From
other judgements it is clear that materiali> ty is influenced by the frequency of the

possible risk and also by its seriousness
should it occur.
C urrent interpretation of legal
judgements dealing with informed con
sent leads to some suggestions that may
assist doctors in meeting Canadian legal
standards.
• Disclose to the patient the nature of
the proposed treatment, its gravity, any
material risks and any special risks
relating to the specific treatment in ques
tion, as opposed to the usual risks (e.g.,
infection) common to most operations.
• Even if a certain risk is a mere
possibility that ordinarily need not be
disclosed, if its occurrence carries serious
consequences as, for example, paralysis
or death, it must be regarded as a material
risk requiring disclosure.
• Answer any specific questions pos
ed by the patient as to the risks involved
in the proposed treatment. The patient
must always be given the opportunity to
ask questions.
• The patient should be told about the
consequences of leaving the ailment un
treated as well as about alternative forms
of treatment and their risks.
• Be alert to a patient’s individual con
cerns and deal with them. Doctors must
remember that a patient’s special cir
cumstances might require disclosure of
potential though uncommon hazards of
the treatment when ordinarily these might
CONSENT TO INVESTIGATION,
TREATMENT OR OPERATIVE PROCEDURE

treatment or the operative procedure,______ _ _ ______,
ordered by or to be performed by Dr._________ ■
(2)

The anticipated effect, the nature, the material risks, and
any special or unusual risks of what Is proposed have been
explained to me by Dr.____________. I am satisfied with
these explanations and I have understood them.

tions, treatments or operative procedures as in Che opinion
of Dr.
________ are immediately necessary.
(A)

I further agree that in his or her discretion, the physician

or operative procedure, and they shall have the same dis-

► *Secretary-Treasurer, Canadian Medical
Protective Association, Ottawa, Ont.
^ * Reprint requests to: Dr. F.N. Brown, PO
Box 8225, Ottawa, Ont. K1G 3H7

FIG. 1—Sample consent form.

not appear relevant. The duty of
disclosure extends to what the doctor
knows or should know the patient deems
relevant to a decision about whether to
undergo treatment.
• Although any particular patient may
waive aside all questions of risk and may
be prepared to submit to the treatment,
whatever the risks may be, doctors must
exercise cautious discretion in accepting
such a waiver.
• When, because of emotional factors,
the patient may be unable to cope with
pretreatment explanations, the doctor
may be justified in withholding or
generalizing information which otherwise
he would be required to give.
• A note by the physician on the record
at the time of consent explanations can
later serve as important confirmation that
a patient was appropriately informed,
particularly if it refers to any special
points that may have been raised in
discussion.
Although litigation has been under
taken dealing with allegations about
obesity surgery, and indeed some actions
are under way at the moment, we do not
yet have court pronouncements on in
formed consent in this specific context.
• It is well established in law that when
any particular form of treatment might
be perceived as unusual, experimental or
even innovative, or if it might be regard
ed as having a cosmetic element, there is
a greater onus on the surgeon to meet a
much higher standard of disclosure in
consent explanations. This is not to sug
gest that surgery for morbid obesity us
ing well-established procedures is ex
perimental, innovative or cosmetic.
However, in legal matters we must deal
with the perceptions of nonmedical peo
ple, specifically lawyers and judges. As
a result of our limited experience with
medicolegal problems arising from obesi
ty surgery, the attitude persists that these
operations may be less essential, more
highly elective and perhaps with a greater
cosmetic element than most abdominal
surgery. More attention should be given,
therefore, to explanations about hazards,
anticipated results and alternatives. Avoid
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saying anything that might be interpreted
as guaranteeing results.
• The most essential element of the
consent process is the oral explanation
given by the doctor and the dialogue be
tween doctor and patient. Although
printed material can be very useful and
the written consent form has evidentiary
value, nothing will substitute for talking
to the patient.

• The consent form itself can be a
relatively simple document, an acknowl
edgement that explanations were given,
naming the doctor who gave them and
confirming that the patient consented
(Fig. 1). If explanatory documentation
has been given the patient beforehand,
reference may be m ade to these
documents with the acknowledgement
that they were read and understood and

P a u lin e B r a z e a u ,

that there was discussion about them.
• Explanatory documentation in the
form of information sheets or pamphlets,
couched in lay language should be used
and can be particularly valuable in ^
specialized (obesity) surgery.
• Finally, when the consent discussions 4
have been completed, the surgeon should
make a brief notation on the hospital oi^ 4
office record.

rp dt

10. Dietary Management of Morbidly Obese Patients
Who Undergo Gastroplasty
I-

ii

The dietary management of morbidly
obese patients who undergo gastroplasty
consists of three phases: preadmission, inhospital and postoperative.
The initial management begins in the
outpatient clinic and entails nutrition
counselling, keeping a food diary and
discussing other important matters such
as activity, exercise and social problems.
No diets are given. Basic nutrition accord
ing to Canada’s Food Guide is reviewed.
The food diary then becomes the most
important tool of the screening period.
The patient receives diary sheets with ex
planation forms. The quantitative aspect
of charting is emphasized. This permits
evaluation of the patient’s attitude and
compliance. The key recommendations
are: (a) eat three meals each day (with a
reduced energy level); (b) avoid snacks;
(c) balance the diet with a variety of lowenergy foods chosen from each food
group; (d) monitor the size of portions,
avoiding empty-calorie and fatty foods;
(e) eat slowly.
The second phase of the dietary
management takes place in hospital.
Before operation, the patient remains on
From the Department o f Dietetics, Ottawa
General Hospital, Ottawa, Ont.
Correspondence to: P. Brazeau, Depart
ment of Dietetics, Ottawa General
Hospital, 501 Smyth Rd., Ottawa, Ont.
K1H 8L6

a controlled-energy diet (3500 to 4000 kJ).
Postoperative feeding is through a jejunostomy tube with an isotonic lactosefree formula. According to the strength
and the rate of infusion, the formula pro
vides 1000 to 4000 kJ. Water is the only
other staple at this point, also infused
through the jejunostomy tube. This feed
ing technique allows proper time for the
stomach to heal and promotes quick
weight loss which motivates the patient.
Four days after operation, the patient is
taught the bolus injection technique.
Before discharge, the formula should be
tolerated at full-strength using a 150-mL
bolus every 4 to 6 hours plus 150 mL of
water, providing 2500 to 3500 kJ daily.
The bolus technique is continued at
home. Milkshakes, eggnog or instant
breakfast prepared as indicated in our
gastroplasty booklet are used. The
feedings are evenly distributed through
out the day. If bloating, cramps and diar
rhea or nausea (or both) occur, the
feedings are reduced in volume and given
six to eight times a day. The total daily
energy intake should not exceed 3500 kJ.
Water must be used, up to 1.5 L/d. A li
quid multivitamin is also prescribed in
order to meet the recommended dietary
allowance.
The use of a feeding jejunostomy,
while routine in our institution, is not
universally practised. We believe that it
is an excellent way to permit adequate

i

•<

. ... .

i

adherence of the staple lines and to
A
eliminate problems associated with early
postoperative vomiting. Should stenosis v
develop, conservative treatment combin
ed with long-term enteral feeding at home *
eliminates the need for prolonged hos
pitalization or reoperation. However, ^
many surgeons make the stoma somewhat
larger and permit early oral feeding after
surgery. No data are available to indicate
j
which technique is superior.
The following step, at home, is the in- ,
troduction of solid foods. Jejunostomytube feedings are replaced one at a time 1
by soft (blenderized), easily digested,
high-quality foods. Some key points are: *
(a) eat three meals per day, only at
mealtime, (b) eat solid foods at mealtime *
to prolong satiety, (c) eat very slowly:
chew foods until they are of mushy con- ’
sistency; put utensils down between each ^
bite, (d) drink liquids between meals, (e)
avoid snacking, (f) stop eating as soon as* -i
you feel full, (g) select a balanced diet;
take small amounts of high-quality foods, '
(h) tailor the diet to your needs and
tolerance.
1
Blenderized foods are taken for a ^
variable length of time, progressing to
normal foods. The total daily energy in- < .
take of 3500 kJ should not be exceeded.
An optimal dietary follow-up is possible
i
if the patient returns to the clinic on a
;
regular basis for up to 2 years
postoperatively.

c
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11. Anesthesia and Intensive Care Management
of the Obese Patient

►
►

k

Major surgery is associated with greater
morbidity and mortality for obese par tients than for those of normal weight.
There are five main problems confronting
i r the anesthetist and the intensive care
f physician.
First, certain endocrine, cardiovascular
k, and respiratory diseases, which are risk
factors themselves, increase the risk of
T surgery on obese patients and may
necessitate a different technique of
*■ anesthesia or choice of drugs.
Technical problems related to airway

^

r

y

From the Department o f Anesthesia,
Ottawa General Hospital, Ottawa, Ont.

-

Correspondence to: Dr. C. Benedict,
Department o f Anesthesia, Ottawa General
Hospital, 501 Smyth Rd., Ottawa, Ont.
K1H 8L6

y

management and vascular access are
notorious, and regional anesthesia is com
plicated by the absence o f bony
landmarks.
The risk of aspiration pneumonitis is
increased for several reasons: a lower than
normal pH of gastric fluid in fasting
obese patients, a higher volume of gastric
fluid, increased intra-abdominal pressure
and a higher incidence of hiatus hernia
with reflux of gastric contents.
Drug metabolism may be altered, with
higher peak levels or prolonged presence
of metabolites of certain anesthetic
agents, or both. The results of this may
be an undesirable degree of sedation postoperatively, or target-organ damage.
Selection of anesthetic drugs for the obese
patient is based partly on the rapidity of
metabolism, for intravenous agents, and
capacity to be excreted largely unchang

ed by the lungs, for inhalation agents.
Finally, oxygenation may be a serious
problem if the key relationship between
functional residual capacity and closing
capacity is altered adversely. Functional
residual capacity is diminished by general
anesthesia, the supine position and obesi
ty itself, while closing capacity is increas
ed by obesity and, probably, by the
supine position. Should functional
residual capacity fall below closing
capacity, small airways will close in the
range of tidal ventilation, and the resul
tant ventilation-perfusion mismatch may
produce arterial hypoxemia. To minimize
this, it is im portant to adopt and main
tain the reverse Trendelenburg position
during and after surgery. The benefit of
end-expiratory pressure here is unproven,
but should be considered if hypoxemia
occurs.

►
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12. Some Psychiatric Aspects of Morbidly Obese Patients
in Relation to Jejunoileal and Gastric Bypass Procedures

^ It is important to realize that on the surv face, morbidly obese patients appear to
be normal psychiatrically, rarely suffer, ing from psychoses or marked symp
tomatic neuroses such as phobia, severe
depressive or anxiety disorders and
disassociative reactions. They are ad► dieted to food and eat whenever possible.
r * From the Department o f Psychiatry,
University o f Ottawa School o f Medicine, and
k
Ottawa General Hospital, Ottawa, Ont.
*Professor and Chairman, Department o f
> Psychiatry, University o f Ottawa School o f
Medicine. Director, Department o f
^ Psychiatry, Ottawa General Hospital
Correspondence to: Dr. G.J. Sarwer-Foner,
y. h Director, Department o f Psychiatry,
Ottawa General Hospital, 501 Smyth Rd.,
Ottawa, Ont. K1H 8L6

They are often enthusiastic about projects
and ideas that interest them. Underneath,
they tend to have a devalued concept of
themselves, their body, their sexuality and
of their personal worth because of their
obesity. They see themselves in this sense
as freaks.
Their very bulk makes it more difficult
to move unless it is in water. Swimming
is thus good exercise for such people if
they can be encouraged to participate.
Other exercises, because of the stress on
the joints, are often resisted and are in
deed difficult to carry out.
Jejunoileal and Gastric Bypass Procedures

Probably the best long-term follow-up

studies, from a psychiatric viewpoint, of
jejunoileal bypass for the superobese have
been done by Castelnuovo-Tedesco.1,2
Most patients who undergo jejunoileal
or gastric bypass procedures do well.
When the surgery is successful, they are
pleased with their steady weight loss, the
changes in their body image, in their self
worth and in their capacity to deal with
life. It should be remembered that 54%
of patients who have had long-term
follow-up of jejunoileal bypass opera
tions have had complications. About two
thirds of these complications are mild or
moderate, and they are gradually over
come. In what has become a highly stan
dardized operation, it is not clear why a
few patients do very poorly. The un-
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predictability of complications in in
dividual cases is striking. The majority of
patients have a positive intrapsychic
response to jejunoileal bypass. They
believe their lives are enhanced by the
operation and they often recommend it
to others. In the Vanderbilt University
studies,1 patients who did not return for
regular follow-up had a less successful
outcome than those who did; but even so,
the outcome was positive in the majority.
One can generalize; patients who have
an uncomplicated postoperative surgical
course do well emotionally. Major me
tabolic or other physical complications
produce adverse intrapsychic reactions,
the majority being severe anxiety and
depression. Most patients with a good
postoperative result maintain the im
provement for years and their intra
psychic adaptation is consistent with their
basic physiologic improvement. People
who have serious physical complications
tend to have them in the first 3 years after

operation. The most common disabling
complications are severe diarrhea, elec
trolytic or hepatic disturbances and
bypass enteritis, with weakness, vomiting
and abdominal pain. The course tends to
stabilize after the first 3 years. Arthralgia
is a late postoperative complication and
is often accompanied by considerable
psychologic distress but usually responds
well to antibiotic therapy. This was
seen in 8 of 24 patients followed up
from 4 to 12 years (mean 6.8 years).1
Nephrolithiasis due to calcium oxalate
deposits occurred in two patients and
there was progressive uropathy. This may
result in renal failure unless it is corrected
by reversing the bypass. There was a strik
ing absence of psychoses or incapacitating
neuroses, while the depressive features
seen were generally mild.
With gastric bypass or gastroplasty, an
important psychiatric variable was pre
sent. If the gastric pouch is stretched by
overeating, the results of an otherwise

technically correct surgical procedure are
undone. Here, in contradistinction to je
junoileal bypass, the issue of overeating
and stretching the stapled or otherwise
reduced stomach is a factor in the success ^
or failure of the procedure. Other than
this, the course of the therapy is much the 4
same.
Major psychiatric illnesses are not seen^ ^
in morbidly obese patients unless they
have metabolic complications. This is true "*
particularly for jejunoileal bypass. For M
gastric stapling or gastroplasty,
overeating may stretch the pouch and of- «
fer a complicating factor.
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13. Nutrition following Intestinal Bypass
and Gastric Operations for Morbid Obesity
A multiple-isotope dilution technique has
been developed1,2 to measure the body
cell mass (i.e., the energy producing,
oxygen-utilizing, active cells of the body),
the extracellular supporting structures of
the body and, quite separately, the lean
body mass. If one knows the total weight
of the patient, the difference between lean
body mass and the total is the fat content
of the body.
Malnutrition is characterized by a con
traction of the body cell mass and an ex
pansion of the extracellular component of
the extracellular mass.3 In patients with
clinically obvious malnutrition, the body
cell mass is reduced to approximately
60% of normal, while the extracellular
mass is expanded approximately 25%
above normal. Less severe degrees of
malnutrition can also be detected by the
isotope-dilution technique so that 5 days
after uncomplicated major surgery, body
cell mass is reduced by 15%, the ex
tracellular mass is increased by 10% and
the total exchangeable sodium (Nae) to
total exchangeable potassium (Ke) ratio
From the Department o f Surgery, Royal
Victoria Hospital and McGill University,
Montreal, PQ
Reprint requests to: Dr. L.D. MacLean,
Surgeon-in-Chief, Royal Victoria Hospital,
687 Pine A ve. W, Montreal, PQ H i A 1AI
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is greater than 1.22, the upper limit of
normal.
Expansion of the extracellular mass
obscures the loss of body cell mass and,
therefore, weight loss does not accurate
ly reflect the loss of cellular mass. The use
of total parenteral nutrition will restore
body cell mass in patients free of sepsis.
In patients with moderate malnutrition (a
Nae to Ke ratio of 1.50), total parenteral
nutrition administered as a solution con
sisting of 25% dextrose and 2.5%
crystalline amino acids and providing 210
kJ/kg daily will restore the body cell mass
at a rate of approximately 60 g/d.
With this background, our group
studied 44 morbidly obese patients who
underwent jejunoileal bypass,3 in which
37.5 cm of proximal jejunum was
anastomosed end-to-side to ileum 12.5 cm
proximal to the ileocecal valve. In 33 pa
tients, a decrease of body fat accounted
for the entire postbypass weight loss while
the body mass remained normal in both
size and composition. In these patients,
at 1 year, body weight had decreased by
25% ± 2.1% while the body cell mass
had decreased by an insignificant amount
— 2.1% ± 7.1%. However, in the re
maining 11 patients the postbypass weight
loss resulted from both a decrease of body
fat and body cell mass. The body weight

at 1 year had decreased by 22% ± 6.1%.
These patients had a body composition 4
characteristic of protein malnutrition with
a contracted body cell mass and an ex- 1"
panded extracellular mass. Six of these 11
patients have required admission to ^
hospital on 10 occasions because of
malaise, anorexia, debilitating weakness,
hypokalemia and abnormal liver func-» i
tion. They were treated during these adi
missions for 14.5 ± 1.9 days with an in^
travenous infusion of amino acids with
'j
additional nonprotein nutrients. The
body composition, initially characteristic ^
of malnutrition, became normal. Their
symptoms disappeared and hepatic func-, ,
tion returned to normal. Subsequently, in
several patients normal intestinal con- -<•
tinuity had to be restored; in others a high
protein diet prevented recurrence of
symptoms and maintained a normal body
composition. The data indicated that pro- 4
tein malnutrition developed in one
<
quarter of patients who underwent jej
junoileal bypass for weight reduction.
j
Similar studies were carried out on 96
j
patients who had various types of i
gastroplasty or gastric bypass.4 All had
lost a mean of 26% of preoperative 4
weight by 24 months. Notable malnutri!
tion occurred in 47 patients whose Nae to 4 4
Ke ratio ranged from 1.23 to 2.17. Body
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fat was reduced by 34%. The malnourish
ed patients lost 10% more body cell mass
by 24 months than did the normally
nourished group. Malnutrition resolved
^ as the stoma enlarged in 19 patients;
dietary counselling solved the problem in
► 8 others. Eighteen patients required
reoperation to make a larger orifice and
r ^endoscopic dilatation was successful in
two patients. A liquid diet, administered
^ through a gastrostomy, was required for
prolonged periods in some malnourished
patients.
v.
Seventeen patients who lost weight
rapidly over a short time had low vitamin
f *-B12, thiamine, serum and red blood cell
folate levels. One patient had a marked^ ly decreased serum thiamine level with

k

neuropathy, which resolved when
thiamine was given parenterally. Symp
toms of weakness, easy fatigability and
lassitude were found in the malnourish
ed patients.
The degree of malnutrition in patients
after gastric operations is as great as that
following intestinal bypass but it is not
associated with liver failure. Malnutrition
with vitamin deficiency is a great hazard
in patients who undergo intake-limiting
operations, especially if the goal of the
operation is to restore near-normal
weight. Current operations are successful
ly designed to maintain a small orifice
size, so the risks of malnutrition are like
ly to increase in the future.
The malnutrition of intestinal bypass

Walter L. P ercival ,

more closely resembles kwashiorkor,
whereas the malnutrition of gastriclimiting operations is much more subtle
without liver dysfunction and more close
ly resembles marasmus.
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4 14. “The Balloon Diet”: a Noninvasive Treatment for Morbid
*
Obesity. Preliminary Report of 108 Patients

A relatively new approach to depress appetite is a balloon bezoar, which is
swallowed to decrease available stomach
volume. This gastric balloon is a
1 physiologic crutch rather than an
1j. anatomical cure for the patient with mor
bid obesity. It assists in changing the patr Hern of overeating by substituting a full
feeling for the hunger of most diets; in
•t fact, the balloon usually makes it difficult
for the subject to overeat without becomp ing uncomfortable or nauseated.
My first patient, a woman aged 27
years, weighed 135 kg. She asked for an
.alternative to surgery. In August 1980,
after work-up including roentgenography
► and gastroscopy, a dime-store balloon to
which a small catheter was attached was
' placed in the stomach (Fig. 1) intranasally. The balloon was inflated with 200 mL,
* of water and 200 mL of air. The first
vballoon broke after 2 weeks and was
replaced. During the 24 weeks that the seL cond balloon was in situ, she lost 34 kg.
[ She had a marked loss of appetite and was
I able to eliminate snacking completely. In
I addition, she gradually increased her exr ercising. Following removal of the
balloon, she lost weight at a slower rate.
' rIn 1982 when her weight of 70 kg was
achieved, a lipectomy was carried out. In
the following 2 years, her weight has
been controlled by sensible dieting.
In 42 subsequent patients, the rate of
►----------------------------------------------------

,
j
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breakage of balloons was high. Various
types were tried with some notable suc
cess to support the concept. In 1982 I
began to use a Dow Corning mammary
implant. This usually lasts for about 10
weeks; in one patient it lasted for 35
weeks. This is usually enough time to give
patients a good start on weight control.
Some are motivated to continue without
a balloon. Others require two or more
balloons.
The mammary implant is resistant to
gastric contents but it is a semipermeable
membrane so that it must be refilled on
a regular basis. If it is overinflated, it pro
duces epigastric tightness that can be
relieved by withdrawing some of the air.If
it is underinflated or breaks, the sensa
tion of hunger returns and weight loss is
unsatisfactory.
The mammary implant was used in
65 of the 108 patients. Eight patients

FIG. 1—Balloon in position in stomach.

inadvertently swallowed the connecting
catheter, which had to be retrieved
gastroscopically. There have been no
other complications except for heartburn
treated by antacids. In one patient with
an ulcer history, cimetidine was prescrib
ed although roentgenograms did not sug
gest a recurrent ulcer. In no case did
gastroscopic examinations show ulcera
tion, hemorrhage or inflammation.
The nasal catheter causes surprisingly
little discom fort even after several
months. The catheter may be taped to the
cheek, looped over an ear, tucked into the
other nostril or tied to the eye-glasses.
It is hoped that a balloon may be
developed that could remain in place for
extended periods. A self-sealing valve is
already available and this could permit
withdrawal of the catheter after suitable
inflation of the balloon.
Slawek (unpublished data) used this
technique in 31 patients who lost an
average of 3.4 kg per week over short
periods. He remarked that “ the balloons
usually pop within two weeks” . Nieben
and Harboe1 reported that five obese pa
tients treated with bezoars for an average
of 12 days lost from 2.1 to 5 kg. Patkin
(personal communication, 1982) and
Olivencia (personal com m unication,
1983) reported 31 patients who lost 0.8
kg per week in 2 to 3 weeks. Geliebter and
associates2 put bezoars into the stomachs
of growing rats. The rats all failed to gain
weight and ate less than controls. When
the bezoars were removed, the rats
promptly increased their food intake and
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regained w eight. A t autopsy, the
stomachs showed no histologic abnor
malities. This suggests that the weight loss
was not due to psychologic diet sup
pression.
The “balloon diet” for morbid obesi
ty is recommended as an alternative to
operation3 and is particularly suitable for
patients with multisystem problems.
Weight is reduced by suppressing hunger
rather than interfering with the anatomy
and physiology of the gastrointestinal
tract. There has been no mortality and no
appreciable morbidity. The only disad
vantages have to do with the quality of
the bezoar itself and inconvenience o f the
connective catheter.
The method is a simple, safe and inex
pensive office procedure.
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NUBAIN
nalbuphine HC1

A C TIO N : N ubain is a synthetic narcotic agonist-antagonist analgesic fo r parenteral use, related chemically to
the narcotic oxymorphone and to the narcotic antagonist naloxone. N albuphine has an analgesic (agonist action)
potency equivalent to th at o f m orphine on a m illigram basis, and an antagonist activity (reversal o f m ajor effects of
opioid drugs) about one-fourth that of nalorphine and ten times that o f pentazocine. The analgesic effect of 10
mg o f nalbuphine is about equal to that of 10 mg of morphine sulfate. The onset of action begins within 2 to 3 minutes
a fter intravenous adm inistration, and w ithin 15 minutes follow ing subcutaneous o r intram uscular injection. The
plasma h a lf life o f nalbuphine is five hours and the duration o f action has ranged from three to six hours.
A t the usual dose o f 10 ma, nalbuphine produces respiratory depression equivalent to th at o f equianalgesic doses
o f morphine. A t much higher doses, above 30 mg i.v. (which produces a respiratory depressant activity equivalent
to 20 mg o f morphine i.v.), the respiratory depressant effect o f nalbuphine does not appear to increase appreciably.
N albuphine may precipitate abstinence, when administered to individuals taking narcotics chronically o r produce
w ithdraw al symptoms when discontinued abruptly after prolonged use. It is reported to have an abuse potential
com parable to that o f pentazocine. The mechanism o f action o f nalbuphine has not yet been established.
INDICATIONS A N D CLINICAL USE: N UBAIN is indicated for the relief o f moderate to severe pain. Clinical studies
indicate th at it can be used fo r preoperative analgesia, as a supplement to surgical anesthesia, and fo r obstetrical
analgesia during labor.
CONTR A l NDICATIONS: NU BAIN should not be administered to patients w ho are hypersensitive to the drug or
to its inactive ingredients (see section 'AVAILABILITY').
W ARNING S: In patients physically dependent on opiate drugs, N U BAIN (nalbuphine hydrochloride) should not
be given p rio r to detoxification since w ithdraw al symptoms are likely to be produced.
O n the basis of behavioural, substitution and direct addiction studies in humans, N U B A IN has been shown to have
low abuse potential which approximates that of pentazocine. Psychological and physical dependence and tolerance
may follow the abuse or misuse o f nalbuphine. Therefore, caution should be observed in prescribing it for emotionolly
unstable patients o r fo r individuals with a history of narcotic abuse. Such patients should be closely supervised,
since increases in dosage o r frequency o f administration in susceptible individuals m ight result in physical
dependence.
A brupt discontinuation o f N U BAIN following prolonged use has been followed by symptoms o f narcotic withdrawal,
such as abdom inal cramps, nausea and vom iting, rhinorrhea, lacrim ation, restlessness, anxiety, elevated
tem perature and piloerection.
N U B A IN may im pair the mental o r physical abilities required fo r the performance of potentially dangerous tasks
such as drivin g a car o r operating machinery. Therefore, N U B A IN should be adm inistered with caution to
am b u la to ry patients, w ho should be warned to avoid such hazards until recovered from the effects o f the drug.
A lthough N U B A IN possesses narcotic antagonist activity, there is evidence that in non-dependent patients it may
not antagonize the analgesic effect o f narcotic analgesics. Patients receiving narcotic analgesics, general
anesthetics, phenothiazines o r other tranquilizers, sedatives, hypnotics, o r other CNS depressants (including
alcohol) concomitantly with NUBAIN may exhibit an additive effect. W hen such combined therapy is contemplated,
the dose o f one or both agents should be reduced.
Because clinical experience in children under the age o f 12 years is lim ited, the adm inistration o f N U B A IN in this
age gro u p is not recommended.
Safe use o f N U B A IN in pregnancy (other than labor) has not been established. A lthough anim al reproductive
studies have not revealed teratogenic or em bryotoxic effects, NU BAI N should only be adm inistered to pregnant
women when, in the judgem ent o f the physician, the potential benefits outweigh the possible hazards.
Since NUBAIN can produce respiratory depression in the neonate, it should be administered with caution to women
delivering prem ature infants.
The possible respiratory depressant effects and the potential of potent analgesics to elevate cerebrospinal fluid
pressure (resulting from vasodilation following C 0 2 retention) may be markedly exaggerated in the presence of
head injury, intracranial lesions, o r a pre-existing increase in intracranial pressure. Furthermore, potent analgesics
can produce effects which may obscure the clinical course o f patients with head injuries. Therefore, NUBAIN should
be adm inistered in these circumstances only when essential, and with extreme caution.
PRECAUTIONS: Caution should be observed when administering NUBAIN (nalbuphine hydrochloride) to patients
with im paired respiration, o r who are receiving other medications which produce respiratory depression. In the
presence o f bronchial asthma, uremia, severe infection, cyanosis, o r respiratory obstruction, N U B A IN should be
adm inistered only with great caution and in reduced doses. Respiratory depression induced by N U BAI N can be
reversed by the adm inistration o f naloxone hydrochloride.
Because N U BAI N is metabolized in the liver and excreted by the kidneys, patients with renal o r liver dysfunction
may show an exaggerated response to customary doses. Therefore, in these individuals N U B A IN should be used
with caution and administered in reduced amounts.
As w ith all potent analgesics, N U B A IN should be used with caution in patients with myocardial infarction who
have nausea or vomiting. Hemodynamic studies in patients with severe arteriosclerotic heart changes reveal that
N U B A IN has circulatory effects similar to those o f morphine, i.e., a minim al decrease in oxygen consumption,
cardiac index, left ventricular endiastolic pressure and cardiac work.
If N U B A IN is inadvertently administered to a patient physically dependent on narcotics and unduly troublesome
narcotic withdraw al symptoms develop, these symptoms may be controlled by the slow intravenous administration
o f small increments of morphine, until relief occurs.
ADVERSE REACTIONS: In clinical trials with NUBAIN (nalbuphine hydrochloride) the most frequently reported
side effects were: sedation (36% of 1066 patients treated), sweating or clamminess (9%), nausea or vomiting (6%),
dizziness o r vertigo (5% ), d ry mouth (4%) and headache (3%).
O th e r adverse reactions which may occur are: Central Nervous System: nervousness, crying, depression, rest
lessness, euphoria, hostility, confusion, faintness, floating, unusual dreams, numbness, feeling o f heaviness, and
psychotomimetic effects such as hallucinations, feeling o f unreality and dysphoria. Cardiovascular: hypertension,
hypotension, bradycardia, tachycardia. Gastrointestinal: cramps, dyspepsia, bitter taste Respiration: depression,
dyspnea, asthma. Derm atological: itching, burning, urticaria. Miscellaneous: speech difficulty, urinary urgency,
b lurred vision, flushing and warmth.
OVERDOSE SYMPTOMS: These are expected to be similar to those o f other drugs of this class. (The administration
o f single I.M . doses of 72 mg o f N U B A IN to eight norm al subjects has been reported to have resulted prim arily
in symptoms o f sleepiness and mild dysphoria).
OVERDOSE TREATMENT: NARCAN (naloxone hydrochloride) administered intravenously is a specific antidote
fo r N U B A IN . Since the duration o f action of N UBAIN may exceed that o f NAR C AN , the patient should be kept
under continued surveillance and repeated doses o f NARCAN should be administered as necessary. Oxygen,
intravenous fluids, vasopressors and other supportive measures should be employed as indicated.
DOSAGE A N D ADM INISTRATION: The usual recommended dose o f N U B A IN (nalbuphine hydrochloride) is 10
mg fo r a 70 kg individual administered subcutaneously, intramuscularly or intravenously. This dose may be repeated
every 3 to 6 hours as required. The recommended dosage range is 10 mg to 20 mg. with a m aximum single dose
o f 20 mg and a maximum total da ily dose o f 160 mg. Dosage should be adjusted according to the severity of the
pain, physical status o f the patient, and other medications which the patient may be receiving. (See interaction
with oth e r CNS depressants under 'W A R N IN G S ').
Patients who have been taking narcotics chronically for pain under medical supervision may experience withdrawal
symptoms upon the adm inistration o f N U B A IN . If N UBAIN is administered to these patients as an analgesic, it
should be introduced gradually. N U B A IN should not be used as a substitute for other narcotics o r fo r withdrawal
purposes in individuals dependent on these drugs.
AVAILABILITY: NUBAIN (nalbuphine hydrochloride) is supplied in glass ampoules of 1 ml and 2 ml. and in multipledose vials o f 10 ml containing 10 mg o f nalbuphine hydrochloride per ml. Each ml also contains 0.1% sodium
chloride, 0.94% sodium citrate, 1.26% citric acid anhydrous, 0.1% sodium metabisulfite and 0.2% o f 9/1 mixture
o f m ethylparaben and propylparaben as preservatives.
STORE AT CONTROLLED ROOM TEMPERATURE (15° TO 3 0°C ). PROTECT FROM EXCESSIVE LIGHT.
®TM
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preoperatively

• analgesic efficacy comparable to morphine
• low incidence of nausea and vomiting

Nubain
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irrtraoperatively

• fast onset of action — within 3 minutes IV
• allows rapid emergence from anesthesia
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• prolonged analgesia
• little or no constipation

r Three-way dosage: !M, IV, SC
* r In ampules and vials
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Pipracil is an effective advanced agent for
gram negative,gram positive and
anaerobic infections.
x ipracil* (piperacillin sodium) is a major advance
in first-line antibiotic mono and combination therapy
Pipracil’s* spectrum of bactericidal activity is broader
than other antibiotics, such as the aminoglycosides,
cephalosporins, penicillins and clindamycin.
Yet Pipracil* has an excellent clinical safety profile,
having a low sodium content and causing no
nephrotoxicity, ototoxicity or pseudomembranous
colitis. In addition, Pipracil* achieves excellent
concentrations in body tissues and fluids.

By providing a high degree of efficacy in a wide
range of mixed infections, Pipracil* is a logical ther
apeutic alternative for first-line therapy in surgery,
urology and gynecology, as well as for the com
promised patient.

PIPRACILThe Spectrum of
a Combination in One Advanced Agent
Cyanamid Canada Inc.
Toronto
"Pipracil is a trade mark of Lederle Piperacillin, Inc.
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PIPRACIL

peracillin sodium

Kteral Antibiotic tor intravenous and Intramuscular Use
tAflONS AND CLINICAL USES: Treatment of serious infections caused by susceptible strains of the designated
nwns in the conditions listed below.
Llntra-abdominal Infections including hepatobiliary and surgical infections caused by Escherichia coli, Pseudoaauginosa, enterococci. Clostridium sp.. anaerobic cocci, and Bacteroides sp„ including B. fragilis.
flrinaf/ Tract Infections (complicated and uncomplicated) caused by Escherichia coli, Klebsiella sp„ Pseudomonas
inosa, Proteus mirabilis and enterococci. Also uncomplicated urethritis caused by Neisseria gonorrhoeae.
jynecological Infections including endometritis and pelvic inflammatory disease caused by Bacteroides sp.,
ding B. fragilis, anaerobic cocci, Neisseria gonorrhoeae, and enterococci (Streptococcus faecalis).
Septicemia caused by Escherichia coli, Klebsiella sp., Serratia sp., Proteus mirabilis, S. pneumoniae, enterococci,
domonas aeruginosa, Bacteroides sp., and anaerobic cocci.
Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella sp., Enterobacter sp., Pseudomonas
ginosa, Serratia sp., Haemophilus influenzae, Bacteroides species and anaerobic cocci. Although improvement
b*gn noted in patients with cystic fibrosis, lasting bacterial eradication may not be achieved.
Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella sp., Serratia sp.. Acinetobacter sp.,
obacter sp., Pseudomonas aeruginosa, indole-positive Proteus sp., Proteus mirabilis, Bacteroides sp., including
gilis,Anaerobic cocci and enterococci.
Bone and Joint Infections caused by Pseudomonas aeruginosa, enterococci, Bacteroides sp., and anaerobic cocci.
IPRACIL* is useful for the treatment of mixed infections and presumptive therapy prior to the identification
causative organisms; infections produced by organisms resistant to other penicillins, some aminoglycosides
cephalosporins; and infections at various sites caused by streptococcus species including Group A beta-hemoStreptococcus and Streptococcus pneumoniae.
‘ IPRACIL* may be administered as single drug therapy in some situations where normally two antibiotics
t be employed. In vitro synergism has been shown between Piperacillin and some aminoglycosides in some
rial strains. PIPRACIL* has been used clinically with aminoglycosides, especially in patients with impaired host
ces. Both drugs were used in full therapeutic doses.
PIPRACIL* can be used safely in combination with a penicillinase-resistant penicillin, e.g. oxacillin, in mixed
'ion:*when beta-lactamase-positive Staphyloccus aureus is isolated along with piperacillin-susceptible
nisms. It may be administered concomitantly with a cephalosporin, provided that an additive or synergistic
arterial action of the two antibiotics is ascertained through in vitro tests. Based on in vitro data, cefoxitin should
given with piperacillin when Pseudomonas infections are suspected or confirmed.
Because PIPRACIL* is excreted not only renally, but also by the biliary route, it can be used in patients with
tobiliary infections, or severely restricted kidney function, and in patients who have had nephrotoxic reactions
‘ et drugs, with appropriate adjustment of dosage (See DOSAGE).
Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted,
propriate, once the results are known,
INDICATIONS: A history of allergic reactions to any of the penicillins and/or cephalosporins.
INGS: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients
ingiherapy with pencillins. These reactions are more apt to occur in persons with a history of sensitivity to
rple allergens.
Cross-sensitivity of patients to penicillins and cephalosporins has been reported. Before initiating therapy with
ACILr careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalospoand other allergens.
If an allergic reaction occurs, the antibiotic should be discontinued.
ERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE
EN, INTRAVENOUS STEROIDS, AIRWAY MANAGEMENT. INCLUDING INTUBATION, SHOULD ALSO BE ADMINISD AS NECESSARY
UTIONS: Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics including
acillin.These reactions have sometimes been associated with abnormalities of coagulation tests such as
ing time, platelet aggregation and prothrombin time and are more likely to occur in patients with renal failure.
Ifbleeding manifestations or significant leukopenia occur, PIPRACIL* should be discontinued and appropriate
py instituted.
The^ossibility of the emergence of resistant organisms and the development of superinfections should be
in mind, particularly during prolonged treatment.
As with other penicillins, patients may experience neuromuscular excitability or convulsions if higher than
mended doses are given intravenously,
osage adjustment should be made in renal insufficiency.
PIPRACIL* is a monosodium compound containing 1.98 milliequivalents (45.5 mg) of Na+per gram based on
"ntent which includes the U.S.P. allowed average. The calculated value, based on molecular weight is 1.85
g (42.55 mg.). Periodic electrolyte determinations should be made in patients with low potassium reserves
he possibility of hypokalemia should be kept in mind with patients who have potentially low potassium
v|g, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during
nged-treatment in patients with impaired cardiac function.
Prior to treatment, patients with gonorrhea should also be evaluated for syphilis. Specimens for darkfield
inatfcin should be obtained from patients with any suspected primary lesions, and serologic tests should be
rmed In all cases where concomitant syphilis is suspected, monthly serological tests should be made for a
num of 4 months.
fhe use of some penicillins (ampicillin, amoxicillin) has been associated with morbilliform rashes in some
s of infectious mononucleosis. PIPRACIL* should be used with caution in the treatment of patients with infecmononucleosis.
nteractions: The mixing of PIPRACIL* with an aminoglycoside in vitro can result in substantial inactivation of the
oglycosides.
faring Pregancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined. Because
arreproduction studies are not always predictive of human response, this drug should be used during pregnancy
if clearly needed. It has been found to cross the placenta in rats. Caution should be exercised when PIPRACIL*
inhered to nursing mothers. It is excreted in low concentrations in milk,
trie Use: Dosages for children under the age of 12 have not been established.
TSE REACTIONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been local in
pe, following intravenous or intramuscular injection.The following adverse reactions may occur:
Local Reactions - In clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or indurat the injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis and
tomas.
Hypersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less frequent findings: pruitis,
ular eruptions, positive Coombs tests.
Gastrointestinal-Diarrhea and loose stools were noted in 2.8% of patients. Less frequent reactions: vomiting,
ea, bloody diarrhea.
' ep?ijc- Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis.
Renal-Elevations of creatinine or BUN.
Central Nervous System - Headache, dizziness, fatigue.
"emic and Lymphatic-Reversible leukopenia, neutropenia, thrombocytopenia and/or eosinophilia, bleeding and
ases in prothrombin time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in
ts receiving prolonged therapy at high dosages or in association with drugs known to cause this reaction,
erum Electrolytes - Individuals with liver disease or individuals receiving cytotoxic therapy or diuretics, were
ed rarely to demonstrate a decrease in serum potassium concentrations with high doses of PIPRACIL*
Musculo-Skeletal - Rarely, prolonged muscle relaxation.
(pter- Superinfection, including candidiasis.
GE AND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously by injecr infusion. Dosage and route of administration should be determined by the severity of the infection and
iotfhf the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a 20 to 30
te infusion administered intravenously.
The maximum daily dose usually administered to adults is 24 g/day, although higher doses have been used.

DOSAGE
Type of Infection
Serious infections such as septicemia, nosocomial pneumonia, intraabdominal infections, aerobic and anaerobic gynecologic infections,
and skin soft-tissue infections.
Complicated urinary tract infections.
Uncomplicated urinary tract infections and most community-acquired
pneumonia.
Uncomplicated gonococcal urethritis.

Usual Total
Daily Dosage
12-18 g IV
(200-300 mg/kg)

Frequency of
Administration

8-16 gl.V.
(125-200 mg/kg)
6-8 g I.M. or I.V.
(100-125 mg/kg)
2 g I.M*

Every 6 to
8 hours
Every 6 to
12 hours
Single dose

Every 4 to
6 hours

*One gram of probenecid given orally 1/2 hour prior to injection.
Dosage In Renal Impairment
Creatinine
Clearance
mL/min.

Urinary Tract
Infection
(uncomplicated)

Urinary Tract
Infection
(complicated)

Serious Systemic
Infection

>4 0

No dosage adjustment necessary

20-40
<20

No dosage adjustment necessary
6 g/day 3 g every 12 hrs.

9 g/day 3 g every 8 hrs.

12 g/day 4 g every 8 hrs.

6 g/day 3 g every 12hrs.

Patients on
Hemodialysis*

'Hemodialysis removes 30-50% of piperacillin in 4 hours;
6 g/day 2 g every 8 hrs.
1 g additional dose should be administered following each dialysis period.

8 g/day 4 g every 12 hrs.

For patients w ith renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* will provide
additional guidance for adjusting dosage.
Infants and Children - Dosages in infants and children under 12 years of age have not been established.
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in which
it is from 3 to 10 days; the duration should be guided by the patient's clinical and bacteriological progress. For most
acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asympto
matic. Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 days to
reduce the risk of rheumatic fever of glomerulonephritis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular administration of 6 to 8 g. daily
of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for mainte
nance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin sodium
treatment. Administration should not exceed 2 g. per injection at any one site. This route has been used primarily in
the treatment of patients with uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12 Years of Age: The reconstituted solution is given by deep intramuscular injection. The
preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also may be given in the
mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and then only with caution
to avoid radial nerve injury. Intramuscular injection should not be made into the lower or mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted with 5 mL of suitable diluent listed below
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation.
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein irritation.
The reconstituted and diluted solution may be administered by intermittent or continuous drip. Intermittent infusion
should be administered over a period of about 30 minutes. During intermittent infusion it is desirable to discontinue
the primary intravenous solution. Any unused portion must be discarded. For continuous infusion the solution may
be administered over a longer period of time.
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for Injection, or if required
'Bacteriostatic Water for Injection,
**Lidocaine HC1 0.5 or 1% (without epinephrine)-For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required.
'Bacteriostatic Water for Injection.
‘ Either parabens or benzyl alcohol.
"Lidocaine HC1 is contraindicated in patients with a known history of hypersensitivity to local anesthetics of
the amide type.
RECONSTITUTION TABLE
Product
VOLUME OF
Approximate
Approximate
Size
Diluent to be added
Available Volume
Average Concentration
Vials 2 g
4.0 mL
5.0 mL
1 g/2.5 mL
6.0 mL
7.5 mL
1 g/2.5 mL
3g
7.8 mL
10.0 mL
1 g/2.5 mL
49
Infusion Bottles
15 mL
17 mL
3g
20 mL
23 mL
4g
The prepared solution may be further diluted to the desired volume with any of the solutions for intravenous
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing
any of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Admixtures:
Intravenous Solutions:
5% Dextrose in Water [D5W]
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cillin sodium equivalent to 2, 3 and 4 grams of piperacillin. Available in boxes of 12 vials.
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Storage:
PIPRACIL* vials and infusion bottles should be stored at controlled room temperatures of 15-30°C (59-86°F).
Piperacillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request.
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Effect of Adrenalectomy on Prostaglandin Protection
of the Rat Gastric Mucosa
Prostaglandins can prevent damage to
gastric mucosa by agents such as
Aspirin and ethanol, but their mechanism
of action is not known. The authors ex
amined the role of the adrenal gland in
prostaglandin protection. Fifty, male
Wistar rats were subjected to bilateral
total adrenalectomy or sham operation.
Adrenalectomized rats with circulating
cortisol were discarded. After allowing 2
weeks for recovery, the authors
measured the susceptibility of the gastric
mucosa to injury by ethanol in an ex-vivo
chamber of the entire stomach. This
model permits the mucosa to be bathed
by a series of solutions and the damage
to be measured by planimetry. Mucosal
damage was induced by applying 40%
ethanol for 10 minutes. The prostaglan
din used was 16,16-dimethyl prostaglan
din E2 (10 g) given for 10 minutes
before the ethanol was introduced.
The results show that mucosal damage
from ethanol is consistently higher in the
adrenalectomized rat but that adrenalec
tomy does not prevent protection by
prostaglandin. The authors conclude that
the mechanism of prostaglandin protec
tion against ethanol injury is not
corticosteroid-dependent.

A
-i

p

Les prostaglandines peuvent proteger la
muqueuse gastrique des dommages cau
ses par des agents tels que I'Aspirine et

------------------------------------------------

I'alcool, mais leur mecanisme d'action
demeure inconnu. Les auteurs ont etudie
le role joue par les surrenales dans la
protection accordee par les prostaglandi
nes. Cinquante rats Wistar de sexe male
ont gte soumis a une surrenalectomie
bilaterale totale ou a une operation simulee. Les rats surrenalectomises montrant
des taux de cortisol circulant ont ete
exclus. Apres une periode de recupera
tion de 2 semaines, les auteurs ont
mesure la sensibility de la muqueuse gas
trique aux lesions provoquees par I’ethanol dans une chambre ex vivo de I'estomac entier. Ce modele permet a la
muqueuse de baigner dans une s6rie de
solutions et de mesurer les dommages h
I'aide d'un planimetre. Les dommages a
la muqueuse ont ete provoques par
exposition h I'ythanol a 40% pendant 10
minutes. La prostaglandine utilisee a ete
la 16,16-dimethyl prostaglandine E2 (10
pg) administree pendant 10 minutes
avant (’introduction d'ethanol.
Les resultats montrent que les domma
ges muqueux causes par l'£thanol sont
immanquablement plus importants chez
les rats surrgnalectomisys mais que la
surrenalectomie n'empeche pas la pros
taglandine de jouer son role protecteur.
Les auteurs concluent que le m£canisme
de protection des prostaglandines contre
les lesions dues a l ethanol n'est pas
corticosteroldo-dependant.
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Prostaglandins are able to protect the
gastric mucosa from a variety of toxic
agents including high concentrations of
ethanol.1 The mechanism of this protec
tion is unknown. Recently, it hast been
suggested that the protective action of
prostaglandins is mediated by glucocor
ticoids.2’4 Adrenalectomy inhibits the
protective effect of a prostaglandin
(PGF2|3) in rats subjected to intragastric
instillation of absolute ethanol.3 Cor
ticosteroids ameliorate the gastric damage
produced by ethanol4 and intestinal
ulceration induced by indomethacin4 in
the rat. We present data suggesting that

the mechanism of prostaglandin protec
tion is independent of corticosteroids in
the rat.
Methods

Experiments were performed on 50
male Wistar rats each weighing approx
imately 250 g. Bilateral adrenalectomy
was performed through subcostal inci
sions, and the 25 animals were allowed
2 to 3 weeks to recover. In 25 animals that
had a sham operation, the adrenal glands
were simply visualized through an iden
tical operative approach. One of these
rats died before any experiment was per
formed. Adrenalectomized rats were
given 0.9% saline in place of drinking
water but no steroid replacement. Gastric
mucosal injury induced by ethanol was
determined using the gastric chamber ap
paratus to be described. To test for com
pleteness of adrenalectomy, blood
samples were taken at the time of sacrifice
to determine serum cortisol-like activity
by radioimmunoassay. Three rats in the
adrenalectomy group with appreciable
levels o f circulating glucocorticoids were
excluded from evaluation.
Gastric Chamber
The construction of the rat whole
stomach chamber has been described
previously.5’6 After being deprived of
food but not water for 36 to 48 hours, the
animal is anesthetized with sodium pen
tobarbital (60 mg/kg body weight intraperitoneally) and placed supine on a
lucite platform. The rectal temperature is
maintained at 38°C with an electric
heating pad placed under the platform
and connected to a temperature controller
(YSI Instruments, Yellow Springs, Ohio).
The abdomen is opened through an up
per midline incision and the stomach
delivered. The esophagus and pylorus are
ligated without injury to the nerves or
vessels. The stomach is opened along its
greater curvature and pulled gently
through a small aperture in a lucite plate
placed over the animal. The stomach is
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pinned out, mucosal side up, to the top
of this plate and a lucite chamber (11-mL
volume) clamped to the mucosa and
plate. Any hair or scales ingested during
grooming are removed from the stomach
by gently rinsing with saline at 37°C.
Warmed solutions (37°C) are added to
and removed from the chamber by syr
inge. A glass paddle, turning at 200 rpm
and not in contact with the mucosa, keeps
the contents of the chamber always well
mixed. In this preparation, the gastric
mucosa is observed continuously and re
mains viable for up to 7 hours. Construc
tion of the chamber requires 10 to 15
minutes.
Ethanol Injury
The gastric chamber experiments con
sisted of six sequential 10-minute inter
vals during which 10-mL aliquots of
warmed solutions were added to the
chamber as detailed in Table I.
The sequence of 40% ethanol follow
ed by 100 mM hydrochloric acid produc
ed circumscribed areas of black
discolouration on the glandular portion
of the gastric mucosa. We have
documented by light microscopic ex
amination that these areas correspond to
regions of hemorrhagic necrosis.7
After the last 10-minute interval in each
experiment, colour transparencies were
made of the mucosa. These slides were
labelled with a code number and pro
jected onto a translucent screen. The total
area of the glandular mucosa of the
stomach and the total area of gross injury
produced by topical ethanol were
measured by planimetry. A single
observer, blinded as to experimental
group, measured all areas on all slides.
For each experiment, the damaged area
was expressed as a percentage of the total
area of glandular mucosa.

pretreated with 16,16-dimethyl prosta
glandin E2 (Upjohn Co., Kalamazoo,
Mich.), 1 pg/mL, for 10 minutes im
mediately before exposure to ethanol.
Statistical Analysis
The arithmetic mean ± standard error
(SE) of the percentage of glandular
mucosa injured was calculated for each
experimental group. The experimental
groups were compared using Student’s ttest. Significance was taken to be p <
0.05.
Results

The results of the experiment are shown
in Table II.
Sham-operated animals showed very
little damage under control conditions.
The mean area of glandular mucosa in
jured in this group was 4.3% ± 1.1 % (n
= 5). The adrenalectomized animals also
showed little damage under similar con
ditions with a mean area of injury of
7.9% ± 4.5% (n = 2). This was not
statistically different from the shamoperated group. Exposure to 40% ethanol
for a 10-minute period caused a signifi
cant increase in the area of mucosal in
jury in both sham -operated and
adrenalectomized animals, producing
33.7% ± 5.6% (n = 10) injury and
42.7% ± 8.7% (n = 11) injury, respec
tively. Pretreatment with prostaglandin
E2 significantly reduced injury in both
sham-operated and adrenalectomy groups
to 9.8% ± 2.0% (n = 9) and 22.3% ±
5.0% (n = 9), respectively. The area of
injury in the adrenalectomized rats was
greater than that of the sham-operated
animals for each set of experimental con
ditions; however, these increases were not
statistically significant.
Discussion

Prostaglandin
Eighteen rats, 9 in each group, were
Table I—Composition of Solution in
Gastric Chamber during Each 10-Minute Period
Composition of solution
10-min
period, no Control
1
2
3
4
5
6

M
M
V
M
A
A

Ethanol

Prostaglandin
+ ethanol

M
M
V
ET
A
A

M
M
PG
ET
A
A

M - 300 mM mannitol, V = 100 /^L absolute
ethanol added to 300 mM mannitol, PG - 10
Mg 16,16-dimethyl prostaglandin E2 in 100 pL
ethanol added to 300 mM mannitol, ET 40% (vfv) ethanol, A - 100 mM HCI in 100
mM mannitol. All volumes were 10 mL and all
solutions were delivered at 37°C .
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Corticosteroids have a complex interac
tion with prostaglandins. Corticosteroids
inhibit the release of arachidonic acid
from cell membrane phospholipids,8'10
possibly by inducing the synthesis of an
inhibitor of phospholipase A2.11,12 They
may also increase the responsiveness of
cells to prostaglandins by preventing the
release of newly synthesized prostaglan
dins from the cell13 or by inducing the
synthesis of a protein that increases the
sensitivity of adenylate cyclase to
prostaglandins.14

The effect of adrenalectomy on the
gastric physiology of most animal species
is to cause acid and pepsin content and *
the volume of gastric secretion to
decrease.15'17 Adrenalectomy reduces the I
gastric secretory response to histamine,
gastrin and insulin hypoglycemia.17 Cor- i
ticosteroids administered as supplement
restored the diminished basal acid secre-^ ^
tion and stimulated acid output in the
adrenalectomized animal but did not in- '
crease acid secretion in the intact
animal.15
Schapiro and Britt17 have reviewed the «
conflicting results reported concerning the
effect of adrenalectomy on restraint'1 ‘
ulceration in the rat. This susceptibility
of rats to restraint ulceration has been 3
reported to be increased, decreased or un- M
changed following adrenalectomy. The
effect of adrenalectomy on indomethacin- ^
induced ulceration in the rat appears to
be equally unclear. Djahanguiri and < .
associates18 found that adrenalectomy
;
did not affect rat susceptibility to ulcera- t
tion caused by indomethacin. Bhargava
and associates19 showed that adrenalec- ‘
tomy suppressed indomethacin-induced ^
ulcers and Urushidani and associates20
reported that adrenalectomy markedly h t
aggravated indomethacin-induced ulcers.
Szabo and colleagues2 reported that
i
adrenalectomy did not alter the severity
of gastric erosions in rats receiving ab
solute ethanol by gavage and that
adrenalectomy inhibited protection by
prostaglandin F2(3.
j
Adrenalectomy increased the mean 4
percentage of glandular mucosa damaged under all our experimental conditions.
\
The increase in injury produced by
adrenalectomy was not statistically
significant; however, these results suggest
that adrenalectomy increases the suscep
tibility of the gastric mucosa to injury, r
Possible explanations for the difference
in the results obtained by Szabo and'*
colleagues2 and ours are first that they
used a different prostaglandin (not one
noted for its protective power) and second
that they induced damage with absolute
J
ethanol which may have caused too severe 4
an injury to demonstrate the subtle
augmentation of protection afforded by *
adrenalectomy in our experiments.
C
Our results show that the synthetic J
prostaglandin analogue 16,16-dimethyl
prostaglandin E2 possesses the capacity
)
for mucosal protection even in adrenalec
tomized rats. This suggests that while

Table ll-Damage to Glandular Mucosa in Response to Ethanol (ET) or
16,16-dimethyl Prostaglandin E2 (PG) and ET, Expressed as Mean Percentage ± Standard Error
Group
Adrenalectomized
Sham operated

Control

ET

PG + ET

7.9 ± 4.5*
4.3 ± 1 . 1 *

42.7 ± 8.7
33.7 ± 5.6

22.3 ± 5.0*
9.8 ± 2.0*

*p < 0.05 compared with ET.
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adrenoprivic tissue may be more suscep
tible to injury, it remains responsive to
the protective action(s) o f the prostaglan
dins.
W e have shown that chronic mild
restraint for up to 10 days protects the rat
gastric mucosa from ethanol injury7 and
that this p ro tectio n is p rob a b ly
prostaglandin-mediated and augmented
by adrenalectomy.21 Therefore, all o f
our experiments in adrenalectomized rats
support the conclusion that prostaglan
din protection o f the gastric mucosa is not
mediated by adrenocortical hormones.
Adrenalectomy also removes circulating
catecholamines, in particular epinephrine,
which acts primarily on a-adrenergic
receptors. The sympathetic system in
hibits release o f acetylcholine and could
theoretically protect against mucosal
damage by reducing acid-pepsin secre
tion. However, all the evidence indicates
that reduction in adrenergic activity
predisposes the stomach to ulceration.22
Our results suggest that prostaglandin
protection, at least against ethanol injury,
is not mediated by catecholamines.
The exact mechanism o f prostaglandin
protection remains obscure and presents
a major challenge for future research.

W e are indebted to Dr. John L. Wallace for
his assistance w ith these studies. W e
acknowledge the secretarial assistance o f Miss
Helen Gigas.

References
1. COHEN M M : Gastric mucosal protection with prostaglan
dins. In PFEIFFER CJ (ed): Drugs and P ep tic Ulcer, vol.
1, C R C Pr, Boca Raton, Fla., 1982: 133-46
2. Sz a b o S, G a l l a g h e r G T , H o r n e r H C , F r a n k e l
P W , TRIER JS: Gastric cytoprotection: role o f adrenal
cortex and sulfhydryl-containing chemicals (abstr).
Gastroenterology 1980; 78: 1273
3. DERELANKO MJ, LONG JF: Influence o f prednisolone
on ethanol-induced gastric injury in the rat. D ig Dis Sci
1982; 27: 149-54
4. Idem: Effect o f corticosteroids on indomethacin-induced
intestinal ulceration in the rat. D ig Dis Sci 1980; 25: 823-9
5. MERSEREAU W A , HlNCHEYEJ: E ffect o f gastric acidi
ty on gastric ulceration induced by hemorrhage in the rat,
utilizing a gastric chamber technique. Gastroenterology
1973; 64: 1130-5
6. M o r r is G P , W a l l a c e JL: The roles o f ethanol and o f
acid in the production o f gastric mucosal erosions in rats.
Virchows A rch [C ell Pathol] 1981; 38: 23-38
7. WALLACE JL, T r a c k NS, C o h e n M M : Chronic mild
restraint protects the rat gastric mucosa from injury by
ethanol or cold restraint. Gastroenterology 1983; 85:
370-5
8. L e w is G P, P ip e r PJ: Inhibition o f release o f prostaglan
dins as an explanation o f some o f the actions o f anti
inflammatory corticosteroids. Nature 1975; 254: 308-11
9. G r y g l e w s k i RJ, P a n c z e n k o B, K o r b u t R, G r o d z in SKA L, OCETKIEWICZ A : Corticosteroids inhibit pro
staglandin release from perfused mesenteric blood vessels
o f rabbit and from perfused lungs o f sensitized guinea
pig. Prostaglandins 1975; 10: 343-55
10. H o n g SL, L e v in e L: Inhibition o f arachidonic acid
release from cells as the biochemical action o f anti
inflammatory corticosteroids. P ro c N a tl Acad Sci USA
1976; 73: 1730-4

11. K a p l a n A P : Coagulation, kinins, and inflammation. In
O p p e n h e im e r JJ, ROSENSTREICH D L (eds): Cellular
Functions in Im m unity and Inflam m ation, Elsevier, New
York, 1981: 397-413
12. K a p l a n A P , Sil v e r b e r g M , D u n n JT, G h e b r e h iw e t
B: Interaction o f the clotting, kinin-forming, comple
ment, and fibrinolytic pathways in inflammation. Ann
N Y A ca d Sci 1982; 389: 25-38
13. C h a n g J, L e w is G P , P ip e r PJ: Inhibition by glucocor
ticoids o f prostaglandin release from adipose tissue in
vitro. B r J Ph a rm a col 1977; 59: 425-32
14. FOSTER SJ, P e r k in s JP: Glucocorticoids increase the
responsiveness o f cells in culture to prostaglandin E l.
P ro c N a tl A ca d Sci U S A 1977; 74: 4816-20
15. COOKE A R : Role o f adrenocortical steroids in the regula
tion o f gastric secretion. Gastroenterology 1967; 52:
272-81
16. KOWALEWSKI K: Histamine and-or cortisol stimulated
gastric secretion in normal and adrenalectomized rats.
A rch In t Pharm acodyn Ther 1971; 189: 328-35
17. SCHAPIRO H , BRITT L G : The effect o f adrenalectomy
on the gastrointestinal tract. A review o f the literature.
Rev Surg 1972; 29: 229-39
18. D j a h a n g u i r i B, H e m m a t i M , A b t a h i F, Fa r r o k h s ia r M : Preventive effects on indomethacininduced gastric ulceration in the rat o f disulfiram, phenoxybenzamine and bile-duct ligation. In GHEORGHIU T
(ed): Experim ental Ulcer, W itzstrock, Baden-Baden,
1975: 31-5
19. Bh a r g a v a K P , G u p t a M B, T a n g r i K K : Mechanism
o f ulcerogenic activity o f indomethacin and oxyphenbutazone. E u r J Pharm acol 1973; 22: 191-5
20. U r u s h id a n i T , K a s u y a Y , O k a b e S: The mechanism
o f aggravation o f indomethacin-induced gastric ulcers by
adrenalectomy in the rat. Jpn J Pharm acol 1979; 29:
775-80
21. W a l l a c e JL, C o h e n M M : Mechanisms o f gastric
mucosal protection by mild restraint. In ALLEN A ,
F l e m s t r Om G , G a r n e r A , S il e n w , t u r n b e r g L A
(eds): M echanisms o f M ucosal P rotection in Upper
Gastrointestinal Tract, Raven, New Y ork 1984: 365-70
22. TAYLOR J A , M ir G N : Alpha adrenergic receptors and
gastric function. D ru g Dev Res 1982; 2: 105-22

Sum m ary o f product information

DEXON * “ S”

DEXON* PLUS

IND IC ATIO N S: DEXON “S ” Sutures and D EXON PLU S Sutures are
indicated whenever absorbable sutures and ligatures are employed.

POLYG LYCO LIC ACID SUTURE
SYNTHETIC. ABSO RBABLE
USP

POLYGLYCOLIC ACID SUTURE
COATED W ITH PO LO XAM ER 188
SYNTHETIC, A BSORBABLE
USP

C O N T R A IN D IC A T IO N S : DEXON "S " Sutures and D EXON PLU S
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Absorbable, USP and DEXON PLU S polyglycolic acid Suture — Syn
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placed in tissues, a minimal tissue reaction occurs which is followed by
a microscopic layer of fibrous connective tissue which grows into the
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Staple Closure of the Left Atrial Appendage
Closure of the fibrillating left atrial ap
pendage has been recommended during
mitral valve repair or replacement to pre
vent systemic emboli postoperatively.
Closure of the left atrial appendage has
been accomplished in the past by direct
intra-atrial suture or by external ligation.
The authors have used the TA-55
automatic stapler in 40 patients to close
the left atrial appendage during mitral
valve surgery. In all patients the closure
was effected successfully at the first at
tempt without complication.

bus formation because it is anatomically
isolated from the main atrial cavity.1,2
Routine closure of the left atrial append
age during mitral valve replacement or
repair has therefore been recommended
to prevent the postoperative formation of

Au cours des operations de reparation ou
de remplacement des valvules mitrales, il
a 6te recommande de proc^der a la fermeture d'un auricule cardiaque gauche
en fibrillation afin d'eviter les embolies
systemiques postopdratoires. Par le
passe, la fermeture de I'auricule cardia
que gauche a ete accomplie par suture
intra-auriculaire directe ou par ligature
externe. Les auteurs ont utilise I'agraffeuse automatique TA-55 chez 40
patients afin de fermer auricule cardiaque
gauche au cours d'operations de la val
vule mitrale. Dans tous les cas la ferme
ture a et£ reussie a la premi&re tentative,
sans complication.

Surgical Technique

Systemic embolism is a well-recognized
complication of mitral valve disease,1
particularly in patients with mitral
stenosis, an enlarged left atrium and atrial
fibrillation in whom the combination of
valvular obstruction and atrial fibrillation
promotes stasis, resulting in the forma
tion of a left atrial thrombus. Although
thrombus is formed in the left atrial
chamber, the fibrillating left atrial
appendage is particularly prone to thromFrom the Department o f Surgery, Division
o f Cardiovascular Surgery, Victoria
General Hospital, Halifax, NS
Supported by a grant from the McLaughlin
Foundation
Accepted for publication May 17, 1983
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a left atrial thrombus and systemic
emboli.3,4
Although closure of the appendage has
been accomplished in the past by direct
intra-atrial suture or external ligation,
both methods have limitations. When the i
left atrial appendage is closed directly
from within the left atrium, the cir
cumflex coronary artery may inadvertent
ly be injured because of its proximity to
the base of the appendage.5 External
ligation techniques for closing the appen
dage employ a single tie that is secured
around the base of the appendage. *
Because the appendage is usually broadbased, the pursestring effect of the tie
may result in tears of the left atrium or,
if the tie is not positioned sufficiently
close to the base of the appendage, a
sizeable portion of the appendage may re
main open to the left atrial cavity. A new
staple technique for closing the left atrial
appendage forms the basis of this report. 4

FIG. 2—Staples in place (arrow) along base
of left atrial appendage following mitral valve
surgery.

Dissatisfied with previous methods for
isolating the left atrial appendage, we
have recently closed it with the TA-55
automatic stapling device (Auto Suture >
Co., Division of United States Surgical
Corp., Norwalk, Conn.), using a 4.8-mm
vascular staple. The TA-55 stapler ap
pears to be satisfactory for the majority
of appendage closures, although we made
use of the TA-90 stapler in one patient
with an exceptionally broad-based atrial ^
appendage.
Most patients with significant mitral
valvular disease have severe left atrial
hypertension; therefore, the closure
should only be carried out when the heart
is empty and arrested because attempted
closure of the appendage with the heart ,
beating and the left atrium full could
result in inadvertent tearing at the base
of the appendage. Furthermore, we
recommend that the closure be carried out
before a prosthetic mitral valve is inserted
as there is always a risk of injury to the
atrioventricular groove if the heart is
elevated out of the pericardial cavity after 4
the insertion of a rigid prosthesis.
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When the aorta has been clamped and
the heart arrested, the tip of the left atrial
appendage is grasped with Russian
forceps, the TA-55 stapler is positioned
at the base of the appendage and the
staples are released (Fig. 1).

i
^
>

» }

Results

Staple closure has been used in 40 consecutive patients with mitral valve disease
and atrial fibrillation. In one patient the
^
staples failed to release on the first at
tempt, resulting in a small tear that was
► repaired with a single Prolene suture. The
t

staple cartridge had probably been im
properly loaded. All the remaining
closures resulted in a complete, secure,
hemostatic closure without complication
at the first attempt. Fig. 2 illustrates the
typical appearance of the initial
postoperative chest roentgenogram
following staple closure of the left atrial
appendage.
We now routinely close the left atrial
appendage using the automatic stapling
device. This technique is rapid and results
in a complete and hemostatic closure of
the fibrillating appendage.
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Hemangiopericytoma: Case Reports

I
X

The authors' experience with two recent
I 4 cases and their review of the literature
suggest that the behaviour of
hemangiopericytoma is unpredictable and
that wide surgical excision is the treat
ment of choice because of the potential
for malignant change.

(.'experience des auteurs de deux cas et
leur revue de la literature suggerent que
j. r _ 1'evolution de I'hemangiopdricytome est
incertaine et que le traitement de choix
...
consiste en une excision large, du fait de
son potentiel malin.

Flemangiopericytoma was first described
by Stout and Murray1 as an aggressive
vascular neoplasm characterized by a patr v tern of endothelial cells surrounded by
cells similar to the pericytes of ZimmerI
mann.1-3 Although only 400 examples4
j
are reported in the literature, the tumour
may not be uncommon; any painless
^ lump on the trunk or extremities increas
ing slowly in size may be a hemangio*- pericytoma. We report two cases that Il
lustrate the unpredictable behaviour of
this tumour.
r

left forearm. An angiogram suggested a malig
nant lesion (Fig. 1). Biopsy revealed the
features of a hemangiopericytoma (Fi.% 2). The
patient was unwilling to have an amputation;
he had partial excision of th e mass com
plemented by radiotherapy. One year later, he
had local recurrence with hung metastases.

Case 2
An 18-year-old mein had a painless mass in
the right hypocho.-ndrium. Angiography and
computerized axial tomography gave equivocal
results but a radionuclide scan of the liver with
colloidal sulfur demonstrated the extrahepatic
nature of (the tumour (Fig. 3). At laparotomy
there wa/J a firm mass inside the muscular ab
dominal wall, which was widely excised. It was
a hemangiopericytoma.

masquerade as hemangiopericytoma
wVicn rhey show a prominent vascular
network5 — synovial sarcoma, mesen
chymal chondrosarcoma, Ewing’s sar
coma and fibrous histiocytoma. In most
cases, however, reticulin silver staining6
will enhance the vascular pattern of
hemangiopericytoma and clearly show
that the tumour cells are located outside
the basement membranes of the vessels
(Fig. 4). Although tumour cells are usual
ly individually surrounded by reticulin
fibres, this is not always the case, especial-

Discussion

The pathologic diagnosis of heman
giopericytoma is difficult. The differen
tial diagnosis includes many of the
spindle- and round-cell tumours that can

Case Reports

r
, f

Case 1
A 21-year-old man had a slightly painful,
slowly growing mass on the volar aspect of the

From the Department o f Orthopedics and
Department o f General Surgery, University
de Sherbrooke, Sher brooke, PQ
^
Accepted fo r publication July 21, 1983
Reprint requests to: Dr. P. Kinnard,
r Department o f 'Orthopedics, Centre
Hospitalier Un iversitaire de Sherbrooke,
Sherbrooke, P Q J1H 5N4

FIG. 1—Case 1. Late venous phase of
angiography in a hemangiopericytoma.

FIG. 2—Case 1. Small spindle-cell tumour
with vascular spaces lined by thin walls.
Cellular lesion with mitoses (hematoxylin and
eosin, reduced by 54% from x 160).
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Since radiotherapy or chemotherapy14
have only a limited action on the tumour,
the treatm ent of choice must be,
whenever possible, a wide excision12 to
avoid recurrence and distant spread.
We acknowledge the help of Dr. A. Trias
in preparing this manuscript.
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FIG. 3— Case 2. Radionuclide scan shows that tumour (arrows) is extrahepatic.

The tumour may develop over a period
of years wherever there are capillaries11
but m ost often is found in the
retroperitoneum and the extremities. Its
malignant potential has been underes
timated — all hemangiopericytomas
should be considered dangerous7 because
it is difficult to tell in advance which
tumour will behave in a malignant
fashion; a major setback in a planned
surgical treatment is an inadequate,
limited excision leaving a potential source
of local recurrence or distant spread.12
The rate of lcxcal recurrence, distant
metastasis and m ortality are high,
reaching 50% within 5 years.4’6’7*11’13
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SESAP IV Question
i
FIG. 4—Silver impregnation demonstrates
vascular channels with intervening tumour cells
surrounded by reticulin fibres (reduced by 54%
from X160).

ly in aggressive or overtly malignant
lesions.
More difficulties are encountered in
evaluating the prognosis of such lesions.
Benign and malignant hemangiopericy
tomas share a similar growth pattern as
recognized on the reticulin stained sec
tions. However, increased cellularity,
necrosis and a high mitotic index usually
indicate aggressive if not malignant
potential, such as seen in case l .7
Hemangiopericytomas are thought to
originate from the pericytes of Zimmermann. The existence of such cells has
been established by ultrastructural
studies8,9 and Stout’s concept has been
confirmed by electron-microscopic study
o f the tu m o u r.10 T herefore, it is
reasonable to consider hemangioperi
cytoma as a separate clinicopathologic
entity.
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Which of the following statements about the use of fluorocarbons as
blood substitutes is NOT correct?
106.

(A)

When injected without emulsification, they may produce
pulmonary embolism

(B)

They are most effective with the hematocrit as near normal as
possible

(C)

They can be stored indefinitely in the frozen state

(D)

They leave the body completely in a matter of days without any
discernible effect on the tissues

(E)

The oxygen dissociation curve is linear with changes in oxygen
tension

For the answer and critique of Item 106 see page 167.
(Reproduced by permission from SESAP IVSyllabus: Surgical Education and
Self-Assessment Program No. 4. For enrolment in the Surgical Education and
Self-Assessment Program No. 4, please apply to the American,, College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
\
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“MALLITENE is the first hemostat that combines the high
hemostatic action of microfibrillar collagen with the easy
a n n lic a h ilitv n f d o t h ” Prof Mylos ChvaPh MD
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Head of Surgical Biology, Department of Surgery, University of Arizona.

MALLITENE’S composition of chemically
pure microfibrillar collagen accounts for its
high hemostatic effectiveness. Its
presentation as a cloth is due to a unique
textile processing which allows for its easy
applicability.
It can easily be cut to the desired size,
folded to increase its hemostatic
effectiveness, sutured to lacerated tissue
(liver, spleen, kidney) or removed in one
piece. It does not stick to instruments and
can be handled by dry gloves.
A comparison of MALLITENE’S hemostatic effectiveness and
handling properties with other hemostatic agents is found
in the graphs below.

Hemostatic Effectiveness+
(Tim e to O b ta in H e m o s ta s is o f S p lenic Bleeding)
Minutes

mallitene
Collagen Fleece

C o lla ge n Felt

C ollagen
Powder

Gelatin
Sponge

Oxidized
C ellulose

Handling Properties+
(Ease of A p p lic a tio n , A d h e sio n , C o m pleteness o f Removal, C o n fo rm a b ility )
-

IDEAL

1

ADVANTAGES

-

Indications: The c o n tro l o f d iffu s e
blood oozing in any tis s u e where it is
im p ra c tic a l or im p o s s ib le to use
lig a tio n or other conve n tio n a l surgica l
procedures.
Contraindications: A fte r hem ostasis
is achieved, M ALLITENE shou ld not
be le ft in the wound if used in
in fected or c o s m e tic a lly im portant
areas. This a p p lie s to all collagen- or
gelatin-based to p ic a l hem o s ta tic
agents.

Handling Instructions: Dry
M ALLITEN E o f the desired size is
app lie d to a bleeding w ound, under
m oderate pressure. It is preferable
fo r excessive blood to be removed
from the bleeding s ite before covering
it w ith the fleece. The cohesiveness
o f the fle e c e allow s the a p p lic a tio n by
hand (it does not adhere to dry rubber
gloves) or by force ps or cla m p. The
fleece can be cut w ith s c is s o rs or
folde d to th e desired size. A patch of
the fleece can be sutured over the
bleeding tis s u e if so required. A fte r
a c hievin g hem ostasis, the fleece may
be rem oved in one piece leaving little
or no fib ro u s residues. It was
e ffe c tiv e in p a tie n ts trea ted w ith a n ti
c o a g u la n ts or aspirin.

MALLITENE is available in the following sizes:

-

Size
POOR

i

Fast Hemostatic Effect due to the large
surface area of the individual fine
collagen fibres of the fleece and the
strong adhesion to the wound.
Does Not Stick to rubber gloves or
surgical instruments. Has no electrical
charge.
Conforms and Adheres firmly to the
bleeding wound.
Can be Sutured to the lacerated wound.
Holds stitches well due to the textile
processing.
Easy to Remove in one piece after
hemostasis is achieved.
Fast Resorbtion in body tissues (avg. rate
of biodegradation: 25 days). Minimizes
risk of adhesions.

Warnings: In p a tie n ts w ith low
plate le t coun t or low c lo ttin g fa cto r
a c tiv ity , the e ffic a c y o f M ALLITENE is
reduced.

-

■

mallitene
Collagen Fleece

C ollagen
Felt

C ollagen
Powder

G elatin
Sponge

O xidized
C e llu lo se

3 x 5 cm
5 x 8 cm

Weight

Pieces Per Pack

375 mg.
1,000 mg.

10
10

Detailed information available on request.
t Adapted fro m S ilverstein, M.E. and Chvapil, M., J. Traum a 21: 388-393, 1981.
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Order #
50003
50008

A

i

A

<

V

k

1 ■ M A LLITE N E is applied to wound in the spleen
under moderate pressure with dry rubber gloves.

2 ■ Hemostasis is^
achieved quickl
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MALLITENE texturized collagen fleece is
another new idea brought to life, manufactured
and distributed exclusively by Malliner
Laboratories.

malliner laboratories inc.
>

“ Bringing new ideas to life.”

10548 - 82nd Avenue, Edmonton, Alberta T6E 2A4
Telephone: (403) 433-8466
Malliner Laboratories Inc. is a Canadian company wholly owned by Canadians.
Copyright Malliner Laboratories Inc. 1983.

Photographs courtesy of the University of Saskatchewan,
Department of Surgery.
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Risks and Benefits of Open-Heart Surgery
in Patients 70 Years of Age and Older
From January 1978 to December 1982,
165 consecutive patients aged 70 to 81
years underwent various open-heart
surgical procedures at the St. Boniface
General Hospital in Winnipeg.
Preoperatively, most of the patients were
in functional class III or IV (New York
Heart Association classification). Overall
operative mortality for the series was
10.9% . Isolated coronary artery bypass
surgery, performed in 71 patients, had
an operative mortality of 2.8 % . Results
were also good in isolated single and
double valve replacement in 58 patients
(operative mortality 8.6% ); there were
no deaths in a group of 27 patients who
underwent isolated aortic valve replace
ment. Thirty-six patients with various
combined, extensive procedures had the
poorest result (operative mortality
30.5% ). More than 90% of surviving pa
tients were in functional class I or II
postoperatively. The complication rate,
although high, was acceptable.
Immediate and long-term clinical im
provement in the majority of patients
justifies a surgical approach except in
patients who require combined, exten
sive procedures.
Entre janvier 1978 et decembre 1982,
165 patients consecutifs ages de 70 &
81 ans ont subi diverses operations d
coeur ouvert a I'Hopital general
St-Boniface de Winnipeg. En preoperatoire, la plupart des patients appartenaient aux classes fonctionnelles III et IV
(classification de la New York Heart
Association). Pour I'ensemble de cette
serie, la mortality peroperatoire a ete de
10.9% . Pratiques chez 71 patients, les
pontages aorto-coronariens, en interven-
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tion isolee, ont 6t6 entaches d'une mor
tality peroperatoire de 2.8% . De bons
resultats ont aussi ete obtenus dans les
cas de remplacements valvulaires sim
ples ou doubles, chez 58 patients (mor
tality peroperatoire de 8.6% ); aucun
dyces n'a ete enregistre chez 27 patients
qui ont subi uniquement un remplacement de valvule aortique. Les plus mauvais resultats ont ete rencontrys chez 36
patients qui ont subi diverses interven
tions etendues, multiples (mortality pero
peratoire de 30 .5% ). Plus de 90% des
survivants se sont retrouves dans les
classes fonctionnelles I et II apres ('ope
ration. Bien qu'elevee, la frequence des
complications a ete acceptable.
L'amyiioration clinique immydiate et a
long terme observes chez la majority des
patients justifie une approche chirurgicale sauf chez les malades qui necessitent des interventions multiples et
etendues.

the St. Boniface General Hospital. The
mean age ( ± standard deviation) of the
patients was 72.6 ± 2.4 years. There were
106 men and 59 women. Seventy-one pa-'
tients had isolated aortocoronary bypass
grafting. Fifty-eight patients had isolated
single or double valve replacements — 27
aortic, 25 mitral and 6 aortic and mitral
valve replacements. Thirty-six patients
had combined procedures such as bypass
grafting plus valve replacement and other
complicated operations such as repair of
aortic dissection. Almost all patients were
in New York Heart Association func
tional class III or IV preoperatively.
Many patients were referred for operation
late in their clinical course, after all
medical therapy had failed. Of the 71 pa
tients who underwent coronary bypass, 57
had unstable angina. Impaired left ven
tricular function (ejection fraction
less than 50%) was documented by ven
triculography in 52 patients (31.5%).

Increasing numbers of elderly patients are
being referred for cardiac surgical pro
cedures. There may be several reasons for
this. First, there is an expanding elderly
population with increased life expec
tancy.1 Second, there is a higher fre
quency of heart disease in this older
population as a result of the normal age
ing process. Many patients are in good
health otherwise but are disabled by heart
disease. However, some physicians are
still reluctant to refer elderly patients for
cardiac surgery because of high surgical
mortality and morbidity reported in the
literature.2'8 Many publications on the
efficacy of open-heart surgery in the
elderly report results in patients aged 60
to 65 years, who are no longer considered
to be elderly. Furthermore, some of these
reports are outdated. The purpose of this
study is to assess the risks and efficacy of
different cardiac surgical procedures in a
group of patients 70 years of age or older,
operated on in the last 5 years.

Operative Technique

Patients

From Jan. 1, 1978 to Dec. 31, 1982,
165 consecutive patients underwent
various open-heart surgical procedures at

Moderate systemic hypothermia (24°C
to 28°C) with moderate hemodilution
(hematocrit 20% to 24%) was used with
m ultidose hypotherm ic crystalloid
cardioplegia in almost all patients.
Usually a bubble oxygenator was used
and there was one period of aortic
cross-clamping. Most often, the distal
vein graft to coronary artery anastomosis
was performed first. The average time of
ischemia was 52 minutes (range from 18
to 137 minutes) with an average
cardiopulmonary bypass time of 103
minutes (range from 34 to 247 minutes).
In coronary bypass operations, the
average number of vessels grafted was 3.5
per patient. Routinely, long saphenous
vein from the thigh and calf, but
occasionally short saphenous vein, was
used as conduits. No internal mammary
artery bypass was performed. In the
valve-replacement group, bioprostheses
were used in the majority of patients.
Results

Operative Mortality
Overall, there were 18 operative deaths
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T a b le 1 - C a u s e s o f E a r ly D e a t h s
G r o u p lc a u s e o f d e a th

No.

A o r to c o r o n a r y b y p a s s
M y o c a r d ia l f a ilu r e

2

V a lv e re p la c e m e n t
In tr a o p e r a t iv e b le e d in g

2

M y o c a r d ia l f a ilu r e

2

C e r e b r o v a s c u la r a c c id e n t

1

C o m b in e d p ro c e d u re s
In t r a o p e r a t iv e b le e d in g

3

M y o c a r d ia l fa ilu r e

6

P o s t o p e r a t iv e m u lt is y s t e m
fa ilu r e

2

FIG. 1—Survival by year of operation.
White bars = survivors, hatched bars = those
who died.

FIG.2—Functional status before and after
heart surgery according to New York Heart
Association classification.

(within 30 days of operation) (10.9%). In
the coronary bypass group, two patients
(2.6%) died. Both deaths were in patients
with critical stenosis of the left main
coronary artery and unstable angina.
There were five deaths (8.6%) in the
isolated valve-replacement group. The
mortality was highest in the combined
procedure group where 11 patients died
(30.6%).
Twelve patients died of myocardial
failure and low-output state (Table I).
The next commonest cause of death was
uncontrolled bleeding intraoperatively.
One such patient had left ventricular
rupture after mitral valve replacement
and another had coronary sinus laceration
from venous cannulation. In four other
patients, bleeding followed emergency
repair of a ventricular aneurysm or of
aortic dissection. The tissues were found
to be more friable in the elderly patients.
There were three late deaths (after 60
months). One died after 2 months of
refractory congestive heart failure, one of
carcinoma of colon and one o f cerebral
hemorrhage. Fig. 1 shows survival by year
from the time of operation.
Functional Improvement
Postoperatively, almost all patients
improved by one functional class. More
than 30% of the surviving patients were
asymptomatic postoperatively (Fig. 2).
Notable postoperative complications
occurred in about 40% of our patients.
The most common problem was that of
supraventricular arrhythm ia (atrial
flutter, fibrillation). Postoperative heart
block occurred in 17 patients and 8
required implantation of a permanent
pacemaker. Low output state occurred in
30 patients (including 10 patients who
died perioperatively) and the intra-aortic
balloon pump was used in 13 of these
patients. Intraoperative bleeding caused
problems in 11 patients (including 5 who
died). Three patients required reoperation
for control of postoperative bleeding.
Twelve patients had mild confusion and
disorientation. In 11, perioperative
myocardial infarction (as judged by
elevated creatine phosphokinase
isoenzymes and new Q waves on the
electrocardiogram ) occurred. Eight

patients required treatment for control of
overt congestive heart failure. Five
patients suffered a stroke perioperatively;
in three cases this was likely due to
embolization o f atheromatous material
from a diseased ascending aorta.
Prolonged ventilatory support was
necessary in five patients. Two patients
had renal failure and required dialysis.
The mean ( ± SD) hospital stay of the
surviving patients was 16.4 ± 11.8 days
(range from 9 to 83 days). Of the total
series, 130 patients (79%) were followed up
postoperatively with periodic visits to the
outpatient clinic or office. The average
follow-up was 33 months (range from 2
to 67 months). There were three late
deaths. When the 5-ryf* probability of
survival was calculated by the life-table
method,6 there was an 84% chance of
survival in our patients compared with the
same age group in the general population
(Fig. 3).
Discussion
Is a patient ever too old to be con
sidered for cardiac surgical procedures?
In the early days of cardiac surgery,2 pa
tients over 50 years of age were considered
old for these operations. Recent reports,
on the other hand, tend to imply no up
per age limit.7' 19 One of the keys to suc
cessful surgical intervention in elderly pa
tients is patient selection. The most im
portant factor in selection is the evalua
tion of physiological age. The functional
status of the patient before the onset of
the last ailment, general health and men
tal status are im portant. Elderly patients
have a rather slim margin of functional
reserve in all organ systems. The effects
of ageing on the cardiovascular structures
and their function are now well known.
A p art from in creasing co ro n a ry
atherosclerosis and calcification, definite
d e te rio ra tio n takes place in the
myocardium.20 There is a substantial in
crease in the collagen tissue content of the
myocardium, and experimental and
clinical studies show that ageing is
associated with increased passive stiffness
and decreased velocity o f fibre
shortening.21'22 There are degenerative
changes in the conduction system that in
crease the likelihood of arrhythmia. These

T a b le I I — O p e r a t iv e M o r t a l i t y o f Is o la t e d C o r o n a r y B y p a s s in C o m p a r a b le S e r ie s
( P a t ie n t s 7 0 Y e a r s o r O ld e r)

S e r ie s

No. of

O p e r a t iv e

■age, y r

g ra fts /p a tie n t

m o r t a l it y , %

50

7 1 .3

2 .0

8 .0

B e r r y a n d a s s o c ia t e s , 1 9 8 1 14

65

7 2 .4

3 .4

3 .0

H o c h b e rg a n d a s s o c ia te s , 1 9 8 2 16

FIG. 3—Life-table analysis of survival after
heart surgery (stars) compared with general
population (circles).

M e d ia n
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No. o f
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121

7 2 .1

2 .9

1 .6

75

7 2 .3

2 .8

1 2 .0

7 2 .0

3 .2

4 .0

P e lle t ie r a n d a s s o c ia t e s , 1 9 8 3 17

23

J a n u s z a n d a s s o c ia t e s , 1 9 8 3 18

67

P r e s e n t s e r ie s

71

—

7 2 .6
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changes are variable and correlate with
the physiological age.22
There have been great advances in our
understanding o f the pathophysiology of
heart disease as well as in the operative
techniques o f cardiac surgery. These have
been reflected in the overall reduction of
surgical mortality and morbidity in all pa
tients. In our centre, there is an acceptable
overall surgical mortality o f 10.9%,
similar to that reported in other major
centres.3'19 The operative mortality of
2.8% in the isolated coronary bypass
group and 0% in isolated aortic valve
replacement are appreciably better than
in most reported series (Table II1318).
The majority o f survivors had gratify
ing results. M o s to-r.tients were restored
to a useful, ind^&ndent life in place of
the highly dependent existence o f the car
diac cripple. It has been suggested that
successful cardiac surgery is more cost ef
fective than medical therapy in the
elderly.12
The postoperative complication rate
was high, but the problems were usually
minor, such as supraventricular tachycar
dia and mild psychosis. Many o f the cen
tral nervous system problems were related
to the diseased atheromatous aorta and
require meticulous surgical technique.
Other postoperative problems are not dif
ferent from those of younger age groups.
Life-table analysis suggests a trend
towards longer survival in patients
operated upon than in the general popula
tion. Immediate and long-term clinical
improvement in the majority o f the pa
tients justifies a surgical approach.
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Open-heart surgery in elderly patients. Can M ed Assoc
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Conclusions
Patients over 70 years o f age can
undergo some types o f open-heart surgery
with an acceptable operative risk, but ex
tensive, combined surgical procedures
carry a notably higher operative risk. In
the majority o f patients, there is satisfac
tory easing o f symptoms. There is risk of
postoperative arrhythmias and central
nervous system complications. The 5-year
cumulative survival rate is high.
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NOTICES
Call for Abstracts,
Second International Conference
on Clinical Factors and
Mechanisms Influencing
Bone Growth
The second international interdisciplinary
conference, to be held at the University
of California, Los Angeles, in early
January 1985, will be a follow-up to the
basic science one held in January 1982 but
will emphasize clinical science aspects of
bone growth. Again, a primary objective
of the conference is to update and inte
grate our understanding of the growth of
bone with new knowledge and to offer
directions for future clinical research.
Factors and mechanisms that influence
normal and abnormal prenatal and post
natal bone growth, both general and cra
niofacial, will be covered, from the subcellular to the gross level. Clinical expecontinued on page 160
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NOW TREAT
po sto per a tiv e
FAIN BEFORE YOU
LEAVETHE O.R.

L MARCAINE* NERVE BLOCK OR INFILTRATION
t * BEFORE CLOSURE GIVES UP TO 15 HOURS OF
POST-OPERATIVE PAIN RELIEF1
' ' POST-OPERATIVE STRESS can be
substantially reduced by preventing
' f post-operative pain in those critical
f first hours after surgery 2

Marcaine blocks this pain, giving an
easier, quicker recovery; often without
the need for narcotic analgesics.3

MARCAINE

►

;»

FOR PAIN RELIEF THAT
STARTS IN THE O.R.
Winthrop Laboratories
Division of Sterling Drug Ltd.**
Aurora, Ontario L4G 3H 6
*Reg. Trade Mark
**Registered User

PAAB
CCPP

Prescribing Information

Marcaine*
(bupivacaine hydrochloride injection)
Indications:

Peripheral nerve block including infiltration,
sympathetic blockade, caudal, epidural, para
cervical and pudendal blocks.
C ontraindications:

Bupivacaine is contraindicated in persons with
known sensitivity to local anesthetics of the
amide type.
The use of bupivacaine is contraindicated in the
presence of sepsis near the site of proposed
injection, in severe shock and in heart block.
W arnings:

Usage in Pregnancy: Reproductive studies have
been performed in rats and rabbits and there is
no evidence of harm to the animal fetus. The
relevance to the human fetus is not known.
Safe use in pregnant women other than those
in labor has not been established.
The obstetrician is warned that severe persis
tent hypertension may occur after adminis
tration of certain oxytocic drugs, if vasopres
sors have already been used during labor (e.g.
in the local anesthetic solution or to correct
hypotension).
Until further experience is gained in children
younger than 12 years, administration of bupiva
caine in this age group is not recommended.
Precautions:

Marcaine should be used cautiously in persons
with known drug allergies or sensitivities, parti
cularly to the amide-type local anesthetics.
Caution is advised in administration of repeat
doses of bupivacaine to patients with severe
liver disease.
The lowest dosage tha t gives effective anes
thesia should be used, to avoid high plasma levels
and serious systemic side effects. Injection of
repeated doses of bupivacaine may cause
a significant increase in blood levels due to
accumulation of the drug or its metabolites or
slow metabolic degradation.
Tolerance varies with the status of the patient.
Debilitated, elderly and acutely ill patients may
require reduced doses commensurate with age
and physical condition.
Fetal bradycardia may follow paracervical block
with local anesthetics of the amide type and
may be associated with fetal acidosis. Fetal
heart rate should always be monitored during
paracervical anesthesia. Added risk appears to
be present in prematurity, toxemia of preg
nancy and fetal distress. The physician should
weigh the possible advantages against dangers
when considering paracervical block in these
conditions. When the recommended dose is
exceeded, the incidence of fetal bradycardia
increases. The incidence of fetal bradycardia
observed in clinical trials with bupivacaine in
which paracervical block was used, varied
between zero and 35%.
It should be remembered that solutions con
taining a vasopressor agent, e.g. epinephrine,
should be used with caution, if at all, in patients

who are receiving monoamine oxidase inhibi
tors or anti-depressants of the triptyline or
imipramine type, because severe, prolonged
hypertension may result. Dose related cardiac
arrhythmias may occur if preparations contain
ing epinephrine are employed in patients during
or immediately following the administration of
chloroform, halothane, cyclopropane, trichloro
ethylene or other related agents. In deciding
whether to use these products concurrently in
the same patient, the combined action of both
agents upon the myocardium, the concentration
and volume of vasoconstrictor used, and the
time since injection, when applicable, should be
taken into account.
The decision to use a local anesthetic contain
ing a vasoconstrictor in areas with a limited
blood supply or in patients with peripheral
vascular disease, will depend on the physician’s
appraisal of the relative advantages and risks.
Local anesthetics which contain preservatives,
i.e. those supplied in multiple dose vials, should
not be used for caudal or epidural anesthesia.
A dverse Reactions:

Reactions to bupivacaine are characteristic of
those associated with amide-type local anesthe
tics. A major cause of adverse reactions to this
group of drugs is excessive plasma levels,
which may be due to over- dosage, inadvertent
intravascular injection, or slow metabolic degra
dation. Other causes of reactions to these local
anesthetics may be hypersensitivity, idiosyn
crasy, or diminished tolerance.
Excessive plasma levels cause systemic reac
tions involving the central nervous system and
the cardiovascular system. The central nervous
system effects are characterized by excitation
or depression. The first manifestation may be
nervousness, dizziness, blurred vision, or
tremors, followed by drowsiness, convulsions,
unconsciousness, and possibly respiratory
arrest. Since excitement may be transient or
absent, the first manifestation may be drowsi
ness, sometimes merging into unconsciousness
and respiratory arrest. Other central nervous
system effects may be nausea, vomiting, chills,
constriction of the pupils, or tinnitus. The
cardiovascular manifestations of excessive
plasma levels may include depression of the
myocardium, blood pressure changes (usually
hypotension), and cardiac arrest.
Allergic reactions are characterized by cuta
neous lesions (e.g. urticaria, edema) and other
manifestations of allergy.
Reactions following epidural or caudal anes
thesia may include: high or total spinal block,
urinary retention; fecal incontinence, loss of
perineal sensation and sexual function; persis
tent analgesia, paresthesia, and paralysis of the
lower extremities; headache and backache; and
slowing of labor and increased incidence of
forceps delivery.
It should be noted that reactions due to
systemic absorption may be slow or rapid in
onset. Those of rapid onset include respiratory
depression, cardiovascular collapse and cardiac
arrest. This type of reaction necessitates a high
degree of preparedness since it can occur with
little warning.
In co-ordinated studies of 3200 procedures
carried out by 15 investigators, there were 2

severe systemic reactions. Both patients exf
rienced convulsions as a result of inadverter
vascular injection.
Fetal bradycardia has been observed with th
use of bupivacaine. Most cases, including
fatalities, occurred when the paracervical roi
was used (see “Precautions”).
* 1
In some subjects bupivacaine may produce
marked peripheral vasoconstriction in unafie
thetized areas which may last for severajjhq
Dosage and Adm inistration:

The duration of anesthesia with bupivacaine
such that, for most procedures, a singlg dos
sufficient. Maximum dosage limit must be in
dualized in each case after evaluating the gj'
and physical status of the patient, as well as
usual rate of systemic absorption from a<pa
cular injection site. Most experience to date
with single doses of bupivacaine up to 2 2 5 f
with epinephrine 1:200,000, and 175 mg
without epinephrine; more or less drugViay'
used depending on individualization of each
case.
At present there is insufficient clinical evigleq
with multiple dosage or intermittent dose te<
niques to permit precise recommendations f
such procedures to be given. However, limits
clinical experience in this area of use in<Sicatl
that bupivacaine may be repeated in 3 to 6
hours up to a maximum dose of 400 mg i1*l
hours. In most cases the duration of anesthe
effect is prolonged by the addition of ^ ’
epinephrine.
The following doses have generally proved
satisfactory for the average adult. They may.
require adjustment in relation to age and the
physical condition of the patient.
i
■
Local infiltration: up to maximum dosage of
0.25% solution.
-i
Peripheral nerve block: 5 to 30 mL of 0.50°/:
5 to 60 mL of 0.25% solution.
”
Sympathetic: 20 to 50 mL of a 0.25% soluti>
Epidural: 10 to 20 mL of a 0.25%, 0.50% o f
0.7 5 . solution.
^
Caudal: 15 to 30 mL of a 0.25% or 0.50% 1
solution.
,
Paracervical: 10 to 20 mL of a 0.25% solutio
Supplied:

*

'

Each 20 mL single dose vial contains: bupiva
caine 0.25%, 0.50% or 0.75% with or withoi
epinephrine 1:200,000. Boxes of 5 vials.,
Each 50 mL multiple dose vial contains: bupl
caine 0.25% or 0.50%. Boxes of 1 vial.
^
Note: Bupivacaine solutions without epinephi
may be autoclaved.
-<
Product Monograph available on request.
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Knitted Polypropylene (Marlex) Mesh in the Repair of
Incisional Hernias

In 5 0 c o n se cu tiv e p atients, large incisional hernias or th o se d ifficu lt to
m an ag e w e re repaired by suture im b rica
tion of the hernial sa c and e xtra fa sc ia l
| ► onlay fixatio n o f M arlex m esh. Sero m as
developed in th ree and w ound infection
'
in tw o . T h e use of clo sed suction drains
for all p atients and antibiotic proph ylaxis
before and a fte r operation for patients
(
4w ith anteced ent w o und in fectio n s m ay
prevent th ese co m p licatio n s. In the
A follow -up period (m ean of 2 .6 y e a rs),
lateral recu rren ce of the hernias occurred
► 4 in three p a tie n ts, but there has been no
recurren ce in th e last 2 y e a rs. The
m ethod of repair is sim ple and e ffe c tiv e .

[
,

D an s 5 0 c a s c o n se c u tifs de hernies lar.
fg e s dues a une incisio n chirurgicale ou
de hernies d ifficile m en t corrigeables, la
reparation a ete faite par suture d'imbricatio n du sa c herniaire et fixatio n aux
* fa s c ia s e xte rie u rs par reco uvrem ent a ve c
de la tulle M arlex. On a note des sero1
m as chez tro is p atients et des infectio ns
Kde plaie chez d e u x. L'u tilisatio n d'un
drainage asp iratif ferm e chez to u s les
y p atients et I'ad m inistratio n a titre
prophylactiq ue d'antib io tiq u es en pre- et
r ► postoperatoire chez les patients poss6dant des a n teced e n ts d'infectio n de plaie
'
p euvent pr6venir c e s com p lications.
D urant la p6riode d 'o bservation post[
therapeutique (m o yenne de 2 .6 an s), des
y recid ives latera les de la hernie sont apparues chez tro is p a tie n ts, m ais aucune n 'a
i * 6te o bservee au c o u rs des 2 dernieres
an n ees. C ette tech nique de reparation
e st sim ple et e ffic a c e .

Most incisional hernias may be repaired
successfully with the patient’s own tissues.
The 20% to 30% that recur following this
are mainly larger hernias, those with
multiple defects, or hernias in patients
with persistent predisposing causes, such
as obesity and wound infection.1 This
implies that recurrence is due to insuffi
cient or weakened autogenous fascia;
Peacock and Madden2 have provided
evidence to support th is. Many
au to g en o u s and p ro sth etic tissue
substitutes have been used for more
lasting repair, but none is entirely
satisfactory.3-6 Knitted polypropylene
(Marlex; Bard Implants, Billerica, Mass.),
originally used by Usher and associates,7
has been the most successful. This report
reviews a personal experience o f 50 con
secutive patients with large incisional her
nias or those difficult to manage, that
were repaired with Marlex mesh.

Technique
An extra-fascial approach to the her
nia repair was used in all but six patients
who required laparotomy to correct an
intra-abdominal problem, most common
ly obstruction by adhesions related to the
hernia. In most patients, the following
standard six-step approach to repair was
used:
1. Preoperative investigation to exclude
an intra-abdominal condition.
2. Perioperative systemic prophylaxis
with an appropriate antibiotic was used

T a b le I I —C h a r a c t e r is tic s of H e rn ia s
C h a r a c t e r is t ic
L o c a tio n o f h e rn ia ,
n o . o f p a tie n ts
U p p er abdom en

25

L o w e r abdom en

14

B o th upper and
lo w e r abdom en

Patients
The 50 patients ranged in age from 27
to 80 years (mean 50 years). Table I sum
marizes the characteristics of these pa
tients and Table II lists data pertaining
to the hernias. The majority o f patients
were overweight, and 20 had had a
previous wound infection at the site of
herniation. H alf the hernias were in the
upper abdomen, most were large and in
almost half repair had been attempted at
least once.

11

M id lin e

28

P a ra m e d ia n

10

T ra n sv e rs e

12
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143 ±
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P re v io u s a tte m p ts a t
re p a ir
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1
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2
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3

3
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‘ M ean ± S EM .
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M ean a g e , y r * (ran g e)

5 0 . 5 ± 2 .2 ( 2 7 - 8 0 )

N o. o f m en/w o m en

2 3/2 7

F a c t o r s p re d isp o sin g to h e rn ia :
No. w it h
R e m o te w o u n d in fe c tio n , yes/n o /u n kn o w n

2 0 /2 1 /9

O b e s ity
a c tu a l/ id e a l w e ig h t, % (ra n g e )*

135 ±

n o . o v e rw e ig h t p a tie n t s t

39

M o d e ra te to s e v e re c h ro n ic lung d isea se

3 .4 ( 9 0 - 2 1 1 )

17

‘ M ean ± s ta n d a rd e rro r of m ean.
t A c t u a l w e ig h t e xce e d in g 1 1 5 % o f id ea l.
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if there was an antecedent wound infec
tion related to genesis of the hernia.
3. Operative repair (Fig. 1). The fascia
is first cleared and hemostasis secured.
The hernia is then imbricated with a con
tinuous polypropylene suture, uniting the
musculofascial edges when possible. A
sheet of Marlex mesh is then applied to
the fascia, bridging or reinforcing the im
bricated repair as an onlay graft; it is fix
ed in this position by a continuous heavy
polypropylene suture, taking bites, 0.5 cm
apart, from the folded edge of the mesh
to the fascia, at least 2.5 cm from the edge
of the hernia. Finally, in patients in whom
the fascial edges have been approximated,
interrupted sutures of polypropylene are
placed in the body of the mesh on either
side of the closure line.
4. Closed suction drainage of the
wound.
5. Abdominal support postoperatively.
6. Follow-up for at least 6 months after
the repair.
Results
In most cases the postoperative course
was uncomplicated and the patients have
remained well. When laparotomy was not
performed, nasogastric suction was unne
cessary, a light oral diet was resumed
within 24 hours of operation and the
patients were usually discharged within 5
days of operation.
Suction drainage was omitted in nine
patients. In three of them seromas deve
loped. In two the seroma resolved spon
taneously after it had been drained by
needle aspiration. The third became
secondarily infected and required opera
tive drainage, placement of closed suction
drains and systemic antibiotic therapy
before the condition resolved. Of the 41
patients in whom closed suction drains
were placed at the primary operation,
only 1, with a malfunctioning drain, had
prolonged drainage. One month after
operation, this patient was readmitted
with a wound abscess. The abscess was
drained, the Marlex mesh was removed
and the wound was left open to heal by
secondary intention. This patient was one
of six with an antecedent wound infection
who did not receive antibiotics prophylactically. The remaining 14 patients with
antecedent wound infections received
antibiotics before repair of the hernia,
and none had postoperative infection. In
two of these patients suture granulomas
were identified. They were excised at the
primary operation and cultures of the spe
cimens grew Staphylococcus pyogenes,
which was also the cause of the antece
dent wound infection.
Recurrent hernias developed in three
patients; all were lateral to the site of the
Marlex mesh repair and two were in
patients who weighed more than 150% of
the ideal body weight for their height. In
156

no case did a recurrent hernia develop
through the mesh. Several patients com
plained of mild, intermittent discomfort
at the edge of the prosthesis for 4 to 6
months after the hernia repair. However,
this discomfort resolved spontaneously in
all. The mean follow-up was 2.6 years
(range from 6 months to 7 years). No
patient had a suture sinus related to the
mesh or polypropylene sutures, and none
required suture removal because of pain.

Discussion
When Marlex mesh is used to repair
incisional hernias, an important objective
is to prevent recurrence. Early recurrence
may result if the sutures break or knots
slip, or if the sutures are placed too far
apart the hernial sac may protrude be
tween them. But such errors of technique
account for few recurrences. Most recur
rent hernias develop when sutures cut
through tissue that is insufficient8 or
weakened.2 Recurrence is inevitable if,
because of the size of the hernia or the
multiplicity of fascial defects, abnormal
tissue is included in the repair.
Marlex mesh is the best material avai
lable to reinforce the repair.9 Fascial
autografts10 gradually become attenua
ted; metallic mesh, such as tantalum and

stainless steel, may eventually fragment
or erode the tissues5 and synthetic
fabrics such as Nylon, Orion, Dacron,
Ivalon and Mersilene are unstable in the
■
presence of infection.4,6 Although it may*
be extruded when used in the presence of
gross infection,11 Marlex mesh generally <
resists infection. The monofilament plas
tic does not allow entrapment of bacte- 4 ‘
ria, and the spaces between the knitted
strands of plastic are large enough to
allow fibrous tissue infiltration without
sacrificing strength.12
The six-step technique of repair recom- J
mended is simple and effective. Earlier
methods for placing Marlex include extrafascial onlay, fascial underlay, single- or
double-layer fascial bridging and intrapes
ritoneai bridging. Of these, the extrafascial onlay technique is simplest and has* '
yielded good results.13,14 When the defect
is very large, fascial bridging is required. ^
Although Usher15 has recently suggested ^ ,
that fascial underlay and intraperitoneal
placement offer a great mechanical
,
advantage, these techniques require con
siderably more dissection and risk intra-* i
operative or delayed bowel injury.11 The
routine use of closed suction drainage, *
selective antibiotic prophylaxis and the ^
technique of suture fixation of the Mar'
lex mesh appear to minimize postopera
tive complications.

FIG. 1—Technique of hernia repair. (A) Clearing of fascia, (B) imbrication of hernia sac
and suture of fascia, (C) onlay fixation of Marlex mesh and (D) continuous and interrupted
polypropylene suture.
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The results reported show that even in
these large and difficult incisional hernias,
v the repair was highly successful. Mild
postoperative discomfort, seromas in
i Athree patients and infection in two were
the only complications. The technique of
> continuous suture of the perimeter of the
mesh and interrupted buttressing sutures
k ^ in the body of the mesh seemed to reduce
postoperative pain at the edge of the mesh
by distributing tension over the whole sur
face. Postoperative abdominal support
also increased patient comfort, allowing
time for fibrous tissue to infiltrate the
mesh.
*- No patient with closed suction drainage
had a seroma, whereas three of nine pa'
tients without drains did have. Jacobs and
associates13 used suction drains in only
*12 of 20 similar patients and 9 (45%) had
seromas, but in Usher’s collected series
of 358 ventral hernias repaired with
r
Marlex mesh and using closed suction
drainage, the incidence of seroma was on► ly 5.8% .16
The identification of bacterial con1 4tamination at operation in the wounds of
patients who had wound infection before
the incisional hernias developed and the
^ 4 absence of postoperative infection in any
such patient given antibiotics prophylactically supports the latter practice. Of the
two patients with infection in our study,
r" the wound in one healed without removal

of the mesh; in the other, we elected to
remove the Marlex mesh because of the
extent of tissue necrosis. Others9’13,16'17
have alluded to the ability o f infected
wounds to heal without removing the
Marlex. The overall 4% infection rate in
these difficult hernias is similar to the 6%
noted in Usher’s collected series.16
Lateral recurrence of the hernia follow
ing repair with Marlex mesh is an infre
quent but unsolved problem.13-14,18 The
6% recurrence in the mean follow-up in
terval of 2.6 years in the present series is,
however, lower than the 10% to 12%
noted by others,13,14 using a variety of
techniques for fixation. It is also con
siderably less than the 20% to 30% recur
rence reported when Marlex mesh is not
used.1,14 In the last 2 years, using the
current technique — continuous poly
propylene sutures at least 2.5 cm from the
hernial edge, stitch intervals of no more
than 0.5 cm and reinforcing interrupted
sutures in the body of the mesh — we
recorded no recurrence in 20 patients. The
follow-up interval on these patients is
short, but the results are encouraging,
since Doeven19 has shown that most
recurrences are seen early with 96% oc
curring within 1 year of repair.
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Intraperitoneal Prolene Mesh in Hernia Repair:
a Comparison of Two Techniques

► ---------------------------------------------------------------------

►

Prolene (polypropylene) mesh is a useful
material for technically difficult repairs of
> ^abdominal wall hernias. In this study,
two insertion techniques were used and
> compared. The first method, in which
2-cm wide strips of mesh were cut
perpendicular to the main part, pulled
through the musculoperitoneal layer and
anchored to the anterior fascial layer,
,
.was abandoned after use in 10 patients
because of complications. The second
r method, using circumferential horizontal
mattress sutures to anchor the mesh.
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gave satisfactory results in the 4 0 pa
tients in whom it was used. There were
no deaths, and complications were few
and easily dealt with.
La tulle (de polypropylene) Prolene
s'avfcre utile dans les reparations techniquement difficiles de hernies de la paroi
abdominale. Dans la presente etude deux
techniques d'insertion ont ete utilisees et
comparees. Avec la premiere methode,
des lambeaux de tulle de 2 cm de large
sont coupes perpendiculairement au plan
principal, tires a travers la couche
musculo-peritoneale et fixes au fascia
anterieur; cette technique fut abandonnee apres 10 patients d cause des com
plications. La seconde methode utilise
pour fixer la tulle, une suture horizontale
a points de matelassier, en circonference. Cette technique a donn6 des
resultats satisfaisants chez 40 patients

chez qui elle fut utilisge. On n'a enregistre aucun deces et les complications
sont demeurees rares et faciles a
corriger.

Prolene (polypropylene) mesh (Ethicon
Sutures Ltd., Peterborough, O nt.), used
as an intraperitoneal binder, can facilitate
the repair of large ventral, and recurrent
inguinal, incisional hernias. A variety of
techniques for inserting polypropylene
mesh have been described112 since the
first was introduced by Usher and
associates13 in 1958. From 1978 to 1982,
we used two techniques for inserting the
Prolene mesh. The techniques were
similar to those described by Lichtenstein
and Shore14 in 1976 and Usher1 in 1979.
Operative Techniques
The skin incision was made over the ab
dominal wall defect in the direction of its
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longest plane and the hernial sac mobiliz
ed and excised. Subcutaneous dissection
down to the anterior musculofascial plane
was extended 4 cm circumferentially
beyond the musculofascial defect. The
edges of the defect were temporarily ap
proximated in order to tailor the mesh to
the dimensions of the defect.
In our first method, Prolene mesh was
anchored intraperitoneally, using a series
of 2-cm wide strips of mesh, cut perpen
dicularly to the sides of the main portion.
The anchoring strips were pulled through
the musculoperitoneal layer with a Gallie
fascial needle and subsequently anchored
to the anterior fascial layer with heavy
nonabsorbable sutures (Fig. 1). The
musculofascial layer was then approx
imated and the skin closed.
The second technique was modified
slightly from that described by Usher.1
The same incision, subcutaneous dissec
tion and sac mobilization, and the same
method of tailoring the mesh to the

musculoperitoneal defect were used as in
the first technique. As in Usher’s
description,1 the hernial sac was always
excised. The mesh was secured cir
cumferentially in an intraperitoneal posi
tion with no. 1 Prolene horizontal mat
tress sutures (Fig. 2). These sutures were
placed 3 to 4 cm beyond the musculo
peritoneal defect and 1 cm inside the edge
of the Prolene mesh. The mesh was plac
ed intraperitoneally only after all sutures
were inserted. The sutures were then
tightened, any mesh wrinkling was cor
rected by repositioning the offending
sutures and the anchoring sutures were
securely tied. The musculoperitoneal layer
was approximated but only if this could
be achieved with minimal tension.
Closed subcutaneous drainage with
Davol or Hemovac drains was used
routinely.

costal, 1 suprapubic and 1 femoral her
nia. The initial 10 repairs used the anchor
ing techniques described by Lichtenstein
and Shore.14 However, we stopped using
this method after the following complica*
tions occurred: one case of mesh slippage,
one of mesh erosion through the skin and ,
two of hernia recurrences beyond the
original mesh repair.
4
The anchoring technique described by
Usher that we modified was used in the
other 40 patients. None of the hernias
recurred following use of this technique*
Postoperative complications (Tables 1 and
II) were minor and successfully dealt
with. There were two cases of transient-,
respiratory distress, two cases of mild
cellulitis resolved following antibiotic
therapy, one patient with bowel obstruc
tion responded to conservative manage31
ment, and one small abscess and two
seromas required drainage.

Patients and Results
Between 1978 and 1982, 50 patients (33
women and 17 men) underwent hernia
repairs with Prolene mesh. There were 39
ventral, 3 umbilical, 4 inguinal, 2 sub

Comment
The use ot
o f Prolene mesh intra
peritoneally can facilitate technically dif-»
ficult hernia repairs. The complications
arising from the first anchoring method a
that was originally described by Lichten
stein influenced us to adopt and modify *
a second technique previously described
by Usher.
We thank Brad C. Nelson for preparing the
illustrations.
_
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►Healing of a Gastrocutaneous Fistula in the Presence of Marlex
I! - ------------------------------------------------------------------------------------------------------------------------------------------------------

/
A gastric leak with perigastric abscesses
I
developed after a revision gastroplasty
'
Reinforced with Marlex, performed on a
|
34-year-old, morbidly obese woman. The
)*■ site of the leak and the abscesses were
^ drained but the Marlex could not be ex
cised. The woman remained on longk
term enteral nutrition at home and her
fistula healed despite the presence of the
j 4Marlex mesh. She continued to lose
weight and was well 8 months after the
A fistula had healed.

I 4 Un epanchement gastrique avec abces
perigastriques est venu compliquer une
revision de gastroplastie renforcee par de
la tulle Marlex, pratiqude chez une
femme de 34 ans souffrant d'obesite
^oathologique. Le siege de I'epanchement
et des abces fut draine mais la fibre Marlex ne put etre excisee. La femme fut
placde sous alimentation entdrale a long
y terme a domicile, et la fistule guerit malgre la presence de la tulle Marlex. Elle
r
continua a perdre du poids et elle se portait bien 8 mois apres guerison de la
' ^fistule.

■ Enterocutaneous fistulas in the presence
, r o f a foreign body are reputed to persist
until the foreign body is removed.1
.
We report a patient with a
gastrocutaneous fistula, which healed
1 \vith conservative management in spite of
|
the presence o f polypropylene mesh
w (Marlex; Bard Implants, Billerica, Mass.).

parts of the stomach. The gastrojejunostomy
was taken down and a gastroplasty perform
ed, creating a 5-mm channel in the greater cur
vature. The greater curvature channel was rein
forced with Marlex mesh and then a 360° fundic wrap performed to protect this area. A
feeding jejunostomy was created.
Postoperatively, the patient had persistent
fever in spite of normal roentgenograms until
11 days after operation when repeat contrast
studies showed an abscess of the lesser sac with
leakage from the stomach (Fig. 1). The abscess
was drained but the inflammatory reaction was
so dense that the leak could not be located. We
were able to identify the Marlex which had
been sutured around the greater curvature
channel but it was firmly adherent to the
stomach. Clearly, removal of the Marlex could
easily have compounded the patient’s gastric
fistula and possibly necessitated a major gastric
resection. Accordingly, we elected to drain and
debride the abscess cavity widely, suturing a
long pedicled omental graft to the presumed
area of the fistula. A distal gastrostomy was
inserted. Multiple Penrose drains were brought
out through large, posteriorly located drainage
incisions, each constructed to admit two fingers
easily. A new feeding jejunostomy was con
structed and the wound was packed open.
Postoperatively, she was treated with
peritoneal lavage, meticulous attention to
patency of the nasogastric and gastrostomy
tubes and antibiotics systemically. Her
temperature returned to normal but drainage
persisted from the left Penrose drain tracts.
Ten days after operation, methylene blue was
given by mouth. It appeared within 20 minutes
in the drainage bag placed over the Penrose
drains. A small amount of methylene blue also

appeared in the gastrostomy, indicating that
the gastrogastrostomy was not obstructed.
With enteral nutritional support, she continued
to improve although drainage from the left
Penrose drains persisted. She was discharged
31 days after operation, taking jejunostomy
feedings on her own but with a a persistent
gastric fistula (Fig. 2).
She was followed up very closely as an out
patient. At each visit, methylene blue in orange
juice was given by mouth and immediately ap
peared in the left flank drainage bag. However,
the wound had healed and she appeared well,
without fever, shoulder pain or other evidence
of systemic infection. The recorded volume in
the drainage bag ranged from 50 to 150 m L /d
but gradually decreased to 25 to 35 m L /d . On
the 59th postoperative day, methylene blue ad
ministered orally did not appear in the drainage
bag. Therefore, the drains were removed and
the wound was allowed to granulate. A soft
diet was begun orally. Three weeks later, an
abscess appeared at the drain site. Incision
revealed gastric contents, and methylene blue
given orally again appeared in the drainage
bag. The drainage fluctuated for several weeks
averaging between 50 and 150 m L /d. By 6
months, the drainage was minimal and repeat
roentgenograms confirmed that the fistula had
closed (Fig. 3).
The patient once again began an oral diet;
she was followed up for an additional 8 months
with no further evidence of gastric fistulization.
Moreover, she continued to lose weight and at
the last follow-up weighed 90 kg, a net total
weight loss of 42 kg from the time o f her ini
tial gastric bypass. Of this weight loss, only 17

^Case Report

'

k
•

A 34-year-old woman, who had lost 45 kg
after gastric bypass 4 years earlier, was admitted because of weight gain and bile reflux
gastritis. At reoperation, the gastric staple line
was found to be disrupted, allowing free com
munication between the proximal and distal
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Ottawa General Hospital, University o f
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4
FIG. 1—Abscess cavity (arrows) with leak
ed contrast material (*) 11 days after
gastroplasty.

FIG. 2—Persistent fistula tract (arrow) from
pouch leading to left abdominal wall. Small
amount of barium has passed into distal
stomach.
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kg were sustained up to the time of reopera
tion, but an additional 25 kg were lost after
conversion to gastroplasty.
Discussion

Removing a foreign body is a basic
principle of fistula management. Yet, in
this case, removal of the Marlex mesh,
surrounded by a fundic wrap and adja
cent to an abscess cavity, would have been
a formidable undertaking. It is unlikely
that the Marlex could have been remov
ed by a procedure short of a proximal
gastrectomy in an infected abdomen. We
opted for simple drainage, and the
resulting fistula closed, albeit slowly, re
quiring 7 months.
A t no time was there any material in
the drainage to suggest sloughing of the
Marlex mesh. We do not believe that the
mesh could have completely sloughed into
the gastric lumen. We must conclude,
then, that the mesh remained in situ on
the stomach.
We are unaware of any reports of deep
abscesses healing in the presence of
Marlex. Healing of superficial abscesses
after hernia repair using Marlex has been
reported, although these did not involve
gastrointestinal tract fistulas.2 Marlex
has been used for abdominal closure in

the presence of intra-abdominal sepsis,13
but fistulization is considered an indica
tion for removal of Marlex from this
site.2
This case illustrates that deep infection
and fistula do not represent absolute in
dications for removal of Marlex mesh. In
most locations Marlex is easily removed

but in cases such as this, removal would
have been exceedingly difficult and would
have resulted in major morbidity for a
benign condition. Avoiding removal ’
resulted in considerable long-term gait* .
for this patient. Recent reports clearly in
dicate that all gastroplasty stomas must *
be supported externally by Marlex or a
similar material. Hence, other surgeons 4 4
may some day find themselves in a posi
tion similar to ours.
This case also demonstrates the value
of a feeding jejunostomy, without which
parenteral nutrition would have been re
quired for many months. As it was, the
patient was managed at home for most
of her course. It is doubtful that either
patient or physician would have had the >
forbearance to withstand 7 months of
hospital management without undertak- ’
ing yet another, much more formidable
operation.
^
’
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all you need on the ward
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rimental approaches to bone growth will
i
be emphasized; limited attention will be
.
given to basic science aspects. English tit
les and abstracts, 100 to 200 words long, -< •
are being solicited from various clinical
and other biologic disciplines including,
i
but not limited to, anthropology; compu
ter science; genetics; metabolism; mor-’* '
phology; oral, maxillofacial and plastic
surgery; orthodontics; orthopedics;
pediatrics and pedodontics. Abstracts,,
should include purpose, method and
material, results and conclusions. They
should be submitted for consideration as
soon as possible, but no later than June
30, 1984. Attendance will be limited. The j
proceedings of the conference will be ^
published.
For more information write: Dr.
Andrew D. Dixon or Dr. Bernard G. Sarnat, Dental Research Institute, School of
Dentristry, School of Medicine, Center,
for Health Sciences, University of Cali
fornia, Los Angeles, Los Angeles, CA v
90024, USA.
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The 48th Annual Surgery Course, spon-x ,
sored by the Department of Surgery at the
University of Minnesota Medical School, 4
will be held June 13-16, 1984, on the uni
versity campus.
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Surgery for Postinfarction Left Ventricular Aneurysm :
Prognosis and Long-Term Follow -up
'

,

.

V

,

To identify preoperative in d icato rs of
outcom e follo w ing surgery fo r p o stin fa rc 
tion left ven tricular an e u rysm , the
authors have analysed the c lin ica l course
of 6 7 c o n se cu tive patients w h o under^ w en t operation from 1 9 7 0 to 1 9 8 2 .
Follow-up extended to 12 y e a rs (m ean
4 .6 years) and w a s 9 7 % co m p lete.
Postoperative m ortality w a s 8 .9 % . F a c 
t o r s th at w ere asso ciate d w ith a
sig nificantly (p < 0 .0 5 ) in cre ase d risk of
early death included em ergen cy su rg ery,
t the presence of ven tricular arrh yth m ias
preoperatively and a left v e n tricu la r enddiastolic pressure of m ore than 2 5 mm
Hg on cardiac cath eterizatio n. Patien ts
w ho und erw ent m yocardial re v a s c u la riza 
tion co nco m itantly had a lo w e r m ortality
*■(7.1% v . 1 8 .2 % for a n e u rysm e cto m y
alone), decreased p o sto p erative morbidity and increased lo ng evity. M arked fu n c 
tional im provem ent w a s noted in all
groups. A ctu aria l su rvival (including
operative m ortality) w a s 6 6 % at 6 y e a rs,
and w a s sig nificantly (p < 0 .0 5 ) better
►in patients operated upon fo r angina

(8 3 .6 % ± 8 .1 % ) than in th o se operated
upon for co ngestive heart failu re (5 3 %
± 1 3 % ).
' r
The authors conclude that th e m ost
im portant predictor of outcom e follow ing
postinfarction aneurysm su rg ery is the
.p reo perative hem odynam ic s ta tu s of the
left ven tricle. S in ce functio n al reco very
^ and prognosis after operation h av e been
e xcellen t, an ag gressive su rg ical ap► proach to sym pto m atic left ve n tricu la r
aneurysm s is w arranted.
>

. Dans le but d 'identifier les in d icateu rs
preoperatoires relies aux re su lta ts de la
».
chirurgie pour anevrism e p o st-in farctu s

k
k
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du ve n tricu le g a u ch e, les a u teu rs ont
an a lyse re vo lu tio n clin ique de 6 7
p atients c o n se cu tifs qui ont subi une
telle operation entre 1 9 7 0 et 1 9 8 2 . Le
su ivi d e s su ite s th erap eu tiq u es s'etend
su r 12 an s (m oyenne de 4 .6 an s) et est
com plet a 9 7 % . La m ortalite p o st
operatoire a et6 de 8 .9 % . L e s facteu rs
a s so c ie s a une aug m entation sig n ificative
( p < 0 .0 5 ) du risque de m ort precoce
so n t: chirurg ie d 'u rg en ce, aryth m ie ventricu laire preoperatoire et te n sio n telediastolique ve n tricu la ire gauche sup£rieure a 2 5 mm Hg au cath e te rism e cardiaque. On a note chez les p atien ts qui
ont subi co nco m itam m ent une re va scu la 
risation du m yo card e , une m ortalite plus
faible (7 .1 % contre 1 8 .2 % pour I'angvrism ecto m ie se u le ), une plus faib le mor
bidity postoperatoire et une am elioration
de la lo n g evity. Une am ylioration fonctionnelle im portante a ete o b servee pour
tous les groupes. La su rvie actuarielle
(com prenant la m ortality peropyratoire)
e st de 6 6 % ap rys 6 a n s ; elle e st
sig n ifica tivem en t m eilleure (p < 0 .0 5 )
chez les p atients qui ont ete operes pour
angine (8 3 .6 % ± 8 .1 % ) que ch e z ceux
qui I'on t yte pour in s u ffis a n c e cardiaque
(5 3 % ± 1 3 % ).
Le s auteurs co n clu en t que I'indicateur
previsionnel le plus im p ortant d e s resulta ts de la chirurgie pour un anevrism e
p o st-in farctu s e st I'y ta t hem odynam ique
preoperatoire du ve n tricu le g a u ch e .
Com m e le retab lisse m en t fo nctio nn el et
le pronostic postoperatoire so n t excellen ts, il e st ju stifie d'ad o p ter une approche chiru rg icale a g re ssive d e van t un anevrism e sym p to m atiq ue du ve n tricu le
gauche.

Development of a left ventricular
aneurysm is the most common
mechanical complication of transmural
myocardial infarction1and is of ominous
hemodynamic and prognostic impor
tance.2’6 Almost 25 years have elapsed
since Cooley and associates7 first
reported resection of a postinfarction
aneurysm using cardiopulmonary bypass.
During the past decade, many reports

have documented the therapeutic benefits
and the improved long-term survival in
large numbers of patients following this
procedure, compared with historical,
medically treated control patients.1,813
Controversy still persists, however, re
garding the influence of preoperative
variables on operative and late mortality
and the contribution of concomitant
m yocardial revascularization to
survival.14’18 A retrospective review of
our institution’s experience with surgery
for left ventricular aneurysm was under
taken to clarify these factors and facilitate
patient selection for this procedure.
Patients and Methods

From September 1970 to July 1982, 67
consecutive patients (49 men, 18 women)
underwent surgical procedures for postin
farction left ventricular aneurysm. The
mean age of all patients was 52.9 years
(range from 31 to 70 years). The mean in
terval from myocardial infarction to
operation was 3 years, 4 months (range
from 2 weeks to 16 years, median 16
months). Although the majority of opera
tions were elective, six patients underwent
emergency surgery for rapidly progressive
hemodynamic deterioration despite op
timal medical management.
Preoperative Symptoms
Patients were categorized into New
York Heart Association (NYHA) func
tional class19 according to the predomi
nant clinical indication for operation.
Congestive heart failure was defined as
being present if there was a history of or
thopnea or dyspnea on minimal exertion
during the preceding 3 months, or if the
precatheterization chest roentgenogram
revealed objective evidence of alveolar or
interstitial pulmonary edema.
Angina alone was the indication for
operation in 35 patients (52%). Eleven
patients (16%) exhibited isolated intrac
table congestive heart failure, whereas 21
patients (32%) manifested a combination
of angina and moderate congestive
failure. Ventricular arrhythmias severe
enough to warrant the administration of
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antiarrhythmic agents were present in
nine patients preoperatively, and three pa
tients had a recent history of systemic em
bolism; in no case, however, was ven
tricular ectopy or embolism the predomi
nant indication for operation. Twenty-six
patients (39%) were classified as NYHA
functional class IV preoperatively, 38
(57%) as class III and 3 (4%) as class II.

followed by a continuous suture over the
margins for hemostasis. When aor
tocoronary bypass grafting was also per
formed, the aorta was clamped, and
either intermittent ischemic arrest (before
1976) or cold crystalloid cardioplegic ar
rest (1976 to the present) was used. In all
cases the left ventricle was decompressed
by venting through the ventriculotomy
site or the right superior pulmonary vein.

Preoperative Angiography
Left ventriculography and selective cor
onary arteriography were performed on
all patients. An angiographic diagnosis of
left ventricular aneurysm was made when
a noncontractile ventricular wall segment
protruded beyond the normal cardiac
outline during both systole and diastole.
Akinetic regions not exhibiting paradox
ical systolic motion were excluded. Oc
clusive coronary artery disease was con
sidered significant if narrowing of luminal
diameter was greater than 50%.
The m ajority of aneurysms were
anterolateral (78%) or apical (18%) in
location. Only three patients had
posteroinferior wall aneuryms. Eight pa
tients (12%) exhibited occlusive disease of
a single coronary artery, 28 patients
(42%) had double-vessel disease and 31
patients (46%) triple-vessel disease on
preoperative coronary arteriography.
The preoperative profile of patients ac
cording to the predominant clinical in
dication for operation is shown in Table I.

Follow-up
The early and late postoperative status
of all patients was determined by direct
contact with them or their attending
physician. Survival curves were con
structed using actuarial methods20 and
functional classification was assigned ac
cording to the most limiting symptom of
angina or heart failure.
Statistical analysis of the results was by
Fisher’s exact test and analysis of
variance.
Results
Operative Mortality
Four patients (6%) died during the first
postoperative month, and two more died
at 31 and 40 days, respectively, for an

T a b le 1— P r e o p e r a tiv e V a r ia b le s A c c o rd in g t o P rin c ip a l O p e r a t iv e In d ic a t io n s *

G ro u p

Operative Procedures

Age,

V e s s e ls

LVE0P,

N Y H A f u n c tio n a l

yr

d is e a s e d

m m Hg

c la s s

C o n g e s t iv e h e a r t

Eleven patients underwent left ven
tricular aneurysmectomy only, 47 patients
had left ventricular aneurysmectomy with
aortocoronary bypass grafting and 9 had
plication of the left ventricular aneurysm
with concomitant aortocoronary bypass
grafting. Patients subjected to left ven
tricular aneurysmectomy and myocardial
revascularization received a mean of 2.1
± 0.2 bypass grafts, whereas those who
underwent plication of a left ventricular
aneurysm and aortocoronary bypass
grafting received a mean of 2.6 ± 0.2
grafts (p < 0.05). Additional procedures
included repair of a ventricular septal
defect in two patients and mitral valve
replacement in one.
All operations were performed using
cardiopulmonary bypass with moderate
systemic hypothermia (28° to 30°C).
Small (usually apical) aneurysms without
notable pericardial adhesions were
plicated with pledgeted sutures. Larger
aneurysms were opened, intramural
thrombus, if present, was evacuated and
the aneurysmal sac was excised, leaving
a 1-cm rim of fibrous tissue to hold
sutures. In no case was scarred septal
myocardium removed. Closure was per
formed with multiple interrupted horizon
tal mattress sutures over felt strips,
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overall perioperative mortality of 8.9%.
Five of the six patients who died were
functional class IV preoperatively; four
of them had undergone emergency opera- '
tion for advanced hem odynam ic
decompensation, despite optimal medical
therapy. One of the four patients died in <
the operating room of cardiogenic shock,
another died 3 hours postoperatively of i *
m yocardial infarction with elec
tromechanical dissociation. The third, a "*
53-year-old woman, died 5 days after
four-vessel aortocoronary bypass grafting
and left ventricular aneurysmectomy; ^
autopsy revealed patent saphenous vein
grafts, an intact aneurysmectomy repair -<
and no evidence of pulmonary embolism.
Her death was attributed to an ar- '
rhythmia. The fourth patient died 18 days
postoperatively after a complicatecf
course characterized by cardiogenic
shock, recurrent ventricular arrhythmias, Y
gastrointestinal bleeding, pneumonia, ^ ,
sternal dehiscence and encephalopathy.
The two patients who died later in
hospital were severely debilitated
preoperatively. One, a 57-year-old*
woman, underwent emergency left ven
tricular aneurysmectomy for intractable A
congestive heart failure following rejec- ^
tion of a renal transplant and previous
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plication of a left ventricular aneurysm;
she died 31 days postoperatively of
gastrointestinal hemorrhage and sepsis.
The other patient was operated on 2
^months after a massive anterolateral
myocardial infarction, complicated by
V aneurysm formation and cardiogenic
shock. The preoperative radioisotope
►ejection fraction was 9%. He died on day
40 from a cerebrovascular accident,

refractory ventricular arrhythmias and
multiorgan failure.
The preoperative determinants of
operative mortality are shown in Table II.
The early mortality was significantly (p
< 0.05) increased in patients who under
went emergency aneurysmectomy and
those with ventricular arrhythmias
preoperatively. Those with congestive
heart failure preoperatively had a higher
mortality than those operated on for relief
of angina, but the difference was not
statistically significant. Advanced
hemodynamic impairment, however, as
manifested by a preoperative left ven
tricular end-diastolic pressure over 25 mm
Hg, was a highly significant predictor of
early postoperative death. Although pa
tients categorized as functional class IV
experienced a 19.2% operative mortali
ty, four of the five patients in this group
who died were operated upon under
emergency conditions. Indeed, if ex
clusively elective procedures are con
sidered, operative mortality was 5%
(1/20) in functional class IV patients, and
the discrepancy in outcome between func
tional class III and IV was no longer
apparent.
Analysis of early mortality according
to the type of operative procedure (Table
III) revealed that the highest perioperative
mortality occurred in patients who under
went left ventricular aneurysmectomy
alone. Addition of one or more bypass
grafts decreased operative mortality
despite increased duration of myocardial
ischemia. Plication of a left ventricular
aneurysm was not associated with any
hospital death in this series.

Table Ill-Early Mortality According
to Operative Procedure
No. of
Operative
Procedure
patients mortality, %
LVA only
11
18.2
LVA + ACBG, 1 vessel
13
7.7
LVA + ACBG, 2 vessels
17
5.9
LVA + ACBG,
3 or 4 vessels
17
11.8
Left ventricular aneurysm
plication + ACBG
9
0
LVA = left ventricular aneurysmectomy,
ACBG = aortocoronary bypass grafting.

Table IV—Major Complications after Operation
______ for Left Ventricular Aneurysm_______
No. of
Complication
complications
Low cardiac output requiring
inotropic support
17
Hemorrhage (necessitating
re-exploration)
5
Sternal infection or dehiscence
5
Neurologic sequelae
4
Recurrent ventricular arrhythmias
4
Upper gastrointestinal bleeding
3
Renal failure
3
Respiratory failure
2

Procedure
LVA only
LVA + ACBG, 1 vessel
LVA + ACBG, 2 vessels
LVA + ACBG, 3 or 4 vessels
Left ventricular aneurysm
plication + ACBG

Operative Morbidity
Major complications were encountered

in 39% of patients (Table IV). Six other
patients had supraventricular tachyar
rhythmias postoperatively, but these were
not considered as major complications,
nor were atelectasis and bronchopneu
monia, which resolved spontaneously.
The intra-aortic balloon pump, which
has been available since October 1973 at
our institution, was used in 14 patients
who could not otherwise be weaned from
cardiopulmonary bypass; 10 survived.
The mean duration of balloon-pump use
was 72 hours (range from 16 to 112
hours). No vascular or septic complica
tion resulted directly from use of the
counterpulsation device.
Examination of the frequency of
postoperative complications according to
operative procedure (Table V) disclosed
that even if early deaths are excluded,
p atien ts who had left ventricular
aneurysmectomy alone had the highest
proportion of major complications. P a
tients who underwent left ventricular
aneurysmectomy and aortocoronary
bypass grafting had a decreased require
ment for inotropic support and counter
pulsation postoperatively. Patients who
underwent plication of a left ventricular
aneurysm in conjunction with aorto
coronary bypass grafting experienced the
lowest rate of complications related to
low cardiac output.
L e ft Ventricular Aneurysmectomy plus
L eft Anterior Descending Artery Grafting
Of 47 patients who underwent left ven
tricu lar aneurysm ectom y and a o r
tocoronary bypass grafting, 12 had
saphenous vein grafting to the proximal
left anterior descending coronary artery.
In patients with relatively small anterior

Table V-Major Complications in Operative Survivors According to Operative Procedure
No. of
operative
Inotropic support,
IABP, no./total
survivors
no./total no. (%)
no. (%)*
9
4/9 (44.4)
3/7 (42.8)
12
3/12 (25)
3/11 (27.3)
16
2/16 (12.5)
1/14 ( 7.1)
15
2/15 (13.3)
2/15 (13.3)

Complications,
no./total no. (%)
5/9 (55.6)
4/12 (33.3)
5/16 (31.3)
4/15 (26.7)

9

2/9 (22.2)
1/9 (11.1)
2/9 (22.2)
‘ Intra-aortic balloon pump counterpulsation, introduced in October 1973 at this institution was not available to the first five patients in this series. The
denominators in the IABP column have thus been readjusted to include only patients at risk for use of the intra-aortic balloon pump.

Table VI—Effect of Left Anterior Descending Coronary Artery Grafting on Mortality and Morbidity
_______________________________ following Left Ventricular Aneurysmectomy and Aortocoronary Bypass Grafting*
A.

A
f-

Mortality, no./
IABP, no./total
Inotropic support
Complications,
Group____________________________________ No_____________ total no. (%)___________ no. (%)__________ no./total no. (%)______no./total no. (%)
LVA + ACBG with LAD graft
12
1/12 (8.3)
2/10 (20)
2/12 (16.7)
3/12 (25)
LVA + ACBG without LAD graft______________35______________ 3/35 (8.6)__________7/34 120.6)_________ 9/35 (25.7)_________ 14/35 (40)
LAD - left anterior descending coronary artery.
*p > 0.05 between all adjacent values by Fisher's exact test.
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provement in symptoms was encountered
in all patient groups (congestive heart
failure alone, angina alone or failure with
angina). Likewise, if the effect of
operative mortality is excluded, signifi
cant and equal clinical recovery occurred
after all types of operative procedure.
Survivors o f acute left ventricular
aneurysmectomy fared as well as any
other group. No significant difference
was detected in functional improvement
at 6 months between patients who under
went aneurysmectomy and received a left
anterior descending coronary artery graft
and those who had aneurysmectomy and
did not receive such a graft.
Late clinical course.—The mean dura
tion of follow-up in surviving patients was
4 years, 7 months (range from 7 months
to 12 years). Two patients were lost to
follow-up; both were in NYHA func
tional class II at 13 and 36 months
postoperatively. There were 14 late
deaths, 13 due to documented cardiac
causes or to sudden death, and 1 to
metastatic carcinoma of the lung. Overall
actuarial survival (including operative
mortality) was 77.4% at 3 years and 66%
at 6 years.
To a large extent, preoperative
hemodynamics and clinical status in
fluenced late postoperative survival. Pa
tients with isolated congestive heart
failure preoperatively exhibited a
significantly (p < 0.05) lower 6-year ac
tuarial survival than those operated upon
exclusively for angina (Fig. 2). The 6-year
actuarial survival of patients with both
angina and congestive failure was iden
tical to that of patients with congestive
failure alone. The presence of ventricular
arrhythm ias preoperatively was an
ominous prognostic sign. Only three of
the nine patients in this group were alive
3 years later; in four of the six deaths,
recurrent ventricular arrhythmias or sud
den death were the main terminal
features.
The relation of operative procedure to
long-term survival is depicted in Fig. 3.
Actuarial survival was higher in patients
who underwent aneurysmectomy and
aortocoronary bypass grafting than in

aneurysms and more distal occlusive
disease in the left anterior descending
artery, the upper part of the ventricular
septum was revascularized by the left
anterior descending coronary artery graft.
Analysis of perioperative data (Table VI),
however, did not show any statistically
significant difference in mortality or mor
bidity between patients who had left
anterior descending artery grafting and
those who did not, even though complica
tions were more frequent in the latter
group.
Acute versus Chronic Left
Ventricular Aneurysmectomy
Although most operations in this series
were performed 3 or more months after
transmural myocardial infarction, in nine
patients surgical intervention was
necessary within 8 weeks of infarction
because of recurrent unstable angina or
refractory congestive heart failure. Two
patients, both of whom were operated
upon as emergencies for cardiogenic
shock, died in hospital. O f the seven
operative survivors, only two experienc
ed major postoperative complications.
Follow-up
Functional status at 6 months.—Fiftynine patients were alive 6 months after left
ventricular aneurysm surgery. Five pa
tients (8%) had no change in NYHA
functional class; 30 (51%) improved by
one functional class, 23 (39%) by two
classes, and one patient (2%) who was
functional class IV preoperatively was
rendered completely asymptomatic by left
ventricular aneurysmectomy and fourvessel aortocoronary bypass grafting.
O peration produced a m arked
amelioration of symptoms in the group
as a whole (Fig. 1). Whereas 96% of pa
tients were categorized as functional class
III or IV preoperatively, 80% of operative
survivors were asymptomatic or minimal
ly symptomatic 6 months postoperatively.
Analysis o f the relation between
postoperative functional status and
preoperative symptoms (Table VII) in
dicated that significant (p < 0.05) im

those who had aneurysmectomy alone.
A lthough patients who underwent
aneurysm plication and revascularization
experienced no operative mortality and
excellent initial postoperative survival^,
there was considerable attrition between
1 and 3 years postoperatively; 6-year ac
tuarial survival was 12% higher in the
aneurysmectomy and revascularization -i
group.
The effect of the number of bypass
grafts on the late survival of patients who
had left ventricular aneurysmectomy is
shown in Fig. 4. Although 2 of 17 patients
who had aneurysmectomy and the inser
tion of three or more bypass grafts died
perioperatively, there was no subsequent
attrition, and 88% were alive at 4 years.
Those who received two bypass grafts had
a 14% lower 4-year actuarial survival,’*
while those who received a single bypass
graft had the shortest survival of this
group.

FIG. 1—NYHA functional classification;
80% were class I or II 6 months post
operatively.
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FIG. 2—Actuarial survival after left ven
tricular aneurysm surgery according to
preoperative symptoms. Six-year survival was
significantly (p < 0.05) better in patients
operated upon for angina than in those
operated upon for congestive heart failure
(CHF).
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The prognosis for patients who
manifested no improvement in symp
tomatic status 6 months postoperatively
’ was dismal. The 3-year actuarial survival
^was only 34% in this subset. Conversely,
94% of those whose functional class im-y proved postoperatively survived 3 years
and 80% survived 6 years following left
►►ventricular aneurysm surgery.
Discussion
c The results of our clinical experience
confirm the findings of recently reported
► series1,8’9'21 that surgery for postinfarc
tion left ventricular aneurysm can be per*• formed with acceptable mortality and an
ticipation of a satisfactory long-term out
come. One must recognize that ven
tricular aneurysmectomy is now inex
tricably interwoven with aortocoronary
^ bypass surgery and that it is difficult to
credit clinical benefit to one or the other
*- procedure. In the past, the principal
surgical indication was intractable con-

tricular (LV) aneurysm surgery according to
"F operative procedure. LVA = left ventricular
aneurysmectomy, ACBG = aortocoronary byv pass grafting.

FIG. 4—Actuarial survival after left ven
tricular aneurysmectomy and aortocoronary
’ e- bypass grafting according to number o f bypass
grafts.

gestive heart failure, with or without ar
rhythmia or arterial embolism.16,22 In
more recent series8,21 patients are
reported to undergo operation before the
appearance of marked left ventricular
dysfunction and angina pectoris has
become the predominant preoperative
symptom. In this study, angina alone was
the main surgical indication in over half
the patients.
In previous reports,10,16 preoperative
symptoms were closely related to the ex
tent of occlusive coronary artery disease.
Patients with single-vessel disease (usually
of the proximal left anterior descending
coronary artery) presented with isolated
congestive heart failure, whereas those
with double- or triple-vessel disease more
often exhibited angina with or without
dyspnea. The present study has verified
this conclusion. The prevalence of
multiple-vessel disease was 88%, higher
than in most other series. Single coronary
artery occlusion was encountered in only
eight patients, all of whom manifested
symptoms of congestive heart failure
exclusively.
Certain subgroups of patients were at
greater operative risk and had greater
postoperative attrition. Thus, like
others,15,23,24 we found that aneurysmec
tomy with or without aortocoronary
bypass grafting failed consistently to con
trol ventricular arrhythmias. Similarly,
patients with congestive heart failure
preoperatively were at high risk for early
and late death. Whereas previous reports
have indicated that preoperative left ven
tricular end-diastolic pressure was not
predictive of initial outcome,25,26 we
found that patients with a preoperative
pressure over 25 mm Hg exhibited a
highly
significant
increase in
postoperative mortality. The 6-year ac
tuarial survival was significantly (p <
0.05) better in patients operated on for
relief of angina than for intractable con
gestive heart failure.
The influence of the number of diseas
ed coronary arteries on operative and late
survival has long been controversial.
Before the widespread adoption of con
comitant myocardial revascularization,
mortality was markedly elevated in pa
tients with multiple-vessel disease.16,22,27
The presence or absence of occlusive
disease in the arteries supplying the lateral
left ventricular wall was a critical deter
minant of operative and long-term
outcom e.16 Recent studies10,15,18 have
noted no relation between the extent of
p reoperative vessel disease and
postoperative outcome. Others28,29 have
reported lower early mortality in patients
who underwent aneurysmectomy with
bypass grafting than in those subjected to
aneurysmectomy alone. In this report, in
itial survival was superior when myocar
dial revascularization accompanied

aneurysmectomy. In addition, 4-year sur
vival was highest in patients receiving the
most bypass grafts.
Although the importance of concomi
tant grafting of the left anterior descend
ing coronary artery has been suggested in
patients who undergo anterior aneurysm
resection,30,31 no objective evidence of
the advantages of such an approach has
been published. We noted no significant
discrepancy in operative mortality or
morbidity whether the artery was grafted
or not. Symptomatic benefit was similar
in both groups. The 6-year actuarial sur
vival was 10% higher in the grafted pa
tients, but this difference was not
significant.
The role of plication in treating
relatively small left ventricular aneurysms
has been stressed.8 However, this does
not ensure removal of intramural throm 
bus and is unlikely to improve left ven
tricular hemodynamics substantially.
Plication is a simpler procedure than
resection and this is reflected in the
absence of operative mortality in this
subgroup. These were of course smaller
aneurysms and the 3-year actuarial sur
vival of 61% is disappointing. The indica
tions for aneurysm plication over excision
remain unsettled and are based on the
preference of individual surgeons.
Although no randomized data are
available, abundant evidence exists that
surgical intervention improves the prog
nosis in patients with symptomatic left
ventricular aneurysms. Several factors
have contributed to the satisfactory
results reported in this and other recent
series. The trend towards earlier opera
tion, before severe left ventricular
dysfunction develops, has positively in
fluenced operative survival. Use of the
intra-aortic balloon pump has been in
valuable in managing perioperative car
diogenic shock. A policy of simultaneous
revascularization of all diseased coronary
arteries has decreased early mortality, and
enhanced functional recovery and long
term survival. Further improvements in
longevity will possibly be achieved if pa
tients presenting with ventricular ar
rhythmias undergo intraoperative m app
ing and excision of arrhythmogenic foci
by endocardial resection.24,32Since symp
tomatic control is often difficult and pro
longed survival rare in medically treated
patients, an aggressive surgical approach
to all sym ptom atic left ventricular
aneurysms is warranted.
We are grateful to Drs. N. Poirier and A.
Grignon for permission to include several of
their patients in this study.
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SESAP IV Critique
ITEM 106
The use of fluorocarbons as blood substitutes in clinical medicine is growing
slowly. These agents have been especially recommended for use when a
Jehovah’s Witness requires an operation. Unless the fluorocarbons are
emulsified with albumin or some similar agent, they do not mix well with blood
and may produce pulmonary embolism. Paradoxically, they are most effec
tive, at least experimentally, when the hematocrit is as low as possible. They
can be stored indefinitely in the frozen state. The fluorocarbon leaves the body
in a matter of days without any discernible effect on the tissues. The oxygen
dissociation curve, unlike that with hemoglobin, is linear with changes in ox
ygen tension, which means that increased oxygen concentrations must be used
to produce effective tissue oxygenation. In a series of experiments with baboons,
reasonable mixed venous P 0 2 was maintained when 100% oxygen was ad
ministered through a cuffed endotracheal tube.
,__,

11
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Wernicke’s Encephalopathy after Gastric Partitioning
for Morbid Obesity
kTwo weeks after gastric partitioning for
morbid obesity, a 45-year-old woman ex
perienced persistent vomiting that led to
a weight loss of 30 kg over 6 weeks.
Wernicke’s encephalopathy and
peripheral neuropathy developed. The
Wernicke's encephalopathy responded
•'well to the administration of thiamine.
This is one of very few reported cases of
Wernicke's encephalopathy following
gastric partitioning.
Deux semaines apres avoir subi une gastroplication pour obesite pathologique,
^ une femme de 45 ans a souffert de
vomissements persistants qui, sur une
periode de 6 semaines, ont entraine une
perte de poids de 30 kg. Une encephalopathie de Wernicke et une neuropathie
p6ripherique s'ensuivirent. L'encephalo*pathie de Wernicke reagit favorablement
a ('administration de thiamine. II s'agit la
d'un des tres rares cas d'encephalopa^thie de Wernicke a avoir ete signale d la
suite d'un gastroplication.

Gastric partitioning has largely replaced
intestinal bypass operations in the surgical
treatment of morbidly obese subjects.1'2
The stomach is incompletely partitioned,
but the anatomical integrity of the
r gastrointestinal tract is maintained. The
procedure is usually effective with few
complications.
r We report a case of Wernicke’s
encephalopathy that followed this
procedure.
►Case Report
A 45-year-old woman who weighed 131 kg
underwent gastric partitioning for her chronic
obesity. Apart from mild hypothyroidism and
chronic depression her history was
unremarkable.
Her early postoperative course was un
complicated. On returning home she failed to
^adhere to the routine pureed diet and did not
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take the recommended vitamins. Two weeks
after operation she became nauseated and
began to vomit. After a further 3 weeks she
could not even retain fluids. Her weight had
fallen to 101 kg. A roentgenogram after barium
swallow and endoscopic examination ruled out
obstruction.
Two weeks later she began to complain of
photophobia and thought she was going blind.
Her daughter noted that her eyes were cross
ed. She became confused, withdrawn and
spoke only in whispers. She could not walk,
stand or get out o f bed without assistance. She
was admitted to the psychiatric service because
of suspected psychotic depression. Her memory
was noted to be impaired. Initial laboratory
data showed a serum sodium value of 141
m m ol/L, potassium 2.7 m m ol/L, chloride 95
m m o l/L , carb on ate 29 m m o l/L and
magnesium 0.56 m m ol/L. The dehydration
was corrected with an intravenous solution
comprising two parts 5<Yo dextrose and one part
0.9% sodium chloride with added potassium
chloride and m agnesium su lfa te . She
deteriorated further. Neurologic evaluation 3
days later demonstrated blinking to visual
threat in all fields, but no response to pain or
shouting. Pupils were normal in size and equal
ly reactive. There were no spontaneous eye
movements; oculocephalic and oculovestibular
testing showed vertical but no horizontal eye
movements. Deep tendon reflexes were present
in the upper limbs but absent in the lower
limbs. Plantar responses were flexor. By this
time the serum potassium, magnesium and
thyroid hormone levels were normal.
Thiamine was given intramuscularly and in
travenously (100 mg by each route). Three
hours later she showed spontaneous lateral eye
movements with nystagmus and some response
to verbal commands. Thirty-six hours later eye
movements were normal and she could stand
with assistance. By 1 week she could walk in
dependently with a broad base. Her confusional state cleared in 4 days, but her recent
memory improved more slowly. Over several
months her neurologic deficits cleared. She is
now functioning well at home with some super
vision o f her dietary habits.

Discussion

Although the absorptive function of
the gastrointestinal tract is maintained in
gastric partitioning, patients who have
had this operation are at risk of vitamin
and protein starvation.3 A danger signal
is excessively rapid weight loss; for exam
ple, more than 5 kg per month or 14 kg

in the first 3 months after operation.3’4
Persistent vomiting after gastric parti
tioning requires an explanation. Usual
causes include narrowing of the stoma
between partitions (edema or stricture) or
obstruction by a foreign body in the nar
row outlet. These causes were ruled out
in our patient. Poor compliance with diet
may have caused her problem.
Ophthalmoplegia, ataxia and mental
confusion were the cardinal features of
the encephalopathy described by Wer
nicke in 1881.5 One of his first patients
was a 20-year-old woman who suffered
persistent vomiting after sulfuric acid
poisoning. Her neurologic syndrome oc
curred 4 weeks later. Wernicke’s other
two cases and most cases in the large
series reported by Victor and associates6
were in alcoholics.
Thiamine in the form of thiamine
pyrophosphate is essential as a cofactor
in two enzyme systems involved in car
bohydrate metabolism. One involves ox
idative decarboxylation of pyruvate and
a-ketoglutaric acid and the second in
volves transketolation in the hexose
monophosphate shunt.7,8 Deficiency of
thiamine is responsible for Wernicke’s
encephalopathy. A glucose load, as given
to our patient, further depletes thiamine
reserves and causes an abrupt worsening
of the condition.8
Our patient probably had a peripheral
neuropathy in view of the absent deep
tendon reflexes in the lower extremities.
A more profound, demyelinating,
primarily sensory neuropathy was
described recently in two patients with
starvation after gastric partitioning.3
After gastric partitioning, patients re
quire close supervision. Excessively rapid
weight loss or persistent vomiting requires
investigation. When patients become defi
cient in thiamine (and probably other
vitamins) they may become anorexic,
compounding the problem.6 A course of
parenteral B vitamins may be warranted
in patients at high risk.
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Staged Resection of a Life-Threatening Aneurysm
of the Descending Thoracic Aorta and a Coexisting
Aneurysm of the Ascending Aorta
The authors report the successful staged
resection of a descending thoracic aortic
aneurysm and a coexisting ascending
aortic aneurysm. The main challenge
was to provide optimal proximal aortic
decompression to prevent rupture of the
ascending aorta during the distal repair.
During the period of aortic arch cross
clamping, organ protection was achieved
with a Gott shunt inserted proximally in
the aortic arch and distally in the left
common femoral artery. The importance
of this shunting procedure, which has
been the basis of our surgical technique
in the treatment of all lesions of the
descending thoracic aorta, is
emphasized.
La coexistence de deux angvrismes
thoraciques est d'incidence rare et peut
poser un probleme sdrieux de technique
chirurgicale. Les auteurs rapportent le
cas inusite d'une malade investigu6e
pour un andvrisme de I'aorte thoracique
descendante rapidement evolutif depuis
5 ans et devenu symptomatique par des
effets de compression trachdo-bronchique severe. L'aortographie a confirme la
presence d'une dilatation andvrismale de
9 cm sur I'aorte descendante et permit
aussi de d6couvrir un anevrisme de 7.5
cm sur I'aorte ascendante non soupconne par roentgenographie simple du
poumon. Le d£fi chirurgical consistait a
assurer une decompression aortique proximale durant le clampage aortique pour
dviter une rupture de I'aorte ascendante

lors de la resection de I'aorte thoracique
descendante. Ceci fut assure avec succes grace £ I'utilisation d'une derivation
externe (shunt de Gott) inseree proximalement au niveau de la crosse aorti
que et, distalement dans la femorale
gauche. Les auteurs insistent sur ce
mode de protection organique qui est la
base de leur technique chirurgicale pour
toutes les lesions de I'aorte thoracique
descendante. Quatre mois apr&s cette
premiere intervention, on entreprenait la
resection de I'anevrisme situe sur I'aorte
ascendante. La periode postoperatoire
fut sans histoire et la malade, revue
recemment e son 16e mois postopera
toire, est asymptomatique et mene une
vie normale.

The appropriate surgical approach to two
coexisting thoracic aneurysms located on
the ascending and on the descending aorta
respectively can present a dilemma.
Primary repair of the distal aneurysm was
successfully carried out by Parr and
Kouchoukos1 but in discussion o f their
paper Helseth presented a similar case
with equally good results in which repair
o f the ascending aorta was done first.1
In the case we describe, surgical treatment
was first applied to the aneurysm situated
on the descending thoracic aorta, follow
ed 4 months later by resection of the
ascending aortic aneurysm. This decision
was dictated by the clinical course.

Case Report
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A 72-year-old normotensive woman com
plained for 2 months of rapidly progressive
dyspnea and dysphagia. When she was referred
to our centre, she was in respiratory distress,
her respiratory rate was 30/min and she had
severe expiratory wheezing and an intractable
cough.
During the previous 2 months, she had lost
9 kg because her dysphagia had become so
severe that she could not swallow solid food.

*

Multiple chest roentgenograms taken previous
ly were available for comparison. Seven years ^
before, the aortic knob was normal. Then, dur
ing the previous 5 years, the roentgenograms
showed a progressive widening of the superior
mediastinum from 4 cm to 9 cm at the levels
of the aortic knob (Fig. 1). The preoperative
chest film showed an enormous aortic shadow
occupying most of the left upper chest (Fig.
lc). Roentgenography after a barium swallow ,
confirmed a posterolateral compression of the
esophagus. Bronchoscopic examination dem
onstrated posterior compression of the lower
third of the trachea and of the left main bron
chus by a pulsatile mass.
Aortography (Fig. 2) established the^
diagnosis of a descending thoracic aortic
aneurysm measuring 8.5 cm in its inner
diameter, and an unsuspected 7.5-cm fusiform
aneurysm of the ascending aorta. On some
films, mild aortic regurgitation was noted and
explained the grade 1/4 diastolic murmur heard
over the precordium.

Surgical Management
It was obvious from serial chest roent
genograms and also on clinical grounds that ^
the descending thoracic aortic aneurysm was
the more life-threatening one. The surgical ap
proach to the lesion was by a left posterolateral
thoracotomy through the bed of the resected,
fourth rib; full extension of the left hip gave
access to the left femoral artery. Once the chest
cavity was fully exposed, the two large
aneurysms could be seen in close proximity, „
forming a very acute angle at their junction
with the normal aortic arch. The finger tip
could not be introduced at this point between
the ascending and the descending aorta and it,
was easily seen that trachea, left main bron
chus and esophagus were sandwiched in the
concavity of the aortic arch.
The external aspect of the descending aorta ,
showed an aneurysm that was acutely inflam
ed and edematous. The whole descending aor
ta, except for the last 3 cm, was involved.
In repairing all lesions of the descending^
thoracic aorta, we have elected for the past 9
years to use an external shunt, the 9-mm Gott
shunt (Sherwood Medical Industries, St. Louis,
Mo.), usually placed between the ascending and ^
the descending aorta to provide proximal
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decompression and distal body perfusion.2 It
is a flexible, transparent polyvinyl chloride tube
and its heparin-coated wall prevents clotting
so that systemic heparinization is not required.
. In this patient, the presence of the proximal
^aneurysm made the ascending aorta unsuitable

for cannulation so the shunt was inserted into
the aortic arch. Involvement of almost all the
descending aorta by the second aneurysm
prevented its usual cannulation. Therefore,
distal perfusion was assured by retrograde can
nulation of the left common femoral artery as
previously described.2
The aorta was repaired with the interposi
tion of a 26-mm woven Dacron graft; the
postoperative course was uncomplicated. Four
months later, because o f multiple episodes of
anterior chest pain, the ascending aortic
aneurysm was resected and replaced with a
tubular, low-porosity, woven graft. This was
achieved through a median sternotomy, using
cardiopulmonary bypass and the protection of
a cardioplegic solution. The patient left the
hospital 10 days later. When she was seen 24
months after the second procedure, she was
completely asymptomatic.

Resection of the descending thoracic
aortic aneurysm necessitated 41 minutes
of cross-clamping between the left carotid
and left subclavian arteries. The major
technical problem was in providing op
timal proximal aortic decompression to
avoid rupture of the ascending aortic
aneurysm during the distal repair. This
was easily achieved with the 9-mm Gott
shunt inserted between the aortic arch and
the left common femoral artery and with
infusion of a nitroglycerin solution at very
low concentration. The blood pressure
was kept between 100 and 110 mm Hg,
which was the patient’s basic pressure.
We have been using this type of shunt
in the resection of the last 88 descending
thoracic aortic aneurysms including 6 rup
tured arteriosclerotic aneurysms. SeventyDiscussion
four (84%) patients survived with no in
stances of cardiac or renal failure.
The coexistence of two large (more Paraplegia occurred in one case because
than 7 cm diameter), fusiform aneurysms the shunt was not properly cannulated in
of the thoracic aorta is rare. Parr and to the descending aortic lumen, but rather
Kouchoukos1 reported their surgical ex into the distended adventitial layer in
perience with two cases of dissection of filtrated by an enormous hematoma.
the upper descending aorta associated There was no perfusion during the period
with a discrete ascending aortic aneurysm of aortic cross-clamping. On the basis of
(size not mentioned).
our results, we firmly believe in organ
Roberts reported an autopsy finding of protection during repair of all lesions of
12 small, saccular aneurysms on a very the descending thoracic aorta. Of 43 con
arteriosclerotic thoracic aorta.3 In our secutive patients who underwent elective
patient, microscopic examination of both resection of an aneurysm of the descend
aneurysms yielded even more surprising ing thoracic aorta, 42 (97.6%) survived,
findings. Syphilitic aortitis was found in proving the safety of the surgical
the descending aorta; this was confirm technique.
Excellent studies have already been
ed by a positive serologic test. Histologic
examination of the ascending aorta reported on the hemodynamic effects of
revealed cystic medial necrosis.
temporary shunts. Wolfe and associates5
Others4 would have recommended demonstrated well that shunts should be
total replacement of the aortic valve and preferentially inserted into the aorta distal
the ascending aorta with a composite to the aortic valve. This position provides
graft. Despite the angiographic evidence the least increase in systolic blood
of mild aortic regurgitation, we elected to pressure and is associated with a lower de
perform the surgical procedure that mand for myocardial blood flow. They
would be quickest and that would effec also found that ventricular pressure in
tively treat the lethal lesion in this 72-year- creased 40% during left ventriculoold woman. She was well and asymp femoral shunting compared with 20% for
tomatic 24 months after her second aortofemoral shunting. When the shunt
operation.
is constructed from the apex of the left
ventricle, the protection of the aortic
valve is lost and regurgitant blood flow
ranges from 10% to 15% of forward
flow.5,6
For all these reasons, in our patient the
aortic arch was preferred to the apex of
the left ventricle for proximal cannula
tion, remembering that she had already
a mild degree of aortic regurgitation.
Conclusions

-*■
,

t_

Fig. lc
FIG. 1—Posteroanterior roentgenograms
show progressive dilatation of descending
thoracic aorta over 5 years.

FIG. 2—Thoracic aortography shows
descending thoracic aortic aneurysm, measur
ing 9 cm in diameter, and unsuspected ascend
ing aortic aneurysm, 7.5 cm in diameter.

The keystone of surgical procedures in
volving the descending thoracic aorta is
the optimal protection of surrounding
organs. This principle should be even
more rigorously followed when such a
surgical procedure is performed in a highrisk patient.
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(diflunisal tablets)

Long-acting NON-NARCOTIC analgesic

For pain relief that lasts

' *

In many patients

■ Analgesia comparable to a
narcotic-containing preparation
■ Up to 12 hours of pain relief with a single dose
■ Generally well tolerated
■ Avoids many of the problems associated with
narcotic-containing analgesics

■

For relief of mild to moderate pain

Stat dose...

The stat dose is the key
to faster pain relief for most patients

d um t

Two 500 mg tablets stat
Then one 500 mg
tablet every 12 hours

Tablets 250 and 500 mg
ANALGESIC/ANTI-INFLAMMATORY

ACTION
Diflunisal is a non-steroidal drug with analgesic,
anti-inflammatory and antipyretic properties.
The precise mechanism of the analgesic and anti
inflammatory actions of diflunisal is not known, however,
it appears to be a peripherally-acting analgesic drug.
Diflunisal is a prostaglandin synthetase inhibitor.
In animals, prostaglandins sensitize afferent nerves and
potentiate the action of bradykinin in inducing pain.
Since prostaglandins are known to be among the
mediators of pain and inflammation, the mode of action
of diflunisal may be due in part to a decrease of
prostaglandins in peripheral tissues.
Pharmacokinetics and Metabolism
Diflunisal is rapidly and completely absorbed following
oral administration with peak plasma concentrations
occurring between 2 to 3 hours. The drug is excreted
in the urine as two soluble glucuronide conjugates
accounting for about 90% of the administered dose.
Little or no diflunisal is excreted in the feces. Diflunisal
appears in human milk in concentrations of 2 - 7 %
of those in plasma. More than 99% of diflunisal in
plasma is bound to proteins.
As is the case with salicylic acid, concentrationdependent pharmacokinetics prevail when diflunisal is
administered; a doubling of dosage produces a greater
than doubling of drug accumulation.
The effect becomes more apparent with repetitive doses.
Following single doses, peak plasma concentrations
of 41 ± 11 (ig/m L (mean ± S.D.) were observed
following 250 mg doses, 87 ± 17 ^g/m L were observed
following 500 mg and 124 ± 11 ^g/m L following single
1000 mg doses. However, following administration of
250 mg b id ., a mean peak level of 56 ± 14 ^g/m L
was observed on day 8, while the mean peak level after
500 mg b.i.d. for 11 days was 190 ± 33 Mg/mL.
The plasma half-life of diflunisal is 8 to 12 hours.
Because of its long half-life and nonlinear pharma
cokinetics, several days are required for diflunisal plasma
levels to reach steady state following multiple doses.
For this reason, an initial loading dose is necessary to
shorten the time to reach steady state levels, and 2 to
3 days of observation are necessary for evaluating
changes in treatment regimens if a loading dose is
not used.

INDICATIONS AND CLINICAL USE
DOLOBID* is indicated for:
- relief of mild to moderate pain accompanied by
inflammation in conditions such as musculoskeletal
trauma, post-dental extraction or post-episiotomy
- symptomatic relief of osteoarthritis.
DOLOBID* has slow onset and long duration of action.
DOLOBID* produces significant analgesia in one
hour and maximum analgesia in 2-4 hours. Analgesic
effect lasts 8 to 12 hours. These characteristics
should be considered when prescribing this drug.

CONTRAINDICATIONS
Patients who are hypersensitive to this product.
Patients in whom acute asthmatic attacks, urticaria, or
rhinitis are precipitated by acetylsalicylic acid or other
non-steroidal anti-inflammatory drugs.
Patients with active peptic ulcer or any other active
inflammatory disease of the gastrointestinal tract.

WARNINGS
When DOLOBID* is given to patients with a history of upper
gastrointestinal tract disease, it should be given only after
consulting the CONTRAINDICATIONS and ADVERSE
REACTIONS sections and under close supervision.
Pregnancy
The safety of this drug in pregnancy has not been
established, and its use during pregnancy is therefore
not recommended.
A dose of 60 mg/kg/day of diflunisal (equivalent to two
times the maximum human dose) was maternotoxic,

embryotoxic, and teratogenic in rabbits. In three of
six studies in rabbits, evidence of teratogenicity was
observed at doses ranging from 40 to 50 mg/kg/day.
Teratology studies in mice, at doses up to 50 m g/kg/
day, and in rats at doses up to 100 mg/kg/day,
revealed no harm to the fetus due to diflunisal. ASA
and other salicylates have been shown to be teratogenic
in a wide variety of species, including the rat and
rabbit, at doses ranging from 50 to 400 mg/kg/day
(approximately one to eight times the human dose).
In rats at a dose of one and one-half times the maximum
human dose, there was an increase in the average length
of gestation. Similar increases in the length of gesta
tion have been observed with ASA, indomethacin, and
phenylbutazone, and may be related to inhibition of
prostaglandin synthetase. Drugs of this class may
cause dystocia and delayed parturition in pregnant
animals.
Because of the known effect of drugs of this class on
the human fetal cardiovascular system (closure of ductus
arteriosus), use during the third trimester of pregnancy
is not recommended.
Nursing Mothers
Diflunisal is excreted in human milk in concentrations
of 2 - 7 % of those in plasma. Because of the potential
for serious adverse reactions in nursing infants from
DOLOBID*, a decision should be made whether to
initiate nursing or to administer the drug, taking into
account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness in infants and children have
not been established, and use of the drug in children
below the age of 12 years is not recommended.
(See TOXICOLOGY.)

PRECAUTIONS
Effect on Platelet Function
As an inhibitor of prostaglandin synthetase, diflunisal
has a dose-related effect on platelet function and
bleeding time. In normal volunteers, 250 mg b.i.d. for
8 days had no effect on platelet function, and 500 mg
b.i.d., had a slight effect. At 1000 mg b.i.d., diflunisal
inhibited platelet function. In contrast to acetylsalicylic
acid these effects of diflunisal were reversible. Bleeding
time was not altered by a dose of 250 mg b.i.d., but
was slightly increased at 500 mg b.i.d. At 1000 mg
b.i.d., a greater increase occurred, but was not statisti
cally significantly different from the change in the
placebo group. Therefore, patients who may be adversely
affected should be carefully observed when DOLOBID*
is administered.
Effect on Fecal Blood Loss
When diflunisal was given to normal volunteers at
500 mg twice daily, fecal blood loss was not significantly
different from placebo. Diflunisal at 1000 mg twice
daily caused a statistically significant increase in
fecal blood loss.
Effect on the Kidneys
Since diflunisal is eliminated primarily by the kidneys,
patients with significantly impaired renal function and
the elderly should be closely monitored; a lower daily
dosage should be anticipated to avoid excessive drug
accumulation.
Uricosuric Effect
In normal volunteers, an increase in the renal clearance
of uric acid and a decrease in serum uric acid was
observed when diflunisal was administered at 500 mg
or 750 mg daily in divided doses. Patients on long
term therapy taking diflunisal at 500 mg to 1000 mg
daily in divided doses showed a prompt and consistent
reduction in mean serum uric acid levels, which were
lowered as much as 1.4 mg%. It is not known whether
diflunisal interferes with the activity of other uricosuric
agents.
Edema
Peripheral edema has been observed in some patients
taking DOLOBID*. DOLOBID* should be used with caution
in patients with compromised cardiac function, hyper
tension, or other conditions predisposing to fluid
retention.
Effect on the Liver
As with other non-steroidal anti-inflammatory drugs,
borderline elevations of one or more liver tests may

occur in up to 15% of patients. These abnormalities
may progress, may remain essentially unchanged, or
may be transient with continued therapy. The SGPT
(ALT) test is probably the most sensitive indicator of
liver dysfunction. Meaningful (3 times the upper limit of <
normal) elevations of SGPT or SGOT (AST) occurred in
controlled clinical trials in less than 1% of patients «
A patient with symptoms and/or signs suggesting liver
dysfunction, or in whom an abnormal liver test has
occurred, should be evaluated for evidence of the develop- **
ment of more severe hepatic reaction while on therapy
with DOLOBID*. Severe hepatic reactions, including *
jaundice and cases of fatal hepatitis, have been reported
with non-steroidal anti-inflammatory drugs. Although such
reactions are rare, if abnormal liver tests persist or
worsen, if clinical signs and'Symptoms consistent with
liver disease develop, or if systemic manifestations
occur (e.g., eosinophilia, rash, etc.), DOLOBID* should t
be discontinued.
Effect on the Eye
•*
Because of reports of adverse eye findings with agents
of this class, it is recommended that patients who
develop eye complaints during treatment with DOLOBID*
have ophthalmologic studies.
-t
Antipyretic Activity
Diflunisal is not recommended for use as an antipyretic ^
agent. In single 250 mg, 500 mg, or 750 mg doses,
diflunisal produced measurable but not clinically useful,
decreases in temperature in patients with fever; however,
the possibility that it may mask fever in some patients,
particularly with chronic or high doses, should be
considered.
„

Drug Interactions
Oral anticoagulants: In some normal volunteers, the
*
concomitant administration of DOLOBID* and warfarin
or acenocoumarol resulted in prolongation of prothrombin *
time. This may occur because diflunisal competitively
displaces coumarins from protein binding sites.
Accordingly, when DOLOBID* is administered with oral
anticoagulants, the prothrombin time should be closely
monitored during and for several days after concomitant
drug administration. Adjustment of dosage of oral
<
anticoagulants may be required.
Tolbutamide: In diabetic patients receiving DOLOBID*
^
and tolbutamide, no significant effects were seen on
tolbutamide plasma levels or fasting blood glucose.
„
Hydrochlorothiazide: In normal volunteers, concomitant
administation of DOLOBID* and hydrochlorothiazide
,
resulted in significantly increased plasma levels of
hydrochlorothiazide. DOLOBID* decreased the hyper- ^
uricemic effect of hydrochlorothiazide.
Furosemide: In normal volunteers, the concomitant
administration of DOLOBID* and furosemide had no
effect on the diuretic activity of furosemide. DOLOBID*
decreased the hyperuricemic effect of furosemide.
*
Antacids: Concomitant administration of antacids may
reduce plasma levels of DOLOBID*. This effect is small
with occasional doses of antacids, but may be clinically
significant when antacids are used on a continuous
schedule.
Acetaminophen: Concomitant administration of DOLOBID* ^
and acetaminophen to normal volunteers resulted in
significantly increased plasma levels of acetaminophen^
Acetaminophen had no effect on plasma levels of
DOLOBID*.
]
Non-steroidal Anti-Inflammatory Drugs
Since no clinical data are available about the safety *
and effectiveness of DOLOBID* when used in combina
tion with other non-steroidal anti-inflammatory drugs, v
no recommendation for their concomitant use can be
made. The following information was obtained from
-<
studies in normal volunteers.
Acetylsalicylic acid: In normal volunteers, a small
decrease in diflunisal levels was observed when
multiple doses of DOLOBID* and acetylsalicylic acid * .
were administered concomitantly.
Indomethacin: The administration of diflunisal to
r,
normal volunteers receiving indomethacin decreased
the renal clearance and significantly increased the
plasma levels of indomethacin. Further, the combined
use of indomethacin and DOLOBID* has been associated
with fatal gastrointestinal hemorrhage. Therefore,
indomethacin and DOLOBID* should not be used

concomitantly.
Sulindac: The concomitant administration of DOLOBID*
and sulindac in normal volunteers resulted in substantial
but not statistically significant lowering of the plasma
► levels of the active sulindac sulfide metabolite.
1 Naproxen: The concomitant administration of DOLOBID*
, and naproxen in normal volunteers had no effect on the
plasma levels of naproxen, but significantly decreased
► the urinary excretion of naproxen and its glucuronide
metabolite. Naproxen had no effect on plasma levels of
, ,pOLOBID*.

ADVERSE REACTIONS

The adverse reactions observed in controlled clinical
trial encompass observations in 2427 patients.
Listed below are the adverse reactions reported in the
1314 of these patients who received long-term
► treatment. Five hundred thirteen patients were treated
I for at least 24 weeks, 255 patients were treated for at
Heast 48 weeks, and 46 patients were treated for
96 weeks. Also listed are the adverse reactions reported
. in 1113 patients who received short-term treatment
(one week or less).
►
PERCENTAGE INCIDENCE
SHORT-TERM LONG-TERM
TRIALS
TRIALS
►
GASTROINTESTINAL
''Gastrointestinal pain
1.4
8.7
Dyspepsia
0.8
8.4
Nausea
4.3
6.5
Diarrhea
0.7
5.4
\fcmiting
1.9
2.1
Constipation
0.1
1.4
i Flatulence
0.1
1.4
Anorexia
0.0
0.7
Eructation
0.2
0.3
Gastrointestinal bleeding
0.1
0.3
Peptic ulcer
0.0
0.1
DERMATOLOGIC
, Rash
0.3
4.0
Pruritis
0.1
1.0
Sweating
0.4
0.8
Stomatitis
0.0
0.8
Dry mucous membranes
0.3
0.6
r CENTRAL NERVOUS SYSTEM
^Headache
3.0
3.7
Dizziness
3.5
2.1
Somnolence
3.9
1.6
r Tinnitus
0.4
1.4
Insomnia
0.2
1.1
1 Vfertigo
0.1
0.9
Nervousness
0.3
0.7
* OTHER
Fatigue/Tiredness
0.6
1.1
’Edema
0.0
0.8
Asthenia
0.6
0.4

CAUSAL RELATIONSHIP UNKNOWN

Other reactions have been reported in clinical trials or
since the drug was marketed abroad, but occurred under
^ circumstances where a causal relationship could not be
r established. However, in these rarely reported events,
,that possibility cannot be excluded. Therefore, these
observations are listed to serve as alerting information
to physicians.
DERMATOLOGIC: erythema multiforme and Stevensjqhnson Syndrome.
RESPIRATORY: dyspnea.
„ CARDIOVASCULAR: palpitation, syncope.
” SPECIAL SENSES: transient visual disturbances.
NERVOUS SYSTEM: paresthesias.
MUSCULOSKELETAL: muscle cramps.
PSYCHIATRIC: depression.
GENITOURINARY: dysuria.
. MISCELLANEOUS: chest pain, fever, malaise, cholestatic
jaundice, hypersensitivity (including interstitial nephritis
A. with renal failure), anaphylactic reaction with
bronchospasm.

,

' 'SYMPTOMS AND TREATMENT
OF OVERDOSAGE
Cases of overdosage have occurred and deaths have
been reported. Most patients recovered without

evidence of permanent sequelae. The most common signs
and symptoms observed with overdosage were drowsi
ness, disorientation or stupor. A dose that is usually
fatal has not yet been identified.
In the event of overdosage, the stomach should be
emptied by inducing vomiting or by gastric lavage, and
the patient carefully observed and given symptomatic
and supportive treatment. Because of the high degree
of protein binding, hemodialysis may not be effective.

DOSAGE AND ADMINISTRATION
For mild to moderate pain, an initial dose of 1000 mg
followed by 500 mg every 12 hours is recommended
for most patients.
A lower dosage may be appropriate depending on such
factors as pain severity, patient response, weight, or
advanced age; for example, 500 mg initially followed
by 250 mg every 12 hours.
For osteoarthritis, the suggested dosage range is
500 mg to 1000 mg daily in two divided doses
according to patient response.
Maintenance doses higher than 1000 mg a day are not
recommended.
DOLOBID* may be administered with water, milk or
meals. Tablets should be swallowed whole, not crushed
or chewed.

AVAILABILITY
Tablets DOLOBID* are capsule-shaped, film-coated
tablets supplied as follows:
8891X - 250 mg, peach coloured, coded DOLOBID on
one side, supplied in bottles of 60 tablets.
8 9 4 7 -5 0 0 mg, orange coloured, coded DOLOBID on
one side, supplied in bottles of 60 tablets.

I Forbes. J. A.: Shackleford. R W Three 12-hour evaluations of the analgesic
efficacy of diflunisal. Proceedings of International Symposium on Diflunisal
Amsterdam. 1980. pp. 143-155.
2. Andrew. A .e ta l Diflunisal six-month experience in osteoarthritis.
Br J Clin Pharmac 4 45S-52S. 1977
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NOTICES
continued from page 160

The major topic of this course will be
advances in hepatic, biliary and pancrea
tic surgery. The course will meet the cri
teria for 26 hours of AMA Category 1
credit. The fee is $400 for surgeons and
$200 for residents.
For more information write: Conti
nuing Medical Education, University of
Minnesota, Box 293, 420 Delaware St.
SE, Minneapolis, Minn. 55455, USA; or
call (612) 373-8012.

Symposium on Infections in the
Immunocompromised Host
The 3rd International Symposium on
Infections in the Immunocompromised
Host will be held at York University,
Toronto, Ont., June 24-28, 1984. The
number of papers presented will be
limited.
For more information contact: Dr.
Ron Feld, Department of Medicine, Prin
cess Margaret Hospital, 500 Sherbourne
St., Toronto, Ont. M4X 1K9.

Canadian Society for Surgery
of the Hand
The annual meeting of MANUS Canada
will be held May 30, 1984, at the Westin
Hotel in Winnipeg, Man. The program
will deal with the management of proxi
mal interphalangeal joint problems. The
guest speaker will be Dr. J. Steichen of
Indianapolis, Minn.
For additional information contact:
Dr. R. McGraw, President, MANUS
Canada, 3rd Floor, 910 West 10th Ave
nue, Vancouver, BC V5Z 4E3; or Dr. R.
M anktelow,
Secretary-Treasurer,
MANUS Canada, Eaton Building North
10-236, Toronto General Hospital, 101
College St., Toronto, Ont. M5G 1L7.

Canadian Lung Association
The annual meeting of the Canadian
Lung Association will be held at the Wescontinued on page 186
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Reaction of Subcutaneous Tissues to Injection
of Fluosol-DA, 20%
To study the extent of tissue reaction,
the blood substitute Fluosol-DA, 2 0 % ,
blood, normal saline and doxorubicin
(Adriamycin) were injected in equal
amounts into the subcutaneous tissues
of four separate regions of the dorsum
of seven rats. The animals were sacri
ficed at 6, 12, 24 and 48 hours, and at
1, 2 and 6 weeks after injection. The in
jected areas were examined by light and
electron microscopy and the reaction
was graded semiquantitatively. Results
indicated the following: (a) saline, as ex
pected, produced only mild inflammation
that quickly resolved; (b) blood caused a
hematoma with recognizable
erythrocytes for 7 days and by 14 days
hemosiderin-laden macrophages and
fibrosis were present; (c) Adriamycin
caused necrotizing lesions that were
delayed for 24 hours, were severe at 2
and 7 days, and caused the disap
pearance of the muscle layer by 14 days
and (d) Fluosol-DA caused the ap
pearance of foamy macrophages at 12
hours that persisted until at least 2
weeks after injection. The authors con
clude that Fluosol-DA, 2 0 % , is not inert
and causes a characteristic inflammatory
response when injected subcutaneously.
Whether a clinically important problem
from subcutaneous infiltration of Fluosol
could arise, for example, around a
peripheral intravenous catheter, has yet
to be determined. At present, it is pro
bably safer to administer this drug
through a central vein.

From the *Division o f Cardiovascular and
Thoracic Surgery and the t Department o f
Pathology, M cG ill University and the
Royal Victoria Hospital, Montreal, PQ
Supported by a grant from the Medical
Research Council o f Canada
Accepted f o r publication Sept. 26, 1983
Reprint requests to: Dr. T.A. Salerno,
Division o f Cardiovascular Surgery,
St. Michael’s Hospital, 30 Bond St.,
Toronto, Ont. M5B IW 8
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Dans le but d'etudier I'etendue des reac
tions tissulaires, le substitut du sang
Fluosol-DA £ 2 0 % , du sang, du solute
physiologique et de la doxorubicine
(Adriamycine) ont 6te injectes, en quan
tity egale, dans le tissu sous-cutane de
quatre regions differentes du dos, chez
sept rats. Ces animaux ont ete sacrifies
6, 12, 24 et 48 heures, et 1, 2 et 6
semaines apres les injections. Les
regions d'injection ont ete examinees au
microscope optique et eiectronique, et
les reactions ont ete appreciees de fagon
semi-quantitative. Les resultats indiquent
que: a) le solute physiologique, tel qu'on
pouvait s'y attendre, produit une inflam
mation legdre qui disparait rapidement;
b) le sang cause un hematome avec per
sistence d'erythrocytes pendant 7 jours
et, apres 14 jours, presence de macro
phages couverts d'hemosiderine, et de
fibrose; c) I'Adriamycine cause des
lesions necrotiques qui apparaissent
apres 24 heures, sont severes le 2e et
7e jour, et entratnent la disparition de
la couche musculaire apres 14 jours; et
d) le Fluosol-DA cause, apres 12 heures,
I'apparition de macrophages spumeux qui
persistent jusqu’a au moins 2 semaines
apres I'injection. Les auteurs concluent
que le Fluosol-DA, e 2 0 % , n'est pas un
materiel inerte et qu'il cause une reaction
inflammatoire caracteristique lorsqu'il est
injecte par la voie sous-cutanee. II n'a
pas encore ete etabli qu'un probleme Cli
nique important pouvait survenir suite a
I'infiltration sous-cutane de Fluosol
autour d'un catheter intraveineux peripherique, par exemple. En ce moment, il
est probablement plus sur d'administrer
ce medicament par une veine centrale.

Fluosol-DA, 20% (Alpha Therapeutics,
Los Angeles, C alif.) is a new perfluoro
chemical with oxygen-carrying capaci
ty 1-4 that is undergoing clinical trials in
N orth A m erica.5-6 This product ap
parently is a valuable vehicle fo r
transporting oxygen at crucial times in
severely anemic patients who, for one

reason or another, refuse or cannot.,
receive human blood. Normally, Fluosol
is infused into a peripheral vein after an ^
initial test dose (0.5 m L) intravenously.
Since certain drugs, such as doxorubicin ■*
(Adriamycin), are known to cause severe
subcutaneous inflammation and necrosis,
we questioned whether Fluosol infiltrated ^
into the subcutaneous tissues would pro
duce a reaction.
,

Materials and Methods
The dorsum o f seven rats was shaved
and, using sterile technique, 0.5 m L o f
normal saline, heparinized rat blood,
Adriamycin or Fluosol-DA, 20%, in nor- +
mally used concentrations, were each in
jected into the subcutaneous tissues o f a
^
different area on the dorsum o f each rat,
separated from each other by at least 3 -*
cm. The animals were sacrificed by
decapitation at 6 and 12 hours and at 1,
2, 7, 14 and 42 days after injection. Each
injected area was removed en bloc and’
fixed in 10% buffered formaldehyde. The
specimens were then sectioned and, after
further fixation, were embedded in paraf- ^
fin, cut and stained with hematoxylin and
eosin, periodic acid-Schiff, mucin and
iron stains. Also, the formalin-fixed sec
tions were stained for fat. The area in-’1
jected with Fluosol in one o f the rats was
used for electron microscope examination
'
2 days after injection. The tissue was cut A
into 1-mm cubes and fixed in 3%
gluteraldehyde in 0.1 M phosphate buf
fer at pH 7.4 for 4 hours. It was then
washed in 0.1 M phosphate buffer, post- fixed in 1% osmium tetroxide and stain
ed en bloc with uranyl acetate. After
dehydration in graded alcohol, the tissue
was embedded in Epon. Sections 1 pm 5
thick were cut and stained with toluidine
blue. From selected areas pale gold sec
tions were cut with a diamond knife , *
stained with lead citrate and examined
with a Philips 300 electron microscope A
(Philips Electronic Instruments, Mahwah,
NJ).
A ll slides were evaluated by a

VOLUME 27, NO. 2, M ARC H 1984 / T H E C A N A D IA N J O U R N A L O F SU RG ERY

pathologist without the knowledge of the
agent injected. The sections were graded
on a scale from 0 (no reaction) to 3 (severe
reaction) for the following parameters:
tedema, congestion, hemorrhage, acute in
flammation, chronic inflammation and
necrosis.

Time after
injection, d
0.25

Results
The semiquantitative grading on the
slides is shown in Table I. Chronic in
flammation includes the presence of the
hemosiderin-laden macrophages in the
group that received blood and of foamy
macrophages in the Fluosol-DA group.

Table 1-Reaction of Tissue to Agents*
Acute
inflammation
Congestion
1
0
1
0
1
0
1
0
1
1
1
0
0
0
0
0
1
2
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Agent
Edema
Adriamycin
2
1
Blood
2
Fluosol-DA, 20%
2
Saline
2
Adriamycin
0.5
2
Blood
Fluosol-DA, 20%
3
1
Saline
Adriamycin
2
1
1
Blood
3
Fluosol-DA, 20%
1
Saline
2
Adriamycin
2
1
Blood
1
Fluosol-DA, 20%
1
Saline
2
Adriamycin
7
0
Blood
1
Fluosol-DA, 20%
0
Saline
Adriamycin
1
14
0
Blood
2
Fluosol-DA, 20%
0
Saline
Adriamycin
0
42
Blood
0
Fluosol-DA, 20%
0
0
Saline
*0 = no reaction, 1 - mild reaction, 2 = moderate reaction, 3 = severe reaction.

The reactions were located beneath the
thin subcutaneous muscle layer.
Saline
At 6 hours, as expected, there was some
edema with minimal inflammation (Fig.
1). The inflammation disappeared by 12

Chronic
inflammation
1
0
1
0
0
1
3
1
1
2
3
1
2
1
3
1
1
2
3
0
1
2
2
0
0
1
2
0

Necrosis
0
0
0
0
0
0
0
0
1
0
0
0
2
0
0
0
3
0
0
0
3
0
0
0
2
0
0
0

Hemorrhage
0
3
0
0
0
3
0
0
0
3
0
0
0
3
0
0
0
1
0
0
0
0
0
0
0
0
0
0

»

A,
FIG. 1—Skin, 2 days after saline injection.
Subcutaneous layer is normal except for rare
lymphocytes (hematoxylin and eosin, reduced
by 52% from x50).

FIG. 2—Two days after blood injection.
Hematoma has formed, with little reaction in
subcutaneous tissue beneath muscle (hematoxy
lin and eosin, reduced by 52% from x50).

FIG. 3—Seven days after Adriamycin injec
tion there is necrotic tissue on either side of
necrotic skeletal muscle but little inflammation
(hematoxylin and eosin, reduced by 52% from
X 200).
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hours and the edema between 2 and 7
days.
Blood
Blood gave rise to a hematoma, with
recognizable erythrocytes until 7 days. By
14 days, it was replaced by hemosiderin
laden macrophages and some fibrosis
(Fig. 2).
Adriamycin
This agent caused predom inantly
necrotizing lesions, which did not appear

until 24 hours after injection. The lesions
were very marked at 2 and 7 days, and
resulted in the disappearance of the mus
cle layer by 14 days. There was little in
flammatory reaction to the necrosis (Fig.
3).
Fluosol-DA, 20%
Fluosol produced a characteristic
response in which foamy macrophages
appeared by 12 hours (Figs. 4 and 5);
these macrophages were numerous until
2 weeks but were markedly decreased at
6 weeks. Electron microscopy showed the
presence of macrophages and some
neutrophils. The former were filled with
large vesicles, each containing numerous
round particles (1 to 2 jun in diameter)
of Fluosol (Fig. 6). In addition, there were
fat globules scattered in the cytoplasm.
The neutrophils, which were seen only
rarely, also contained Fluosol particles.
Surrounding the inflammatory cells were
strands of fibrin.
Discussion

FIG. 4—Two days after Fluosol-DA, 20%
injection, low-power photomicrograph shows
extensive infiltration of subcutaneous tissue by
macrophages (hematoxylin and eosin, reduc
ed by 52% from x50).

Fluosol-DA is given to patients through
a peripheral intravenous catheter, after a
test dose of 0.5 mL, in the volume of 20
mL/kg body weight. An additional 10
mL/kg may be infused 24 hours later if
necessary. To our knowledge, the
clinicopathological effects of Fluosol that
infiltrates the subcutaneous tissues dur
ing infusion are not known. In particular,
we were concerned that the ensuing in
flammatory response might be severe,

leading to damage to skin and underly
ing structures. It is known that FluosolDA, given intravenously, is retained
primarily in the liver and spleen, with only
traces being detected in the lungs and *
kidneys.7 Histologic examination of
these organs between 1 and 3 weeks has A
revealed foamy macrophages in the spleen
and in Kupffer cells of the liver.7'8
Perfluorochemical particles are also
found in hepatocytes, endothelium of the
lung capillaries and in endothelial cells .<
and mesangial cells of the kidneys.7’8
Autopsy performed in patients who died
<
7 months after the administration of
1
Fluosol-DA revealed no vacuolation in
any organs, and gas chromatography con
firmed the lack of perfluorochemical
particles.9 Little is known about the ef- ^
fects of Fluosol injected into the sub
cutaneous tissues — a very important
*
concern, considering that Fluosol is nor^
mally infused into a peripheral in- i
travenous catheter.
In our investigation, Fluosol injected
subcutaneously caused a characteristic in
flammatory response consisting of exten- *
sive infiltration by macrophages that per
sisted for at least 2 weeks. Obviously, we
do not know what the long-term effects c
would be if Fluosol inadvertently in
filtrated the surrounding tissues at an in
travenous site. Further research is
necessary to determine the reaction of
nerves, and peripheral arteries and veins
to Fluosol. Until then, our study suggests *
that it should be administered through a
central vein.
-i

We thank Mrs. France Burdon for her
technical assistance.

References
1. Clark LC jr , GOLLAN F: Survival o f mammals breathing
organic liquids equilibrated with oxygen at atmospheric
pressure. Science 1966; 152: 1755-6
2. GEYER RP, Monroe RG, T aylor K: Survival o f rats
having red cells totally replaced with emulsified fluorocar
bon (abstr). Fed Proc 1968; 27: 384

,

A

3. GEYER RP: Fluorocarbon-polyol artificial blood
substitutes. N Engl J Med 1973; 289: 1077-82
4. GOULD SA, ROSEN AL, SEHGAL LR, SEHGAL HL, RICE
CL, MOSS GS: How good are fluorocarbon emulsions as
0 2 carriers? Surg Forum 1981; 32: 299-301

,

^
^

5. T remper KK, F riedman AE, Levine EM, La pin R,
CAMARILLO D: The preoperative treatment of severely
anemic patients with a perfluorochemical oxygen-transport
fluid, Fluosol-DA. N Engl J M ed 1982; 307: 277-83
6. T rem per KK, L a pin R, L evine E, F riedman A,
SHOEMAKER WC: Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, Fluosol-DA
(20%). Crit Care M ed 1980; 8: 738-41

-*
A

7. N anney L, F ink LM, VIRMANI R: Morphologic
demonstration of per fluorocarbon retention in liver, spleen,
lung and kidney of rabbits (abstr). Lab Invest 1983; 48: 624

FIG. 5—High-power photomicrograph of
area in Fig. 4 shows macrophages with little
lymphocytic infiltrate at 2 days after injection
(hematoxylin and eosin, reduced by 52% from
X 1300).
178

FIG. 6—Seven days after injection of
Fluosol-DA, electron photomicrograph shows
macrophage containing numerous membranebound phagocytosed Fluosol particles (arrows)
and some lipid-filled vacuoles (L). There is
dark-staining fibrillar fibrin in extracellular
space surrounding macrophage (reduced by
57% from x 2 2 500).

8. O hnishi Y, Kitazawa M: Application of perfluoro- ^
chemicals in human beings — a morphological report of
a human autopsy case with some experimental studies us
ing rabbit. Acta Pathol Jpn 1980; 30: 489-504
L9. N a it o
R,
YOKOYAMA K:
Supplem ent
to
Perfluorochemical Blood Substitutes (FC 43 Emulsion,
Fluosol-DA, 20% a n d 35%), Technical Information Ser.,
no. 7, Green Cross Corp., Osaka, Japan, 1981: 117

VOLUME 27, NO. 2, M A R C H 1984 / THE CANADIAN JOURNAL OF SURGERY

-4

C .W . N o h r ,

m d

,

cm

; D .G . M

a rsh a ll, m d

,

f r c s [C]

Primary Peritonitis in Children
Ten cases of primary peritonitis in
children demonstrate that the usual
presentation is one of rapid onset of
lower abdominal pain in girls, clinically
indistinguishable from acute appendicitis.
Recovery after appendectomy is rapid.
Fewer cases have positive peritoneal
cultures or associated illnesses than in
historical descriptions. Contemporary
primary peritonitis follows a more benign
course than in the past.
Oix cas de peritonite primaire chez des
enfants ont ete analyses. Celle-ci se
manifeste habituellement par I'apparition
soudaine de douleurs abdominales chez
les filles, non-differenciables cliniquement de I’appendicite aigiie. La guerison
est rapide apres I'appendicectomie. Les
cas de cultures peritoneales positives
sont plus rares que dans les descriptions
antgrieures. La peritonite primaire contemporaine prend une forme plus benigne que par le passe.

Suppurative peritonitis is usually secon
dary to perforation of a viscus, traumatic
contamination or ascending genital infec
tion. Tuberculous peritonitis is often at
tributed to bowel lesions, salpingitis or
retroperitoneal lymph nodes. Chemical
peritonitis may be due to early gastric or
duodenal perforation or to hemoperitoneum. Periappendicitis,1 spontaneous
bacterial peritonitis in adult cirrhosis,2
actinomycosis, amebic and fungal
peritonitis, medical peritonitis in systemic
lupus erythem atosus, and prim ary
peritonitis in adults3 are other intra
abdom inal inflam m atory diseases.
Primary peritonitis in children excludes
these and refers to an acute purulent in
flammation of the peritoneal cavity in
children without an identifiable intra
abdominal source.
Historically the term referred to a
“terrible abdominal catastrophe of infanFrom the Division o f Pediatric Surgery,
University o f Western Ontario, London,
Ont.
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cy and early childhood” .4 Reported boy
to girl ratios vary from 1:15 to 1:3.4
Many cases were associated with
nephrotic syndrome or postnecrotic cir
rhosis. The usual presentation was the
rapid development of an acute abdomen
with high fever and leukocytosis. Definite
diagnosis was made on clinical grounds
or occasionally by paracentesis, but close
mimicry of perforated appendicitis led
to frequent laparotomy and appendec
tomy. While in 1953 operation was
thought to be harmful,5 in 1957 it was
stated to be innocuous6 and in 1975 it
was recommended.7 Peritoneal exudate
in most cases contained Pneumococcus or
Streptococcus organisms. The mortality
was high; in a report of 23 patients
published in 1926, it was 100%.4 The in
troduction of antibiotics and improved
surgical care coincided with or resulted in
a fall in mortality from 100% in 1926 to
26% in 1953s and 5% in 1971.8 Concur
rently there was a change in the bacterial
spectrum. In papers published between
1926 and 1955,4,5,9 Pneumococcus or
Streptococcus organisms were isolated
from the peritoneal fluid in 239 of 248
cases. Between 1956 and 1975,6‘8’10these
organisms were found in only 90 of 201
cases. Specimens from 32 cases grew a
variety of gram-negative, staphylococcal
and anaerobic organisms, while 32 show
ed no bacterial growth. From two of these
cases, viruses were isolated.8 Theories of
etiology have focused on ascending
genital infection, lym phatic or
hematogenous seeding from remote infec
tions and transmural migration of in
testinal organisms.11
A retrospective review of cases from
1970 to 1980 was undertaken to study the
disease and its most recent clinical and
microbiologic characteristics.
Patients
A review of medical records from 1970
to 1980 in two University of Western On
tario teaching hospitals with pediatric
units identified 10 cases (all girls) of
peritonitis without any evident source of
infection in patients younger than 18
years. A retrospective chart review was
performed and a representative case
selected for presentation.

Case Report
A previously well 6-year-old girl was admit
ted to hospital with a 3-hour history o f lower
abdominal pain. Apart from mild dysuria,
there were no associated throat, genitourinary
or abdominal complaints. Her temperature was
36.8°C and heart rate 110 beats/m in. She ap
peared mildly ill. The abdomen was slightly
tender in both lower quadrants; there were no
other positive physical findings. The leukocyte
count was 9.5 x 109/L and urinalysis show
ed 5 leukocytes per high-power field. Three
hours later, the patient had increased diffuse
abdominal pain more marked in the right lower
quadrant contained 10 to 20 mL o f cloudy
a temperature o f 39°C. On examination o f the
abdomen, decreased bowel sounds were noted
and diffuse tenderness with guarding in the
right lower quadrant. Ampicillin (500 mg) and
gentamicin (35 mg) were given intravenously
and the patient was operated upon.
The peritoneal cavity in the right lower
quadrant contained 10 to 20 mL o f cloudy
odourless fluid. The appendix and right fallo
pian tube showed minimal surface inflamma
tion only. The distal small bowel and cecum
were normal. Appendectomy was done without
drainage. The patient’s postoperative course
was uncomplicated and her temperature return
ed to normal in less than 24 hours.
Gram-staining o f the peritoneal fluid showed
numerous leukocytes but no bacteria. Neither
aerobic nor anaerobic cultures showed any
bacterial growth. Histologic examination o f the
appendix showed surface inflammation.

Results
The 10 girls ranged in age from 3 to 14
years (mean 9 years). All were previous
ly well.
The duration of abdominal pain was
less than 12 hours in seven cases. Nausea
with vomiting or diarrhea was present in
five, two and two cases respectively. One
patient had had a recent upper respiratory
tract infection, while four had dysuria.
One 12-year-old girl complained of ab
normal vaginal discharge.
Temperature was higher than 38°C in
all cases but two. Only one child appeared
extremely toxic.
Abdominal tenderness was found to
vary in degree and location, being either
diffuse or localized in one or both lower
quadrants. Guarding was present in the
area of maximal tenderness in all cases.
Five children had rectal examination; the
findings in all were abnormal with
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anterior or right-wall tenderness. One
pelvic examination was done and reported
as normal. In no case was evidence of
concomitant or predisposing disease
found on examination. Leukocyte counts
ranged from 7.7 to 26 x 109/L . Only
one count was greater than 21 x 109/L
(in the patient who was extremely toxic)
and two were less than 10 x 109/L .
Urinalysis in four cases showed more than
10 leukocytes per high-power field. Two
patients had abdominal roentgenograms;
one showed ileus and the other no
abnormality.
In all patients operated on, the
preoperative diagnosis was peritonitis
secondary to acute appendicitis. In only
one case was primary peritonitis suspected
preoperatively. At laparotomy, purulentlike peritoneal fluid was present in all.
The appendix showed surface inflamma
tion only in eight cases and no abnormali
ty in two. The right fallopian tube was
normal in five cases and mildly inflamed
in the remainder without any fluid emerg
ing from it. Appendectomy was done in
all cases, with peritoneal drainage in one.
One patient also had an ovarian cystec
tomy. All wounds were closed primarily.
There were no deaths and no
postoperative complications; in par
ticular, no ongoing peritonitis, abdominal
or pelvic abscess, bowel obstruction,

pyelophlebitis or wound infections
developed before discharge from hospital.
The mean duration of hospitalization was
8 days (range from 4 to 15 days). The
temperature returned to normal in less
than 24 hours in all cases but one, in
which defervescence occurred between 24
and 48 hours.
Three patients received antibiotics
before operation. All three received ampicillin (25 mg/kg); two were also given
gentamicin (1 mg/kg) and one cloxacillin
(25 m g/kg). Blood cultures taken
preoperatively from two patients were
negative, and only sporadic throat and
vaginal cultures were done. Three of five
urine cultures showed bacterial growth;
two grew Escherichia coli and one Strep
tococcus faecalis and Staphylococcus
albus. Immediate Gram-staining of
peritoneal fluid on nine specimens show
ed numerous leukocytes but no bacteria.
Specimens from the extremely toxic pa
tient subsequently showed growth of
Streptococcus pyogenes and in two pa
tients E. coli grew on subculture. All pa
tients were treated postoperatively with
antibiotics intravenously and orally for 3
to 11 days. The following dosages were
used: penicillin G (2 to 8 million units/d),
ampicillin and cloxacillin (100 mg/kg dai
ly), gentamicin and tobramycin (3 mg/kg
daily). All patients received one or two

o f penicillin G, ampicillin or cloxacillin,
with an aminoglycoside added in four
cases.
Discussion

4

Only one of the cases in this review fits
the historical description o f primary A
peritonitis. This 10-year-old girl was toxic
on presentation and had the highest fever ’
and leukocyte count in the group. Im
mediate Gram-staining was not done, but
peritoneal exudate cultures grew S. <
pyogenes. The other cases followed a
milder clinical course. The peritoneal ex•<
udate in two cases grew E. coli on sub
culture only, and in the remainder there *
was no growth. Also at variance with
earlier series are the absence o f boys and
the lack o f patients with nephrotic syn- <
drome or cirrhosis. The reason for these
differences cannot be determined from ^
this retrospective review. Possible reasons
include improved medical care for chil- 1
dren with nephrotic syndrome, earlier
diagnosis and treatment of upper respira
tory tract infections that in the past may
have hem atogenou sly seeded the
peritoneum or a change in diagnostic ,
terminology.
Although primary peritonitis has not t
been demonstrated to be an infectious
disease by strict criteria, etiologic theories
have focused on the role of microbiologic
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agents. There are four routes by which
organisms may reach the intact peritoneal
, cavity: hematogenous seeding may occur
| from remote foci of infection, such as up>per respiratory tract infections or lym
phatic seeding from more local infections
> is possible; the preponderance of girls im
plicates the genital tract; migration of
' ^ organisms across the bowel wall is possi
ble and this has received experimental
support;11 reflux of urine into the
^peritoneal cavity in girls has also been
suggested.12 Once bacterial contamina
te tion of the peritoneal cavity has occurred,
i the lack of omental development in
*- children may allow an inflammatory pro
cess to spread in the peritoneal cavity.
The contemporary presentation of
prim ary peritonitis is sufficiently similar
to previous descriptions that it may still
.
be confused with acute appendicitis. A
1 decade ago laparotomy was said to be un*. necessary when fluid from paracentesis
showed gram-positive cocci.8 In this
’ series, paracentesis would not have been
helpful because Gram-staining of the
^ peritoneal fluid was negative in all cases.
The lack of mortality and morbidity after
appendectomy supports surgical explora4 tion. Prim ary perito n itis may be
suspected preoperatively, predominantly
on the basis of a rapidly developing ear
ly clinical course.

Apart from whether or not to operate,
decisions regarding surgical drainage and
antibiotic treatment are the most impor
tant. Drainage of the peritoneal cavity is
a much-discussed issue and has been sug
gested as the primary treatm ent.5 In this
series, it was unnecessary after appendec
tomy. The use of antibiotics is a more dif
ficult question. Negative bacterial cultures
could be attributed to the preoperative use
of antibiotics in three cases, but the only
girl with a clearly positive culture also
received antibiotics before operation.
Most patients in this review did not have
an identified bacterial infection. Ap
propriate antibiotic therapy therefore
cannot be determined.
Conclusions
Primary peritonitis in children is
clinically, pathologically or microbiologically distinguishable from peritonitis
secondary to bowel perforation, periap
pendicitis, sp o ntaneous bacterial
peritonitis and primary peritonitis in
adults. Our patients differed from those
of historical descriptions particularly with
respect to the absence of boys, the infre
quency of positive bacterial cultures and
the more benign course. The exact place
of primary peritonitis in our understand
ing of inflammatory abdominal disease

remains unclear. The term itself may be
properly applicable to only a very occa
sional case; most cases seem more aptly
described by the term benign aseptic
peritonitis, used by Grob13 in 1957.
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Eosinophilic Gastroenteritis
Eosinophilic gastroenteritis is a rare con
dition, characterized by diffuse infiltra
tion of the gastrointestinal tract by
eosinophils. This involves mainly the
stomach, duodenum and small bowel
and rarely the esophagus, colon, pan
creas, gallbladder, prostate and urinary
bladder.
Most reported cases have occurred in
adults in the third decade of life. The
authors report on a 15-day-old infant who
initially presented with rectal bleeding
and a scan that indicated a Meckel's
diverticulum was present. At laparotomy,
however, a Meckel's diverticulum was
not found. The appendix was slightly
distended and there was a mild inflam
matory reaction. Appendectomy was
performed. Microscopically the appendix
showed diffuse eosinophilic infiltration.
The blood eosinophil count was
elevated. The patient recovered well, but
had several minor episodes of rectal
bleeding following ingestion of milk. He
remained asymptomatic on a milk-free
diet.
The etiology of eosinophilic gastro
enteritis is unknown and there is no
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specific treatment. In uncomplicated
cases, diet, corticosteroids and adrenocor
ticotropic hormone are used. Operation is
reserved for cases of obstruction and
hemorrhage.
La gastro-enterite eosinophile est une
affection rare caracteris6e par une
infiltration diffuse des voies gastrointestinales par les cellules eosinophiles.
II y a atteinte surtout de I'estomac, du
duodenum et du petit intestin et, rarement, de I'oesophage, du colon, du pan
creas, de la vdsicule biliaire, de la pros
tate et de la vessie.
La plupart des cas signales sont survenus chez les adultes dans leur troisieme
decennie. Les auteurs d6crivent le cas
d'un bebe de 15 jours qui a ete recu
souffrant de saignement rectal et dont la
scintigraphie indiquait la presence d'un
diverticule de Meckel. On n’en trouva
toutefois pas trace a la laparotomie.
L'appendice etait legdrement distendu et
il y avait presence d'une legere reaction
inflammatoire. A la microscopie apres
I'appendicectomie, l'appendice montrait
une infiltration eosinophile diffuse. Le
compte des eosinophiles sanguins etait
eleve. Le petit patient se retablit bien
mais eut plusieurs courts episodes de
saignement rectal apr£s I'ingestion de
lait. II demeura asymptomatique grace &
un regime sans lait.
L'etiologie de la gastro-enterite dosinophile n'est pas connue et il n'existe pas
de traitement specifique. Dans les cas
simples, le regime, les corticosteroides et

I'hormone corticotrope sont utilises.
L'operation est reservee pour les cas oil
il y a obstruction et hemorragie.

Eosinophilic gastroenteritis is a rare con
dition characterized by diffuse eosino
philic infiltration o f the gastrointestinal
tract. Its cause is unknown. Usually it in
volves the stomach, duodenum and small
bowel and rarely the esophagus and col
on. Eosinophilic infiltration also affects
the pancreas, gallbladder, prostate and
urinary bladder.1-5
This condition was originally describ
ed by Kaijer in 19376 and in 1961 Ureles
and associates7 reviewed the literature
and proposed a classification.
Over 100 cases have been described in
the literature. Most are in adults with
predominance in the third decade. Only
26 cases in children had been reported up
to 1982.8-11
The purpose of this report is to describe
a case o f eosinophilic gastroenteritis in a
15-day-old boy, to review the literature
and to outline the clinical presentation,
classification, diagnosis and management
of this unusual condition.
Case Report
A 15-day-old boy had rectal bleeding for 3
days. The blood was bright red and mixed with
mucus and stool. He was a full-term infant,
weighing 4 kg at birth. The pregnancy and
delivery were normal. He was breast fed for
10 days, when a commercial baby formula was
introduced.

Table 1-Laboratory Data
D a y after
admission

Hemoglobin,
b /l

Hematocrit,
%

Leukocyte
count,
X 1 0 9/L

0
1
2
3
20
42
55

160
158
160
130
113
126
120

45
44
46
37
33
36
35

1 1 .6
1 1 .0
1 4 .6
1 5 .6
9 .8
8.9
7.8

182

Neutrophils,
%

Lymphocytes,

42

48

—

—

24
65
27

63
28
54

17
25

75
58

%

M onocytes,
%

Eosinophils,
%

6

4
_

_

4
5
5
7
5

Platelets,
X 1 0 9/L
680

_
_

9
2
14

555

1
8

600

_

-
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The laboratory investigations are outlined in
Table I.
A plain roentgenogram of the abdomen was
normal. Sigmoidoscopy to 12 cm gave normal
^findings, revealing only mild irritation of the
rectal mucosa. Roentgenography after barium
enema showed an irregular mucosal pattern in
the rectum and sigmoid colon.
^
A technetium-99m scan for Meckel’s diver
ticulum showed increased uptake in the right
lower quadrant of the abdomen; a diagnosis
o f a bleeding Meckel’s diverticulum or enteric
iduplication containing ectopic gastric mucosa
was made.
At laparotomy neither Meckel’s diverticulum
nor enteral duplication was found. The small
,. bowel and colon appeared normal but unusual
ly large lymph nodes were noted throughout
the mesentery and the appendix was enlarged
and swollen. Appendectomy was performed.
t. Microscopically the appendix showed diffuse
infiltration of the lamina propria, muscularis
mucosae, serosa and fatty tissue by mature
eosinophils (Fig. 1). Small granulomas were
,. also seen with multinucleated giant cells. There
was no ulceration of the mucosa. Plasma cells
were rarely seen.
The postoperative course was smooth and
^the baby was discharged on a soya-based in
fant formula at 21 days of age.
He was admitted 3 weeks later after several
more episodes of bleeding. He was, however,
4 thriving and the stools were of normal frequen
cy and consistency. Finds on physical examina
tion were normal apart from the laparotomy
scar (Table I).
All other investigations gave normal results
including IgG, IgA and IgM levels. Repeat
^ sigmoidoscopy revealed small ulcerations in the
rectal mucosa, but rectal biopsy did not show
an increased number of eosinophils.
He has continued to thrive and has been
followed up for 3 years. During that time he
has had two minor episodes of gastrointestinal
bleeding.

Ureles and associates7 described two
forms of eosinophilic gastroenteritis, one
diffuse and the other localized. Three
anatomicopathologic patterns have also
been described — a mucosal disease
characterized mainly by iron-deficiency
anemia, hypoproteinemia, peripheral
edema and malabsorption; a muscular
disease presenting with marked thicken
ing and rigidity of the intestine with or
without obstructive symptoms; and a
serosal and subserosal form associated
with peritonitis and ascites, showing
marked eosinophilia in the ascitic fluid.9
The O ’Neill classification14 includes
two groups: group 1 with peripheral
eosinophilia and group 2 w ithout.1,15
The clinical presentation depends on
the degree and extent of intestinal involve
ment. Diffuse forms present with ab
dominal discomfort, recurrent abdominal
pain, abdominal distension, nausea,
vomiting and diarrhea, weight loss,
anemia and ascites. Localized forms may
present with gastrointestinal obstruction
or hemorrhage. In some of the latter cases
a tum our may be suspected. Because of
the variation in presentation, the
diagnosis may be difficult. Eosinophilic
gastroenteritis should be suspected in all
patients presenting with the symptoms
just described in whom other morecommon gastrointestinal conditions have
been excluded.1,5,8 Roentgenographic in
vestigation such as upper gastrointestinal
series with follow-through may be
v aluable
to
determ ine
gross
involvement.9 The diagnosis is suggested
when high blood eosinophil levels are
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»Discussion

Eosinophilic gastroenteritis is more
common in adults, only a few cases hav*"ing been reported in children.9'11 We
have found only two other cases of the
condition occurring in the neonatal
^period.
Church and associates12 reported a
p case of eosinophilic proctitis and hyperimmunoglobulinemia E in a premature
k newborn. In this case only the mucosa
and lamina propria showed infiltration
with eosinophils.
Sherman and Cox13 recently reported
a similar case and attributed the
eosinophilic colitis to a transplacental sen
sitization of the colon by bovine milk
►antigens.
The etiology of eosinophilic gastroen■ teritis is unknown but several possible
underlying factors have been postulated,
1 *■such as allergies, reaction to foreign
bodies, parasitic disease and infection by
r fungi and bacteria.1'5,8'9,14 A chronic
^ disease, with relapses and exacerbations
'
and an acute disease of short duration
have both been described.

fo u n d , but should be co n firm ed
histologically if possible. Biopsy o f the
small-bowel mucosa will not be helpful
when there is no mucosal involvement
and full-thickness biopsy at laparotomy
in acute cases is often not justifiable. In
some cases, biopsy of the stomach helps
to confirm the diagnosis. Eosinophilic
gastroenteritis occurring in children has
been also called allergic gastroenteropathy.9
There is no specific or definitive treat
ment for this condition. The management
for uncomplicated cases is medical. This
may include dietary manipulation, the use
of corticosteroids and adrenocorticotro
pic hormone. More recently, cromolyn
sodium , an inhibitor o f m ast-cell
m ed iato r
substance,
has
been
suggested.5,8,16 Correction of fluid and
electrolyte imbalance and anemia are also
important. Operative treatment is reserv
ed for patients with intestinal obstruction,
hemorrhage and uncertain diagnosis.1
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FIG. 1—Operative specimen shows full
thickness infiltration of appendix by
eosinophils (hematoxylin-phloxine-saffron,
reduced by 62% from x 140 [inset, Giemsa,
X 560]).
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Enterobronchial Fistula
Enterobronchial fistula is a rare condi
tion. The authors describe a 47-year-old
man who had a fistula between the small
bowel and tracheobronchial tree, 8 years
after resection of an adrenal carcinoma.
The report illustrates the difficulties in
diagnosis and the surgical treatment. In
particular, the use of hyperosmolar,
water-soluble contrast medium in
radiologic investigations is to be avoided
and the use of a double-lumen endo
tracheal tube is mandatory if a general
anesthetic must be given. Despite its
rarity, enterobronchial fistula can be
diagnosed through a carefully taken
history, confirmed safely by roent
genography and cured surgically.
La fistule entero-bronchique est une
affection rare. Les auteurs decrivent le
cas d'un homme de 47 ans qui presenta
une fistule entre I'intestin grele et I'arbre
trachdo-bronchique, 8 ans apr6s la resec
tion d'un cancer surrenalien. Cet article
illustre les difficultes diagnostiques et le
traitement chirurgical. En particulier,
I'emploi pour I'examen radiologique d'un
agent de contraste hydrosoluble hyperosmolaire doit etre evitd et I'utilisation
d'une sonde endotracheale a double
lumiere est necessaire si une anesthdsie
generale doit etre administree. En depit
de sa rarete la fistule entdro-bronchique
peut etre diagnostiquee grace a une
anamn&se soigneusement prise, confir
mee avec assurance par la radiographie
et gu6rie par la chirurgie.

is described in standard textbooks.
Gastrobronchial,1'3 biliary bronchial,4'5
nephrobronchial6'7 and colobronchial7
fistulas are less common. Anomalous
communication between small bowel and
tracheobronchial tree, enterobronchial
fistula, has apparently not previously
been reported.
Case Report

A 47-year-old white man had a carcinoma
of the left adrenal gland removed surgically.
For 6 V2 years he remained well. Then he pre
sented with upper abdominal pain and a mass
in the left upper quadrant of the abdomen. A
laparotomy was performed. Extensive recur
rence of the adrenal carcinoma was found,
involving the left hemidiaphragm, spleen and
tail of the pancreas. The tumour was resected
as were the involved areas of the diaphragm
and pancreas. The diaphragm was closed with
sutures. A splenectomy was performed.
The patient received 4326 rad of cobalt-60
radiation in 24 treatments to the left upper
abdomen over a 416-week period.
For 8 months the patient was well, then
small-bowel obstruction developed. At opera
tion, dense adhesions were seen involving small
bowel in the left upper abdomen. There was
no evidence of recurrent tumour. Initial at
tempts to free the small bowel with blunt
dissection and jejunojejunostomy failed. A se
cond laparotomy with gastrojejunostomy suc
cessfully relieved the obstruction. Postoper-

Fistulous communications between the
tracheobronchial tree and infradiaphragmatic structures are uncommon. Hepatobronchial fistula, secondary to rupture of
a hepatic abscess through the diaphragm,
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FIG . 1—Air-fluid levels (arrows) in base of
left lung.

atively, upper abdominal pain, fever and a left
sided pleural effusion developed. A search for
infection in the left subphrenic space by
ultrasonography, computerized tomography
and gallium scanning was fruitless. The pleural
fluid was sterile but culture of the wound iden
tified the infecting organism and he was treated
with appropriate antibiotics. Fever and ab
dominal pain subsided. The patient was
discharged 9 days following completion of the
course of antibiotics.
For the next year he was well except for a
single episode of pneumonia in the left lower
lobe. This was successfully managed with an
tibiotics and the patient returned to his occupa
tion as a fisherman.
Then a severe cough productive of large
amounts of foul-smelling sputum developed.
He became febrile, anorexic and lost 7 kg over
3 weeks. He reported the peculiar sensation of
gas rising upwards from his left upper ab
domen into his left hemithorax followed by a
taste of food in his mouth. He was admitted
to the respiratory service for evaluation.
He appeared chronically ill and wasted. His
temperature was 40° C. Physical findings were
confined to the respiratory system. Diminish
ed movement, dull percussion note and diffuse
crackles over the lower lobe of the left lung
were present. Bowel sounds were audible over
the lower left hemithorax. The abdomen, ex
cept for multiple surgical scars, appeared
normal.
Laboratory investigation revealed moderate
anemia, marked leukocytosis and moderate
reduction of the serum albumin level. While
breathing room air, the patient’s arterial oxy
gen pressure was 61 mm Hg. Chest roent
genogram revealed a loss of volume in the left
lower lobe with a multilocular cavity posterior
ly and air space disease in the right lung (Fig.
1). Culture of the sputum grew Escherichia
coli. Blood cultures gave negative results.
Since the patient’s history suggested a com
munication between upper bowel and tra
cheobronchial tree, an upper gastrointestinal
series and left bronchogram (Figs. 2 and 3)
were obtained and they confirmed the
diagnosis.
While in hospital, the patient was treated
with broad-spectrum antibiotics but he remain
ed febrile. Following radiologic confirmation
of the diagnosis, he was transferred to the
surgical service.
A double-lumen endotracheal tube was us
ed for intubation and a left thoracotomy was
performed. The cavity seen on chest roent
genogram was in the posteromedial part of the
left lower lobe and opened directly onto the
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diaphragm. There was a hole in the diaphragm
through which intestinal contents passed into
the cavity. A left lower lobectomy was per
formed. The abdomen was then opened, and
a loop of small bowel identified, which adhered
to the left hemidiaphragm and communicated
directly through the hole in the diaphragm with
the cavity in the left lower lobe (Fig. 4). The
fistula was closed. There was no evidence of
tumour or subphrenic abscess.
Postoperatively, the patient made a remark
ably rapid recovery. He was discharged from
hospital 3 weeks after operation. Three months
later he felt entirely well and had gained 7 kg
in weight.

Discussion
Perhaps the most interesting aspect of
this case was the unusual symptom of gas
rising from the left upper abdomen into
the left hemithorax followed by a taste of
food in the mouth. We have never before
encountered this. It prompted inexpe
rienced members of the housestaff to list
fistula between stomach or small bowel
and tracheobronchial tree at the top of
their list of differential diagnoses. We
believe that this symptom is diagnostic of
such fistulous communications.
The clinical circumstances in which
enterobronchial fistula developed in our
patient are complex. We believe that a
combination of partial resection of the
left hemidiaphragm with radiation injury
to small bowel and diaphragm provided
the critical setting for development of the
fistula. We were unable to document
either infection in the left subphrenic
space or tumour as contributing factors.
Finally, we wish to comment on diag
nostic procedures and surgical manage
ment in this setting. The use of
hyperosmolar, water-soluble contrast

media, such as Gastrografin, is extreme
ly hazardous and should be avoided
especially in patients with compromised
lung function.8 Where possible, diagnos
tic procedures, especially those requiring
roentgenographic contrast media, should
be done with the patient awake so as to
preserve the cough reflex. This markedly
reduces the risk of spillage of infected
material into the unaffected lung. Should
it be necessary to perform a procedure
under a general anesthetic, it is imperative
that the patient be intubated with a
double-lumen endotracheal tube to isolate
the involved lung and protect the unaf
fected lung. Operation must be done tak
ing the same precaution. Failure to follow
these safeguards can result in tragedy.6
Although enterobronchial fistula is
rare, it can be diagnosed by a carefully
taken history, confirmed safely using
standard radiologic procedures and,
depending on underlying etiology, can be
cured surgically.
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tin Hotel in Edmonton, Alta., June
10-13, 1984. It will consist of structured
and free communication sessions, dealing
with such topics as clinical care, occupa
tional and environmental health and
research activities.
For further information contact:
Pamela Murray, Public Relations Direc
tor, Canadian Lung Association, Ste.
908, 75 Albert St., Ottawa, Ont. KIP
5E7.

Wound Management Workshop

FIG. 3—Selective bronchogram of left lower
lobe, left posterior oblique projection, shows
contrast medium entering cavity (arrow) in
posterior part o f left lower lobe.

FIG. 2—Upper gastrointestinal series,
delayed film, shows barium in muitilocular
cavity (arrows) in base of left lung. Earlier films
had shown barium entering cavity well before
any filling of colon.
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FIG. 4—Diagram illustrating enterobronchial fistula.

The Plastic Surgery Research Founda
tion, along with the Office of Continuing
Medical Education and the Division of
Plastic Surgery, University of California
School of Medicine, San Diego, will be
offering a wound management workshop,
Apr. 5-8, 1984, at the San Diego Hilton
Hotel, San Diego, Calif.
This 4-day workshop is designed to
provide primary care physicians, pedia
tricians, emergency room physicians, der
matologists and family practitioners the
latest information on the process of
wound healing and how it can be helped.
The prevention, diagnosis and treatment
of wound problems will be thoroughly
discussed. Practical experience in suturing
techniques will be provided, using pigs’
feet and cadavers, and will be supervised
by plastic surgeons.
For further information write: Edith S.
Bookstein, PO Box 2586, La Jolla, CA
92038, USA; or call (619) 454-3212.
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Poids et taille de la patiente et stade du cancer du sein
au moment du diagnostic
Cette etude avait pour but d'evaluer la
relation entre le poids et la taille de la
patiente, et le stade du cancer
du sein au moment du diagnostic.
L'information sur le poids, la taille et le
stade a ete tiree des dossiers medicaux
de 466 nouveaux cas de cancer du sein
traites a I'Hopital du Saint-Sacrement de
Quebec du 1er janvier 1975 au 31 mars
1981. Le pourcentage des patients ayant
un cancer au stade regional ou des metastases a distance passe de 35 .5% chez
les femmes pesant moins de 55 kg a
51.2% chez celles de 65 kg et plus. La
valeur de la palpation (incluant I'autoexamen des seins) pourrait etre plus limitee ou le cancer du sein biologiquement
plus agressif chez les patientes obeses.
The aim of this study was to evaluate
the relation of body weight and height to
the stage of breast cancer at the time of
diagnosis. Information on weight, height
and stage was abstracted from the
medical records of 4 6 6 women with
newly diagnosed breast cancer treated at
the Hopital du Saint-Sacrement in
Quebec City from Jan. 1, 1975 to Mar.
31, 1981. The percentage of patients
with regional disease or distant
metastases was found to increase from
35 .5% among women weighing less
than 55 kg to 51.2% among those 65
kg or more. Palpation (including breast
self-examination) may be less valuable
or breast cancer biologically more ag
gressive in obese women.

pronostic du cancer du sein. Plusieurs etu
des ont montre que le risque de cancer du
sein tend a etre relativement plus grand
chez les femmes dont le poids est plus
eleve.1 Cette relation a surtout ete mise
en evidence parmi les femmes qui ont
depasse la periode de la menopause. Par
ailleurs, d’autres etudes ont evalue l’association entre le poids de la patiente et
le pronostic du cancer du sein.2’9 Ces
etudes suggerent que le cancer du sein
a atteint un stade plus avance au mo
ment du diagnostic chez les patientes
dont le poids est plus eleve.M,s’9 La survie
semble aussi moins bonne chez ces patien
tes, meme lorsque l’on tient compte du
stade.2’4’8'9 Nous avons voulu evaluer la
relation entre le poids et la taille de la
patiente, et le stade du cancer du sein au
moment du diagnostic parmi un groupe
de patientes de Quebec.
Patientes et methodes

Du ler janvier 1975 au 31 mars 1981,
466 femmes atteintes de cancer du sein
ont ete traitees initialement a I’Hopital du
Saint-Sacrement. Au moins 85% de ces
femmes avaient ete vues a la Clinique des
maladies du sein de cet hopital. Seules ont
ete exclues les patientes qui, au moment
d’une premiere hospitalisation pour la
maladie, avaient deja ete traitees pour un
cancer (du sein ou de tout autre site),
conformement aux criteres adoptes par le
“End Results Group” de 1’Institut Natio
nal du Cancer des Etats-Unis.10

diagnostic a ete evalue selon la classifi
cation en trois categories adoptee par le
“End Results Group” des Etats-Unis12
et le Registre du Cancer du Connecti
cut.13 Le stade a ete determine a partir
de toutes les informations disponibles a
la premiere sortie de l’hopital.10 Le stade
localise indique l’absence de signe d’extension de la tumeur au-dela du sein. Le
stade regional indique la dissemination de
la tumeur aux ganglions axillaires ou susclaviculaires, a la peau ipsilaterale ou a
la cage thoracique. Finalement, le stade
des metastases a distance correspond a la
presence de metastases au-dela de la
region.
Analyse
Le chi-carre de Mantel14 a ete utilise
pour evaluer si le pourcentage des patien
tes ayant un cancer au stade regional ou
a celui des metastases a distance tend a
changer de fagon statistiquement signifi
cative avec le poids, la taille ou 1’indice
de Quetelet. Selon une etude anterieure,
certains facteurs (l’age au moment du dia
gnostic, le nombre d’enfants, Page a la
naissance du premier enfant a terme et le
statut matrimonial) pourraient confondre
Passociation entre poids ou taille et
stade.15 L’ajustement pour controler
l’effet de ces variables a ete fait par stan
dardisation directe.16 Les femmes pour
lesquelles certaines donnees sont manquantes ont ete exclues des tableaux
correspondants.

Resultats
Le poids d’une femme semble etre asso- Source des donnees
cie non seulement au risque mais aussi au
La relation entre le poids de la patiente
Les caracteristiques des patientes,
et
le stade au moment du diagnostic est
incluant
le
poids,
la
taille
et
Page
au
Des departements de *medecine sociale et
moment du diagnostic, le nombre d’en- presentee au tableau I. Le pourcentage
preventive et de Ichirurgie, University
fants nes vivants ou mort-nes, l’age a la des patientes dont le cancer est au stade
Laval, Quebec, PQ
du premier enfant a terme et le regional ou de metastases a distance augTravail subventions en partie par le Fonds naissance
statut matrimonial, ont ete recueillies a mente regulierement avec le poids. Ce
de la Recherche en Santi du Quebec (no
partir d’un questionnaire complete lors de pourcentage passe de 35.5% chez les fem
76-0400)
la premiere visite a la Clinique des mala mes de moins de 55 kg a 51.2% chez cel
Accept^ pour publication le 20 septembre
dies du sein. L’indice de Quetelet qui les qui pesent 65 kg ou plus. Le pourcen
1983
mesure 1’exces de tissu adipeux a ete cal- tage des cas avec metastases a distance
Les demandes de tirds-a-part doivent etre
adressees au Dr J. Brisson, Departement de cule; celui-ci se definit comme le rapport chez les patientes de 65 kg et plus est 2.1
du poids a la taille mise au carre.11
fois plus eleve que chez celles dont le
medecine sociale et preventive, University
Laval, Quebec, PQ G1K 7P4
Le stade de la maladie au moment du poids est inferieur a 55 kg. Lorsque la
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plus. De meme, la relation entre la taille
et le stade est clairement apparente surtout parmi les femmes dont le poids est
plus eleve (65 kg ou plus). Par contre, le
stade semble varier tres peu avec le poids
ou la taille pour les femmes pesant moins
de 65 kg et mesurant 155 cm ou plus.
L’indice de Quetelet permet egalement
d ’exprimer l’effet conjoint du poids et de
la taille sur le stade (tableau IV). Le pour
centage des patientes ayant un cancer au
stade regional ou de metastases a distance
est de 30.8% chez les femmes minces
(indice de Quetelet, inferieur a 21). Ce
pourcentage augmente regulierement avec
l’exces de tissu adipeux pour atteindre

taille augmente, le pourcentage des patientes avec cancer au stade regional ou
de metastases a distance tend a diminuer
(tableau II). Cependant, l’association
^ observee entre la taille et le stade n ’est
pas statistiquement significative.
^
La relation conjointe du poids et de la
^ taille avec le stade est montree au tableau
III. L’association entre le poids et le stade
est particulierement prononcee chez les
patientes plus petites (moins de 155 cm).
*■Parmi ces femmes, le pourcentage des
patientes atteintes de cancer au stade rek gional ou de metastases a distance passe
de 31.6% pour celles qui pesent moins de
* 55 kg a 65.4% chez celles de 65 kg ou

b

Tableau 1—Repartition, en pourcentage, des patientes selon le stade
au moment du diagnostic, par poids
Poids, kg

b

Stade

**

<55
(n = 152)

5 5 -6 4
(n - 171)

>65
(n - 133)

Total
(n = 456)

64.5
32.2
3.3

60.8
33.3
5.8

48.9
44.4
6.8

58.6
36.2
5.3

Localise
Regional
Metastases a distance

X2 Mantel - 7.301, p = 0.007 .

J

-4

Tableau II—Repartition, en pourcentage, des patientes selon
le stade au moment du diagnostic, par taille
Taille, cm
Stade

<155
(n - 129)

1 5 5 -1 6 4
(n = 230)

>165
(n - 94)

Total
(n = 453)

55.8
37.2
7.0

59.1
36.5
4.3

61.7
34.0
4.3

58.7
36.2
5.1

Localise
Regional
Metastases a distance

b

X2 Mantel = 0.801, p = 0.37.
V

Tableau III—Pourcentage des patientes avec cancer au stade regional
ou de metastases a distance, et nombre de patientes,
selon le poids et la taille

*■

Poids, kg

►
►

>65

5 5 - 64

<55

%

No

% moyen No

Taille, cm

%

No

%

No

<155
1 5 5 -1 6 4
>165

31.6
37.5
35.7.

57
80
14

47 .8
35.8
34.9

46
81
43

65.4
50.7
43.2

26
69
37

44.2
40 .9
38.3

129
230
94

% moyen et no

35.1

151

38.8

170

51.5

132

41 .3

453

Tableau IV—Repartition des patientes (pourcentage) selon le stade par indice de Quetelet
Indice de Quetelet, kg/m2
Stade
Localise
Regional
Metastases a distance
b

<21
(n - 94)

2 1 -2 3
(n - 1331

2 4 -2 6
(n = 117)

>27
(n = 109)

Total
(n - 453)

69.1
28.7
2.1

60.9
34 .6
4.5

57.3
36.8
6.0

48 .6
44.0
7.3

58.7
36.2
5.1

X2 Mantel = 8.946, p - 0.003.

51.3% chez les femmes relativement obeses (indice de Quetelet, de 27 ou plus). Le
pourcentage des patientes avec metastases
a distance est de 3.5 fois plus eleve dans
ce dernier groupe comparativement au
premier groupe de femmes plus minces.
Les resultats presentes aux tableaux I
a IV ne sont pas ou sont peu affectes lorsque l’ajustement est fait pour certains facteurs possiblement confondants (l’age au
moment du diagnostic, le nombre d ’enfants, l’age a la naissance du premier bebe
a terme et l’etat matrimonial). L ’ajuste
ment pour la taille accentue legerement
la relation observee entre le poids et le
stade. De meme, l’association entre la
taille et le stade est un peu plus forte apres
ajustement pour le poids mais cette asso
ciation reste statistiquement non signifi
cative. Finalement, les resultats sont presque identiques pour les femmes de moins
de 50 ans et celles de 50 ans ou plus.
Discussion
Cette etude suggere que le stade du can
cer du sein tend a etre relativement plus
avance au moment du diagnostic parmi
les patientes obeses comparativement aux
femmes minces. Dans cette relation, le
poids plutot que la taille, semble etre le
facteur important. II est peu probable que
nos observations soient dues a la chance.
Les resultats sont statistiquement significatifs et sont en accord avec ceux des
recherches anterieures.2'9 De plus, nos ob
servations ne peuvent etre expliquees par
les facteurs dont il a ete tenu compte dans
l’analyse (l’age au moment du diagnos
tic, le nombre d ’enfants, Page a la nais
sance du premier enfant a terme et 1’etat
matrimonial). Par contre, il paralt raisonnable de penser que revaluation clinique
et pathologique des ganglions axillaires
puisse etre moins fiable chez les patien
tes obeses. Dans ce cas, l’association reelle
entre l’obesite et le stade serait plus forte
que celle observee ici.
Nos resultats sont compatibles avec
deux types de phenomene. D ’une part, le
stade reflete le delai entre 1’apparition du
cancer au niveau cellulaire et le diagnos
tic. Les femmes obeses tendent a avoir des
seins volumineux dans lesquels un cancer
est possiblement plus difficile a detecter
par palpation. La palpation (incluant
l’auto-examen des seins) etant la principale methode de detection du cancer du
sein, les patientes obeses ou leur medecin pourraient ne decouvrir la tumeur que
lorsque la maladie est relativement plus
avancee. D’autre part, le stade semble
aussi refleter l’agressivite biologique des
cellules tumorales.17 Il est possible que
certains caracteristiques des femmes obe
ses telles que leur regime alimentaire ou
leur statut hormonal, puissent influencer
la rapidite de croissance de la tum eur et
sa capacite a donner des metastases. Quel-
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ques donnees semblent appuyer cette
hypothese. La differentiation cellulaire est
un indicateur de Pagressivite des cellules
cancereuses, les tumeurs les moins bien
differenciees etant les plus agressives.18
Une etude a montre que le cancer du sein
tend a etre moins bien differencie chez les
patientes obeses.2
Cette recherche suggere que la valeur
de la palpation (incluant l’auto-examen
des seins) et de la mammographie dans
la detection du cancer du sein devrait etre
comparee chez les femmes obeses et nonobeses. Une telle etude permettrait de
mieux preciser 1’apport relatif de ces examens pour ces differents groupes de fem
mes. Par exemple, la palpation pourrait
etre plus limitee mais la mammographie
plus utile chez les femmes obeses. De plus,
la grande majorite des etudes epidemiologiques s’efforcent d’identifier les facteurs de risque du cancer du sein. Nos resultats suggerent qu’il serait egalement
important d’identifier les facteurs qui
pourraient influencer revolution de cette
maladie. Parmi les facteurs possiblement

associes au pronostic du cancer du sein,
une attention particuliere devrait etre portee a l’effet potentiel des habitudes
alimentaires.
Nous remercions sincerement Widna Morin
pour son aide dans la collecte des donnees,
Suzanne Brisson pour sa contribution au traitement de l’information et Celine Langlais pour
son travail lors de la preparation du manuscrit.
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Survey of Surgical Management of Malignant Melanoma
in Canada: Optimal Margins of
Excision and Lymph-Node Dissection
The feasibility of clinical trials involving
the surgical management of primary
melanoma was assessed through a
survey of Canadian surgeons who treat
this disease. Surgeons were polled as to
their current practice regarding node
dissection and margins of resection of
the primary lesion. Their interest in ran
domized trials addressing these practices
was also assessed. Tw o hundred and
forty questionnaires were distributed to
20 centres across Canada. The total
number of patients with melanoma seen
annually by the 131 surgeons who
responded was 790 — of the approx
imately 1000 new cases of melanoma
diagnosed in Canada each year. Of
responding surgeons, 6 3 % currently per
form wide excision (taking 3 to 5 cm of

Accepted fo r publication Sept. 20, 1983

normal tissue) for lesions less than 1.5
mm in depth and 3 7 % perform limited
excision (including 1 to 2 cm of normal
tissue). Of all surgeons responding, 7 6 %
were interested in a randomized trial
comparing wide and limited excision in
these superficial lesions. Currently, 9 0 %
of surgeons perform wide excision of le
sions 1.5 mm or more in depth and 10%
perform limited excision. Fifty-nine per
cent were interested in a randomized
trial comparing wide and limited excision
in these deeper lesions. Twenty-four per
cent of surgeons routinely perform pro
phylactic node dissection on all patients
with lesions 1.5 mm or more in depth;
6 6 % wait until there is clinical suspicion
of nodal metastases and 9 % follow
some other policy. The results of this
survey indicate that (a) surgical manage
ment is varied, (b) radical surgery re
mains common practice and (c) surgeons
are interested in randomized trials that
will determine optimal treatment.

Reprint requests to: Dr. W. Shelley,
Queen’s University, NCIC Clinical Trials
Group, 82-84 Barrie St., Kingston, Ont.
K7L 3N6

Afin d'evaluer la possibility de r£aliser
des essais cliniques impliquant le traitement chirurgical des meianomes primai-
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res, une etude des chirurgiens canadiens
qui traitent cette maladie a ete faite. Les "*
chirurgiens ont ete interviewes d'apres
leurs pratiques courantes envers la dis
section des ganglions et des marges de
*
resection de la lesion primaire. L'interet
envers des essais cliniques s'adressant a
ces pratiques a aussi ete evalue. Deux
cents quarante questionnaires ont ete
distribues dans 20 centres a travers le
Canada. Le nombre total des patients
vus annuellement par les 131 chirurgiens
t
qui ont repondu est 790 — de 1000
nouveaux cas diagnostiques au Canada.
Des chirurgiens qui ont repondu, 6 3 %
executent presentement une excision
large (marges de 3 a 5 cm) pour les
lesions de moins de 1.5 mm de profondeur et 3 7 % executent une excision limitee (marges de 1 a 2 cm). De tous les
*
chirurgiens qui ont repondu. 7 6 % s'interessent aux essais randomizes qui cornparent I'excision large et I'excision limi^
tee dans les lesions superficielles.
Quatre-vingt-dix pourcent des chirurgiens
ex6cutent presentement I'excision large
des lesions de plus ou egales e 1.5 mm
-*
de profondeur et 10% executent I'exci-
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sion limitee. Cinquante-neuf pourcent
s'interessent a un essai randomize comi
parant I'excision large a I'excision limitee
dans les lesions plus profondes. Vingt►quatre pourcent des chirurgiens executent routinement la dissection prophylacy
tique des ganglions sur tous les patients
^ avec des lesions de plus ou egales a 1.5
mm de profondeur; 6 6 % attendent qu'il
y ait manifestation clinique de metastases ganglionnaires et 9 % suivent quel•.ques autres lignes de conduite. Les resultats de cette etude indiquent que a) le
k
traitement chirurgical varie, b) la chirurI
gie radicale demeure la pratique courante
^ et c) les chirurgiens s'interessent aux
essais randomizes qui delimitent le traite
ment optimal.

The standard surgical therapy for primary
malignant melanoma is wide local exci
sion, including 3 to 5 cm of normal tissue
y around the primary lesion. This often re
quires skin grafting and is associated with
increased morbidity and cost compared
^with simple local excision and primary
closure. The need for wide excision has
j never been supported.1 Recent reports
suggest that survival of patients with no
-t evidence of nodal metastases at the time
of presentation is not related to margins
of resection of the primary lesion. The
World Health Organization Melanoma
Group, reviewing 593 patients with stage
I disease, confirmed that survival was
related to maximum tumour thickness but
not to the margins of surgical resection.2
Breslow and Macht3 reported a 5-year
► disease-free survival of 100% in 62 pa
tients with melanoma less than 0.76 mm
1 in depth, despite resection margins rang
ing from 0.1 to 5.15 cm. Fourteen of these
y patients had resection margins of less than
0.5 cm of normal tissue. This observation
' was confirmed by Balch and associates4
y in 36 stage I patients with melanomas less
than 0.76 mm deep.
A second area of controversy is the
need for regional node dissection at the
Mime of primary excision when there is no
clinical or radiologic evidence of nodal
V metastases.
This approach presumes that there are
patients who have microscopic nodal
metastases without systemic metastases
and that the cure rate can be increased by
.-excising these m icroscopic nodal
metastases before systemic dissemination
>- occurs. The procedure would benefit on

y

ly those who have microscopic deposits.
Patients without microscopic node
deposits and patients who already have
systemic dissemination would be sub
jected to an unnecessary lymph-node
dissection with its associated morbidity
and cost. The alternative to prophylactic
node dissection is to wait until there is
clinical suggestion of nodal metastases
and then to perform regional node dissec
tion. Advocates of immediate prophylac
tic node dissection argue that delaying the
dissection until nodal disease is evident
clinically, decreases the cure rate because
the chance of systemic dissemination is
much greater at this stage in the course
of the disease than it is at the time of
presentation.
Two major randomized clinical trials
have addressed the problem of prophylac
tic node dissection. One study, done by
the Mayo Clinic, showed no significant
difference between patients receiving im
mediate prophylactic node dissection,
prophylactic node dissection performed
electively, 3 months after excision of the
primary, and dissection delayed until
nodal metastases become clinically
evident.5 However, in this study, the
number of patients at highest risk of hav
ing microscopic nodal metastases (lesions
greater than 1.5 mm thick) made up only
one third of the total number of patients
studied. This study has therefore not
disproved the need for prophylactic node
dissection in patients at high risk of nodal
disease.
The second study was conducted by the
World Health Organization.6 Here too,
no significant difference in survival was
detected between patients who had pro
phylactic node dissection and those who
had delayed dissection. The major
criticism of this study is that it was con
fined to extremity melanomas and the
population was largely female. Historical
ly, women with extremity melanomas
have a good prognosis regardless of the
type of treatment, so the results from this
study cannot be applied to melanoma pa
tients in general.
Because the questions of optimal
margins of primary excision and the need
for prophylactic dissection remain con
troversial, the National Cancer Institute
of Canada (NCIC) Melanoma Commit
tee became interested in clinical trials ad
dressing these issues. However, such
studies require the support and active par

T a b le 1— C u r re n t S u r g ic a l P ro c e d u re P e rfo r m e d fo r
T r e a t m e n t o f a P rim a ry M e la n o m a

T y p e of
p ro c e d u re
W id e e x c is io n
L im ite d e x c is io n

L e ve l II o r III
< 1 . 5 m m in d e p th ,
n o . (% )

L e ve l III, IV o r V
> 1 . 5 m m in d e p th ,
n o . (% )

81 (6 3 )
4 8 (3 7 )

1 1 8 (9 0 )
13(10)

ticipation of surgeons across Canada.
Therefore, a survey was carried out to
assess current practice and interest in
these questions among surgeons.
Method
The survey, conducted by question
naire, was designed to assess current prac
tice regarding lymph-node dissection and
margins of excision. Interest in randomiz
ed clinical trials comparing wide and
limited excision in both superficial and
deep melanomas and prophylactic versus
delayed lymph-node dissection in patients
with deeper melanomas was also polled.
Included were questions regarding the
number of melanoma patients seen an
nually and whether lymphography was
used to assess regional lymph nodes in pa
tients with lower extremity lesions.
Surgeons were asked to describe
themselves as either general or plastic
surgeons or surgical oncologists.
To achieve the widest possible distribu
tion, names of surgeons who treat
melanoma at each Canadian medical
school were obtained. Medical on
cologists at some institutions who wish
ed to distribute the questionnaires directly
to their referring surgical colleagues did
so. Two hundred and forty questionnaires
were distributed to surgeons in 20 cities
across Canada.
Results
The response rate was 55%; 131 ques
tionnaires were returned from 19 o f the
20 cities polled. The approximate total
number of patients with melanoma seen
annually by those who replied was 790,
of about 1000 new cases of melanoma
diagnosed annually in Canada. Surgical
oncologists were responsible for 17% of
the responses, plastic surgeons for 39%
and general surgeons for 44%.
Current surgical treatment of primary
melanoma is summarized in Table I. For
the purposes of this survey, a wide exci
sion was one including margins o f nor
mal tissue at least 3 cm from the primary
tumour, followed by primary closure,
rotation flap or skin grafting as indicated.
Limited excision was one that included
margins of normal tissue only 1 to 2 cm
away from the primary, followed also by
primary closure, rotation flap or skin
grafting as indicated. Of the Canadian
surgeons who responded, 63% perform
a wide excision for level II or III (Clark’s
classification) melanomas less than 1.5
mm in depth and 90% of Canadian
surgeons perform a wide excision for level
III, IV or V melanoma greater than 1.5
mm in depth.
The current policy of lymph-node
dissection for patients with level III, IV
or V primary melanoma greater than 1.5
mm in depth is summarized in Table II.
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1.5 mm in depth and 75% were interested
in a study of prophylactic versus delayed
lymph-node dissection for patients with
level III, IV or V melanoma greater than
1.5 mm in depth.

O f the Canadian surgeons who respond
ed to the questionnaire, 24% routinely
perform prophylactic lymph-node dissec
tion on all of these patients.
The survey also showed that 34% of
responding surgeons use lymphography
to assess regional nodes in patients with
lower extremity lesions and 66% do not.
Of responding surgeons, 78% perform
prophylactic node dissection “ in continui
ty” with the primary melanoma when the
primary is located directly over a lymphnode region.
Table III summarizes the current level
of interest in randomized clinical trials of
surgical m anagem ent o f prim ary
melanoma; 76% of the surgeons indicated
an interest in a study of wide excision ver
sus limited excision for level II or III
melanoma less than 1.5 mm in depth,
59% were interested in the same study for
level III, IV or V melanoma greater than

Despite the publication of retrospective
reviews indicating extremely low local
recurrence rates when the primary tumour
is excised with limited margins of normal
tissue and no improvement in overall sur
vival when wide margins are used,1'3
wide excision remains the dominant
surgical procedure for the treatment of
primary melanoma, particularly the
deeper lesions. The majority of surgeons
do regional node dissections only if there
is a clinical suspicion of metastases, but
24% perform routine, prophylactic node
dissection.

T a b le I I — C u r re n t P o lic y on L y m p h -N o d e

T a b le I l l - C u r r e n t L e v e l o f In te re s t in

D is s e c tio n f o r P a tie n ts w i t h L e ve l III, IV

R a n d o m iz e d C lin ic a l T r ia ls o f S u rg ic a l
M a n a g e m e n t in M e la n o m a

o r V P r im a r y M e la n o m a M o re T h a n 1 .5
m m in D e p th
P o lic y

N o . (% )

P r o p h y la c t ic lym p h -n o d e
d is s e c tio n o n all p a tie n ts
L y m p h - n o d e d is s e c tio n o n ly if

3 2 (2 4 )

th e re is c lin ic a l o r ra d io lo g ic
s u g g e s tio n o f m e t a s ta s e s

8 7 (6 6 )
1 2 (9 )

F o llo w a n o t h e r p o lic y

Discussion

T y p e o f tria l
W id e
fo r
W id e
fo r

e x c is io n v . lim ite d e x c is io n
le v e l II o r III, < 1 . 5 m m
e x c is io n v . lim ite d e x c is io n
le v e l III, IV o r V , > 1 . 5 m m

N o . (% )

9 9 (7 6 )
7 7 (5 9 )

P r o p h y la c t ic v . d e la y e d lym p h -n o d e
d is s e c t io n f o r le v e l III, IV o r
V , > 1 .5 mm

9 8 (7 5 )

Even though more radical surgery is
commonly practised, the results of the
survey indicate that Canadian surgeons
are willing to randomize their patients to
less-aggressive treatment in order to deter s
mine whether more radical surgery is, in
deed, of any benefit. The survey also a
shows that the interested surgeons could
make an important contribution to ran- 4
domized clinical trials in terms of patient
numbers.
For these reasons, the NCIC is pro-^
ceeding to help organize participation of
Canadian surgeons in clinical trials ,
designed to answer these important ques
tions regarding the surgical management -*
of malignant melanoma.
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One-Stage Bilateral Inguinal Herniorrhaphy in the Adult
Between 1977 and 1981, the author
treated 141 consecutive patients with
uncomplicated bilateral inguinal hernia by
one-stage bilateral herniorrhaphy. He has
compared the results with those from
141 comparable age-matched patients
with unilateral hernia treated over the
same period. There was no increase in
morbidity with the one-stage bilateral
procedure. There were no deaths in
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either group. One-stage bilateral hernior
rhaphy has several advantages: (a) only
one anesthetic and operating session are
required, thus saving the patient the
stress of waiting for a second operation,
and there is considerable financial saving
to the patient; (b) more efficient use is
made of hospital beds; and (c) the small
risk of strangulation on the unoperated
side is avoided.
De 1977 d 1981 I'auteur a traite consecutivement 141 patients atteints d'hernie
bilaterale inguinale par herniorraphie uni
que sans complication. II a compare les
resultats avec ceux de 141 patients
d'age similaire atteints d'hernie unique et
qui furent traites pendant la meme
periode. L'auteur a constatd qu'il n'y

avait pas d'augmentation du taux de
morbidity dans le groupe des malades
traites par herniorraphie simple. Tout au
«
contraire cette methode comporte des
avantages: a) l'auteur ne pratique qu'une
seule anesthesie et une seule interven
tion chirurgicale, ce qui libere les
patients de la tension psychologique
creee par I'attente d'une seconde operation sans compter l'6conomie financiere
realisee par les malades; b) le temps
d'occupation des lits d'hopital est reduit;
c) l'auteur elimine le petit risque d'etranglement du cot£ non opdrd.
^

Inguinal hernia is the commonest surgical condition encountered at the Wesley
Guild Hospital: Ife University Teaching
Hospital in Ilesha, Nigeria. Of the 920
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inguinal hernias seen and treated in this
hospital between 1977 and 1981, 20.5%
were bilateral.
Our interest in the one-stage bilateral
^ herniorrhaphy for adult bilateral inguinal
hernia was aroused by the death of a
1 48-year-old man with bilateral hernias. A
^ two-stage operation in another hospital
had been planned but the hernia on the
unoperated side became strangulated;
shock and septicemia developed before
*-the second operation and he died within
2 hours of admission to our hospital.
I could find only two published reports
k on this topic — by Palumbo and
associates1 and Ger and associates.2 I
undertook the present study to determine
if the surgical trauma of a one-stage bila*- teral herniorrhaphy in adults increases the
morbidity over that of unilateral herniy orraphy.
►

Patients and Methods

Our group reviewed the medical
, records of 141 consecutive patients with
uncomplicated bilateral inguinal hernia
x treated by one-stage bilateral hernior
rhaphy (group 1) and those of 141 age4 matched patients who underwent
unilateral herniorrhaphy (group 2) be
tween January 1977 and December 1981.
All the operations were carried out on
the day after admission by me or the resiy dent staff under my supervision. Spinal
anesthesia was used in all patients, but
r
had to be supplemented with general
anesthesia in two patients with bilateral
hernia and in six with unilateral hernia.
We reconstructed the posterior wall us
ing the Bassini technique and silk suture.
A Tanner slide-relaxing incision was
employed in 98% of the patients.
The records yielded the following information: age of the patient, sex,
socioeconomic status, operating time,
duration of hospital stay postoperatively, complications related to the operation,
►complications related to the anesthetic
and recurrence.
^
The follow-up period was from 1 to 5
years. Statistical significance was assess
ed by the Student’s /-test.

Results

Discussion

There were no deaths. The mean age
of patients who underwent bilateral her
niorrhaphy (group 1) was 46.3 years
(standard deviation 4.52 years) and for
those who underwent unilateral hernior
rhaphy (group 2) 41.1 years ( ± 4.5 years)
(Table I). Of the 141 patients in group 1,
122 were men and 19 women, while in
group 2, 115 were men and 26 were
women. The low- and middle-income
groups accounted for 94.4% of the pa
tients in group 1 and 91.5% of patients
in group 2 (Table II).
Postoperative complications (Table III)
were similar in the two groups; the dif
ferences were not statistically significant.
There were five recurrences (3.5%) in
group 1 and three (2.1%) in group 2. This
difference is not significant.
When the average operating time and
duration of postoperative stay in hospital
for group 2 patients is doubled, as would
be required for the staged bilateral her
niorrhaphy, the difference becomes
statistically significant (p < 0.01). The
average operating time and postoperative
stay for one-stage bilateral herniorrhaphy
are much lower than in a two-stage pro
cedure necessitating two operations and
possibly two admissions.

The two groups of patients are com
parable. The data clearly indicate that
there is no statistically significant dif
ference in the results achieved in patients
with bilateral hernia treated by one-stage
herniorrhaphy from those in patients with
unilateral hernia. The complications asso
ciated with the one-stage bilateral pro
cedure are similar to those associated with
unilateral herniorrhaphy. Thus, the
magnitude of the surgical trauma involv
ed in the one-stage bilateral repair did not
increase morbidity. This finding is also
true for infantile bilateral groin explora
tion for inguinal hernia even in the face
of such odds as urinary or fecal incon
tinence, or both.3'5 Ger and associates2
also showed that there was no increased
morbidity or mortality associated with the
one-stage as compared with the two-stage
procedure.
The argument that the one-stage pro
cedure subjects both sides to increased
tension that may jeopardize the repair was
neither substantiated by our findings at
operation nor by the description of the
anatomy of the inguinal canal by
Thorek.6
The advantages of a one-stage bilateral
inguinal herniorrhaphy are; (a) only one
anesthetic and one operating session are
required. This eliminates the psychologic
stress on the patient of waiting for a se
cond operation, a second anesthetic with
its risks is avoided and the cost and loss
of working time involved in a second
operation are eliminated; (b) there is im
proved use of hospital beds; (c) the risk
of strangulation on the unoperated side
is eliminated.
This study shows that the one-stage
bilateral herniorrhaphy does not increase
morbidity when compared to hernior
rhaphy in patients with unilateral hernia.
Therefore, a one-stage bilateral inguinal
herniorrhaphy is strongly recommended.

Table II -Socioeconomic Status
Income
group*

Group 1,
no. (%)

Group 2,
no. (%)

Low
Middle
High

1 0 5 (7 4 .5 )
2 8 (1 9 .9 )
8 (5 .7 )

7 4 (5 2 .5 )
55 (39.0)
1 2 (8 .5 )

*Low income - farmers, petty traders, house
boys; middle income - nurses, students,
teachers; high income = doctors, lawyers,
engineers, architects.

7

Table 1-Age Distribution
Age, yr

Group 1,
no. (%)

Group 2,
no. (%)

1 0 -2 0
2 1 -3 0
3 1 -4 0
4 1 -5 0
5 1 -6 0
6 1 -7 0
7 1 -8 0
Unknown

5 (3 .5 )
1 2 (8 .5 )
2 8 (1 9 .9 )
40 (28.4)
29 (20.6)
1 6 (1 1 .3 )
8 (5 .7 )
3 (2 .1 )

8 (5 .7 )
2 3 (1 6 .3 )
34 (24.1)
42 (29.8)
1 8 (1 2 .8 )
1 0 (7 .1 )
4 (2 .8 )
2 (1 .4 )

141 (100)

141 (100)

Total

Table III—Clinical Data
Data
Type of hernia
Indirect
Direct
Pantaloon
Operating time, min
Range
Mean
Duration of postoperative
hospital stay, d
Range
Mean
Complications
Wound infection
Scrotal hematoma
Scrotal abscess
Urinary retention
Urinary tract infection
Spinal headache
Recurrence
Deaths

Group 1, Group 2,
n = 141 n - 141
188
89
5

91
50

6 0 -1 1 5
85

4 5 -9 0
64.5

4 -1 8
5.9

-

3 -1 6
4.8

1 sincerely thank the medical records staff
and the entire surgical team of Wesley Guild
Hospital: Ife University Teaching Hospital,
Mr. J. Ukhuriegbe for his secretarial help and
Professor N. Serpos-Tijani for his help with
the French translation.
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BOOK REVIEWS
C U R R E N T T R E N D S IN U R O LO G Y.
Volume 2. Edited by Martin I. Resnick. 168
pp. Illust. Williams & Wilkins, Baltimore,
1982. $33.50. ISBN 0-683-07218-8.

A number of specific common and uncommon
urologic problems are reviewed in this text. The
subjects discussed vary greatly, and there is no
clear theme to the volume. However, it is well
written, is up to date in most chapters and con
tains an excellent bibliography. Most chapters
deal with the technical aspects of urologic
surgery, the surgical details are clear and
accurate, and the authors provide clear, con
cise evaluation and management information.
The intelligent use of small bowel as a
substitute for ureter is well presented by Tveter
and Goodwin. The indications, selection of pa
tients and invaluable surgical tips, along with
potential complications and how to assess
them, constitute the theme of the chapter.
Similar principles would apply also to other
surgical procedures (ileocystoplasty, the con
tinent urinary pouch and undiversion).
The technical aspects in the surgical repair
of hypospadias are reviewed critically by
Duckett. The surgical methods and complica
tions are presented in detail, making this
chapter extremely valuable to the urologist with
little pediatric experience.
Coagulum pyelolithotomy provides an effec

tive method of dealing with multiple renal
calculi. In the chapter on this subject, the
biochemistry of clot formation is well describ
ed, and the clinical indications and techniques
for performing coagulum pyelolithotomy in
renal surgery are presented.
Immunologic techniques are being used ex
tensively to search for tumour markers that
may help to predict the biologic behaviour of
malignant tumours, and to plan appropriate
treatment for patients. There is a clear review
of this subject that provides a detailed look at
transitional cell cancer of the urinary tract, and
an update on the results obtained with the use
of markers in testicular tumours.. The current
status of tumour markers in prostate, kidney,
and adrenal is also discussed. The potential for
further development in this field remains. In
vestigators are searching for improvements in
early diagnosis of disease, in early detection of
metastases, and in the use of chemotherapeutic
drugs combined with markers for treating
secondary disease.
Bladder exstrophy, “ the ultimate challenge
to the pediatric urologist” , is carefully
presented by King, who gives details of surgical
repair; the role of the artificial sphincter in this
syndrome is also discussed.
The subject of endourology is receiving a
great deal of attention from urologists in all
countries, and the treatment of renal stone

disease is evolving rapidly. Increased use of
percutaneous nephrostomies, ureteric stenting
and percutaneous nephrolithotomy, has chang
ed dramatically the treatment of the obstructed
kidney and renal and ureteric calculi. The cur
rent techniques are well presented in the
chapter devoted to this subject by Smith, yet
further developments are occurring rapidly,
and urologists and radiologists must keep
abreast of this expanding technology.
The chapter by Uehling and Iversen on
urinary tract infection in the female is well
presented. Controversial areas such as the
urethral syndrome are discussed, susceptibili
ty factors are reviewed, and a clear guide to
diagnostic work-up and choice of antibiotics
is provided.
Peyronie’s disease is a rare urologic problem,
yet provides a challenge in pathogenesis and
management. Leach, O’Donnel and Raz
describe the various methods of treatment,
both medical and surgical, and emphasize the
proper timing and indications for each. Incon
tinence secondary to any cause is still a major
problem in urologic practice. Ball reviews the
subject briefly, and presents clearly the various
methods of treatment from bladder-neck plasty
and urethral compression devices, to the new
artificial sphincter.
A .W . B r u c e , m d , fr c s , fr csic ]
Chairman,
Division of Urology,
University of Toronto,
Ste. 6-249,
Toronto General Hospital,
Toronto, Ont.
M5G 1L7

EARLY CARE OF THE INJURED PA 
TIENT. 3rd ed. Committee on Trauma,
American College of Surgeons. 413 pp. Il
lust. W.B. Saunders Company Canada Ltd.,
Toronto, 1982. $28.60. ISBN 0-7216-1165-6.
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The third edition of this magnificent
monograph was commissioned by the commit
tee on trauma of the American College of
Surgeons, which has been a world leader in the
standardized and progressive approach to the
care of the injured patient. Walt has carefully
edited the contributions of 27 authorities on
this field.
The inside covers of the book contain
thumb-nail and specific instructions for the
primary assessment and management of the in
jured — aphorisms for the immediate treat
ment of shock and fractures, which will be of
incalculable help to emergency room staff.
The book covers the general areas of
pathology of the injured patient in a wellwritten and edited manner. The text deals with
global principles of management and does not
reflect the individual biases of the contributors.
The bibliography at the end of each section
suggests only a few additional references. The
diagrams and figures are simple.
This book should be in every emergency
department and should be required reading for

all candidates taking higher qualifying ex
aminations in surgery. Emergency room physi
cians will refer to it as “The Bible” . It will have
world-wide appeal and the committee on
trauma of the American College of Surgeons
►is to be congratulated on this outstanding con
tribution to the early care of the injured
► patient.

I C.M.

COUVES, MD, FRCS[C], FACS

3104 Cox Rd.,
Kelowna, BC
►VIZ 2B4

* k FEATURES OF THE HISTORY OF
DIABETOLOGY. Jacob E. Poulsen. 155
pp. Illust. Munksgaard International
Publishers Ltd., Copenhagen, 1982.
t
$14.15. ISBN 87-16-09139-6.

Any physician who treats a large number of
diabetic patients will find this book of interest.
With the emphasis now on exciting new
y
developments, such as perfect control, islet-cell
transplants, closed-loop pumps, and preven
tion of complications, it is good to look back
on the history of diabetes mellitus and read
■> how painstakingly each discovery was made.
Three parts of this book are of particular in>
terest. The first deals with concepts of the
disease dating back to 1550 BC. However, it
4 was only in 1674 that Willis discovered the
sweet taste of diabetic urine, although he at
tributed it to different salts and acids. Final
ly, in 1775, Dobson showed that the sweet taste
was due to sugar.
Galen considered diabetes a kidney disease,
r Rollo in 1796 thought it was a gastric disease.
Then in 1875, the pancreas and eventually islet
*
cells were implicated and much experimental
work was done in many countries and is cited
y
in this book.
The second part deals with the discovery of
insulin. Although Banting and MacLeod were
awarded the Nobel prize in 1923 for its
v discovery in 1922, Poulescu of Rumania claim
ed he had discovered it first in 1921. Gley of
France claimed to have discovered it in 1905
and P. Zuelzer of Germany in 1908.
»Banting and MacLeod shared the Nobel
prize with Best and Collip. None of these
T oronto workers sought any personal
economic advantage from their discovery and
y shared it freely with the world.
The third, most interesting part deals with
f
the discovery of oral hypoglycemic agents. Janbon and Loubatieres of France in 1942
► discovered th a t patients treated with
sulfonamides suffered from hypoglycemia,
around the same time as Franke and Fuchs of
Germany were making similar observations.
>In view of a growing interest in the historical
aspects of disease, I recommend this book,
y.
which can be easily read in a few hours, to any
physician actively involved in the management
t
of diabetic patients.
A

m no n
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INFECTION AND THE PERIOPERATIVE
PERIOD. Alix Mathieu and John F.
Burke. 455 pp. Illust. Grune & Stratton,
Inc., New York, 1982. $44.50. ISBN
0-8089-1325-5.
The goal of this text is to provide information,
primarily for anesthesiologists, on the develop
ment and spread of infection and the clinical
implications for its management in patients
perioperatively. The information is divided into
preoperative, operative and postoperative con
siderations and problems. The field of
anesthesia has expanded to include the inten
sive care unit and this book bridges the two
major interests of anesthesiologists: the
management of patients preoperatively and
operatively, and then in the intensive care unit.
In general, the book meets its goal. The sec
tion of the book on preoperative aspects, which
discusses the mechanisms of host defence and
the effect of anesthesia and surgery on these
mechanisms, is well described. Similarly,
preventive measures used in the care of patients
with infection who undergo operation and the
sterilization of anesthetic apparatuses are both
well discussed. It is surprising that a textbook
edited by Burke has no reference in the sec
tion on antibiotics and prevention of
postoperative infection to his signal work,
describing how to use antibiotics prophylactically. Although the text is aimed at a North
American audience, this chapter reflects more
of a British viewpoint and refers to many ar
ticles that will be unfamiliar to its readers.
The techniques of anesthesia discussed in the

intraoperative section are ap p ro p ria te .
However, some of the perceptions o f infected
states appear outdated. The discussion on sep
tic shock is short and somewhat inappropriate.
Most students of septic shock do not believe
there are major differences between the
organisms that produce it. Even though this
particular chapter has 53 references, there are
virtually none after 1977.
Some of the best chapters in the book deal
with the management of respiratory failure
presenting in the intensive care unit and the
management of respiratory failure preopera
tively; naturally, there is some overlap here.
Another excellent chapter covers nutritional
support perioperatively for post-traumatic and
infected patients.
As with all multiauthored books, it is
uneven, some chapters presenting a scholarly
approach to their subject and others a super
ficial approach. The number of references
range from very few to more than 150 for an
individual chapter. Very few references are
cited for the years following 1977; while I did
not examine all the references, I could find only
two for the 1980s. This is a major flaw in a
text dealing with a field that is evolving as
rapidly as is the physiologic and metabolic ef
fects of infection in the surgical patient.
Moreover, the part of the book dealing with
components of the intensive care unit is limited
because little information is presented after
1978.
In terms of the mechanisms and general
management of the patient with infection, this
book will be useful to residents in anesthesia
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ANTIBIOTIC
ACTION
In v itro studies dem onstrate that the
bactericidal action of cefoxitin, a cephamycin
derived from cephamycin C, results from the
inhibition of bacterial cell wall synthesis.
Evidence suggests that the methoxy group in
the 7a position is responsible for the
resistance of cefoxitin to degradation by
bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdom inal infections such as
peritonitis and intra-abdominal abscess
2 - G yne colo gica l in fe ction s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo int infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the
susceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms p a rticularly appropriate for
therapy with MEFOXIN* are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing
and non-producing strains)

E. coli
Kl e b s i e l l a s p e c ie s (in c lu d in g
pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species

K.

Anaerobes

Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that
MEFOXIN* can be administered to patients
who are also receiving c a rb e n ic illin ,
gentamicin, tobramycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration

The intravenous route is preferable for
p a tie n ts w ith ba cte re m ia , b a c te ria l
septicemia, or other severe or life-threatening
infections, or for patients who may be poor
risks because of lowered resistance resulting
from such d e b ilita tin g co n d itio n s as
malnutrition, trauma, surgery, diabetes, heart
failure, or malignancy, particularly if shock is
present or impending.
PROPHYLACTIC USE

MEFOXIN* may be administered perioperatively (preoperatively, intraoperatively and
postoperativeiy) to patients undergoing
vaginal or abdominal hysterectomy and
abdominal surgery when there is a significant
risk of postoperative infection or where the
occurrence of postoperative infection is
considered to be especially serious.
In patients undergoing cesarean section,
intraoperative (after clamping the umbilical
cord) and postoperative use of MEFOXIN*
may reduce the incidence of surgery related
postoperative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before
the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
administration of any antibiotic beyond
*®Trademark

24 hours following surgery increases the
possibility of adverse reactions but, in the
majority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens for culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hypers e n s itiv ity re a c tio n s to MEFOXIN*,
cephalosporins, penicillins or other drugs.
MEFOXIN* should be given with caution to
penicillin-sensitive patients.
There is some clinical and laboratory evidence
of pa rtial cross-allergenicity between
cephamycins and the other beta-lactam
antibiotics, penicillins and cephalosporins.
Severe reactions (including anaphylaxis) have
been reported with most beta-lactam
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is important to consider a diagnosis of
pseudomembranous colitis in patients who
develop diarrhea in association with antibiotic
use. While studies indicate that a toxin
produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form
of allergy, particularly to drugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs,
a d m in istra tion of the drug should be
discontinued. Serious hypersensitivity
reactions may require treatm ent with
epinephrine and other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN* is administered to patients
with transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
high and prolonged serum a n tib io tic
concentrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling’s solutions
but not with the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum
concentrations of cefoxitin exceed 100 /yg/mL.
Serum samples from patients treated with
MEFOXIN* should not be analyzed for
creatinine if withdrawn within two hours of
drug administration.
Increased nephrotoxicity has been reported
following concomitant administration of
c e p h a lo s p o rin s and a m in o g lyco sid e
antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
esta blished . If the a d m in istra tio n of
MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition
is essential and if super-infection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.
In children 3 months of age or older, higher
doses of MEFOXIN* (100 mg/kg/day and
above) have been associated with an
increased incidence of eosinophilia and
elevated SGOT.

The safety and efficacy of MEFOXIN* for the
treatment of infections in infants from birth to
three months of age have not yet been
established.

ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse
reactions rarely required cessation of
treatment and usually have been mild ar^:
transient.
Local Reactions
»
T h ro m b o p h le b itis has occu rred w ith ~
intravenous administration. Some degree ot
pain and tenderness is usually experience®
after intramuscular injections using water.
Induration has occasionally been reported.
Allergic

Maculopapular rash, urticaria, pruritus,
eosinophilia, fever and other allergic reactiorts
have been noted.
Gastrointestinal

Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported*
rarely.
:l
Blood

T ra n s ie n t e o s in o p h ilia , le u ko p e n ia ,
neutropenia, hemolytic anemia, and thrombocytopenia have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests ,
during therapy with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum*
LDH, and serum alkaline phosphatase have
been reported.
Kidney

Elevations in serum creatinine and/or blooft
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure
has been reported rarely. The role of L
MEFOXIN* in changes in renal function tests
is d iff ic u lt to assess, since factors,
predisposing to prerenal azotemia or tof"
impaired renal function have often been
present.
j

TREATMENT OF OVERDOSE

]

Other than general supportive treatment, no
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with renal
insufficiency.
*

f

DOSAGE AND ADMINISTRATION

<

TREATMENT DOSAGE

f,

MEFOXIN* may be administered intra
venously or intramuscularly when required.''
(See monograph for Preparation of Solution.)
Adult Dosage

The usual adult dosage is 1 g or 2g of
MEFOXIN* every 6 to 8 hours. Dosage an^
route of administration should be determined ;
by severity of infection, susceptibility of the
causative organisms, and condition of the v
patient. The usual adult dosages are shown in
the Table below.
^
Usual Adult Dosage
Type of
o f in fe c t io n

D a ily
Dosage

j
F re q u en c y
a n d R o u te

U ncom plicated
form s* o f in
fections such as
pneum onia,
urinary tract
infectio n, soft
tissue infection

3 -4 g

M ode ra te ly
severe or severe
infections

6 -8 g

Infections
c om m only
ne eding a n ti
biotics in higher
d osage (e.g. gas
gang ren e )

12 g

’ I n c l u d i n g p a tie n t s
a b s e n t o r u n lik e ly

in w h o m i b a c t e r e m ia

1 g every 6 -8 h
I.V. o r I.M.

4

1 g every 4 h
or
2 g eve ry 6 -8 h I.V *
2 g every 4 h
or
3 g every 6 h I.V.

is

---------------------------------*4

Therapy may be started while awaiting the
results of susceptibility testing.
j
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk oh*
rheumatic fever or glomerulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.

Dosage In Adult Patients with Impaired Renal
Function
MEFOXIN* may be used In patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
^ impairment.
r In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
>
A fte r a lo a d in g dose, the fo llo w in g
recommendations for maintenance dosage
^ may be used as a guide:
RENAL
FUN CTION

CRE A TININE
CLEARANC E
m L /m ln

DOSE

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

FREQUENCY

K Mild

im pairm ent
M oderate
im pairm ent
Severe
im pairm ent
Essentially
no function

k-

r

V

'

j

y

*-

-

In the patient undergoing hemodialysis, the
loading dose of 1 - 2g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.
Infants and Children
The recommended dosage in children three
months of age and older is 80 to 160 mg/kg of
body weight per day divided into four to six
equal doses. The higher dosages should be
used for more severe or serious infections.
The total daily dosage should not exceed 12 g.
At this time no recommendation is made for
children from birth to three months of age (see
PRECAUTIONS).
At present there is insufficient data to
recommend a specific dosage for children
with impaired renal function."However, if the
administration of MEFOXIN* is deemed to be
essential the dosage should be modified
consistent with the recommendations for
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN4 is recommended as follows:
Vaginal or abdominal hysterectomy and
abdominal surgery
2 g a d m in iste re d in tra m u s c u la rly or
in tra v e n o u s ly ju s t p rio r to surg ery
(approximately one-half to one hour before
initial incision).
The second and third 2 g doses should be
administered at 2-6hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord
has been clamped. The second and third
2 g doses should be given intravenously or
intramuscularly four hours and eight hours
after the first dose.

AVAILABILITY
r

Sterile MEFOXIN* is a dry white to off-white
powder supplied in vials containing cefoxitin
sodium as follows:
No. 3356 1 g cefoxitin equivalent in boxes of
10 vials
No. 3357 2 g cefoxitin equivalent in boxes of
>10 vials.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST
1. Quintiliani, R.: Overview of cephalosporin
an tib io tics in the 1980’s, in “ Con
siderations in the selection of anti
microbial chemotherapy, a round-table
discussion on treatment concepts", Merck
n
& Co. Inc., 1982, pp 6-25.
2. Trunkey, D.D.: Cephalosporin in the
management of trauma, Ibid, pp 44-52.
*

and to anesthesiologists, and should therefore
be in the libraries of anesthesiology
departments.
J o n a t h a n L. M e a k in s ,
FRCS[C], FACS

m d, d sc,

Associate Professor of Surgery
and Microbiology,
Department of Surgery,
Royal Victoria Hospital,
687 Pine Ave. W,
Montreal, PQ
H3A 1A1
PROCEDURES AND TECHNIQUES IN
EMERGENCY MEDICINE. Robert R.
Simon and Barry E. Brenner, 404 pp. IIlust. Williams & Wilkins, Baltimore, 1982.
$52. ISBN 0-683-07715-5.

In the preface, the authors promise to deliver
a text that is both academic and complete
regarding procedures and techniques perform
ed in the emergency and outpatient setting.
They also state that the text will be presented
in an organized and comprehensive way by
dividing it into three parts: preparatory steps,
procedural steps and after care. In my opinion
the authors have achieved their goals ad
mirably. The text is clear, the illustrations are
excellent and the research is comprehensive in
all 11 chapters.
I disagree with some of the techniques the
authors have espoused; however, this would
be the case with any such textbook. In their
defence, the authors do give alternatives and
provide sufficient references. In some cases
they have described more than is appropriate
in the emergency setting as, for example, in
their coverage of cesarean section. I would not
take issue with this because they make it clear
that the procedure would be done only under
extraordinary circumstances. Having worked
as a missionary in Africa, I am quite familiar
with such circumstances and certainly would
have appreciated this type of book when I was
there.
Finally, one must consider whether there is
a need and, specifically, a market for this book.
I think there is and I strongly recommend this
volume for all those interested in emergency
medicine, either as a full-time practice or a ma
jor part-time interest. It is also appropriate for
residents in most medical and surgical
specialties who might find themselves respon
sible for many of the procedures described. It
has a useful role to play for the established
practitioner as a reference to procedures that
he may not have undertaken for a few years.
R.Y. M c M urtry , MD, FRCStC]
Director,
Emergency Services,
Sunnybrook Medical Centre,
Toronto, Ont.
M4N 3M5
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SURGERY OF THE NEUROGENIC BLAD
DER. Peter Magasi. 148 pp. Illust.
Akademiai Kiado, Budapest, 1982. $18.
ISBN 963-05-2892-4.

| PAAB

3hoy>t

P.O. BOX 1005, POINTE-CLAIRE
DORVAL, QUEBEC H9R 4P8

This book, translated into English, is aimed at
the practising urologist, neurologist and
paraplegic specialist. It is divided into two sec

tions, the first covering anatomy and
physiology and the second encompassing ex
perimental and clinical observations.
The first section, containing a few pages on
the anatomy, embryology and innervation of
the bladder and bladder neck, is somewhat dis
jointed and appears to have lost some of its
readability in the translation. There is no defini
tion of a neurogenic bladder and no attempt
to classify it according to either anatomic or
physiologic factors. The chapter on the struc
ture of the bladder muscle and trigone is ade
quate but the chapter on innervation is not.
This is particularly amiss, as the initial treat
ment of any type of neurogenic bladder de
pends critically on understanding the neuro
pharmacology of the bladder and urethra.
The second section of the book is basically
a series of experiments reported by the author
with a few editorial comments. In one chapter,
he uses dogs to determine the urethral length
necessary for continence, and in the next two
experiments the unique method of endoscopic
visualization of the bladder via a cystotomy is
used in order to evaluate the functional rela
tion between the detrusor and the bladder neck.
The author forms his basic premise here,
stating that bladder contraction is elicited by
tension in the muscles of the bladder neck and
not by urinary chemical stimuli. This statement
would certainly spark debate in most
urodynamic centres. Also in this section are
three short chapters that discuss the types of
neurogenic bladder according to Macrae, the
diagnosis of bladder dysfunction and, brief
ly, vesicoureteral reflux.
The bulk of the second section deals with dif
ferent forms of surgery for neurogenic blad
ders; brief mention is made of some of the wellknown surgical procedures while the remainder
is reserved to describe electrical stimulation of
the bladder, which is the author’s area of ex
pertise. He describes his experimental work
with dogs involving stimulation with elec
tromagnetic induction, followed by his clinical
experience of implanting electrodes in 22
paraplegics. His results are documented with
case histories and graphs charting regional
volume and capacity and are interpreted as be
ing generally successful, with most patients
emptying their bladders fully. Sixteen devices
are still in use 2 to 9 years after implantation.
In summary, this book is interesting because
it gives a different approach to the understan
ding and treatment of the neurogenic bladder.
However, it lacks several features and that
precludes its acceptance as a textbook on
neurogenic bladders. It is shallow in several
areas and does not mention the use of inter
mittent catheterization or artificial sphincters
as alternatives. The section on electrical
stimulation of the bladder is interesting but the
author’s criteria for patient selection are
obscure and thus it is not clear when this pro
cedure is indicated. In general, it leaves the
reader with an unsatisfied appetite.
R .J. Bu c k l e y ,
Resident,
M. Bu l b u l ,

md

md

Resident,
Department of Urology,
Toronto General Hospital,
101 College St.,
Toronto, Ont.
M5G 1L7
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SURGICAL CARE OF THE PATIENT
WITH RENAL FAILURE. Edited by
Nicholas L. Tilney and J. Michael Laza
rus. 224 pp. Illust. W.B. Saunders Com
pany Canada, Ltd., Toronto, 1982. $50.15.
ISBN 0-7216-8850-0.

PRESCRIBING INFORMATION:
PRECAUTIONS:

Many surgeons approach the patient on long
term dialysis with uneasiness because of the
many pitfalls involved. This volume attempts
to acquaint the surgeon, internist and house
officer with this patient who requires a modi
fied form of management and is susceptible to
many complications. In achieving its objective
as well as it does, this book is a compliment
to the editors — a surgeon and a nephrologist,
respectively.
The first chapter outlines broadly the accel
erating growth in the number of persons requir
ing dialysis, explains some o f the basic equip
ment and techniques used and provides some
lessons in regard to electrolyte and volume
management, anticoagulation, modification of
drug doses and anesthesia for the patient with
chronic renal failure.
There follows a chapter on acute renal fail
ure as it occurs in the previously healthy sur
gical patient. The surprisingly high mortality
—- even in the best of hands — is noted, with
contributory factors shown to include the
underlying surgical disease, as well as the phe
nomenon of sequential organ failure. Once
acute renal failure has supervened, early and
frequent dialysis as well as principles of nutri
tion are emphasized. Current theories of the
pathogenesis of acute renal failure are
reviewed.
A further chapter recalls the history of vas
cular access, beginning with the insertion of
glass tubing into vessels, followed by the exter
nal Teflon-Silastic arteriovenous fistula, to the
present use of the endogenous Brescia-Cimino
subcutaneous fistula or those constructed with
synthetic materials such as polytetrafluoroethylene. Multiple variations in the connecting
of arteries and veins, their complications and
management, are described.
The common infections that occur in dialy
sis and transplantation are covered. A distinc
tion is drawn between nosocomial infections,
which occur following invasive procedures, and
opportunistic infections, resulting from immu
nosuppression. Peritonitis in patients on peri
toneal dialysis, bacteremia in transplant
patients as well as tuberculosis, fungal infec
tion, and many viral illnesses including hepa
titis, cytomegalovirus and herpes zoster are all
covered.
The increase in atherosclerosis in chronic
renal failure is well known and a chapter is
devoted to cardiovascular disease. This inclu
des a lucid discussion of the uremic pericar
dial effusion with both medical and surgical
approaches to management considered. The
management of both valvular and coronary
bypass surgery in the uremic patient is
reviewed.
The chapter on gastrointestinal complica
tions emphasizes the frequency of peptic ulcer
disease with gastrointestinal bleeding in ure
mia accentuated by periodic heparinization
during hemodialysis. Elevated levels of gastrin
(enhanced production or decreased excretion,
or both) or hypochlorhydria may be found.
Paradoxically, many asymptomatic uremic
patients may have false-positive radiographic
findings suggestive of both duodenal and gas

Sodium T u sida te B P

ADVERSE

REACTIONS

AND

Fucidin is indicated for the treatment of severe skin and soft tissue
infections and osteomyelitis due to susceptible strains of Staphy
lococcus aureus. As Fucidin is excreted mainly in the bile a revers
ible jaundice may appear especially where high doses are used or
when the drug is given for prolonged periods. Liver function should
be monitored in patients with liver dysfunction when used for
prolonged periods.
Safety in pregnant women and nursing mothers has not been
established. There is evidence suggesting Fucidin penetrates the
placental barrier and Fucidin is detectable in the milk of nursing
mothers.
Rare adverse reactions may include gastrointestinal upset and al
lergic reactions. Local Venospasm and thrombophlebitis have been
associated with intravenous therapy.
DOSAGE RANGE

FUCIDIN TABLETS
(each white tablet contains 250 mg sodium fusidate, enteric coated)
Two 250 mg tablets 3 times daily given with food. In severe infec
tions four 250 mg tablets 3 times daily.
FUCIDIN SUSPENSION
(each 5 ml of aqueous banana-flavoured suspension contains the
therapeutic equivalent of 175 mg sodium fusidate)
0-1 years:

1 m l/k g body weight
daily divided into 3 equal doses.
1- 5 years: 5 ml 3 times per day.
5-12 years: 10 ml 3 times per day.
Adult dose: 15 ml 3 times per day.
FUCIDIN for INTRAVENOUS INFUSION
Vial 1 - diethanolamine fusidate BPC dry powder 580 mg (equiv
alent to 500 mg sodium fusidate B.P.)
Vial 2 - 50 ml sterile phosphate-citrate buffer (pH 7 4-7.6)
Adults weighing more than 50 kg: 580 mg diethanolamine fusidate
three times daily. Children and adults weighing less than 50 kg:
7 mg diethanolamine fusidate per kg body weight three times daily.
RECOMMENDED PROCEDURE FOR PREPARING SINGLE DOSES:

1. For adults weighing more than 50 kg: Dissolve 580 mg
diethanolamine fusidate powder (Vial 1) in the 50 ml buffer
provided (Vial 2). Add this fusidate/buffer solution to 500 ml of
sodium chloride injection or other suitable infusion fluid and infuse
slowly over a period of not less than six hours
2. For children and adults weighing less than 50 kg: Dissolve
580 mg diethanolamine fusidate powder (Vial 1) in the 50 mi buffer
provided (Vial 2). Take 0.7 ml of this fusidate/buffer solution for
every kg body weight. This volume of fusidate/buffer solution
should be further diluted, at least tenfold, with the appropriate
infusion fluid, and infused slowly over a period of not less than six
hours.
Infusion should be made into a wide bore vein with a good blood
flow.
Suitable Infusion Fluids include:
Saline. Dextrose. Dextrose-Saline
OFFICIAL PRODUCT MONOGRAPH AVAILABLE ON REQUEST.

Leo Laboratories Canada Ltd.
1305 Sheridan Mall Pkwy., Suite 704
Pickering, Ontario L1V 3P2
Telephone: (416) 831 -2332
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tric disease. A variety of colonic afflictions is
discussed including pseudomembranous coli
tis secondary to Clostridium difficile infection
as well as the prevalence of severe constipation
in uremic patients.
A chapter on endocrine dysfunction is con- 4
cerned mainly with osteomalacia related to im
paired renal production of vitamin D
metabolites and to the osteitis fibrosa of secon
dary hyperparathyroidism. Carbohydrate in
tolerance, sexual dysfunction and thyroid func
tion are more briefly dealt with.
The particular problems of the diabetic pa
tient with chronic renal failure are considered
separately. Several centres have reported sur
prisingly high survival rates after transplanta
tion with the results only 10% worse than in
nondiabetics. Musculoskeletal problems
described include the carpal tunnel syndrome,
bone fractures, particularly those involving the
limb with an arteriovenous fistula, and os
teonecrosis of the hip, shoulder and knee. 1
With regard to obstetric and gynecologic
problems, it is noted that excessive menstrual
bleeding is not a problem in those women who
continue to menstruate, despite the use of an
ticoagulants and the bleeding tendency of
uremic patients. Few patients on a long-term
hemodialysis program conceive and fewer still
are delivered of a viable infant. On the other
hand, transplantation may restore fertility and
child-bearing potential.
Multiple eye problems that occur in these pa
tients are considered. Early cataract formation
is encountered in patients who receive steroids.
Glaucoma is also more common in this group.
Etiologies for the “ red eyes” in the dialysis pa
tient are reviewed as are corneal and conjunc
tival calcification occurring from disordered
calcium metabolism. The classification of
diabetic retinopathy is well explained.
The volume concludes with an excellent
chapter on renal transplantation. Allograft sur
vival has shown steady, but gradual improve
ment while survival of the recipient has great
ly improved with less aggressive use of im
munosuppressants. The cut-off age for reci
pients has risen to 60 years of age and beyond.
A number of renal diseases have now been
shown to be safe from recurrence in the
transplanted kidney, while others, which may
be detected in the transplanted kidney, rarely
provoke significant clinical involvement. The
screening of the living, related donor is discuss
ed and reasons given for the unacceptability
of the donor, such as renovascular anomalies, -<
nephrolithiasis, ureterovesical reflux, affliction
by renal disease and psychologic ambivalence.
The procedures for obtaining cadaver kidneys
are also outlined. Pre-, peri- and postoperative
care of the transplant recipient is detailed. The
assessment of allograft function and the
diagnosis of complications including acute re
jection, vascular and neurologic problems are
all well covered.
In many respects, this slim volume is a
modified textbook of nephrology. It is well
written and the views expressed are current,
conservative and reliable.

David D. Bercovitch , md , frcp [C]
Division of Nephrology,
Sir Mortimer B. DavisJewish General Hospital,
3755 C6te Ste-Catherine,
Montreal, PQ
H3T 1E2
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The
* deadline is 1 month before issue date. Regular classified rates (for each insertion): $35.00 for the first 40 words or less, additio
nal words 35C each (additional $13.00 for frame). Special Display under 75 words, 2 1/4" x 2" $85.00. $5.00 charge (first inser
tion only) for CJS box numbers. Display rates available on request,
i
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
ORTHOPEDIC SURGEON: ON - required to join
a multispecialty group in Thunder Bay, Ontario.
Liberal guarantee, plus incentive formula and fringe
benefits. Clinic in modern office building complex
adjacent to city hospital with considerable scope for
orthopedic practice. Please write to: Executive
Chairman, The Spence C linic, Ste. 500, 1265 A r
th u r St., E., Thunder Bay, ON P7E 6E7 — or —
tel: (807) 623-4335 collect.
—S83-030
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OBSTETRICIAN/GYNECOLOGIST: ON - r e quired to join other obstetricians/gynecologists in a
multispecialty group in Thunder Bay, Ontario. Clinic
in modern office building complex adjacent to city
hospital. Liberal guarantee, plus incentive formula
and fringe benefits. Please write to: Executive
Chairman, The Spence C linic, Ste. 500, 1265 A r
thu r St., E, Thunder Bay, ON P7E 6E7 — or —
tel: (807) 623-4335 collect.
—S83-031

GENERAL SURGEON - FRCS(C), wide experience in vascular and thoracic surgery and en
doscopy wishes to relocate, solo or group. Reply:
BOX S103, CJS.
-S84-003

C LIN IC AL FELLOWSHIP - Ewart Angus
Surgical Intensive Care Unit. Wellesley
Hospital, Toronto. Available July 1, 1984 for a
period of one year in a multidisiplinary acute
surgical unit with 650 admissions per year.
Duties comprise clinical research in a strong
academic and teaching unit. Present research
includes metabolism, sepsis, and non-invasive
tissue oxygen monitoring. Reply to: Doctor
D.P. Jones, D irector, S urgical ICU, Suite
219, E.K. Jones B ldg., 160 W ellesley St. E,
T o ro n to , ON M4Y 1J3, (416) 966-6656.
— S83-029

GENERAL SURGEON: AB — Required by a well
established 15-doctor group. Laboratory and x-ray
facilities in clinic. Accredited 120-bed active treat
ment hospital in community of 12 000 and servicing
the regional needs of 30 000 people. Camrose is a
beautiful place to live; close, but not too close to
Edmonton, with a Junior College and active recrea
tional, sports and cultural programs. Relocation ex
penses will be provided. Contact: M r. T.C. O frim ,
A d m in is tra to r, S m ith C lin ic, 4825-51 S t.,
Camrose, A B, Canada T4V 1R9. Tel: (403)
672-2424.
—S83-007

GENERAL SURGEON: NS - Additional general
surgeon and/or general and vascular surgeon re
quired immediately to join a busy group practice in
an expanding regional hospital. Must be certified or
exam eligible. Reply to: Box S104, CJS.
— S84-010

GENERAL SURGEON
NB
Required for
accredited 90-bed
general hospital.
McGill affiliation.

St. Joseph's Hospital
Dalhousie, NB
E0K 1B0
—S83-026

r

University of Alberta
FIREFIGHTERS CHAIR IN BURNS

r

The endowed position, known as the Firefighters Chair in
Burns, is a geographic full-time academic appointment in the
Division of Plastic Surgery of the Department of Surgery,
Faculty of Medicine, University of Alberta.
The appointee will be responsible for initiating research
programs in the general field of the treatment and rehabilita
tion of burn patients and for the supervision of under
graduate and graduate teaching in these areas in the Faculty
of Medicine and other Health Science Faculties.
The appointee will act as the Director of the Firefighters
Burn Treatment Unit, which is physically located in the
University Hospitals.

t

Rank and salary: negotiable.
The University of Alberta is an equal opportunity
employer, but, in accordance with Canadian Immigration re
quirements, this advertisement is directed to Canadian
citizens and permanent residents.

r

>

Please send curriculum vitae and names o f three referees
to:
Dr. H.T.G. Williams
Professor and Chairman
Department of Surgery
University of Alberta
11-105 Clinical Sciences Building
Edmonton, Alberta
T6G 2G3
Closing date for receipt o f applications is April 30, 1984.
-S84-011

Chief of Staff-Surgery
Alberta Children's Hospital
Academic Appointment
The position is a jo in t appointm ent betw een the Faculty o f M edicine,
University o f Calgary, and the Alberta Children's Hospital.
The Chief of S ta ff, Surgery, is responsible fo r the quality o f surgical
care provided to patients at the Alberta C hildren's H ospital; the
incumbent is also responsible and has overall authority fo r the
organization and supervision o f the medical s ta ff and fo r the qu a lity o f
education and research program s w ith in the section of surgery.
The Chief o f S ta ff, Surgery, w ill be accountable to the Professor and
Head, University Departm ent o f Surgery, for the academic program and
to the Executive D irector o f the Alberta Children's Hospital to ensure
the highest standards o f patient care.
Candidates m ust have a m inim um o f 5 years' experience in pediatric
surgical practice and m ust be eligible fo r certification as a specialist in
the Province o f Alberta. In addition, they m ust be eligible fo r the
academic rank o f full professor or senior associate professor. Preference
w ill be given to applicants w ith dem onstrated adm inistrative skills and
leadership qualities.
For further in form ation contact:
Dr. Peter Cruse
OR
Professor and Head
Department o f Surgery
University o f Calgary
2500 U niversity Dr. NW
Calgary, A lta . T2N 1N4
(403) 2 7 0 -1 1 1 0

M r. Robert L. Innes
Executive Director
Alberta C hildren's Hospital
1 8 2 0 Richm ond Rd. SW
Calgary, Alberta
T 2T 5C7
(403) 2 2 9 -7 2 1 3

Interested applicants are requested to s ubm it an
application together w ith a current curriculum
vitae and the nam es o f fo u r references to : M r.
Robert Innes, address as above. Deadline fo r
applications: M ay 3 0 , 1984.

Personnel D e p a rtm e n t
A lb e rta C h ild re n 's H o s p ita l
1820 R ic h m o n d Road S.W.
C algary. A lberta T2T 5C7
''t/U T H C
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UPDATE ON GENERAL S URG ICAL O N 
COLOGY — The Division of General Surgery at the
Toronto General Hospital will present a Clinical Day
for Surgeons on Monday, June 4, 1984. The pro
gram will be entitled “ An Update on General
Surgical Oncology". Guest speakers will include Dr.
Murray Brennan, Chief of Gastric and Mixed tumour
Services, Memorial Sloan Kettering Cancer Centre,
New York, NY and Dr. Charles Balch, Professor of
Surgery, University of Alabama at Birmingham.
Contact: Miss Ines Pontoriero, Eaton Building,
8th floor, Rm. 315, Toronto General Hospital,
101 College St., Toronto, ON, Canada M5G 1L7.
Tel: (416) 595-3556
-S 84-013
ACADEM IC APPOINTMENT: ON - Applica
tions are invited for a full-time position in the
Department of Urology at Queen's University. The
successful applicant will have responsibility for
teaching in an established postgraduate program in
volving clinical practice and administration. There are
excellent opportunities for basic and clinical
research. The applicant must be able to conduct in
dependent research. In accordance with Canadian
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STAFF SURG EON/LECTURER: ON A
research scientist/clinical surgeon is required for a
large metropolitan University teaching hospital
(80-bed Orthopedic/Neurosurgical Unitl. The suc
cessful applicant must have proven research ex
perience in spinal mechanics, spinal cord physiology
and research applications of spinal cord function
monitoring. Clinical interest must encompass
trauma, as well as all other facets of general or
thopedics in an adult population. Qualifications;
MD, FRCS, minimum of 18 months' laboratory and
research experience. The successful applicant must
have special training in spinal surgery, both in the
management of degenerative spinal disorders, as
well as the management by conservative and
surgical measures of spinal deformity. The applicant
should be prepared to spend 2 days a week in the
laboratory and be willing and capable of functioning
in an adult clinical practice. The applicant must be
willing to enter into an income limiting partnership
with other members of the Orthopedic Division, as
well as with other members of the Department of
Surgery of the hospital and must be prepared to
devote a significant percentage of their time to basic
science research. Salary: minimum for rank
($21 2001. Effective date of appointment is July 1,
1984 with closing date for receipt of applications be
ing April 1, 1984. In accordance with Canadian im
migration requirements, this advertisement is
directed to Canadian citizens and permanent
residents. Forward replies or enquiries to: Dr. J.P.
W addell, Surgeon-in-C hief, St. Michael's
Hospital, 30 Bond St. N., Toronto, ON M5B
1W6.
S84-005

Thrombostat Prescribing Information
(Thrombin, USP) Bovine Origin—
formerly: Thrombin, Topical
INDICATIONS: Thrombostat is indicated as an
aid in hemostasis wherever oozing blood from
capillaries and small venules is
accessible.
In various types of surgery,
solutions of Thrombostat may/
be used in conjunction with
absorbable gelatin sponge
USP for hemostasis.
CONTRAINDICATION:
Thrombostat is contra
indicated in persons
known
to be
sensitive
to any of
its components and/or to material of bovine origin.
WARNING: Because of its action in the
clotting mechanism, Thrombostat must not be
injected or otherwise allowed to enter large blood
vessels. Extensive intra-vascular clotting and even
death may result. Thrombostat is an antigenic
substance and has caused sensitivity and allergic
reactions when injected into animals.
PRECAUTIONS: Consult the absorbable gelatin
sponge product labelling for complete informa
tion for use prior to utilizing the thrombostat
saturated-sponge procedure.
ADVERSE REACTIONS: An allergic type reaction
following the use of thrombin for treatment of
epistaxis has been reported. Febrile reactions
have also been observed following the use of
thrombin in certain surgical procedures but no
cause-effect relationship has
been established.
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Immigration requirements, this advertisement is
directed to Canadian citizens and permanent
residents. Please send curriculum vitae with names
of three referees to: Dr. A. Morales, Head,
Department of Urology, Queen's University,
Kingston, ON K7L2V6.
-S84-012
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The Western Regional Health Centre,
which includes a fully accredited 175-bed
hospital with physician offices attached,
has an immediate need for:
E.N.T.Surgeon
A second person is required to provide
general E.N.T. services.
Ophthalmologist
A se co n d
p e rson
to
p ro v id e
ophthalmology services for the area is re
quired.
General Surgeon
A good opportunity for an applicant
qualified in general surgery and preferably
with additional training and competence
in peripheral vascular and thoracic surgery.
Fellow or eligibility for fellowship of the
Royal College of Physicians and Surgeons
of Canada is required.
We serve a population of approximately
70 000 in southwestern Nova Scotia, and
our location offers an attractive nonurban lifestyle with convenient facilities
and transportation services:
— Air Canada to Boston — 55 minutes;
Halifax — 25 minutes.
— Ferry service to Portland, Maine and
Bar Harbour, Maine.
— Via Rail service to Halifax daily; bus
line service; and 3 hours to Halifax
by car.
Interested parties should submit a cur
riculum vitae to, or for further informa
tion, contact:
Mr. J.G. McEachern
Executive Director
Western Regional Health Centre
Yarmouth, Nova Scotia
B5A 2P5

DOSAGE AND
ADMINISTRATION:
Solutions of Thrombostat
may be prepared in sterile
distilled water or isotonic
saline. The intended use determines the strength
of the solution to prepare. For general use in
plastic surgery, dental extractions, skin grafting,
neurosurgery, etc. solutions containing approx
imately 100 units per mL are frequently used. For
this, 10 mL of diluent added to the 1000 unit
package (Bio 2077) is suitable. Where bleeding is
profuse, as from cut surfaces of liver and spleen,
concentrations as high as 1000 to 2000 units per
mL may be required. For this the 5000 unit vial
(Bio 2073) dissolved in 5 mL or 2.5 mL respectively
of the diluent supplied in the package is convenient.
Intermediate strengths to suit the needs of the
case may be prepared by selecting the proper
strength package and dissolving the contents in
an appropriate volume of diluent. In many situations,
it may be advantageous to use Thrombostat in
dry form on oozing
surfaces.
Caution: Solutions
should be used the day
they are prepared. If
several hours are to elapse,
the solution should be refrigerated,
preferably frozen, and not used
after 48 hours.
Complete dosage and administration for topical
application of Thrombostat is available upon request.
Supplied: 10mL vials of 1000 N.I.H. units; packages
containing a 5,000 N.I.H. vial and a 5 mL vial of
diluent; 10 mL vials of 10,000 N.I.H. units.
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Thrombostat
(Thrombin, U .S.E)
Rapid hem ostatic action
with versatility

A

In many fields of
surgery
• v>

abdominal surgery
orthopedic surgery
• bum or plastic surgery
•»neurosurgery
• vascular surgery
A

Fast-Acting

Versatile

Contents of a 5,000 U.S. (NIH)
unit vial dissolved in 5 mL of
saline diluent:
• can clot an equal amount of
blood in less than a second
• can clot 1,000 mL in less than
a minute

May be applied:
• as a solution alone (either in
spray or by flooding the surface)
• in conjunction with absorbable
gelatin sponge, USP
• as a dry powder
*T.M. Warner-Lambert Company
Parke-Davis Canada Inc. auth. user
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Davis + Geek Introduces

SFTGUT
Surgical Chromic Suture

Something
you’re used to
without
the problems
you’re used to
You told us that you liked using catgut but you didn’t like its
problems. So we took catgut and made it
•
•
•
•

Cyanamid Canada Inc.

soft and supple
easy to tie
less likely to curl, “pigtail” and tangle
easy to handle and control

Atria North, 2255 Sheppard Avenue East, Willowdale, (Ontario) M2J 4Y5
•Trademark American Cyanamid Company

